Age-related Macular Degeneration: from risk profiles towards prediction models by Buitendijk, G.H.S. (Gabrielle)
AGE-RELATED
MACULAR DEGENERATION
FROM RISK PROFILES
TOWARD PREDICTION MODELS
GABRIËLLE H.S. BUITENDIJK

Age-related Macular Degeneration:
from risk profiles towards prediction models
Gabriëlle H.S. Buitendijk
Financial support
The studies described in this thesis were supported by the Netherlands Organization of Scientific 
Research (NWO) (170885606 to the BRAMD Study), NWO investments (175.010.2005.011, 911-
03-012 to the Rotterdam Study), the Netherlands Genome Initiative (NGI)/NOW (050-060-081 to 
the Rotterdam Study), Erasmus Medical Center and Erasmus University, Rotterdam, Netherlands 
Organization for the Health Research and Development (ZonMw), the Research Institute for Diseases 
in the Elderly (014-93-015; RIDE2), the Ministry of Education, Culture and Science, the Ministry for 
Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of Rotterdam, 
Stichting Macula Fonds, Stichting Nederlands Oog Onderzoek (SNOO), Rotterdamse Stichting 
Blindenbelangen, Stichting Oogfonds Nederland, Landelijks Stichting voor Blinden en Slechtzienden, 
Algemene Nederlandse Vereniging ter Voorkoming van Blindheid, Erasmus Trustfonds, Prof. Dr. 
Henkes stichting.
Printing of this thesis was supported by
Rotterdamse Stichting Blindenbelangen, Stichting Blindenhulp, Stichting Ooglijders, Landelijke 
Stichting voor Blinden en Slechtzienden, afdeling Epidemiologie Erasmus MC, Koolhaas 
Paprika, Springfield Nutraceuticals, Medical Workshop, Ergra Low Vision, Théa Pharma, Bayer, 
Vitaminenoprecept, Ursapharm, Laméris Ootech, Tramedico, Oculenti, Sanmed B.V., Horus Benelux 
B.V., Low Vision Totaal, Oogplein, Chipsoft, ZEISS, Laservision, Synga Medical, MediTop, Ophtec, 
Rockmed, Slechtziend.nl and Allergan.
Cover image: A whippet in a forest of neovascularization under a sky filled with drusen
Cover design: Evelien Jagtman (evelienjagtman.com)
Layout: Design Your Thesis (designyourthesis.com)
Printed by:  Ridderprint B.V. (ridderprint.nl)
ISBN:  978-94-6299-856-8
 
 
Copyright © 2018 G.H.S. Buitendijk
All rights reserved. No part of this book may be reproduced, stored in a retrieval system, or 
transmitted in any form or by any means without prior permission from the author of this thesis, or, 
when appropriate, from the publishers of the publications in this thesis.
Age-related Macular Degeneration:
from risk profiles towards prediction models
Leeftijdsgebonden Maculadegeneratie:
van risicoprofielen tot predictiemodellen
P R O E F S C H R I F T
ter verkrijging van de graad van doctor aan de
Erasmus Universiteit Rotterdam
op gezag van de
rector magnificus
Prof.dr. H.A.P. Pols
en volgens besluit van het College voor Promoties.
De openbare verdediging zal plaatsvinden op
woensdag 28 maart 2018 om 15.30 uur
door
Gabriëlle Helena Susanne Buitendijk
geboren te Rotterdam
PROMOTIECOMMISSIE
 
Promotoren: Prof. dr. C.C.W. Klaver
 Prof. dr. J.R. Vingerling
Overige leden: Prof. dr. M.A. Ikram
 Prof. dr. A.I. den Hollander
 Prof. dr. C. Delcourt

TABLE OF CONTENTS
Chapter 1 – Introduction
1.1 General introduction 9
1.2 Aims of this thesis and study populations 17
Chapter 2 – Burden of AMD
2.1 Prevalence of age-related macular degeneration in Europe: the past and the 
future
21
2.2 Visual consequences of refractive errors in the general population 35
Chapter 3 – Aspects of imaging techniques in population-based research
3.1 Epidemiology of reticular pseudodrusen in age-related macular degeneration: 
The Rotterdam Study
51
3.2 Automatic identification of reticular pseudodrusen using multimodal retinal 
image analysis
67
Chapter 4 – Environmental risk factors
4.1 Trace elements, vitamins, and lipids and age-related macular degeneration: an 
overview of the current concepts on nutrients and AMD
83
4.2 Recommended diet intake of vegetables, fruit, and fish is beneficial for age-
related macular degeneration
103
4.3 Thyroid function and age-related macular degeneration: a prospective 
population-based cohort study: The Rotterdam Study
121
4.4 Antiplatelet and anticoagulant drugs do not affect visual acuity in neovascular 
age-related macular degeneration in the BRAMD trial
135
Chapter 5 – Genetic markers and gene-environment interactions
5.1 Genetics and gene-environment interactions in age-related macular 
degeneration
153
5.2 Seven new loci associated with age-related macular degeneration 175
5.3 Genetic susceptibility, dietary antioxidants, and long-term incidence of age-
related macular degeneration in two populations
191
Chapter 6 – Prediction and personal genome testing
6.1 Prediction of age-related macular degeneration in the general population:
The Three Continent AMD Consortium
207
6.2 Direct-to-consumer personal genome testing for age-related macular 
degeneration
229
Chapter 7 – General discussion and summary
7.1 General discussion 245
7.2 Summary 259
7.3 Samenvatting 263
Chapter 8 – Epilogue
8.1 Acknowledgements – Dankwoord 269
8.2 PhD portfolio 273
8.3 Bibliography 277
8.4 About the author 285

Chapter 1.1
General introduction
10 Chapter 1.1
GENERAL INTRODUCTION
This thesis comprises studies on the common eye disorder age-related macular degeneration (AMD). 
In the introduction, I will first focus on the structures of the eye most important to the disease, then 
explain the state of knowledge prior to my studies, and subsequently discuss the outline of my thesis.
Anatomy and physiology of the eye
To create vision, light needs to travels through many structures of the eye: cornea, anterior chamber, 
through the pupil, lens, vitreous body, and retina (Figure 1). Photoreceptor cells in the retina absorbs 
light photons by the visual pigment and translate these first in a biochemical message and then in an 
electrical signal that can stimulate the succeeding neurons of the retina. This signal is subsequently 
transmitted through the optic nerve to the occipital cortex of the brain via the visual pathway.
The retina consists of two primary layers: the neurosensory retina and the retinal pigment epithelium 
(RPE). Directly underneath the RPE lies Bruch’s membrane, which separates the RPE from the 
choriocapillaris and the choroid, which are vascular structures that nourishes the retina. The deepest 
outer fibrous layer of the eye is the sclera, which functions as the external shell of the eye.
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FIGURE 1 - Anatomy of the human eye (Figure adapted from www.biology-questions-and-answers.com/images/
Human-Eyes.jpg).
The neurosensory retina consists of eight layers, including the photoreceptor cell layer (Figure 2). 
There are two types of photoreceptor cells, rods and cones. Cones have optimal function in bright 
light and are responsible for fine resolution, spatial resolution, and color vision, while rods function 
optimal in dim-light and sense contrast, brightness, and motion. A yellow colored pigment is 
highly concentrated in the ganglion cells, cone axons, and Muller cells of the optical center of the 
posterior pole, called macula lutea. This macular pigment consists of lutein, zeaxanthin and meso-
zeaxanthin, and these pigments offer protection to the retina by absorbing hazardous ionizing blue 
and ultraviolet light. Fine detailed and color vision is mainly acquired in the fovea, which is located in 
the center of the macula. Underneath the photoreceptor layer lies the RPE, a monolayer of epithelial 
cells that are in close contact with the photoreceptors. This cell layer has many functions that are 
critical to the visual process, such as phagocytosis of photoreceptor outer segments, synthesis 
of interphotoreceptor matrix, absorption of light, vitamin A metabolism, and transport of other 
molecules. If the RPE becomes dysfunctional, like in AMD, the neurosensory retina will not function 
properly and vision is disturbed.
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FIGURE 2 - Layers of the human retina. The following layers are disclosed in the optical coherence tomography 
image of a human macula, from top to bottom: internal limiting membrane (ILM), nerve fiber layer (NFL), 
ganglion cell layer (GCL), inner plexiform layer (IPL), inner nuclear layer (INL), outer plexiform layer (OPL), outer 
nuclear layer (ONL), external limiting membrane (ELM), ellipsoid zone (EZ), retinal pigment epithelium/Bruch’s 
membrane (RPE/BM), choriocapillaris (CC), choroid (C), choroid sclera junction (CSJ).
Age-related macular degeneration
AMD is a chronic disease of the macula and is the leading cause of blindness in elderly, particularly 
in those of European descent. About 30-50 million persons are affected in the world and this 
number is expected to increase dramatically with the exponentially aging population.1 AMD can be 
stratified in two severity stages: early and late AMD (Figure 3). Early AMD is mostly asymptomatic and 
characterized by drusen (sub-RPE deposits), reticular pseudodrusen (deposits above the RPE), and 
pigmentary changes. Late AMD is the visual threatening end-stage of AMD which can be subdivided 
into geographic atrophy (dry AMD) and choroidal neovascularization (wet AMD). Geographic atrophy 
is characterized by atrophy of the RPE and neurosensory retina. In choroidal neovascularization 
abnormal new blood vessels from the choroid grow into the retina, which can easily bleed, leak fluids 
and cause fibrovascular scarring.2 Having signs of early AMD will increase the risk of developing late 
AMD. The larger the area, size and the type of drusen and pigmentary changes, the higher the risk of 
developing late AMD.3,4
Epidemiology
Disease frequency
The prevalence of early and late AMD has been established in several parts of the world. For 
Caucasians in the United States of America, over 40 years of age, the overall prevalence of early AMD 
(indicated by large drusen) showed much more variation than that of late AMD; overall prevalence 
of early AMD was estimated at 6.12%; prevalence of late AMD at 1.47%.5 Age-specific prevalence for 
both early and late AMD increased with advancing age in all ethnicities. As for incidence figures, the 
10-year risk of late AMD was estimated to be virtually nil for those aged 55 years, but increased to 
11% for those aged 80 years and older.6 Studies in Europe show comparable estimates for both early 
and late AMD.4,6,7
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FIGURE 3 - Stages of age-related macular degeneration (AMD) disclosed using different imaging methods. 
The different images represent 1) normal retina without signs of AMD, 2) early AMD, 3) late AMD – subtype 
geographic atrophy, and 4) late AMD – subtype choroidal neovascularization, and were obtained using A) 
fundus color photographs, B) near-infrared imaging, C) fundus autofluorescence, D) optical coherence 
tomography.
Risk factors
Many risk factors for AMD have been identified; including age, smoking, higher body mass index 
and increased serum complement activation. Cardiovascular risk factors such as hypertension and 
lipid levels may be associated with an increased risk of AMD.6,8-10 Intake of antioxidants, in particular 
lutein and zeaxanthin, from diet and supplements have been associated with a protective effect.11-13 
Positive family history has been known for many years to be an important risk factor14, indicating that 
genetic predisposition plays an significant role. Genetic studies have confirmed this hypothesis and 
found several genes associated with AMD. These genes include commonly occurring risk variants. 
The most important and frequently replicated variants are located in the CFH, ARMS2, C2/CB and 
C3 genes. Smaller effects were found in several other genes, including APOE, LIPC, LPL, CETP, ABCA1 
and TIMP3 genes.6 The known variants in these associated genes do not fully explain the heritability 
of AMD, which has been determined to be between 65-70%.15,16 Unknown variants, gene-gene 
interactions, and gene-environment interactions could explain the missing heritability in AMD.
Treatment
Preventive measures like cessation of smoking, healthy diet and supplementation of anti-oxidants 
are at this time the only option for those with early and dry AMD. For wet AMD, anti-vascular 
endothelial growth factor treatment aimed at cessation of blood vessel growth and impermeability 
of endothelium is currently the only available treatment.17,18 However, this is not a definite cure and 
will improve and maintain visual acuity only for a limited period of time.19 Many trials are currently 
testing newly developed medication focusing on other disease mechanisms in early and dry AMD.
Imaging techniques
AMD features can be disclosed using various imaging techniques (Figure 3). Ophthalmoscopy can 
be used to identify the majority of disease features, and the obtained image can be captured using 
color fundus photography (CFP). Other techniques can help identify lesions with an increased 
sensitivity. Confocal scanning laser ophthalmoscopy can be used for non-invasive imaging like 
fundus autofluorescence (FAF) and near-infrared imaging (NIR). FAF uses short wavelengths (blue 
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light) to excite lipofuscin in the retina, while NIR uses wavelengths in the infra-red spectrum and 
reveals structures based on light reflectivity. CFP, FAF and NIR imaging are two dimensional, while 
optical coherence tomography (OCT) provides a cross-sectional image of the retina and thereby 
reveals the Z-axis. OCT distinguishes the retinal layers based on differences in light reflectivity. In 
particular anatomical changes and their relation to location can easily be identified using this non-
invasive technique.
Gaps of Knowledge
AMD is a chronic complex disease of a predominantly unknown etiology for which limited 
treatment options are available. In general, the late stages of the disease ultimately cause severe 
visual impairment provided that the patient lives long enough. Identification of new risk factors 
and in depth comprehension of interactions between risk factors may help elucidate the intricate 
pathogenesis of this disease. Current epidemiologic studies often do not allow valid extrapolation of 
findings, because they are too small or lack appropriate study designs to obtain conclusive results. 
They barely go beyond the study of single relationships. In order to expand current genetic and 
epidemiologic knowledge, large, well designed longitudinal studies, international collaborations 
using harmonized methodology and grading protocols, and applications of new imaging techniques 
are needed. Implementation of these strategies will help gain more homogeneous phenotypes and 
a plethora of risk factors for analysis. Improved risk profiling is likely to lead to better identification 
of high-risk groups, and may offer new leads for therapy. Validated prediction models can be used in 
the clinic for patient management. These gaps of knowledge and the inference that arises by filling 
them was the driving force behind this thesis.
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AIMS OF THIS THESIS
This thesis describes epidemiologic and genetic studies on AMD. The major goals of our studies were:
Chapter 2: to assess the frequency and impact of AMD in Europeans
Chapter 3: to evaluate the merit of new imaging techniques for diagnosis and risk assessment
Chapter 4: to identify new environmental risk factors for AMD
Chapter 5: to investigate genetic associations and gene-environment interactions in large study 
populations
Chapter 6: to assess the predictive value of risk factors associated with AMD
STUDY POPULATIONS ON WHICH THIS THESIS IS BASED
We have addressed these aims in various study populations. We joined efforts with study populations 
outside the Netherlands to enlarge the study population in order to improve statistical power for 
analysis, and enable risk calculations for relatively rare exposures in a relatively infrequent disease 
outcome (Late AMD occurs in ~1-2% of the elderly population). A short description of these studies 
and consortia is listed below.
The Rotterdam Study1 – a population-based study which started in 1990. The current study consists 
of three cohorts and includes almost 15,000 participants living in the suburb Ommoord, a district 
of Rotterdam, the Netherlands. The aim of this study is to identify risk factors in cardiovascular, 
endocrine, hepatic, neurological, ophthalmic, psychiatric and respiratory diseases in elderly people. 
(Chapter 2, 3 & 4)
BRAMD Study2 –a double blind randomized-controlled multicenter trial comparing the efficacy of 
intravitreal bevacizumab versus ranibizumab in persons diagnosed with exudative AMD. (Chapter 4)
Three Continent AMD Consortium3 – a consortium of three population-based studies representing 
three continents. The entire study population consists of almost 24,500 participants which are 
derived from the Beaver Dam Eye study, from Beaver Dam, Wisconsin, United States of America; the 
Blue Mountains Eye study from Sydney, Australia, and our own Rotterdam Study. Epidemiology of 
AMD is their main focus. (Chapter 5 & 6)
European Eye Epidemiology (E3) Consortium4 –a collaborative network of 41 studies across Europe, 
including the Rotterdam Study, providing ophthalmologic data on 170,000 European participants. 
The aim of this consortium is to increase understanding of eye diseases and vision loss in Europe. 
(Chapter 2)
AMD Gene Consortium5 – a worldwide collaborative study analyzing the genetics of AMD, involving 
18 studies (including the Rotterdam Study) with over 17,000 cases of late AMD and 60,000 controls. 
(Chapter 5)
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ABSTRACT
Purpose Age-related macular degeneration (AMD) is a frequent complex disorder in elderly of 
European ancestry. Risk profiles and treatment options have changed considerably over the years, 
which may have affected disease prevalence and outcome. We determined prevalence of early and 
late AMD in Europe from 1990-2013 using the European Eye Epidemiology (E3) consortium, and 
made projections for the future.
Design  Meta-analysis of prevalence data. 
Participants A total of 42080 individuals aged 40 years of age and older participating in fourteen 
population-based cohorts from ten countries in Europe.
Methods AMD was diagnosed on fundus photographs using the Rotterdam Classification. 
Prevalence of early and late AMD was calculated using random effects meta-analysis stratified for 
age, birth cohort, gender, geographic region, and time period of the study. Best-corrected visual 
acuity (BCVA) was compared between late AMD subtypes geographic atrophy (GA) and choroidal 
neovascularization (CNV). 
Main outcome measures Prevalence of early and late AMD, BCVA, and number of AMD cases.
Results Prevalence of early AMD increased from 3.5% (95% confidence interval [CI] 2.1-5.0) in those 
aged 55-59 years to 17.6 % (95% CI 13.6-21.5) in aged 85+ years; for late AMD these figures were 0.1% 
(95% CI 0.04 - 0.3) and 9.8% (95% CI 6.3-13.3) respectively. We observed a decreasing prevalence of 
early and late AMD after 2006, which became most prominent after age 70. Prevalences were similar 
for gender across all age groups except for late AMD in the oldest age category, and a trend was 
found showing a higher prevalence of CNV in Northern Europe. After 2006, fewer eyes and fewer 80+ 
year old subjects with CNV were visually impaired (p =0.016). Projections of AMD showed an almost 
doubling of affected persons despite a decreasing prevalence. By 2040, the number of individuals 
in Europe with early AMD will range between 14.9-21.5 million, and for late AMD between 3.9-4.8 
million. 
Conclusion We observed a decreasing prevalence of AMD and an improvement in visual acuity in 
CNV occurring over the past 2 decades in Europe. Healthier lifestyles and implementation of anti-
vascular endothelial growth factor treatment are the most likely explanations. Nevertheless, the 
numbers of affected subjects will increase considerably in the next two decades. AMD continues to 
remain a significant public health problem among Europeans.
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INTRODUCTION
Age-related macular degeneration (AMD) can cause irreversible blindness and is the leading cause 
of visual impairment in the elderly of European ancestry.1 Two stages are known for this disease: 
early AMD, which is characterized by drusen and pigmentary changes, and late AMD, which can be 
distinguished in two subtypes; geographic atrophy (GA) and choroidal neovascularization (CNV).2
Worldwide estimates approximated that 30 to 50 million people are affected by AMD3,4, and these 
numbers are expected to increase over time due to the aging population.1,5-9 Although multiple small 
studies have assessed the prevalence of AMD and its relation with visual decline at various places in 
Europe10-12, a clear overview for Europe as a whole is lacking13. Comprehensive epidemiologic figures 
on AMD in Europe would help proper planning for public health and eye care policy makers. 
Recent studies report a decrease in AMD associated blindness and visual impairment14,15, which are 
likely to be due to improved diagnostic procedures and hence earlier diagnosis, and the introduction 
of anti-vascular endothelial growth Factor (VEGF) therapy.14-16 Anti-VEGF therapy for CNV was 
introduced in 2004 and, since 2006, it has been widely used for clinical care in Europe.17,18 However, 
the impact of anti-VEGF therapy on general visual function of persons with AMD in Europe has not 
been sufficiently studied.1,16
In this study, we investigated the prevalence of both early and late AMD in Europe using summary 
data of cohort studies from the European Eye Epidemiology (E3) Consortium. We analyzed changes 
in prevalence over time, compared geographic regions and studied differences between men 
and women. Moreover, we analyzed the visual acuity of affected individuals before and after the 
introduction of anti-VEGF therapy and predicted the number of persons with AMD by 2040 in Europe. 
METHODS
Study population
Fourteen population-based cohort studies participating in the E3 consortium contributed to this 
analysis. This consortium consists of European studies with epidemiologic data on common eye 
disorders; a detailed description of the E3 consortium has been published elsewhere.16 For the 
current analysis, studies with gradable macular fundus photographs (n=42,080 participants) and 
participants aged 40 years and older provided summary data. Participants were recruited between 
1990 and 2013 from the following countries: Estonia, France, Germany, Greece, Italy, Northern Ireland, 
Norway, Netherlands, Spain and Portugal19,20, United Kingdom (Table 1).16 The composition of AMD 
in each cohort is shown in Figure 1 (available at www.aaojournal.org). The study was performed in 
accordance with the Declaration of Helsinki for research involving human subjects and the good 
epidemiological practice guideline.
Grading of age-related macular degeneration
Both eyes of each participant were graded and classified separately by experienced graders or 
clinicians and the most severe AMD grade of the worse eye was used for classification of the person. 
To harmonize classification of AMD, studies were graded or re-classified according to the Rotterdam 
Classification as previously described21 . Main outcomes of this study were early AMD (grade 2 or 
3 of the Rotterdam Classification) and late AMD (grade 4 of the Rotterdam Classification). Persons 
with late AMD were stratified in GA and CNV or MIXED (both GA and CNV present in one person, 
either both types in the same eye, or one type per eye), which is henceforth in this article referred to 
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as CNV. The Tromsø Eye Study, Thessaloniki Eye Study and European Prospective Investigation into 
Cancer and Nutrition (EPIC) study had fundus photograph grading that could not be converted to 
match the definition of early AMD of the Rotterdam Classification. Therefore, these three studies only 
participated in the Late AMD analysis.
Visual impairment
Visual acuity was measured for each eye separately as best corrected visual acuity (BCVA) in two 
categories; ≥0.3 and <0.3. When BCVA differed in the two eyes, visual acuity of the best eye was used 
to classify the person. Low vision and blindness were defined as visual acuity of <0.3 and further 
referred to as visually impaired.
Visual acuity was measured for each eye separately as best corrected visual acuity (BCVA) in two 
categories; ≥0.3 and <0.3. When BCVA differed in the two eyes, visual acuity of the best eye was used 
to classify the person. Low vision and blindness were defined as visual acuity of <0.3 and further 
referred to as visually impaired.  
Projection of AMD
The projection of AMD cases in Europe from 2013 to 2040 was calculated using the prevalence data 
for 5-year age categories obtained from the meta-analysis. Two different scenarios were used to 
calculate the projection. In the first scenario, it was assumed that the prevalence of both early and 
late AMD will remain stable until 2040. This scenario accounted for changes in population structure 
only. The second scenario followed the trend of decreasing prevalence based on data from the meta-
analysis of the E3 consortium regarding the period 2006-2013. We calculated the rate of decline, 
with 2013 as the starting point and 2040 as the end point, and made the assumption that the rate 
of decline was decelerating and zero at the end point. For each projected year, prevalences were 
calculated for every 5-year age group, for early AMD from 45 years of age and onwards and for late 
AMD 65 years and onwards. The projected prevalences were multiplied by the predicted European 
population estimates obtained from Eurostat for all 28 countries in Europe, and the sum of individuals 
from all age groups was calculated.22
Statistical analysis
The crude prevalence of early and late AMD were calculated per study for each 5-year age group. 
A random effects meta-analysis was performed by weighing the studies according to sample size, 
for early and late AMD separately for 5-year age groups and for people aged 70 years and older. In 
case of reported zero prevalence, the Haldane correction was used 23. In case of 100% prevalence, 
0.01 was subtracted to prevent exclusion from the analysis. This analysis was repeated, stratified for 
the midpoint year of the study recruitment period before and after the year 2006, for ten-year birth 
cohorts. Furthermore, it was repeated for gender, and for geographical area in Europe based on the 
United Nations Geoscheme.24 A chi-square test was used to compare time trends.
In addition, a meta-analysis was performed for eyes with visual impairment owing to late AMD, and per 
subtype of late AMD. Subsequently, the analysis was stratified for studies conducted before and after 
2006, for which the midpoint year of the study recruitment period was used. The number of visually 
impaired people was calculated before and after 2006. Meta-analysis was performed with Stata 
(StataCorp. 2013. Stata Statistical Software: Release 13, version 13.1. College Station, TX: StataCorp 
LP.) using metaprop. Graphical outputs were constructed with GraphPad Prism 7 (GraphPad Prism 
version 7.00 for Windows, GraphPad Software, La Jolla California USA, www.graphpad.com). 
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FIGURE 3 - Meta-analysis of Early (A) and Late (B) AMD in Europe per age category for the participating studies. 
Meta-analysis of the prevalence of Early (C) and Late (D) AMD before and after 2006
RESULTS
The total study population included in this analysis comprised of 42,080 individuals from 14 studies 
with a median age group of 65-69 years and a slight female predominance (55.8%). The prevalence of 
all age groups together varied per study between 2.3% and 16.8% for early AMD (total N= 2703) and 
between 0.2% and 5.6% for late AMD (total N= 664) (Figure 2A and B, available at www.aaojournal.org; 
to avoid biased estimates only groups larger than 30 individuals are shown; this applied only to the 
Rotterdam Study III age-category 85+). Owing to moderate to high heterogeneity (I2: >= 75% in 73 of 
141 analyses), which was not related to time trends, we applied a random effects model for the meta-
analysis. This provided a prevalence of early AMD increasing with age from 3.5% (95% confidence 
interval [CI] 2.1-5.0) at 55-59 years to 17.6% (95% CI 13.6-21.5) in persons aged 85+ years (Figure 3A, 
and Table 2, available at www.aaojournal.org). The prevalence of late AMD rose from virtually naught 
in the youngest age group to 9.8% (95% CI 6.3-13.3) for those in the highest age group (Figure 3B). 
Taking together all people aged 70+ years, the overall prevalence was 13.2% (95%CI 11.2-15.1) for 
early AMD, and 3.0% (95%CI 2.2-3.9) for late AMD. We investigated prevalence changes over time by 
splitting the E3 consortium into studies conducted before and after 2006. The prevalence of early 
AMD before and after 2006 seemed to rise similarly. For late AMD, a trend of decreasing prevalence 
was observed for the higher age categories after 2006 (Figure 3C and D). Even after exclusion of the 2 
cohorts (Rotterdam Study [RS]-II and European Eye Study [EUREYE]) with the highest prevalences in 
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the highest age category before 2006, results remained similar (data not shown). When we analyzed 
prevalence data as a function of birth cohort, a relatively stable prevalence of early AMD was visible 
across all birth cohorts, whereas a decreasing prevalence of late AMD was seen for the more recent 
birth cohorts (Figure 4A and B).
FIGURE 4 - Meta-analysis of Early (A) and Late (B) AMD in Europe by ten year birth cohort.
Gender and Geographic region
We studied the relation with gender and found no differences in the prevalence of early and late AMD 
between men and women except for the age category of 85 years and older for late AMD (Figure 
5A and B, available at www.aaojournal.org). This category shows a trend for a higher prevalence in 
women compared to men, although confidence intervals overlap. 
To address differential distribution of AMD in Europe, we stratified studies according to three regions 
defined by the United Nations24. In older individuals, we observed a trend towards a higher prevalence 
of early AMD in the North (16% in 70+ years; [95%CI 14-17]) compared to the West (12%; [95% CI 
10-14]) and South (14%; [95% CI 10-17]) (Figure 6A, available at www.aaojournal.org). Likewise, late 
AMD had the highest prevalence in the North (4.2% [95% CI 2-6]), compared to the West (3.1%; [95% 
CI 2-4]) and South (3.1%; [95%CI 2-4]) (Figure 6B, available at www.aaojournal.org). More detailed 
analyses showed that a frequency difference was only present for CNV (Figure 6C and D, available at 
www.aaojournal.org), however, confidence intervals of the regional differences overlapped.
Visual consequences 
As most countries implemented anti-VEGF therapy for CNV from 2006 onwards, we compared visual 
impairment from AMD in studies carried out before and after this year. Before 2006, 54.2% of eyes 
with GA were visually impaired, and 79.8% of eyes suffering from CNV were visually impaired. From 
2006 onwards, the proportion of visually impaired eyes remained the same for GA (47.6%, P = 0.40), 
but dropped to 66.2% (P = 0.026) for CNV (Figure 7A). This improvement was also observed for the 
number of bilaterally visually impaired persons; 120 out of 345 (34.8%) before 2006 to 75 out of 259 
(28.9%, P = 0.13) after 2006. The largest drop was seen for people aged 80 years and older; 85 out of 
175 (48.6%) before 2006 to 46 out of 132 (34.8%, P = 0.016) after 2006 (Figure 7B).
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FIGURE 7 - A) Proportion of visually impaired eyes within each subgroup of Late AMD. The proportion of visually 
impaired eyes remained the same for GA (47.6%, P = 0.40), but dropped to 66.2% (P = 0.026) for CNV after 2006. 
B) Proportion of persons with Late AMD with bilateral visual impairment before and after 2006 (P = 0.016).
* Corresponds with P < 0.05.
Projections of AMD in Europe for 2040
Assuming that the prevalence of early and late AMD will remain stable over time, an increase from 
15.0 million in 2013 to 21.5 million for early AMD can be expected by 2040. The number of people 
with late AMD will almost double during this time period; from 2.7 million in 2013 to 4.8 million in 
2040. 
Assuming a more realistic scenario for which E3 historic data and a decelerating slope were used, we 
found that the prevalence of early AMD will first decrease and then slightly increase between 2013 
and 2040. The model estimated that the number of people with early AMD would remain the same: 
from 15.0 million in 2013 to 14.9 in 2040. This model also displayed that the number of people with 
late AMD in Europe will increase from 2.7 million in 2013 to 3.9 by 2040 (Figure 8).
FIGURE 8 - Predicted number of persons with AMD in years 2013-2040 as a function of two prevalence scenarios
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DISCUSSION
AMD prevalence and its time trends
Our study provides insight in the prevalence of both early and late AMD in Europe. Based on meta-
analyzed data from fourteen population-based cohort studies included in the E3 consortium, the 
overall prevalence of early and late AMD was 13.2% and 3.0%, respectively, in the age-category 70+ 
years. These estimates are comparable to persons from European descent living in other continents.3,25 
Our data showed a trend towards a slightly decreasing prevalence of AMD in the older age categories. 
It is unlikely that this is explained by differential mortality in AMD patients before and after 2006, 
although studies have shown conflicting results on death as a competing risk factor for AMD, and we 
cannot exclude that this plays a role.26-28 The decreasing trend in time has also been observed in the 
Beaver Dam Eye study, indicating that these trends are not confined to Europe.29 Decreasing rates 
have also been observed for other aging disorders such as cardiovascular disease 30-33, and may to 
be related to improved lifestyle among the elderly34-36, for example, the number of smokers declined 
by 30.5% from 1990 to 2010 in Europe37. Taken together, the decline in prevalence suggests that the 
increases in the number of AMD patients may not be as substantial as previous prediction studies 
suggested.38
Gender and Geographic regions
Our data showed no difference in the prevalence of early and late AMD with respect to gender. In 
the oldest age category of 85 years and older, women seemed to have a higher prevalence of late 
AMD, but detailed analysis showed that this was mostly owing to imprecision of the estimate in men, 
caused by a lower number of men in this age group. (Figure 9, available at www.aaojournal.org). This 
has also been observed in other studies.7,39 
As for regional differences, we noticed that the Northern region of Europe showed a slightly higher 
prevalence of early and late AMD. This trend was the result of a higher prevalence of CNV AMD in the 
North. Our findings are in concordance with the results earlier published by the Tromsø Eye Study40, 
but contrast with other studies performed in the North of Europe finding a higher prevalence of GA 
(EUREYE, Reykjavik eye study and Oslo Macular Study).41-43 Considering the larger sample size and 
high response rate of the Tromsø Eye Study compared to the other studies, these findings might 
be more legitimate. No consistent differences were observed for West and South regions of Europe.
Visual consequences 
The proportion of eyes affected by CNV that were visually impaired was reduced after the year 
2006. Unfortunately, our study lacked actual data on interventions for CNV, but it is likely that the 
reduction is attributable to the use of anti-VEGF injections, which were introduced as a therapy for 
CNV in Europe from 2006 onwards.18 This notion is supported by findings from clinical trials44,45 and 
other studies, which show an up to 2-fold decrease in legal blindness due to AMD after 2006.14,15,46,47 
The public campaigns which were initiated after the introduction of anti-VEGF have undoubtedly 
contributed to the reduction of visual loss, as they made elderly more aware of the symptoms and 
stimulated prompt therapy.48,49 
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Projections of AMD in Europe
It is unclear whether the prevalence rates of AMD will decrease even more in the coming years, 
but an increase is not likely to be expected. Therefore, we performed projections of the estimated 
number of AMD affected persons until the year 2040 based on two different scenarios: one based 
on a stable prevalence and one following the trend of declining prevalences. The results of the first 
scenario suggests that the absolute number of persons with late AMD will increase by 2.1 million, a 
1.5 times increase. A Norwegian study predicted, under the assumption of a stable prevalence, the 
same relative increase of affected subjects, with a total of 328,000 cases of late AMD in Scandinavia 
by 2040.5,8 A study in the USA calculated a 2.2 times increase in absolute numbers and estimated a 
total number of affected subjects to be 3.8 million by 2050.5,8 Worldwide projections have shown a 
doubling of late AMD and an increase of 9 million cases by 2040.3 
The second scenario was based on declining rates, and showed a small increase in the number of 
people with Early AMD from 14 million in 2016 to 14.9 million by 2040, and a larger relative increase in 
the number of people with Late AMD, from 2.9 million in 2016 to 4.0 million by 2040. Considering the 
declining rates of smoking and implementation of healthier diets in elderly, the second projection 
may be more legitimate. 
Study Limitations
A limitation to this E3 consortium meta-analysis is the heterogeneity across studies regarding 
study design and inclusion criteria. For example, age at inclusion and method of recruitment 
varied between studies. Although in every study AMD was classified according to the Rotterdam 
Classification, studies differed in AMD grading, especially for pigmentary changes and drusen size. 
Given the heterogeneity, we therefore performed a random effects meta-analysis for both early and 
late AMD. Furthermore, patient management and access to healthcare may have differed between 
study sites, resulting in differences in preventative and treatment options.50,51 
When data collection started in 1990, fundus photography was the golden standard for grading 
AMD. Since 1990, imaging techniques evolved rapidly, greatly improving the diagnosis of AMD 
features with non-invasive techniques such as optical coherence tomography, auto-fluorescence 
and near-infrared photographs. In addition, multimodal imaging better visualizes edema and 
subtle changes resulting from CNV, which may not be so apparent when the patient was treated 
with anti-VEGF therapy.52,53 Although macular edema due to subretinal neovascularization often 
coincides with prominent retinal changes such as hemorrhages or hard exudates, our data may have 
underestimated the true prevalence of CNV.53 
In summary, this study estimates the prevalence of early and late AMD per age category in Europe 
over the past two decades. Prevalence of both these forms remained stable or showed a slight 
decrease. Nevertheless, we observed a significant reduction in the proportion of visually impaired 
eyes due to CNV after 2006. Unfortunately, due to the aging population, the number of people with 
AMD will increase during the next decades, indicating a continuous need to develop comprehensive 
modalities for prevention and treatment of AMD.
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ABSTRACT
Objective To study the frequency and causes of visual impairment in relation to refractive error.
Design Population-based cohort study
Participants: A total of 6,597 participants from Rotterdam Study I (baseline and 4 follow-up 
examinations) and of 2,579 participants from Rotterdam Study II (baseline and 2 follow-up 
examinations), all aged 55+ years, were included.
Methods Participants underwent an extensive ophthalmic examination including best-corrected 
visual acuity and objective refraction, fundus photography, visual field perimetry, and OCT imaging 
of macula and optic disc. We calculated cumulative risks and odds ratios of visual impairment for 
various refractive error categories, determined causes by using all screening information as well as 
medical records.
Main Outcome Measures Unilateral and bilateral low vision (WHO criteria: VA <0.3 and VA ≥0.05; US 
criteria: VA <0.5 and VA ≥0.1) and blindness (WHO criteria: VA <0.05; US criteria: VA<0.1).
Results Cumulative risks of visual impairment ranged from virtually 0 in all refractive error categories 
at age 55 to 9.5% (standard error (se) 0.01) for emmetropia, 15.3% (se 0.06) for high hyperopia to 
33.7% (se 0.08) for high myopia, at age 85. The major causes of visual impairment in highly hyperopic 
persons were age-related macular degeneration (AMD), cataract, and combined causes (each 25%); in 
highly myopic persons the major cause was myopic macular degeneration (38.9%). The major causes 
of visual impairment for the other refractive error categories were AMD and cataract. Compared to 
emmetropes, high myopes had a significantly increased risk of visual impairment; those with ≤-6 D 
& ≥-10 D had a risk of OR 3.4 (95% CI 1.4-8.2) of visual impairment; those with <-10 D had OR 22.0 
(95% CI 9.2-52.6).
Conclusion Of all refractive errors, high myopia has the most severe visual consequences. Irreversible 
macular pathology is the most common cause of visual impairment in this group.
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INTRODUCTION
Refractive errors - both myopia and hyperopia - are very common human eye disorders and leading 
causes of visual impairment worldwide.1-3 Myopia is characterized by an elongation of the eye, and is 
accompanied by structural changes of the retina and choroid.4 These changes can lead to potentially 
blinding complications such as myopic macular degeneration, open-angle glaucoma and retinal 
detachment.5,6 Although all myopic eyes are at risk for complications,4,7,8 highly myopic eyes, i.e., -6 
diopters (D) or worse, are particularly at risk to develop functional blindness at a relatively young 
age. Hyperopia (farsightedness), by contrast, is a condition in which the eye is shortened. For this 
refractive error category, the risks of visual impairment are less well studied, but it is known that 
persons with hyperopia have a higher risk of amblyopia, strabismus and closed-angle glaucoma.9 An 
association with age-related macular degeneration (AMD) has also been described.10
Although numerous studies have addressed population frequencies of low vision and blindness 
none have focused on visual loss as a function of the full spectrum of refractive errors. In addition, 
frequency of causes of blindness and low vision specified per refractive error category have not been 
described until now. Given the current rise in prevalence of this trait11-13, this information can be 
useful for clinicians, patients, and researchers, and will increase awareness of the visual consequences 
of refractive errors.
In this study, we investigated the frequency and causes of blindness and low vision stratified for 
various refractive error categories in 2 independent cohorts of the population-based prospective 
Rotterdam Study.
MATERIAL AND METHODS
Study population
The rationale and design of the Rotterdam Study have been described in detail elsewhere.14 In brief, 
this prospective population-based follow-up study focuses on chronic ophthalmologic, neurologic, 
cardiovascular, and locomotor diseases in middle aged and elderly participants living in Ommoord, 
a city district of Rotterdam, the Netherlands. Baseline data for the ophthalmic part were collected 
between 1991 and 2002 and follow-up examinations were performed at 2-4 years (Figure 1). A 
total of 99% of study participants were from European descent. For this analysis, we included 9,176 
participants from two independent cohorts of the Rotterdam Study. The first is Rotterdam Study I 
(RS-I): 6,597 participants aged 55 years and older. Baseline examinations took place between 1990 
and 1993, and four follow-up examinations were performed in 1993-1995, 1997-1999, 2002-2004, 
and 2009-2011 (Figure 1). The second cohort is Rotterdam Study II (RS-II), which included 2,579 
participants aged 55 years and older. Baseline examinations took place in between 2000 and 2002, 
and two follow-up examinations were performed in 2004-2005 and 2011-2012 (Figure 1). Persons 
with bilateral pseudophakia or aphakia at baseline with no knowledge of prior refractive error were 
excluded (n = 278). From these two cohorts, 9,176 participants with data on refractive error and 
visual acuity at baseline were eligible for the current analysis. The Medical Ethics Committee of the 
Erasmus University had approved the study protocols, and participants had given a written informed 
consent in accordance with the Declaration of Helsinki.
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FIGURE 1 - Participation and ophthalmological measurement from each examination interval of the Rotterdam 
Study
Abbreviations: RS = Rotterdam Study
Ophthalmic data collection
All patients underwent an extensive ophthalmological examination. Visual acuity was measured 
using the Lighthouse Distance Visual Acuity Test, a modified Early Treatment Diabetic Retinopathy 
Study chart.15 To evaluate the best-corrected visual acuity (BCVA), refraction was initially obtained 
after objective autorefraction (Topcon RM-A2000, Topcon Optical Company, Tokyo, Japan), and then 
subjectively adjusted. Screening of visual fields was performed using a modified 76-point supra-
threshold perimetry test (Humprey Visual Field Analyzer, Zeiss, Oberkochen, Germany); visual field 
defects were confirmed by Goldmann perimetry. After pupil dilation, optic nerve head and macular 
area imaging was performed using simultaneous stereoscopic photography (Topcon TRC-SS2, 
Topcon optical Company, Tokyo, Japan), followed by a 35° film fundus camera (Topcon TRV-50VT, 
Topcon Optical Company, Tokyo, Japan). During the last examination rounds, RSI-4, RSI-5 and RSII-2 
respectively, a Topcon digital 35° colour fundus camera (Topcon TRC 50EX with a Sony DXC-950P 
digital camera; 0.44 megapixel) was used.
Low vision and blindness were classified according to the WHO criteria16 and US criteria:
Low Vision: WHO: VA < 0.3 and ≥ 0.05; US: VA < 0.5 and ≥ 0.1
Blindness: WHO: VA < 0.05; US: VA < 0.1
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For participants with bilateral blindness and low vision, three clinical investigators (C.C.W.K, V.J.M.V., 
and K.T.W.) reached consensus on the final determination of the cause of visual impairment after 
reviewing all screening information, fundus transparencies, and medical information provided by 
ophthalmologists.
Statistical analysis
Mean spherical equivalent (SE) was calculated according to the standard formula (SE=spherical value 
+ ½*cylinder). When data from only one eye were available, the SE of this eye was used. Mean SE was 
categorized into high myopia (≤ -6 diopters (D)), moderate myopia (>-6D & ≤-3D), low myopia (<-3D 
& ≤-0.75D), emmetropia (>-0.75D & <0.75D), low hyperopia (≥0.75D & <3D), medium hyperopia (≥ 
3D & <6D), and high hyperopia (≥ 6D), using previously defined criteria.17 High myopia and high 
hyperopia were further classified as high myopia <-10 D and ≤-6 D & ≥-10 D and high hyperopia 
>10 D and ≥6 & ≤10 D. Visual acuity at last visit was categorized into normal vision, low vision, and 
blindness according to WHO and US criteria as defined above. For bilateral visual impairment, BCVA 
was used. Unilateral visual impairment was defined as visual impairment in only one eye.
We calculated the number of cases with bilateral and unilateral blindness and low vision as a 
percentage of the total number of all cases with blindness and low vision at the endpoint of the 
study per refractive error category.
Cumulative risks of bilateral visual impairment were estimated per refractive error category using 
Kaplan Meier product limit analysis. We assigned the age at diagnosis of blindness or low vision 
as the mean between the examination at which this endpoint was first observed and the previous 
examination. For participants who did not develop the endpoint, we used age at last examination 
for censoring. Participants who died or were lost to follow-up were counted at the time of the last 
examination. All participants aged 85+ years were censored at age 85 years to maintain unbiased 
estimates. Cumulative risks per refractive error category were compared with the log-rank test of 
equality (Mantel-Cox) using emmetropia as the reference group.
Causes of bilateral blindness and low vision (according to the WHO criteria) were categorized, and 
frequencies of causes were calculated per refractive error category. We calculated mean age at 
diagnosis of bilateral visual impairment per refractive error category, and calculated mean spherical 
equivalent per refractive error category, stratified by normal vision, low vision and blindness. 
Statistical differences at nominal P-value <0.05 between refractive error categories for age at 
diagnosis and between visual acuity categories for mean SE were calculated using Student’s T test. 
The risk of blindness and low vision (reference normal vision) for persons with various refractive error 
categories (reference emmetropia) was assessed using logistic regression analysis with blindness 
and low vision as a combined outcome, correcting for age and sex. We used SPSS version 20.0.0 (SPSS 
Inc.) for all analyses.
RESULTS
General characteristics of the 9,176 study participants are presented in Table 1. At baseline, we 
identified 98 prevalent cases (1.1%) with bilateral low vision and 29 cases (0.3%) with bilateral 
blindness (WHO criteria). After a mean follow-up time of 9.6±6.1 years, respectively 62 and 26 persons 
developed incident bilateral low vision and blindness. Subjects in RS-I were generally younger (mean 
age at inclusion 69.0 versus 64.1 years) and were less myopic (mean SE 0.84 vs. 0.47 D) than those in 
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RS-II, due to a cohort effect described in our previous work.17 The characteristics of all cases who had 
received a diagnosis of bilateral low vision or blindness by the end of the study can be found in Table 
2 (WHO-criteria) and Table 3 (US-criteria; available at http://aaojournal.org).
The distribution of bilateral and unilateral blindness and low vision (WHO criteria) per refractive error 
category is shown in Figure 2. The high myopia group showed the highest percentage of bilateral 
blindness (9.6%) and low vision (25.0%). Persons from the high hyperopia group had the highest 
proportion of unilateral blind eyes (39.1%).
TABLE 1 - Characteristics of the study population
  Rotterdam Study I Rotterdam Study II Total
N at baseline 6597 2579 9176
Follow-up time, mean ± sd (yrs) 9.8 ± 6.0 8.9 ± 2.9 9.6 ± 6.1
Baseline age, mean ± sd (yrs) 69.0 ± 9.0 64.1 ± 7.4 67.6 ± 8.8
Sex, % men 41.0 45.0 42.0
Visual acuity at last measurement - WHO criteria
Bilaterally visually impaired subjects 2.2 0.5 1.7
Bilaterally blind subjects 0.8 0.1 0.6
Unilaterally visually impaired subjects 6.1 3.8 5.5
Unilaterally blind subjects 3.4 2.1 3.0
Visual acuity at last measurement - US criteria
Bilaterally visually impaired subjects 6.6 1.8 5.2
Bilaterally blind subjects 1.1 0.1 0.8
Unilaterally visually impaired subjects 12.5 4.8 10.3
Unilaterally blind subjects 3.4 2.2 3.1
Refractive error
Spherical equivalent, mean ± sd (D) 0.84 ± 2.54 0.47 ± 2.49 0.74 ± 2.53
High myopia ≤-6D 1.8 1.8 1.8
Medium myopia >-6D & ≤-3D 5.2 7.3 5.8
Low myopia -3D & ≤-0.75D 9.5 12.8 10.4
Emmetropia >-0.75D & <0.75D 25.4 26.9 25.8
Low hyperopia ≥0.75D & <3D 44.4 41.1 43.4
Medium hyperopia ≥3D & <6D 12.3 9.2 11.4
High hyperopia ≥6D 1.5 1.0 1.3
Numbers displayed are percentages, unless stated otherwise.
Abbreviations:; D = diopters, sd = standard deviation, WHO = World Health Organization
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TABLE 2 - Characteristics of subjects with bilateral blindness, low vision and normal vision (WHO criteria)
 
 
Bilaterally blind 
subjects
Bilaterally visually 
impaired subjects
Subjects with bilateral 
visual acuity ≥ 0.3
N = 55 N = 160 N = 8961
Age of onset, mean ± sd (yrs) 78.1 ± 11.3 79.7 ± 10.1 -
Range age of onset 55.4-96.3 56.4-106.2 -
Sex, % men 31.0 53.0 51.0
Spherical equivalent, mean ± sd (D) -0.05 ± 5.78 0.09 ± 4.03 0.75 ± 2.45
Range spherical equivalent -19.13; 12.25 -15.31; 8.50 -19.13; 15.13
High myopia ≤-6D, % 9.1 8.1 1.7
Moderate myopia >-6D & ≤-3D, % 5.5 7.5 5.7
Low myopia -3D & ≤-0.75D, % 10.9 10.6 10.4
Emmetropia >-0.75D & <0.75D, % 16.4 19.4 26.0
Low hyperopia ≥0.75D & <3D, % 38.2 38.1 43.6
Moderate hyperopia ≥3D & <6D,% 12.7 13.8 11.4
High hyperopia ≥6D, % 7.3 2.5 1.3
Abbreviations: D = diopters, sd = standard deviation;
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FIGURE 2 - Bar graph showing the distribution of bilateral and unilateral blindness and low vision (World Health 
Organization criteria) per refractive error category. The number of cases with bilateral and unilateral blindness 
and low vision is shown as a percentage of the total number of prevalent and incident cases with blindness and 
low vision per refractive error category. For data of visual impairment as a percentage of the entire population, 
see Table 1.
Abbreviations: D = diopters.
Kaplan Meier curves showing cumulative risk of visual impairment for high myopia, emmetropia 
and high hyperopia appear in Figure 3. Cumulative risks ranged from virtually 0 in all refractive 
error categories at age 55 to 9.5% (standard error (se) 0.01) for emmetropia, 15.3% (se 0.06) for high 
hyperopia to 33.7% (se 0.08) for high myopia, at age 85. Risks for high myopia started to increase 
gradually before age 60; for high hyperopia between 60 and 70 years of age, whereas emmetropia 
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showed a more steady increase in risk from the age of 70. Cumulative risks for persons with low 
to moderate myopia and hyperopia were not significantly different from persons with emmetropia 
(P 0.09; P 0.78). Kaplan Meier curves for US criteria can be found in Figure 4 (available at http://
aaojournal.org). Cumulative risks ranged from virtually 0 in all refractive error categories at age 55 to 
28.9% (standard error (se) 0.03) for emmetropia, 41.5% (se 0.08) for high hyperopia to 59.2% (se 0.08) 
for high myopia, at age 85.
FIGURE 3 - Cumulative risk of bilateral visual impairment (WHO criteria) stratified for high myopia, emmetropia 
and high hyperopia. The X-axis represents the age at diagnosis for all cases with blindness or low vision at the 
end point of the study and age at last examination for non-cases; the Y-axis represents the cumulative risk for 
persons with visual impairment. The number of persons at risk at each decade per refractive error category is 
presented below.
Abbreviations: D = Diopters.
The causes of bilateral visual impairment according to WHO criteria are provided in Figure 5. For 
persons with emmetropia, low to moderate myopia, and low to moderate hyperopia, AMD was the 
major cause of visual impairment. The most important cause of visual impairment in high myopic 
persons was myopic macular degeneration (38.9%), followed by combined mechanisms (33.3, 
including myopic macular degeneration, cataract, and maculopathy) and cataract (16.7%). In highly 
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hyperopic persons, the major causes of visual impairment were AMD (25%), cataract (25.0%), and 
combined causes (25%, including amblyopia, corneal dystrophy, cataract, maculopathy, age-related 
macular degeneration).
Ϭ͘Ϭ ϭϬ͘Ϭ ϮϬ͘Ϭ ϯϬ͘Ϭ ϰϬ͘Ϭ ϱϬ͘Ϭ ϲϬ͘Ϭ ϳϬ͘Ϭ ϴϬ͘Ϭ ϵϬ͘Ϭ ϭϬϬ͘Ϭ
ĐŽŵďŝŶĞĚŵĞĐŚĂŶŝƐŵƐ
ƵŶŬŶŽǁŶ
ƌĂƌĞĐĂƵƐĞƐ
ĂƋƵŝƌĞĚ
ĂŵďůǇŽƉŝĂ
ĐŽƌŶĞĂůĚǇƐƚƌŽƉŚǇ
ĐĂƚĂƌĂĐƚ
ŽƉƚŝĐŽŶĞƵƌŽƉĂƚŚǇ
ƉƌŝŵĂƌǇŽƉĞŶͲĂŶŐůĞŐůĂƵĐŽŵĂ
ǀĂƐĐƵůĂƌ
ƌĞƚŝŶĂůĚĞƚĂĐŚŵĞŶƚ
ĚŝĂďĞƚŝĐƌĞƚŝŶŽƉĂƚŚǇ
ŵĂĐƵůŽƉĂƚŚǇ
ŵǇŽƉŝĐŵĂĐƵůĂƌĚĞŐĞŶĞƌĂƚŝŽŶ
ĂŐĞͲƌĞůĂƚĞĚŵĂĐƵůĂƌĚĞŐĞŶĞƌĂƚŝŽŶ ,ŝŐŚŵǇŽƉŝĂчͲϲ
Ŷсϭϴ
ĂƵƐĞŽĨǀŝƐƵĂůŝŵƉĂŝƌŵĞŶƚ
ŽŵďŝŶĞĚĐĂƵƐĞƐŽĨǀŝƐƵĂůŝŵƉĂŝƌŵĞŶƚ
Ϭ͘Ϭ ϭϬ͘Ϭ ϮϬ͘Ϭ ϯϬ͘Ϭ ϰϬ͘Ϭ ϱϬ͘Ϭ ϲϬ͘Ϭ ϳϬ͘Ϭ ϴϬ͘Ϭ ϵϬ͘Ϭ ϭϬϬ͘Ϭ
ĐŽŵďŝŶĞĚŵĞĐŚĂŶŝƐŵƐ
ƵŶŬŶŽǁŶ
ƌĂƌĞĐĂƵƐĞƐ
ĂƋƵŝƌĞĚ
ĂŵďůǇŽƉŝĂ
ĐŽƌŶĞĂůĚǇƐƚƌŽƉŚǇ
ĐĂƚĂƌĂĐƚ
ŽƉƚŝĐŽŶĞƵƌŽƉĂƚŚǇ
ƉƌŝŵĂƌǇŽƉĞŶͲĂŶŐůĞŐůĂƵĐŽŵĂ
ǀĂƐĐƵůĂƌ
ƌĞƚŝŶĂůĚĞƚĂĐŚŵĞŶƚ
ĚŝĂďĞƚŝĐƌĞƚŝŶŽƉĂƚŚǇ
ŵĂĐƵůŽƉĂƚŚǇ
ŵǇŽƉŝĐŵĂĐƵůĂƌĚĞŐĞŶĞƌĂƚŝŽŶ
ĂŐĞͲƌĞůĂƚĞĚŵĂĐƵůĂƌĚĞŐĞŶĞƌĂƚŝŽŶ >ŽǁΘŵŽĚĞƌĂƚĞŵǇŽƉŝĂхͲϬ͘ϳϱΘчͲϯ
Ŷсϯϴ
ĂƵƐĞŽĨǀŝƐƵĂůŝŵƉĂŝƌŵĞŶƚ
ŽŵďŝŶĞĚĐĂƵƐĞƐŽĨǀŝƐƵĂůŝŵƉĂŝƌŵĞŶƚ
Ϭ͘Ϭ ϭϬ͘Ϭ ϮϬ͘Ϭ ϯϬ͘Ϭ ϰϬ͘Ϭ ϱϬ͘Ϭ ϲϬ͘Ϭ ϳϬ͘Ϭ ϴϬ͘Ϭ ϵϬ͘Ϭ ϭϬϬ͘Ϭ
ĐŽŵďŝŶĞĚŵĞĐŚĂŶŝƐŵƐ
ƵŶŬŶŽǁŶ
ƌĂƌĞĐĂƵƐĞƐ
ĂƋƵŝƌĞĚ
ĂŵďůǇŽƉŝĂ
ĐŽƌŶĞĂůĚǇƐƚƌŽƉŚǇ
ĐĂƚĂƌĂĐƚ
ŽƉƚŝĐŽŶĞƵƌŽƉĂƚŚǇ
ƉƌŝŵĂƌǇŽƉĞŶͲĂŶŐůĞŐůĂƵĐŽŵĂ
ǀĂƐĐƵůĂƌ
ƌĞƚŝŶĂůĚĞƚĂĐŚŵĞŶƚ
ĚŝĂďĞƚŝĐƌĞƚŝŶŽƉĂƚŚǇ
ŵĂĐƵůŽƉĂƚŚǇ
ŵǇŽƉŝĐŵĂĐƵůĂƌĚĞŐĞŶĞƌĂƚŝŽŶ
ĂŐĞͲƌĞůĂƚĞĚŵĂĐƵůĂƌĚĞŐĞŶĞƌĂƚŝŽŶ ŵŵĞƚƌŽƉŝĂхͲϬ͘ϳϱΘфϬ͘ϳϱ
ŶсϰϬ
ĂƵƐĞŽĨǀŝƐƵĂůŝŵƉĂŝƌŵĞŶƚ
ŽŵďŝŶĞĚĐĂƵƐĞƐŽĨǀŝƐƵĂůŝŵƉĂŝƌŵĞŶƚ
C
B
A
44 Chapter 2.2
Ϭ͘Ϭ ϭϬ͘Ϭ ϮϬ͘Ϭ ϯϬ͘Ϭ ϰϬ͘Ϭ ϱϬ͘Ϭ ϲϬ͘Ϭ ϳϬ͘Ϭ ϴϬ͘Ϭ ϵϬ͘Ϭ ϭϬϬ͘Ϭ
ĐŽŵďŝŶĞĚŵĞĐŚĂŶŝƐŵƐ
ƵŶŬŶŽǁŶ
ƌĂƌĞĐĂƵƐĞƐ
ĂƋƵŝƌĞĚ
ĂŵďůǇŽƉŝĂ
ĐŽƌŶĞĂůĚǇƐƚƌŽƉŚǇ
ĐĂƚĂƌĂĐƚ
ŽƉƚŝĐŽŶĞƵƌŽƉĂƚŚǇ
ƉƌŝŵĂƌǇŽƉĞŶͲĂŶŐůĞŐůĂƵĐŽŵĂ
ǀĂƐĐƵůĂƌ
ƌĞƚŝŶĂůĚĞƚĂĐŚŵĞŶƚ
ĚŝĂďĞƚŝĐƌĞƚŝŶŽƉĂƚŚǇ
ŵĂĐƵůŽƉĂƚŚǇ
ŵǇŽƉŝĐŵĂĐƵůĂƌĚĞŐĞŶĞƌĂƚŝŽŶ
ĂŐĞͲƌĞůĂƚĞĚŵĂĐƵůĂƌĚĞŐĞŶĞƌĂƚŝŽŶ >ŽǁΘŵŽĚĞƌĂƚĞŚǇƉĞƌŽƉŝĂшϬ͘ϳϱΘфϯ
Ŷсϭϭϭ
ĂƵƐĞŽĨǀŝƐƵĂůŝŵƉĂŝƌŵĞŶƚ
ŽŵďŝŶĞĚĐĂƵƐĞƐŽĨǀŝƐƵĂůŝŵƉĂŝƌŵĞŶƚ
Ϭ͘Ϭ ϭϬ͘Ϭ ϮϬ͘Ϭ ϯϬ͘Ϭ ϰϬ͘Ϭ ϱϬ͘Ϭ ϲϬ͘Ϭ ϳϬ͘Ϭ ϴϬ͘Ϭ ϵϬ͘Ϭ ϭϬϬ͘Ϭ
ĐŽŵďŝŶĞĚŵĞĐŚĂŶŝƐŵƐ
ƵŶŬŶŽǁŶ
ƌĂƌĞĐĂƵƐĞƐ
ĂƋƵŝƌĞĚ
ĂŵďůǇŽƉŝĂ
ĐŽƌŶĞĂůĚǇƐƚƌŽƉŚǇ
ĐĂƚĂƌĂĐƚ
ŽƉƚŝĐŽŶĞƵƌŽƉĂƚŚǇ
ƉƌŝŵĂƌǇŽƉĞŶͲĂŶŐůĞŐůĂƵĐŽŵĂ
ǀĂƐĐƵůĂƌ
ƌĞƚŝŶĂůĚĞƚĂĐŚŵĞŶƚ
ĚŝĂďĞƚŝĐƌĞƚŝŶŽƉĂƚŚǇ
ŵĂĐƵůŽƉĂƚŚǇ
ŵǇŽƉŝĐŵĂĐƵůĂƌĚĞŐĞŶĞƌĂƚŝŽŶ
ĂŐĞͲƌĞůĂƚĞĚŵĂĐƵůĂƌĚĞŐĞŶĞƌĂƚŝŽŶ ,ŝŐŚŚǇƉĞƌŽƉŝĂшϲ
Ŷсϴ
ĂƵƐĞŽĨǀŝƐƵĂůŝŵƉĂŝƌŵĞŶƚ
ŽŵďŝŶĞĚĐĂƵƐĞƐŽĨǀŝƐƵĂůŝŵƉĂŝƌŵĞŶƚ
FIGURE 5 - Causes of bilateral low vision and blindness (WHO criteria) stratified by refractive error category. The 
X-axis represents the percentage of visual impairment explained by the different causes mentioned on the 
Y-axis stratified by subjects with high myopia (A), low & moderate myopia (B), emmetropia (C), low & moderate 
hyperopia (D) and high hyperopia (E).
Abbreviations: D = diopters, NA = not applicable, WHO = World health organization.
The age at diagnosis of visual impairment for persons with high myopia (75.4±13.7 yrs) and 
high hyperopia (75.4±10.0 yrs) was slightly, albeit non significantly, lower than for persons with 
emmetropia (80.3±11.0 yrs; P =0.152; and P = 0.250, respectively).
Boxplots of the SE distribution among visually impaired participants with high myopia and high 
hyperopia are provided in Figure 6. Among the high myopes, persons with bilateral blindness (SE=-
15.25 ± 5.23 D; P = 0.034) and low vision (SE=-10.91 ± 2.57 D, P = 0.0036) had a significantly lower 
SE (i.e. more myopia)than persons with normal vision (SE=-8.25 ± 2.59 D). In the other refractive 
error groups, no statistical SE differences were found between the visual acuity categories (data not 
shown). The risk of blindness or low vision for high myopes versus emmetropes was OR 3.4 (95% CI 
1.4-8.2, P<0.001) for those with SE ≤-6 D & ≥-10 D, and OR 22.0 (95% CI 9.2-52.6, P 0.01) for those with 
SE <-10 D (Figure 7).
E
D
45Visual consequences of refractive errors
2
FIGURE 6 - Distribution of spherical equivalent in relation to bilateral visual impairment (WHO criteria) in 
participants with high myopia (A) and high hyperopia (B). Boxplots for the distribution of spherical equivalent 
stratified by bilateral blindness, bilateral low vision and normal vision (based on WHO criteria) for all subjects 
with high myopia SE ≤-6D (A) and high hyperopia ≥ 6 D (B).
Abbreviations: D= diopters, NS = not significant, WHO= World Health Organisation
A
B
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FIGURE 7 - Risk of bilateral blindness and low vision (WHO criteria) for high myopes. Odds ratios with 95% 
confidence intervals for blindness and low vision (reference normal vision) for persons with high myopia with 
SE ≤-6 D & ≥-10 D or SE <-10 D (reference emmetropia) are shown.
Abbreviations: CI = Confidence Interval, D = Diopters, OR = Odds Ratio, R = reference, WHO = World Health Organisation;
*, statistically significant OR (P < 0.05) compared to the reference group
DISCUSSION
In this population-based longitudinal study, we found that persons with high myopia (SE≤-6D) 
and high hyperopia (SE≥6D) are at a considerable risk of visual impairment. Blindness or low vision 
occurred in one third of high myopes, mainly caused by myopic macular degeneration. The blind and 
visually impaired persons within this group had a higher degree of myopia than the ones with normal 
vision; the risk of visual impairment was 22x increased for those with refractive errors of -10 D or 
more when compared to emmetropes, but also 6x higher than those with refractive errors between 
-6 and -10 D. The onset of visual impairment appeared to occur at a younger age; cumulative risks 
of visual impairment rose at least 10 years earlier for high myopia (before the age of 60) than for 
emmetropia (from the age of 70). For high hyperopia, we found that 15% of the persons were visually 
impaired. Causes of visual impairment for this refractive error showed more variation, and included 
cataract, AMD, and combined mechanisms.
This is the first report on refractive error specific risks and causes of blindness and low vision. 
Strengths of this study are the investigation of the full spectrum of refractive errors, the large sample 
size, and the lengthy follow-up time. In addition, our ophthalmic examination was extensive, which 
enabled an accurate determination of the cause of visual impairment. Our study also had limitations. 
Despite the large sample size, subgroup numbers were relatively small, jeopardizing precision of 
the risk estimates. Also, we focused on causes of visual impairment in persons with bilateral low 
vision, and did not study those with unilateral visual impairment. Therefore, we may have missed 
refractive error specific causes of visual impairment that are more likely to occur unilaterally, such 
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as rhegmatogenous retinal detachment18, and closed-angle glaucoma19 in (high) myopes and 
amblyopia in (high) hyperopes. Lastly, selective non-participation of disabled persons may have 
caused an underestimation of the frequencies of blindness and visual impairment.
Our findings are in line with results from previous studies that showed a highly increased risk for high 
myopes (SE≤-6D).8,20 Except for one person with moderate myopia, all persons with myopic macular 
degeneration were highly myopic. Those with extreme refractive error values of ≥ -10 D had the 
highest risk of visual impairment. We could not confirm the previously described mildly increased 
risk of visual impairment for persons with low to moderate myopia.8,20
Myopia is a growing public health problem since the prevalence is rapidly increasing, particularly 
in East Asia.11-13 With time, this trend is predicted to occur in other regions as well, and the increase 
in myopia and high myopia prevalence will result in a higher frequency of complications. Atropine 
eyedrops can currently be used as a therapy in children to slow the progression of myopia and 
decrease the final adult value of myopic refractive error.21 Our data underscore the objective of this 
therapy, because realisation of a lower refractive error will lower the risk of visual impairment later 
in life.22
It was previously shown that clinically significant pathological changes can be noted in highly myopic 
patients who are middle-aged or even younger.23,24 Our mean age at diagnosis of visual impairment 
is likely to be overestimated, since we included persons over age 55 years with visual impairment at 
baseline; baseline age was 69 years for RS-I and 64.1 years for RS-II. We did not have information on 
the actual age of onset of visual impairment occurring before this age.
The frequency of visual impairment in the high hyperopia group was relatively high. The number of 
cases with blindness or low vision in this group was very small (n = 8). Also, the proportion of high 
hyperopes in our older study sample was quite large, so these data are not necessarily applicable to 
the general population. Previous research has mainly focused on high myopia rather than on high 
hyperopia, but our results at least show that high hyperopia should be subject to further studies as 
well. Cataract was an important cause of visual impairment in all refractive error categories. This may 
be an overestimation of the current situation, since the majority of the data had been collected in 
the 1990’s, and since then cataract surgery has become a more easily accessible and safer procedure. 
Several studies showed an increased incidence of nuclear cataract and subcapsular posterior cataract 
in high myopes.25 We considered whether the exclusion of pseudophakic and aphakic persons might 
have introduced a selection bias and an underestimation of the risks of visual impairment in high 
myopic persons in our study. This does not seem to be the case, since only 2 out of 287 excluded 
participants (0.7%) with pseudophakia or aphakia were blind or visually impaired due to myopic 
macular degeneration diagnosed on the fundus photograph.
In summary, our data indicate that risks and causes of visual impairment vary with refractive error. 
The risks for high myopes are by far the highest with more than 1 in 3 persons with high myopia 
developing bilateral blindness or low vision. This large health risk requires public awareness and a 
focus to initiate strategies to reduce this burden in those at risk of myopia.
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ABSTRACT
Purpose Reticular pseudodrusen (RPD) are considered to be a distinct feature in age-related macular 
degeneration (AMD). Population studies have studied the epidemiology of RPD using standard color 
fundus photographs (CFP). However, recent studies have shown that RPD are better imaged using 
near-infrared (NIR) imaging. We studied the epidemiology of RPD in a large population-based study 
using NIR and CFP.
Methods Participants aged 65+ years from the Rotterdam Study underwent ophthalmological 
examination including NIR and CFP. Both images were graded for the presence of RPD and soft 
indistinct drusen (SID). Associations with demographic and environmental factors, 26 genetic 
variants, and total genetic risk score were analyzed using logistic regression analysis.
Results RPD were detected in 137 (4.9%) of 2,774 study participants; of these, 92.7% were detected 
with NIR imaging and 38% on CFP. The majority of eyes with RPD showed presence of SID, while 
other drusen types coincided less frequently. RPD were significantly associated with age (Odds 
Ratio (OR) 1.21 (95% Confidence Interval (CI) 1.17-1.24)) and female sex (OR 2.10 (95% CI 1.41-3.13)). 
Environmental factors did not show a significant association with RPD. Major AMD risk variants were 
significantly associated with RPD and SID, however, ARMS2, C3 and VEGFA were more associated with 
RPD (RPD vs SID P<0.05). Total genetic risk score did not differ significantly (P=0.88).
Conclusion Detection of RPD was better with NIR imaging than on CFP in a population-based 
setting. Presence of RPD often coincided with presence of SID, however, they showed quantitative 
differences in genetic risk profile.
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INTRODUCTION
Reticular pseudodrusen (RPD), also known as subretinal drusenoid deposits (SDD), are depositions 
located in the subretinal space between the outer segments of the photoreceptors and the retinal 
pigment epithelium (RPE).1-3 RPD carry a much higher risk of developing end-stage AMD than other 
AMD lesions, such as soft indistinct drusen (SID).4-7 RPD have first been described in 1990 and it was 
already then pointed out that RPD are better visualized using blue reflectance photography than 
regular color fundus photographs (CFP).8 RPD can also be detected using other imaging modalities. 
A comparative study between various image modalities showed that near-infrared imaging is one of 
the image modalities that has the highest sensitivity for RPD detection9, and that sensitivity of RPD 
detected only on CFP can be as low as 36%.10
Several risk factors have been identified for RPD, which include age, smoking, higher body mass 
index, female predominance, and genetic risk factors including CFH(Y402H) and ARMS2(A69S).4,6,7,11-13 
Previous studies have shown that RPD were present in 60-90% of patients with late AMD.14-16 Boddu 
et al. studied risk profiles of RPD versus large soft drusen in a small clinic-based study.13 These 
researchers could not find many significant differences between these patient groups, however, 
individuals with RPD were older and more often female.
Since the population-based studies on RPD have based their grading solely on CFP, and the clinic-
based studies were carried out only in small groups, risk estimates are likely to be imprecise.11 
Improved detection of RPD in a large population-based study may provide more accurate prevalence 
figures, and could enhance risk profiling for RPD.
In this study, we aimed to investigate the epidemiology of RPD using CFP and NIR images and 
compare this with SID in a large, unselected population. We have chosen to use the term RPD instead 
of SDD, since this is more commonly used in clinical-based papers. However, where RPD is written 
SDD can be read.
METHODS
Study population
The Rotterdam Study is a prospective population-based cohort study that focuses on chronic 
ophthalmologic neurologic, cardiovascular, and locomotor diseases in middle aged and elderly 
subjects living in Ommoord, a suburb of Rotterdam. The aims and design of the Rotterdam study 
have been described elaborately elsewhere.17 In brief, the study started in 1989 and since then 
every 2-4 years follow-up examinations were performed. During these follow-up examinations new 
techniques and devices were implied, such as the Heidelberg Retina Angiograph 2, a scanning laser 
ophthalmoscope (SLO). The Rotterdam Study has been approved by the Medical Ethics Committee of 
the Erasmus MC and by the Ministry of Health, Welfare and Sport of the Netherlands, implementing 
the “Wet Bevolkingsonderzoek: ERGO (Population Studies Act: Rotterdam Study)”. All participants 
provided written informed consent to participate in the study and to obtain information from their 
treating physicians.
For the current cross-sectional analysis, we included 3,108 participants from the last examination 
round from two independent cohorts of the Rotterdam Study; 1,542 participants from the Rotterdam 
Study I (RS-I), aged 70 years and older and 1,566 participants from the Rotterdam Study II (RS-II), aged 
65 years and older. Participants were excluded from the analyses if they had ungradable CFP (N=17) 
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or ungradable NIR images (N=68). Since the Heidelberg Retina Angiograph 2 was operational a few 
weeks after the start of the examination round an additional 266 participants were excluded from 
the study due to absence of NIR images. From these two cohorts, 2,774 participants with gradable 
CFP and gradable NIR imaging were eligible for analysis.
Grading of AMD, SID and RPD
All eligible participants underwent 35° digital CFP of the macula (Topcon TRC-50EX, Topcon Optical 
Company, Tokyo, Japan with a Sony DXC-950P digital camera; 0.44 megapixel, Sony Corporation, 
Tokyo, Japan) after pharmacologic mydriasis. Next, NIR images, (λ=820 nm) 30°x30° of the macula, 
were taken with a Heidelberg Retina Angiograph 2 (Heidelberg engineering, Heidelberg, Germany).
CFP were graded for presence of all AMD-related features according to the Wisconsin Age-Related 
Maculopathy Grading18 and Rotterdam classification (for definition see Table 1), a modified 
International Classification System, using the standard grading grid for AMD (central circle 1000 μm, 
inner circle 3000μm and outer circle 6000μm in diameter).19,20 In short, the Rotterdam classification 
consists of 5 grades with grade 0 defined as no AMD, grade 1 as preliminary early AMD, grade 2 and 
3 together as Early AMD and grade 4 as Late AMD. SID were defined as yellow lesions with indistinct 
borders and ≥ 125μm in size. These type of soft drusen are associated with a higher risk of developing 
advanced AMD compared to soft distinct drusen.20 RPD were defined as indistinct yellowish lesions 
interlacing in networks125-250μm in width.18,19
NIR images of the macula were graded based on the presence of RPD, detectable as groups of hypo-
reflectant lesions against a mildly hyper-reflectant background in regular patterns.9,10,21,22 Since SID 
and other drusen types are less visible on NIR imaging, these lesions were not graded on NIR, only 
on CFP.
On CFP, RPD and/or SID were graded in and outside the ETDRS grading grid . On NIR, RPD was graded 
if present on the image, this equals grading in and outside the ETDRS grid on CFP.
All images were graded by trained graders, while being masked for the grading of the other image 
modality, under the supervision of senior retinal specialists (P.T.V.M.d.J., J.R.V., C.C.W.K.). Between 
grader comparisons were assessed. For drusen grading on CFP, the weighted κ values ranged from 
0.60 for hard drusen to 0.82 for soft distinct drusen. For RPD grading on CFP, the κ value was 0.72. For 
NIR imaging, this κ value was 0.84. The eyes of each participant were graded and classified separately, 
and the eye with the more severe grade was used to classify the person.
Genotyping and selection of genetic variables
Genomic DNA was extracted from peripheral blood leukocytes. All study participants in the RS-I were 
genotyped with the Illumina Infinium II HumanHap550 array or Taqman assays (Applied Biosystems, 
Foster City, CA). Study participants from the RS-II were genotyped with the Illumina Human610-
Quad array. HapMap CEU data (release #22) was used for imputation. Genetic variables associated 
with AMD were selected based on previous publications.23,24
Risk score Three Continent AMD Consortium prediction model
The Three Continent AMD Consortium (3CC) developed a validated prediction model including a 
total risk score based on 31 variables; 26 genetic variants associated with AMD, age, sex, smoking, 
BMI, and AMD phenotype.23 The total risk score was based on the sum of the beta coefficients from a 
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Cox proportional hazard analysis, which included all the selected variables. In this analysis we used 
the total genetic risk score, which is a variant of the total risk score and has been calculated using 
only the beta coefficients from the genetic variables of the 3CC prediction model.
Assessment of nongenetic variables
Information on the history of diabetes mellitus, education level and cigarette smoking were derived 
from computerized questionnaires administered during home interviews. Smoking was categorized 
in never, past and current smokers. Blood pressure, systolic and diastolic, was calculated as the 
average of two consecutive measurements, using a random-zero mercury sphygmomanometer. 
Hypertension was defined as having a systolic blood pressure ≥ 140 mmHg or a diastolic blood 
pressure ≥ 90mmHg or using anti-hypertensive medication at baseline. Cholesterol, high density 
lipoprotein (HDL) and triglycerides were measured at baseline by the Central Clinical Chemical 
Laboratory of the Erasmus University Medical Center. A subgroup of measurements was carried out 
in the laboratory of the Department of Epidemiology & Biostatistics, Erasmus University Medical 
Center. Body-mass index (BMI) was calculated as weight kilograms divided by height squared in 
meters. Waist circumference and hip circumference were measured in centimeters.
Statistical analysis
Prevalence of RPD as a function of age was calculated per image modality. The prevalence of Early 
AMD based on CFP diagnosis of AMD lesions was compared with the prevalence of Early AMD based 
on both NIR and CFP grading.
We investigated the association with demographic, genetic and environmental variables using 
various outcomes: soft indistinct drusen versus no drusen; RPD versus no drusen, and RPD versus soft 
indistinct drusen. Outcomes were binary and the association was assessed with logistic regression 
analysis. Total genetic risk scores were calculated for each individual using only the genetic variables 
from the 3CC prediction model. Risk scores were grouped and stratified for RPD, SID and no RPD/SID; 
strata were compared using Chi-Square statistic test. Analyses investigating concurrence of drusen 
types were eye-based, all other analyses were person-based, which were eye based. All statistical 
analyses were performed using SPSS version 21 (SPSS IBM, New York, U.S.A).
RESULTS
RPD were detected in 137 (4.9%) of 2,774 study participants, of which 52 (38.0%) were identified on 
CFP and 127 (92.7%) on NIR imaging (numbers do not add up to 100% due to overlap). RPD were 
mostly present from age 70 years onwards (Figure 1) and were bilaterally present in 69.3%. Only one 
person had been diagnosed with RPD at the age of 64.0 years, and RPD were visible on CFP as well as 
on NIR imaging. Frequency of RPD increased per age category, however, the steep rise in those aged 
90+ years was most pronounced when RPD were diagnosed on NIR imaging.
In the Rotterdam classification system, RPD are part of the criteria for staging. To investigate how 
much the improved detection of RPD by NIR imaging influenced AMD prevalence, we classified 
each person using the two gradings, one solely based on CFP and the other based on CFP and NIR 
imaging. Inclusion of the NIR imaging increased the prevalence of Early AMD (stage 2 & 3) from 19% 
to 20.5% (Table 1).
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TABLE 1 - Prevalence per AMD severity grade according to the Rotterdam Classification based on color fundus 
photographs only versus color fundus photographs and near-infrared imaging 
Grade  Definition 
Grading CFP
N=2774
Grading CFP + NIR
N=2774
0 No signs of AMD at all OR hard drusen (< 63 μm) only 42.70% 42.30%
1 Soft distinct drusen (≥ 63 μm) only OR pigmentary abnormalities only 36.10% 35.00%
2 Soft indictinct drusen (≥ 125 μm) / reticular drusen only OR soft distinct 
drusen (≥ 63 μm) AND pigmentary abnormalities
13.60% 14.50%
3 Soft indictinct (≥ 125 μm) / reticular drusen AND pigmentary abnormalities 5.40% 6.00%
4 Atrophic, neovascular or mixed AMD 2.20% 2.20%
Abbreviations: AMD = age-related macular degeneration, CFP = color fundus photographs, NIR = near-infrared imaging
We then investigated the number and type of other drusen present in eyes with RPD (N=232) (Figure 2 
and Supplementary Figure 1). We performed this analysis for drusen within and outside the grid. The 
majority of eyes with RPD had SID, both within and outside the grid. These eyes also presented with 
other types of drusen, but they were less frequent compared to SID. Of eyes with RPD, only 14 eyes 
(6.0% of eyes with RPD) did not have any type of soft drusen, and 9 eyes (3.9% of eyes with RPD) had 
no other type of drusen at all. Of these, the contralateral eye of 2 persons had drusen. Only 5 persons 
with RPD had no drusen at all, not even in the contralateral eye.
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FIGURE 2 - Frequency of other drusen types in eyes with reticular pseudodrusen. Other drusen types coinciding 
with reticular pseudodrusen. Grading based on most severe drusen type, beside reticular pseudodrusen, on 
color fundus photographs, according to the Wisconscin Age-Related Maculopathy Grading. Frequencies of 
other drusen types were stratified for drusen presence within and outside the grading grid.
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Table 2 shows the frequency of characteristics between persons with SID, RPD, and those without 
SID or RPD. Table 3 shows the associations of these characteristics with SID only, with RPD, and 
with RPD versus SID. The odds ratio represents the risk for a certain parameter on a drusen type 
(RPD or SID) in reference to the other drusen type or to absence of RPD/SID. Both SID and RPD were 
associated with age (OR 1.09 (95% CI 1.06-1.11) and OR 1.21 (95% CI 1.17-1.24)), respectively. For SID 
there was no association with sex (OR 1.02 (95% CI 0.77-1.34)) while occurrence of RPD was strongly 
associated with female sex (OR 2.10 (95% CI 1.41-3.13)). HDL cholesterol (OR 1.83 (95% CI 1.30-2.59)) 
and triglycerides (OR 0.66 (95% CI 0.51-0.86)) in serum were both significantly associated with SID, 
but not with RPD. No other demographic or environmental risk factors were significantly associated 
with SID or RPD. Table 4 shows the association of RPD/SID with genetic factors. Genetic variants in 
the CFH gene (rs1061170, rs12144939, rs800292), the ARMS2 gene (rs10490924) and the C2/CFB gene 
(rs641153) were significantly associated with both drusen types. A variant in the IER3/DDR1 gene 
(OR 2.54 [95% CI 1.32-4.86] for rs3130783, GG vs AA) was only associated with SID, while a variant 
in the C3 gene (OR 1.61 (95% CI 1.08-2.40)] for rs22130199, CG vs CC) was only associated with RPD. 
Two variants were significantly more associated with RPD than SID. These included the variant in 
the ARMS2 gene (OR 2.48 (95% CI 1.001-6.17) for rs10490924, TT vs GG) and a variant in the VEGFA 
gene (OR 2.00 (95% CI 1.05-3.8) for rs943080, CT vs CC). Genetic risk score frequencies did not differ 
significantly between SID and RPD (P = 0.88, Chi-Square test) (Supplementary Table 1).
TABLE 2 - Frequency of clinical parameters stratified for drusen type 
Variables
No RPD/SID
N=2416
SID
N=221
RPD
N=137
Age, yrs (sd) 75.0 (5.6) 77.8 (6.2) 82.1 (6.2)
Sex, % females 54.6 54.8 71.5
Education, %      
 < 12 years 26.8 23.3 29.1
 ≥ 12 years 73.2 76.7 70.9
Smoking, %      
 never 31.2 32.1 37
 past 57 57 48.9
 current 11.9 10.9 14.1
Diabetes Mellitus, % 13 12.4 13
Hypertension, % 86 86.8 89.7
Systolic bloodpressure, mmHg (sd) 152.3 (21.4) 154.0 (21.4) 154.0 (23.7)
Diastolic bloodpressure, mmHg (sd) 85.2 (11.0) 85.9 (11.1) 85.3 (13.3)
Cholesterol, mmol/l (sd) 5.4 (1.1) 5.4 (0.9) 5.3 (1.1)
HDL cholesterol, mmol/l (sd) 1.5 (0.4) 1.6 (0.4) 1.5 (0.4)
Triglycerides, mmol/l (sd) 1.4 (0.7) 1.3 (0.6) 1.4 (0.8)
BMI, kg/m2 27.5 (4.1) 27.1 (4.1) 27.2 (3.9)
Waist circumference, cm (sd) 93.7 (12.0) 92.0 (11.7) 91.5 (11.0)
Hip circumference, cm (sd) 102.9 (8.2) 102.6 (9.3) 102.6 (8.7)
Abbreviations: BMI= body mass index, HDL = high density lipoprotein, LDL= low density lipoprotein, RPD = reticular 
pseudodrusen, sd = standard deviation, SID = soft indistinct drusen
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TABLE 3 - Comparison of clinical parameters among drusen types 
Variables
SID vs no RPD/SID
OR (95% CI)
age and sex adjusted
RPD vs no RPD/SID
OR (95% CI)
age and sex adjusted
RPD vs SID
OR (95% CI)
age and sex adjusted
Age* 1.09 (1.06-1.11) 1.21 (1.17-1.24) 1.12 (1.07-1.16)
Sex **      
 male 1 1 1
 female 1.02 (0.77-1.34) 2.10 (1.41-3.13) 2.16 (1.34-3.49)
Education      
 < 12 years 1 1 1
 ≥ 12 years 1.31 (0.93-1.83) 1.24 (0.82-1.89) 0.90 (0.53-1.52)
Smoking      
 never 1 1 1
 past 0.98 (0.70-1.35) 1.06 (0.69-1.62) 0.97 (0.57-1.65)
 current 0.98 (0.60-1.62) 1.77 (0.97-3.23) 1.54 (0.71-3.32)
Diabetes Mellitus      
 No 1 1 1
 Yes 0.96 (0.59-1.55) 1.05 (0.57-1.94) 1.41 (0.64-3.09)
Hypertension      
 No 1 1 1
 Yes 0.88 (0.58-1.33) 0.89 (0.49-1.61) 0.91 (0.44-1.89)
Cholesterol, mmol/l 1.06 (0.93-1.21) 0.89 (0.75-1.06) 0.78 (0.61-1.00)
HDL cholesterol, mmol/l 1.83 (1.30-2.59) 1.28 (0.80-2.05) 0.68 (0.39-1.20)
Triglycerides, mmol/l 0.66 (0.51-0.86) 0.95 (0.70-1.28) 1.39 (0.97-1.98)
BMI      
 ≤ 25 kg/m2 1 1 1
 > 25 kg/m2 0.83 (0.61-1.11) 1.13 (0.75-1.70) 1.50 (0.90-2.48)
Waist circumference      
 ≤ 90 cm 1 1 1
 > 90 cm 0.82 (0.61-1.11) 1.21 (0.82-1.80) 1.51 (0.93-2.47)
Hip circumference      
 ≤ 100 cm 1 1 1
 > 100 cm 0.87 (0.65-1.15) 1.18 (0.81-1.72) 1.29 (0.81-2.06)
Abbreviations: BMI = body mass index, CI = confidence interval, HDL = high density lipoprotein, LDL = low density lipoprotein
OR = Odds' Ratio, RPD = reticular pseudodrusen, SID = soft indistinct drusen
* Adjusted for sex 
** Adjusted for age
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TABLE 4 - Genetic risks among drusen types
Genes
SID vs no RPD/SID
OR (95% CI)
age and sex adjusted
RPD vs no RPD/SID
OR (95% CI)
age and sex adjusted
RPD vs SID
OR (95% CI)
age and sex adjusted
CFH (Y402H) rs1061170      
 TT 1 1 1
 CT 1.65 (1.17-2.34) 1.45 (0.95-2.23) 0.91 (0.52-1.58)
 CC 3.84 (2.50-5.90) 2.78 (1.57-4.93) 0.83 (0.42-1.66)
CFH rs12144939      
GG 1 1 1
GT/TT 0.34 (0.23-0.51) 0.28 (0.17-0.47) 0.89 (0.47-1.71)
CFH rs800292      
GG 1 1 1
GA 0.54 (0.39-0.76) 0.55 (0.36-0.84) 0.88 (0.51-1.50)
AA 0.38 (0.17-0.83) 0.30 (0.11-0.87) 0.96 (0.24-3.74)
ARMS2 (A69S) rs10490924      
GG 1 1 1
GT 1.81 (1.33-2.47) 2.41 (1.60-3.62) 1.24 (0.75-2.05)
TT 3.25 (1.70-6.20) 7.85 (3.75-16.45) 2.48 (1.001-6.17)
C2/CFB (L9H) rs4151667      
TT 1 1 1
TA/AA 0.65 (0.35-1.19) 0.43 (0.17-1.10) 0.78 (0.25-2.44)
C2/CFB (R32Q) rs641153      
GG 1 1 1
GA/AA 0.56 (0.34-0.90) 0.38 (0.19-0.75) 0.66 (0.29-1.54)
C3 (R102G) rs2230199      
CC 1 1 1
CG 1.19 (0.86-1.64) 1.61 (1.08-2.40) 1.32 (0.80-2.19)
GG 1.28 (0.64-2.56) 1.81 (0.80-4.13) 1.18 (0.41-3.40)
C3 rs433594      
GG 1 1 1
GA 0.80 (0.58-1.12) 0.84 (0.55-1.28) 1.16 (0.68-1.96)
AA 0.83 (0.52-1.32) 0.94 (0.51-1.71) 1.01 (0.47-2.16)
CFI rs10033900      
CC 1 1 1
CT 1.27 (0.87-1.85) 0.82 (0.52-1.30) 0.68 (0.38-1.24)
TT 1.33 (0.86-2.06) 0.90 (0.52-1.54) 0.62 (0.31-1.24)
LPL rs256      
CC 1 1 1
CT/TT 0.88 (0.62-1.25) 0.75 (0.48-1.19) 0.83 (0.46-1.47)
LIPC rs12912415      
AA 1 1 1
AG/GG 0.90 (0.64-1.26) 0.75 (0.48-1.17) 0.98 (0.56-1.71)
MYRIP rs2679798      
AA 1 1 1
AG 1.04 (0.73-1.49) 1.42 (0.88-2.27) 1.34 (0.75-2.42)
GG 1.23 (0.81-1.87) 1.36 (0.77-2.39) 1.22 (0.61-2.47)
SKIV2L rs429608      
GG 1 1 1
GA/AA 0.57 (0.38-0.84) 0.55 (0.33-0.91) 1.01 (0.53-1.92)
ABAC1 rs1883025      
CC 1 1 1
CT 0.78 (0.56-1.09) 1.00 (0.67-1.50) 1.03 (0.61-1.74)
61Epidemiology of RPD
3
TABLE 4 - (continued) 
Genes
SID vs no RPD/SID
OR (95% CI)
age and sex adjusted
RPD vs no RPD/SID
OR (95% CI)
age and sex adjusted
RPD vs SID
OR (95% CI)
age and sex adjusted
TT 1.09 (0.61-1.94) 0.53 (0.19-1.53) 0.38 (0.11-1.28)
CETP rs3764261      
CC 1 1 1
CA 1.27 (0.92-1.76) 1.15 (0.76-1.73) 1.06 (0.63-1.79)
AA 1.40 (0.84-2.32) 1.02 (0.50-2.07) 0.68 (0.29-1.63)
TIMP3 rs5749482      
GG 1 1 1
CG/CC 0.87 (0.60-1.27) 0.62 (0.37-1.04) 1.17 (0.40-3.40)
VEGFA rs943080      
CC 1 1 1
TC 0.81 (0.56-1.17) 1.34 (0.79-2.24) 2.00 (1.05-3.81)
TT 1.09 (0.72-1.65) 1.51 (0.84-2.73) 1.50 (0.73-3.08)
COL8A1 rs13081855      
GG 1 1 1
GT/TT 1.15 (0.78-1.68) 0.90 (0.53-1.52) 0.85 (0.45-1.59)
TNFRSF10A rs13278062      
TT 1 1 1
GT 0.92 (0.65-1.30) 0.73 (0.46-1.14) 0.89 (0.51-1.57)
GG 0.72 (0.46-1.12) 0.77 (0.45-1.31) 1.11 (0.57-2.18)
FRK/COL10A1 rs3812111      
TT 1 1 1
AT 0.93 (0.68-1.29) 0.92 (0.61-1.39) 0.96 (0.57-1.60)
AA 0.86 (0.52-1.44) 0.53 (0.24-1.15) 0.71 (0.28-1.79)
SLC16A8 rs8135665      
CC 1 1 1
CT 1.17 (0.85-1.61) 0.83 (0.54-1.28) 0.73 (0.43-1.24)
TT 1.31 (0.61-2.82) 0.74 (0.21-2.63) 0.74 (0.17-3.18)
ADAMTS9 rs6795735      
CC 1 1 1
TC 0.96 (0.68-1.36) 1.03 (0.66-1.61) 1.10 (0.63-1.92)
TT 1.34 (0.88-2.06) 1.35 (0.77-2.37) 0.90 (0.45-1.80)
TGFBR1 rs334353      
TT 1 1 1
GT 0.92 (0.66-1.27) 1.09 (0.72-1.64) 1.29 (0.76-2.18)
GG 1.03 (0.55-1.94) 0.62 (0.24-1.63) 0.61 (0.20-1.87)
RAD51B rs8017304      
AA 1 1 1
AG 0.82 (0.59-1.13) 0.85 (0.56-1.29) 1.26 (0.74-2.14)
GG 0.63 (0.38-1.03) 0.85 (0.46-1.56) 1.46 (0.67-3.19)
IER3/DDR1 rs3130783      
AA 1 1 1
AG 0.85 (0.61-1.19) 0.83 (0.54-1.28) 0.95 (0.55-1.64)
GG 2.54 (1.32-4.86) 1.48 (0.49-4.51) 0.34 (0.10-1.20)
B3GALTL rs9542236      
TT 1 1 1
CT 0.77 (0.55-1.09) 1.11 (0.70-1.74) 1.57 (0.89-2.76)
CC 0.92 (0.60-1.39) 1.02 (0.58-1.83) 1.49 (0.73-3.04)
Abbreviations: CI = Confidence Interval, OR = Odds' Ratio, RPD = reticular pseudodrusen, SID = soft indistinct drusen
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DISCUSSION
In this cross-sectional analysis of a population-based study, we showed that NIR imaging is superior 
to traditional CFP in the detection of RPD. We also found that RPD generally coincide with soft 
drusen, and were seldom seen as the only AMD feature. However, the AMD risk profile of RPD showed 
quantitative differences with that of SID. Those with RPD were more likely to be women, have older 
age, and carry risk variants in the C3, ARMS2 and VEGFA genes.
Our study confirms that NIR imaging is preferred over the use of CFP for detection of RPD.11,13,21,25 Of 
all persons diagnosed with RPD, 62.7% were not visible on CFP, only on NIR. By contrast, 7% of those 
with RPD were diagnosed on CFP and failed to be detected on NIR. This implies that multimodal 
imaging for complete AMD grading is better than using single imaging devices. Suzuki et al. described 
three subtypes of RPD: two were better visualized by NIR-imaging, and one, the ribbon like subtype, 
was more easily spotted on CFP.26 Indeed, we acknowledge that diagnosis of RPD on CFP is mostly 
based on recognition of the pattern of this feature. Aside from NIR and CFP, other image modalities 
can also reveal RPD, such as fundus auto fluorescence, optical coherent tomography (OCT), confocal 
blue reflectance, and indocyanine green angiography. Whether incorporation of all these methods 
further improves detection of RPD is questionable. A recent study assessed the accuracy of RPD 
detection using all these modalities, and found that NIR and OCT have the highest sensitivity, both 
94.6%.9
Using NIR imaging increased our estimate of the overall prevalence of RPD to 4.9%. All previously 
reported population estimates of RPD were based on CFP only, and were therefore lower; the Beaver 
Dam Eye Study reported an overall prevalence of 0.7% in a population aged 45+ years,6 the Blue 
Mountain Eye Study reported an overall prevalence of 1.95% in a population aged 50+ years,12 
and the Melbourne Collaborative Cohort Study recently reported an overall prevalence of 0.41% 
in a population 48-86 years of age.4 In our study, RPD were bilateral in 69% of cases, while other 
population-based cohorts reported a slightly lower frequency of bilaterality, 51-63% respectively.4,6,12 
The higher rates in our study could be due to the improved detection of RPD using NIR.
We identified several risk factors for RPD and SID. For RPD, demographic risk factors were older age 
and female sex, factors which have been reported by several studies.6,7,11-13,27 We did not find any 
statistically significant environmental risk factors, although the relationship with current smoking 
was suggestive. Other studies reported risks of RPD for hypertension, lower income, lower education, 
higher body mass index, angina pectoris, HDL cholesterol, and triglycerides, but we and many others 
could not confirm these findings. 6,7,11-13,21,27 Associations which showed a preference for SID were 
increased HDL-cholesterol, and decreased triglycerides. These trends have been observed previously 
for Late AMD, and have not been explained thus far.20 With respect to AMD risk variants, those in the 
CFH, C2/FB and ARMS2 genes were significantly associated with both RPD and SID in this study. C3, 
however was only associated with RPD. The lack of association with other risk variants may be due to 
our limited statistical power to find minor associations. Remarkably, ARMS2 appeared to have a strong 
predilection for RPD. Homozygous carriers of the ARMS2 risk variant were twice as likely to have RPD 
than SID. We did not find this differential distribution for the CFH nor C2/FB risk variants. Prior reports 
found stronger associations with ARMS2 than CFH.27,28 Another gene showing a tendency for RPD 
was VEGFA. Although this gene was not significantly associated with either phenotype, it showed a 
significant risk difference between RPD and SID.
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Eyes featuring RPD without any type of drusen were rare in our study. We evaluated the risk profiles 
of these participants (N=5), and these were not remarkably different from the entire group of RPD 
(Table 2 and 3). Noteworthy, none of the RPD in these participants were observed on CFP, only on NIR 
imaging. RPD without any type of drusen may represent other phenotypes than AMD; in literature, 
RPD have been reported to accompany Sorsby fundus dystrophy, pseudoxanthoma elasticum, 
acquired vitelliform lesions, and systemic disorders such as vitamin A deficiency, cardiovascular 
disease and complement mediated IgA nephropathy.28-33 In our study, these 5 patients showed no 
other retinal pathology aside from RPD. A focus on unravelling the etiology of isolated RPD may help 
shed light on overarching molecular mechanisms in retinal disease.
Current insights into RPD pathogenesis are still highly limited, but a vascular etiology has been 
suggested.27,28 The genetic predilections in our study may point toward this hypothesis. ARMS2 
was found to be expressed in the ellipsoid layer of the photoreceptors and in the intercapillary 
pillars of the choroid.34,35 The first is close to the location of RPD,34 and the latter may help explain 
the vascular hypothesis.35 Another hint in this direction is the higher susceptibility of VEGFA 
and ARMS2 for neovascular AMD24, although RPD do not preferentially accompany this AMD 
subtype.4,6,7,36 Furthermore, the genes CFH, C3, and, VEGFA have been associated with cardiovascular 
and coronary artery disease.27,28 Morphologic changes in eyes with RPD, suggest that these lesions 
follow the pattern of the watershed zones of the choroid, and correspond with local thinning of 
this layer.37 Spaide found that choroidal thinning is even more pronounced when RPD regress 
and photoreceptors shorten38. A recent study of retinal imaging with adaptive optics showed that 
photoreceptor changes precede RPD regression.39 Several histopathologic studies have studied 
the molecular content of RPD and SID and found significant overlap: both contain unesterified 
cholesterol, complement factor H, apolipoprotein E, and vitronectin.16,40 There are also remarkable 
differences: RPD lack immunoreactivity for photoreceptors, Müller cells, and RPE marker proteins, 
and have only low concentrations of esterified cholesterol and other neutral lipids.16,40 Why the 
deposit in RPD is located above rather than below the RPE cell is unclear. Several hypotheses 
have been made. Rudolf et al. suggested that loss of RPE cell polarity may lead to deposition of 
unphagocytized photoreceptor outer segments above rather than below the RPE cell.41 Curcio et al. 
suggest that perturbation of cholesterol homestasis and the lipid transfer between the RPE cell and 
the photoreceptor cell in the context of an outer retinal lipid-recycling program, could explain the 
formation of these deposits.16 Another hypothesis may be that shortening of the RPE villi42 jeopardize 
close contact with photoreceptor outer segments, and may hamper uptake of shedded discs from 
the photoreceptor by the RPE cell. In AMD, the formation of RPD appears to follow that of soft drusen, 
since the concurrence of these lesions carry a higher risk of progression to Late AMD.4,6,20 How the 
associated genes, the choroidal anatomic changes, and formation of drusenoid material above the 
RPE are related remains an intriguing question for future studies.
To our knowledge, this is the first population-based study, studying RPD using another imaging 
device aside from CFP. Other strengths include the large sample size of unselected persons, the 
study of RPD within the context of other Early AMD features, and the comparison of risk profiles 
of RPD versus soft drusen. Other reports did not specify the frequency of concurrent AMD lesions 
in eyes with RPD. Furthermore, we analyzed a much more comprehensive set of demographic, 
environmental and genetic risk factors for RPD than previous population-based and clinical studies, 
which led to new insights into the genetic background of RPD. A limitation of our study is the lack of 
follow up data with NIR imaging, hampering the study of RPD incidence and progression. This needs 
to be addressed in prospective studies.
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ABSTRACT
Purpose To examine human performance and agreement on reticular pseudodrusen (RPD) detection 
and quantification using single- and multi-modality grading protocols and to describe and evaluate 
a machine learning system for the automatic detection and quantification of reticular drusen using 
single- and multi-modality information.
Methods Color fundus, fundus autofluoresence and near infra-red images of 278 eyes from 230 
patients with or without presence of RPD were used in this study. All eyes were scored for presence 
of RPD during single- and multi-modality setups by two experienced observers and a developed 
machine learning system. Furthermore, automatic quantification of RD area was performed by the 
proposed system and compared with human delineations.
Results Observers obtained a higher performance and better inter-observer agreement for RPD 
detection using multi-modality grading, achieving areas under the Receiver operating characteristics 
(ROC) of 0.940 and 0.958, and a kappa agreement of 0.911. The proposed automatic system achieved 
an area under the ROC of 0.941 using a multi-modality setup. Automatic RPD quantification resulted 
in an intra-class correlation (ICC) value of 0.704, which was comparable with ICC values obtained 
between single modality manual delineations.
Conclusion Observer performance and agreement for RPD identification improved significantly using 
a multi-modality grading approach. The developed automatic system showed similar performance 
as observers and automatic RPD area quantification was in concordance with manual delineations. 
The proposed automatic system allows for a fast and accurate identification and quantification of RD, 
opening the way for efficient quantitative imaging biomarkers in large dataset analysis.
69RPD detection by multimodality grading
3
INTRODUCTION
Age-related macular degeneration (AMD) is a progressive eye disease affecting mainly the elderly 
and causing vision loss at advanced stages.1 The early stages of AMD are characterized by the 
presence of pigmentary changes and drusen, which are deposits accumulating between the retinal 
pigment epithelium (RPE) and the Bruch's membrane. A sub-type of drusen, commonly addressed as 
subretinal drusenoid deposits or reticular pseudodrusen (RPD), present different characteristics and 
distribution than normal drusen and have been proven to be a strong risk factor for progression to 
advanced AMD.2-7 Therefore, their identification and quantification is of paramount importance for a 
better understanding of disease progression.
RPD are visible on color fundus (CF) photography, fundus autofluorescence (FAF) imaging and near 
infra-red (NIR) imaging amongst other retinal imaging modalities such as confocal blue reflectance, 
indocyanine green (ICG) angiography, spectral-domain optical coherence tomography (SD-OCT) 
and fluorescein angiography.8-13 On CF images, RPD are described as indistinct, yellowish interlacing 
networks of 125 μm to 250 μm wide.14 On FAF images, RPD are characterized as hypofluorescent 
lesions, while on NIR images, RPD are characterized as groups of hyporeflectant lesions against a 
mild hyper-reflectant background.15-17 Previous studies have reported a difference in sensitivities 
for RPD detection among image techniques.12,17 However, RPD identification using a single image 
modality is challenging as the characteristic changes associated to RPD are often subtle and might 
not always be detected using only one imaging technique. Therefore, for an accurate diagnosis, RPD 
detection should be performed using two or more image modalities.11 Although other studies have 
investigated and compared the performance of individual image techniques for RPD detection,12,17 
a study of the performance obtained using multiple image modalities simultaneously has not been 
performed as far as we are concerned.
Despite its expected higher accuracy, grading of multi-modality images represents a considerable 
workload for a human grader. Machine learning algorithms have huge potential for dealing with 
complex information extracted from different image modalities. Furthermore, automatic systems 
are not influenced by fatigue and mindset and, therefore, less prone to variability than humans. 
Previously developed systems for the automatic detection of drusen showed good performance on 
CF images.18-21 Whether they also perform well fusing information from different image modalities is 
currently unknown. As far as we are concerned, there is no method for the automatic identification 
of RPD fusing information from different image modalities.
The aim of the present study is two-fold. Firstly, we evaluate the performance and the agreement 
between human observers using single- as well as multi-modality grading approaches for RPD 
detection. In the single-modality approach, RPD detection is performed using only one image 
technique (namely, CF, FAF or NIR). In contrast, during the multi-modality grading session, the 
observers evaluate the three available image modalities simultaneously. Secondly, we aim to 
investigate the effectiveness of a novel machine learning algorithm for the automatic identification 
and quantification of RPD using combined information from different image modalities by comparing 
its performance to human observers.
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METHODS
Study dataset
A set of subjects with and without RPD were selected from the Rotterdam Study, a prospective 
cohort study aimed to investigate risk factors for chronic diseases in the elderly.22 The study adhered 
to the tenets set forth in the Declaration of Helsinki and Investigational Review Board approval was 
obtained. Only patients with CF, FAF and NIR images available were included in this study. CF images 
were taken using a 35° field of view Topcon TRC 50EX fundus camera (Topcon Optical Company, 
Tokyo, Japan) with a Sony DXC-950P digital camera with a resolution of 768 x 576 pixels. FAF and 
NIR images were taken with a Heidelberg Retina Angiograph 2 (Heidelberg engineering, Heidelberg, 
Germany) with a field of view of 30° and a resolution of 768 x 768 pixels. In total 278 eyes of 230 
patients aged 65 years and older were selected from the last examination round of the Rotterdam 
Study. All CF images were graded according to the Wisconsin Age-related Maculopathy Grading23 
and the International Classification and Grading System for age-related maculopathy and age-
related macular degeneration24 by local graders of the Rotterdam Study using visual assessment. 
These annotations constitute the reference standard for our study. We selected all the eyes where 
RPD based on CF images were identified in this round (N=72). Status of RPD was also confirmed 
on FAF and NIR. For positive and negative controls we selected eyes that were graded by the local 
Rotterdam Study graders as having soft distinct or soft indistinct drusen but not with RPD (N=108) 
and eyes that did not contain any type of drusen (N=98). The positive and negative controls did not 
have any signs of RPD in the other modalities (FAF and NIR). As the database did not contain any 
information about the extent of RPD area, two human observers (G.B. and C.B.) made in consensus 
RPD area delineations using the three modalities simultaneously for the eyes containing RD. These 
delineations were used as reference standard for the quantification of RPD area.
Observer study: single- versus multi-modality grading
All images were evaluated independently by two human observers (G.B. and C.B.) for evidence of 
RD. RPD were defined as indistinct, yellowish interlacing networks of 125 μm to 250 μm wide on CF 
image;14 groups of hyporeflectant lesions in regular patterns on FAF15-17 and groups of hyporeflectant 
lesions against a mildly hyper-reflectant background in regular patterns on NIR images images.17 
Observer 1 has 4 years of reading experience for all three imaging modalities, whereas Observer 2 
has 19 years of reading experience on CF imaging and 5 years on FAF and NIR imaging. The observers 
were asked to give a score ranging from 0 to 1, indicating the likeliness of presence of RD. Two 
different grading approaches were performed: single- and multi-modality grading. During single-
modality grading, the observers graded each image modality separately in a randomized order. 
CF, FAF and NIR images were pooled and shown randomly to the observers. Observers were also 
asked to indicate whether the image was of sufficient quality for grading. Bad quality was assigned 
if the observer was not confident in assessing the image for RPD as a result of low image quality. 
During multi-modality grading, observers were asked to diagnose RPD after observing CF, FAF and 
NIR images from the same eye simultaneously. The eyes were shown in a randomized order in this 
grading session as well.
In a separate grading session, the observers manually delineated in consensus the area covered by 
RPD based on one single modality, i.e. single-modality RPD delineation on CF, FAF or NIR images. 
Only the 72 eyes containing RPD as indicated by the reference were taken into account for the 
quantification of RPD area.
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Automatic reticular drusen identification
The proposed machine learning algorithm analyzed simultaneously the available modalities from 
an eye examination to automatically identify reticular drusen areas. The algorithm assigned the 
complete eye examination a probability between 0 and 1 indicating the probability of presence of 
RPD and provided a quantification of the area covered by them. To accomplish this, the algorithm 
performed three steps: preprocessing, feature extraction, and classification and quantification.
Preprocessing
In the preprocessing step, two different methods were applied to the images: image registration and 
vessel removal.
1. Registration will provide a geometrical alignment across modalities to identify corresponding 
pixels that represent the same scene. This multi-modal image registration was performed using 
a semiautomatic affine method, where the images are deformed to accurately match user 
specified points or landmarks.25 In this study, three corresponding landmarks on prominent 
image locations, such as vessel bifurcations, were manually selected on each modality and 
used to perform the registration.
2. To reduce intensity variations due to presence of vessels, the retinal vasculature was removed 
from the images. The vasculature was automatically extracted using a previously developed 
algorithm26 and used as input in an inpainting algorithm,27 which removes the vessels by 
interpolating intensities at the supplied image locations. Figure 1 shows an example eye after 
vessel removal.
FIGURE 1 - Co-registered (A) color fundus photograph, (B) fundus autofluorescence and (C) near infra-red images 
and their corresponding results after vessel removal (D-F).
                   (A)                                                      (B)                                                      (C)
                   (D)                                                      (E)                                                      (F)
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Feature extraction
To perform an automatic analysis of the images, the machine learning algorithm uses information 
which is extracted from the images and encoded in numerical values or so called features. To do so, 
each color channel of the CF image as well as the FAF and NIR image were separately convolved with 
a set of Gaussian filters. These filters are based on Gaussian derivatives up to second order at different 
scales and are invariant to rotation and translation.28 For each resulting filtered image, the mean, 
standard deviation, skewness and kurtosis values in a circular neighborhood around each pixel were 
calculated. The corresponding features for each pixel were then obtained by concatenating these 
extracted values in a single feature vector.
Classification and quantification
To determine whether a pixel is part of a RPD area, a random forest classifier was used to obtain 
an automatic classification based on the calculated features. This classifier operates by constructing 
a multitude of decision boundaries (trees) to make a separation between multiple classes.29 
After training, the random forest classifier provided a probability between 0 and 1 indicating the 
probability that the pixel belongs to a RPD area based on labeled training examples and the input 
pixel feature vector. Figure 2 shows an example eye exam with the output of the classifier. Finally, an 
image score indicating the likelihood of the eye exam to contain RD, was assigned by taking the 99th 
percentile of the obtained probability map.
FIGURE 2 - Example of the classification result obtained by the proposed machine learning algorithm. Given an 
eye exam consisted of (A) a color fundus photograph, (B) a fundus autofluorescence image and (C) a near infra-
red image; the algorithm outputs (D) a probability map indicating the likelihood for each pixel to be part of a 
reticular drusen area. Red values indicate higher probability to be reticular drusen.
                            (A)                                                                       (B)
                            (C)                                                                       (D)
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To quantify the area covered by RD, a threshold was set on the probability map. This threshold 
was image based and experimentally determined as the 55th percentage of the maximum value of 
the probability map. Only the area inside the Early Treatment Diabetic Retinopathy Study (ETDRS) 
grading grid was taken into account for the quantification.
Statistical analysis
The performance of the observers and the proposed machine learning algorithm for the single- and 
multi-modality approaches was evaluated by measuring the area (Az) under the Receiver Operating 
Characteristic (ROC) curve.30 Statistical comparisons were made using bootstrap analysis with 5000 
bootstraps.31 Bootstrap analysis is an nonparametric test that is commonly used to estimate the 
variance of ROC analysis. Results with a p-value lower than 0.05 were seen as statistically significant. 
Bonferroni correction was applied to counteract the problem of multiple comparisons.32 For observers, 
kappa statistics were also reported to assess inter observer variability.33 As the proposed machine 
learning algorithm requires labeled example data for training, the evaluation was performed using a 
patient-based leave-one-out strategy.34
Automatic quantification of RPD area was evaluated by calculating the percentage of detected RPD 
area inside the ETDRS grading grid and was compared with the observer delineations. RPD area 
agreement with observers was measured using intra-class correlation (ICC) statistics.
RESULTS
Image quality assessment
Table 1 shows the image quality analysis of the observers for the different image modalities. Of 
the 278 eyes, only 172 (61.9%) were graded by both observers to have all image modalities with 
good quality and were established as the "good quality" set for the subsequent data analysis. Bad 
quality of the FAF image was the main reason for a bad quality indication for the multi modal exam 
(CF+FAF+NIR).
TABLE 1 - Number and percentage of good quality images as indicated by observers for the different image 
modalities independently. Last column shows the number of images where both observers agree that the 
image is of good quality.
Observer 1 Observer 2 Consensus
CF 272 (97.8%) 268 (96.4%) 264 (95.0%)
FAF 211 (75.9%) 195 (70.1%) 185 (66.5%)
NIR 269 (96.8%) 265 (95.3%) 264 (95.0%)
Abbreviations: CF = color fundus photographs, FAF = fundus autofluorescence images, NIR = near infra-red images.
Comparison of single- and multi-modality grading
Figure 3 shows the ROC curves for the single- and multi-modality grading approaches. The point on 
the curve closest to the upper left corner in the ROC curve is used to compute sensitivity/specificity 
pairs.
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FIGURE 3 - ROC curves for the identification of eyes with reticular drusen using (A) color fundus photographs, (B) 
fundus autofluorescence images, (C) near infra-red images and (D) a multi-modality setup.
Table 2 shows the Az values and sensitivity/specificity pairs for the single- and multi-modality 
grading of Observer 1 and Observer 2, respectively, calculated on the full data set and on the subset 
of good quality images as indicated by both observers. The performance of both observers for RPD 
detection considerably increased when performing a multi-modality grading.
Kappa statistics were calculated to measure inter-observer variability during single-modality and 
multi-modality grading sessions. Table 3 shows the kappa values between the observers for the 
different grading sessions. Observers achieved a higher agreement using multi-modality grading. 
When considering only good quality images, observers also achieved high agreement using FAF 
images.
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TABLE 2 - Performance of Observer 1 and 2 for RPD detection using single- and multi-modality grading.
All Good quality
Az Se Sp Az Se Sp
Observer 1 Single-modality CF  0.879* 0.778 0.951  0.888* 0.789 0.974
FAF  0.881* 0.889 0.806 0.959 0.946 0.966
NIR 0.936 0.903 0.956 0.936 0.929 0.918
Multi-modality 0.940 0.917 0.961 0.956 0.944 0.963
Observer 2 Single-modality CF 0.944 0.944 0.989 0.944 0.930 0.917
FAF  0.793* 0.653 0.951 0.961 0.973 0.946
NIR 0.932 0.903 0.922 0.929* 0.900 0.918
Multi-modality 0.958 0.972 0.942 0.974 1.000 0.949
Area (Az) under the ROC values and optimal sensitivity (Se) and specificity (Sp) values are reported.
*Indicates a statistical significant difference of the Az value with respect to the multi-modality approach.
Abbreviations: CF = color fundus photographs, FAF = fundus autofluorescence images, NIR = near infra-red images, RPD = 
reticular pseudodrusen, ROC = receiver operating curve.
TABLE 3 - Kappa agreement and 95% confidence intervals between observers for single-modality and multi-
modality reading sessions.
All Good quality
κ 95% CI κ 95% CI
Single-modality CF 0.654 (0.556-0.752) 0.724 (0.632-0.817)
FAF 0.468 (0.363-0.572) 0.938 (0.879-0.998)
NIR 0.884 (0.822-0.945) 0.839 (0.767-0.910)
Multi-modality 0.911 (0.857-0.965) 0.936 (0.874-0.998)
Abbreviations: CF = color fundus photographs, CI = confiodence interval, FAF = fundus auotofluorescence images, NIR - near 
infra-red images.
Performance of the automatic method
The ROC curves for the proposed machine learning algorithm are shown in Figure 3. The 
corresponding Az values and the sensitivity/specificity pairs for the single- and multi-modality 
approaches are summarized in Table 4.
Quantification of the area covered by reticular drusen
The boxplots in Figure 4 show the RPD area percentage inside the ETDRS grading grid as delineated 
by the observers and as identified by the automatic system. Only eyes which were of good quality 
as indicated by both observers were taken into account. The multi-modality area delineations 
made during consensus grading of the two observers was used as the reference for the RPD area 
quantification.
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The agreement between single-modality RPD area delineations made by the observers and the 
reference delineations set using multi-modal information reached ICC values of 0.580 (-0.034;0.830), 
0.790 (0.409;0.920) and 0.930 (0.763;0.976) for the CF, FAF and NIR delineation, respectively. For the 
automatic quantification of the RPD area, ICC values of 0.637 (0.395;0.796), 0.389 (0.082;0.631) and 
0.557 (0.280;0.747) were obtained for the single-modality analysis of CF, FAF and NIR with respect to 
the reference delineations. Comparing the automatic multi-modality approach with the reference 
standard, an ICC value of 0.704 (0.495;0.837) was obtained.
TABLE 4 - Performance of the automatic system for RPD detection using single- and multi-modality grading.
All Good quality
Az Se Sp Az Se Sp
Single-modality CF 0.942 0.833 0.922 0.939 0.887 0.860
FAF 0.844* 0.806 0.747 0.935 0.919 0.891
NIR 0.927 0.847 0.893 0.919 0.814 0.902
Multi-modality 0.941 0.875 0.873 0.949 0.861 0.882
Area (Az) under the ROC values and optimal sensitivity (Se) and specificity (Sp) values are reported.
*Indicates a statistical significant difference of the Az value with respect to the multi-modality approach.
Abbreviations: CF = color fundus photographs, FAF = fundus autofluorescence images, NIR = near infra-red images, RPD = 
reticular pseudodrusen, ROC = receiver operating curve.
FIGURE 4 - Box-plots showing the percentage of reticular drusen area inside the ETDRS grading grid. Manual 
multi-modality was seen as the reference and is shown in grey. Single modality manual area percentages are 
shown in blue. The area percentage obtained by the automatic method for single- and multi-modality analysis 
are shown in red.
Abbreviations: CF = color fundus photographs, ETDRS = Early Treatment Diabetic Retinopathy Study, FAF = fundus 
autofluorescence images, NIR = near infra-red images, RPD = reticular pseudodrusen.
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DISCUSSION
In this study, we assessed the performance achieved for RPD detection using multimodal information 
and compared it to the one obtained using several single image techniques. In our larger dataset,11-13,17 
we demonstrated that a significantly higher performance, as well as a better inter-rater agreement, 
was achieved when the reticular pattern was assessed in a multi-modality grading approach. 
Moreover, our automatic machine learning algorithm for RPD detection and quantification using 
multimodal information proved to perform within the same range as the human graders.
Two independent human observers identified RPD areas using two different grading protocols. During 
the single-modality grading session, only information from a single image techniques was available; 
while, during the multi-modality approach, the observers evaluated evidence of RPD using all the 
modalities simultaneously. Both observers achieved higher performance using the multi-modality 
approach reaching Az values of 0.940 and 0.958, respectively (see Figure 3 and Table 2). Although 
previous studies only evaluated the accuracy for detecting RPD of single image modalities,8,11,12 our 
results confirm their conclusions that a more accurate diagnosis of RPD is obtained using multiple 
image modalities.
In contrast to observer 1, observer 2 achieved high performance on RPD assessment using CF 
images. Possible reasons for this are the larger experience of this observer on this modality and the 
lower sensitivity that this image technique has.12 The disparity between observers' performance was 
substantially reduced when the assessment was performed using multiple image modalities (see 
Table 2). When the observers scored FAF images, the performance was significantly lower than when 
they used multi-modality reading. This may be due to the poor quality level of the FAF images. Only 
66.5% of the images were considered of good quality by both observers, as it is shown in Table 1. 
During the FAF acquisition, a mean intensity image is constructed to reduce noise in the image. 
However, eye movements may cause displacement errors resulting in a lower contrast and thus 
lower quality of the FAF image. Another reason is the presence of cataracts in the study population. 
The wavelength used for FAF imaging is more affected by cataract than the one used in NIR 
imaging, resulting in lower image quality. As it is shown in Table 2, the adoption of a multi-modality 
grading approach can overcome image quality issues, maintaining a high detection performance 
independently of the quality level of a particular image techniques. When considering only the 
subset of good quality images, the performance of both observers increases for both single- and 
multi-modality gradings.
Inter-observer agreement was also investigated using the two grading protocols. Table 3 shows 
that the agreement between observers substantially increased when multiple imaging techniques 
were used to evaluate the evidence of RD. When taking only the subset of good quality images into 
account, the agreement between observers improved using CF, FAF and the multi-modal approach. 
However, the agreement using CF images is still substantially lower than using the other modalities. 
Other studies included multiple graders but no information about inter-observer agreement was 
reported.12
In this study, we also developed and evaluated a machine learning algorithm for the automatic 
identification and quantification of RPD using multimodal information. The results showed that the 
proposed system achieved similar performance as the observers, see Figure 3 and Table 4. Similar to 
the observers' gradings, the incorporation of multimodal information improved the performance 
of the algorithm. Using multimodal information, the proposed algorithm achieved an Az value of 
0.941 and a sensitivity/specificity pair of 0.875/0.873. Compared to the observers, that reached a 
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kappa agreement of 0.87 with the reference, the automatic system has a kappa agreement of 0.70. 
However, 20% of the misclassified cases corresponds to cases where the observers also disagree. Of 
the false positive cases, 9 cases contained low quality images, 3 cases presented geographic atrophy, 
1 case showed a neovascular macular detachment and 12 cases contained soft indistinct drusen. As 
described in other publications11,35,36, RPD and drusen have very similar characteristics and might 
therefore more easily be misinterpreted by the automatic system. Better discriminant features, such 
as image context information or local intensity changes, might improve the performance of the 
automatic system, but this has to be further investigated.
Quantification of RPD area is a more difficult task due to the undefined boundaries of RD.15-17 When 
comparing the manual delineations performed on CF images with the reference delineations based 
on multi-modal information, an ICC value of 0.580 was achieved. When comparing the FAF or NIR 
delineations with the reference delineations, the agreement was better, reaching ICC values of 0.790 
and 0.930, respectively. As presented in Figure 4, the RPD area was underestimated using CF images 
when compared to the other image techniques. As reported in previous publications,12,17 the visibility 
of RPD differs over modalities, causing these differences. As RPD are more pronounced on FAF and 
NIR, the delineations on these modalities were more similar to reference delineations. The quantified 
RPD area, which was automatically obtained by the proposed algorithm, was in agreement with the 
area delineated by the observers, reaching an ICC value of 0.704. It has to be noted that only images 
of good quality were used for RPD area quantification as images with insufficient quality were not 
suitable as it was nearly impossible for observers to delineate RPD area on these images. Another 
limitation of this study was that the multi-modal approach only included fundus images, excluding 
information obtained with spectral domain optical coherence tomography (SD-OCT). Including 
this modality in the multimodal protocol, a better understanding of the reticular pattern might be 
obtained and, consequently, an increased accuracy in their identification.9,10,35 SD-OCT can provide 3D 
information about RPD formation and is essential for RPD volume measurements. This enhancement 
will be of great importance for clinical trials studying the development and progression of RPD. We 
will investigate this improvement in further studies.
In conclusion, we were able to show that a multimodal approach significantly increased observer 
performance and inter-observer agreement for detection of reticular drusen in fundus images when 
the information of different imaging modalities was evaluated simultaneously. Furthermore, an 
automatic machine learning algorithm for detection and quantification of RPD using multimodal 
information was developed and evaluated, showing comparable results with those obtained by 
observers. The area covered by RPD was also automatically quantified by the algorithm, tallying the 
values manually provided by the observers. The absence of SD-OCT is regarded as a limitation of this 
study and will be investigated in future work. This automatic algorithm yields a quick and reliable 
diagnosis and quantification of reticular drusen, allowing for large dataset analysis within population 
studies and to gain insights into risk factors involved in AMD and disease progression.
79RPD detection by multimodality grading
3
REFERENCES
1. de Jong PT. Age-related macular degeneration. N Engl J Med, 2006;355:1474-1485.
2. Sarks J, Arnold J, Ho IV, Sarks S, Killingsworth M. Evolution of reticular pseudodrusen. Br J Ophthalmol, 
2011;95:979-985.
3. Schmitz-Valckenberg S, Alten F, Steinberg JS, et al. Reticular drusen associated with geographic atrophy in 
age-related macular degeneration. Invest Ophthalmol Vis Sci, 2011;52:5009-5015.
4. Klein R, Meuer SM, Knudtson MD, Iyengar SK, Klein BEK. The epidemiology of retinal reticular drusen. Am J 
Ophthalmol, 2008;145:317-326.
5. Finger RP, Wu Z, Luu CD, et al. Reticular pseudodrusen: A risk factor for geographic atrophy in fellow eyes of 
individuals with unilateral choroidal neovascularization. Ophthalmology, 2014;121:1252-1256.
6. Pumariega NM, Smith RT, Sohrab MA, Letien V, Souied EH. A prospective study of reticular macular disease. 
Ophthalmology, 2011;118:1619-1625.
7. Boddu S, Lee MD, Marsiglia M, Marmor M, Freund KB, Smith RT. Risk factors associated with reticular 
pseudodrusen versus large soft drusen. Am J Ophthalmol, 2014;157:985-993.e2.
8.  Suzuki M, Sato T, Spaide RF. Pseudodrusen subtypes as delineated by multimodal imaging of the fundus. Am 
J Ophthalmol, 2014;157:1005-1012.
9.  Querques G, Canouï-Poitrine F, Coscas F, et al. Analysis of progression of reticular pseudodrusen by spectral 
domain-optical coherence tomography. Invest Ophthalmol Vis Sci, 2012;53:1264-1270.
10. De Bats F, Wolff B, Mauget-Faÿsse M, Meunier I, Denis P, Kodjikian L. Association of reticular pseudodrusen 
and early onset drusen. ISRN Ophthalmol, 2013;2013:273085.
11. Spaide RF, Curcio CA. Drusen characterization with multimodal imaging. Retina, 2010;30:1441-1454.
12. Ueda-Arakawa N, Ooto S, Tsujikawa A, Yamashiro K, Oishi A, Yoshimura N. Sensitivity and specificity of 
detecting reticular pseudodrusen in multimodal imaging in Japanese patients. Retina, 2013;33:490-497.
14. Sohrab MA, Smith RT, Salehi-Had H, Sadda SR, Fawzi AA. Image registration and multimodal imaging of 
reticular pseudodrusen. Invest Ophthalmol Vis Sci, 2011;52:5743-5748.
15. Arnold JJ, Sarks SH, Killingsworth MC, Sarks JP. Reticular pseudodrusen. A risk factor in age-related 
maculopathy. Retina, 1995;15:183-191.
16. Lois N, Owens SL, Coco R, Hopkins J, Fitzke FW, Bird AC. Fundus autouorescence in patients with age-related 
macular degeneration and high risk of visual loss. Am J Ophthalmol, 2002;133:341-349.
17. Smith RT, Chan JK, Busuoic M, Sivagnanavel V, Bird AC, Chong NV. Autouorescence characteristics of 
early, atrophic, and high-risk fellow eyes in age-related macular degeneration. Invest Ophthalmol Vis Sci, 
2006;47:5495-5504.
18. Smith RT, Sohrab MA, Busuioc M, Barile G. Reticular macular disease. Am J Ophthalmol, 2009;148:733-743.e2.
19. van Grinsven MJJP, Lechanteur YTE, van de Ven JPH, et al. Automatic drusen quantification and risk 
assessment of age-related macular degeneration on color fundus images. Invest Ophthalmol Vis Sci, 
2013;54:3019-3027.
20. Chen Q, Leng T, Zheng L, et al. Automated drusen segmentation and quantification in SD-OCT images. Med 
Image Anal, 2013;17:1058-1072.
21. Mora AD, Vieira PM, Manivannan A, Fonseca JM. Automated drusen detection in retinal images using 
analytical modelling algorithms. Biomed Eng Online, 2011;10:59.
22. Sivagnanavel V, Smith RT, Lau GB, Chan J, Donaldson C, Chong NV. An interinstitutional comparative study 
and validation of computer aided drusen quantification. Br J Ophthalmol, 2005;89:554-557.
23. Hofman A, Darwish Murad S, van Duijn CM, et al. The Rotterdam study: 2014 objectives and design update. 
Eur J Epidemiol, 2013;28:889-926.
24. Klein R, Davis MD, Magli YL, Segal P, Klein BEK, Hubbard L. The Wisconsin age-related maculopathy grading 
system. Ophthalmology, 1991;98:1128-1134.
25. Bird RE, Bressler NM, Bressler S, et al. An international classification and grading system for age-related 
maculopathy and age-related macular degeneration. Surv Ophthalmol, 1995;39:367-374.
26. Besl PJ, McKay ND. A method for registration of 3D shapes. IEEE Trans Pattern Anal Mach Intell, 1992;14:239-
256.
27. Niemeijer M, Staal JJ, van Ginneken B, Loog M, Abràmoff MD. Comparative Study of Retinal Vessel 
Segmentation Methods on a New Publicly Available Database. In Medical Imaging, volume 5370 of 
Proceedings of the SPIE. 2004; 648-656.
28. Emile-Male G. The restorer's handbook of easel painting. Van Nostrand Reinhold, New York, 1st edition, 1976.
29. ter Haar Romeny BM. Front-End Vision and Multi-Scale Image Analysis: Multi-scale Computer Vision Theory 
and Applications, written in Mathematica. Kluwer Academic Publishers, 2003.
80 Chapter 3.2
30. Breiman L. Random forests. Machine Learning, 2001;45:5-32.
31. He X, Frey E. ROC, LROC, FROC, AFROC: An alphabet soup. J Am Coll Radiol, 2009;6:652-655.
32. Efron B. Bootstrap methods: Another look at the jackknife. Ann Stat, 1979;7:1-26.
33. Bland J, Altman D. Multiple significance tests: the Bonferroni method,. BMJ, 1995;310:170.
34. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics, 1977;33:159-
174.
34. Arlot S, Celisse A. A survey of cross-validation procedures for model selection. Statistics Surveys, 2010;4:40-
79.
35. Zweifel SA, Spaide RF, Curcio CA, Malek G, Imamura Y. Reticular pseudodrusen are subretinal drusenoid 
deposits. Ophthalmology, 2010;117:303-312.e1.
36. Rudolf M, Malek G, Messinger JD, Clark ME,Wang L, Curcio CA. Sub-retinal drusenoid deposits in human 
retina: organization and composition. Exp Eye Res, 2008;87:402-408.


Chapter 4.1
Trace elements, vitamins, and lipids and age-
related macular degeneration. An overview of 
the current concepts on nutrients and AMD
Gabriëlle H.S. Buitendijk and Caroline C.W. Klaver
Adapted from chapter in: Preedy VR (Ed.), Handbook of nutrition, diet, and the eye, (pp55-63). Waltham, MA: Elsevier
84 Chapter 4.1
SUMMARY
In this chapter we provide an overview of the current concepts on trace elements, vitamins, lipids in 
their relationship to age-related macular degeneration (AMD). Intake zinc, and omega-3 fatty acids 
can help lower the risk of AMD, in particular in those at high genetic risk. Vitamin D and nutrients 
influencing epigenetics appear to have a beneficial effect, but more research is needed before 
recommendation of these nutrients is warranted.
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Dietary nutrients have been implicated in the development of age-related macular degeneration 
(AMD) for years. The first paper reporting a beneficial effect of a nutrient on AMD was published 
in 1988, in which the National Health and Nutritional Examination Survey 1 (NHANES-1) study 
investigated the dietary intake of vitamin A (P trend =0.058) in AMD.1 Since then, many more papers 
on this topic have been published. This chapter will provide an overview of nutrients investigated in 
relation with AMD.
CAROTENOIDS
There are many different carotenoids; over 600 are known to date. These can be split in two groups: 
carotenes, which refer to hydrocarbon carotenoids, and xanthophyll, a carotenoid with one or more 
oxygen groups. Carotenoids are pigments and can be found in chloroplasts and chromoplasts in 
predominantly plants and algae. Their function is to absorb blue light to protect the plants and 
algae from photo-damage, and absorb the light energy for use in photosynthesis. In the eye, 
lutein and zeaxanthin are xanthophylls which protect the macula from blue and ultraviolet (UV)-
light damage. All dietary carotenoids have antioxidant function; α carotene, β carotene, γ carotene 
and β cryptoxanthin also have vitamin A activity. These four carotenoids are converted to retinal in 
herbivores and omnivores.2
Astaxanthin
Astaxanthin is a red pigmented xanthophyll, and can be found in salmon and other red colored sea 
foods (Table 1). Two studies added this carotenoid to a cocktail of anti-oxidants, including lutein and 
zeaxanthin. Both studies reported a positive effect of this cocktail on visual functions. Nonetheless, a 
specific beneficial effect for astaxanthin cannot be concluded from these results.3,4
α Carotene
This carotene is an antioxidant and has vitamin A activity (Retinal Activity Equivalents; RAE); 1 RAE = 1 
μg retinol or 24μg α carotene. A meta-analysis based on four prospective cohort studies reported no 
significant association for α carotene and the risk of developing early AMD (Odds’ ratio (OR) 1.05; 95% 
CI 0.87-1.26).5 However, one of these studies did find a trend for intake of α carotene ten years prior to 
baseline examination and incident large drusen (P trend = 0.02).6 Another study found a trend with 
pigmentary changes (P trend = 0.03), but not with drusen.7
Recently, a study investigated serum levels of carotenoids and the risk of AMD in a Chinese population 
sample.8 Serum levels of α carotene were significantly lower in subjects with exudative AMD versus 
controls (P < 0.001), while subjects with early AMD had higher serum levels versus controls (P 
<0.001). The relative risk was reduced for exudative AMD (Relative risk (RR) 0.24; 95% CI 0.12-0.51), 
and increased for early AMD (RR 2.22; 95% CI 1.37-3.58). Why α carotene would increase the risk for 
early AMD and not for late is not clear. 
β Carotene
This antioxidant has vitamin A activity; 1 RAE = 12μg β carotene and has been studied intensively 
in many diseases. A meta-analysis on this nutrient reported no association with incident early AMD 
(RR 1.04; 95% CI 0.86-1.25).5 Contradictory results were found for late AMD. Two studies from the US 
on exudative AMD reported a lower risk for those with higher intakes; 9,10 in contrast, a study from 
Australia found a higher risk (P trend = 0.027).11 β carotene supplements have also been tested. A 
meta-analysis based on two randomized controlled trials showed neither a significant association 
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with any AMD (RR 1.03; 95% CI 0.89-1.19) nor with advanced AMD (RR 0.97; 95% CI 0.69-1.36).12 
Serum levels of β carotene were investigated in a Chinese population. The investigators found higher 
levels to be associated with an increased risk of exudative AMD (RR 2.36; 95% CI 1.30-4.29).8 This 
would favor the diet findings from the earlier mentioned Australian study. Differences in population 
structure, definition of the outcome, and measurement error of the exposure may explain the 
difference of study results.
TABLE 1 - Nutrients in Foods 
Nutrient Foods
Astaxanthin Salmon, throut, shrimp, crayfish
Betaine Grain products, fish, spinach, sugar beets
α Carotene dark-leafy vegetables (spinach, kale) yellow/orange vegetables (carrots, bell peppers)
β Carotene dark-leafy vegetables (spinach, kale) yellow/orange vegetables (carrots, bell peppers)
β Cryptoxanthin Orange rind, egg yolk, papaya, apples
Lutein dark-leafy vegetables (spinach, kale) yellow/orange vegetables (carrots, bell peppers)
Lycopene Red fruits and vegetables (tomatoes, bell peppers, watermelon)
Meso-zeaxanthin Sea foods
Methionine Poultry, fish, dairy products
Omega-3 fatty acids - ALA vegetable oils (flaxseed, canola oil)
Omega-3 fatty acids - DHA/EPA Oily fish (herring, salmon, sardines, trout)
Omega-6 fatty acids - LA vegetable oils (canola oil, safflower oil, corn oil)
Omega-6 fatty acids - AA poultry, meat
Resveratrol Skin red grapes, other fruits, red wine
Selenium Shellfish and crustacea, egg yolk
Vitamin A liver, butter, cheddar cheese, milk
Vitamin C Fruits and vegetables (kiwi, peppers, parsley, rose hips)
Vitamin D* Oily fish, dairy products, beef and fish liver
Vitamin E# Corn oil, soybean oil, margarine, dressings
Zinc Fortified cereals, meats, dairy products, nuts, seeds
Zeaxanthin dark-leafy vegetables (spinach, kale) yellow/orange vegetables (carrots, bell peppers)
Abbreviations: AA, arachidonic acid; ALA, α-liolenic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; LA, linoleic 
acid
* Levels of vitamin D depends on country. Some foods (mostly dairy products) are fortified with vitamin D
# There are many different forms of vitamin E, the most common is α-tocopherol
β carotene may have interaction with genetic factors. Dietary intake was analyzed for AMD genotypes 
and the risk of early AMD in the Rotterdam Study.13,14 Carriers of the risk variant CFH (Y402H) had a 
higher risk of developing AMD in particular in those that had a low intake of β carotene. Carriers 
could reduce their AMD risk by increasing their intake (P trend = 0.05) (Figure 1). There are several 
explanations. β Carotene is inversely related to CRP levels, and CRP is related to the CFH (Y402H) 
genotype and AMD.15 These results imply that the genetic risk can be ‘eaten’ away. Whether 
supplementation would further decrease the risk is not clear and requires a note of caution. The 
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results of two randomized controlled trials indicated that β carotene supplementation in smokers 
increased risk of developing lung cancer, and many commercial supplements do not include this 
nutrient anymore.16,17
β Cryptoxanthin
This carotenoid is very similar to β carotene, except for one oxygen group. The retinal activity of β 
cryptoxanthin is two times lower than β carotene; 1 RAE = 24 μg β cryptoxanthin. In the literature, 
an inverse correlation of β cryptoxanthin with lung cancer has been reported in in vitro studies. This 
nutrient could potentially act as a chemoprotective agent in cancer, 18 but this beneficial effect is 
questionable since it appears to cause a lower survival in patients with malignant glioma.19
No consistent associations have been found for β cryptoxanthin and AMD.5,7-11,20,21
Lutein, zeaxanthin and meso-zeaxanthin
The pigment of the macula consists of lutein, zeaxanthin and meso-zeaxanthin. These carotenoids 
absorb blue light and UV, and protect the retina from damage by free radicals. Dietary intake (Table 1) 
is very important, because the human body cannot synthesize lutein/zeaxanthin. However, there 
are some reports that meso-zeaxanthin might be synthesized from lutein in the retina.22 Because of 
the macular location, these nutrients have been of high interest in ophthalmic research, especially 
in AMD.
Serum levels lutein/zeaxanthin
Many studies have investigated serum levels of lutein/zeaxanthin in patients and controls. In the 
majority of the studies an inverse association was found for lutein/zeaxanthin levels in serum with 
early, late and any AMD. In stratified analysis, zeaxanthin was more significantly associated with AMD 
than lutein.23
Dietary lutein/zeaxanthin
A meta-analysis of observational studies on diet has been performed with data from six studies. 
Overall, the risk of early AMD was not significantly associated with intake of lutein/zeaxanthin (RR 
0.96; 95% CI 0.78-1.17).24 The meta-analysis for advanced AMD did show an association with intake 
of lutein/zeaxanthin (RR 0.74; 95% CI 0.57-0.97), most prominent for exudative AMD (RR 0.68; 95% 
CI 0.51-0.92).
Case control studies also reported a significant association of lutein/zeaxanthin intake with a lower 
risk for advanced AMD.9,10 Seddon et al (1994) also showed an inverse trend with intake of lutein/
zeaxanthin, a trend which was particularly present in smokers.
As β carotene, lutein/zeaxanthin also interacted with genetic factors. High intake of these nutrients 
was associated with a reduced genetic risk for carriers of CFH risk variants (P trend = 0.05) (Figure 1).15
Supplementation of lutein/zeaxanthin
A number of small studies have investigated this topic. Some studied the retina of healthy subjects 
who received supplementation of lutein and/or zeaxanthin, with or without meso-zeaxanthin. After 
duration of 8-52 weeks, the macular pigment optical density (MPOD) was significantly higher than 
at baseline.23 Consumption of lutein/zeaxanthin rich foods like egg yolks or spinach improved serum 
lutein and zeaxanthin levels significantly. MPOD did improve in all groups, but only significantly in 
those with low MPOD at baseline and consumption of 4 egg/yolks per day.25,26
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FIGURE 1 - Gene-environment interactions in the Rotterdam Study
A - D. Joint effect of dietary nutrient intake and CFH Y402H genotype on the risk of Early AMD;
E – F. Joint effect of dietary nutrient intake and LOC387715 (ARMS2) A69S genotype on the risk of Early AMD.
R is the common reference group.
HRs are estimates of the relative risk of Early AMD, and represent the risk of disease (Early AMD vs No AMD) 
in the various genetic-environmental risk groups divided by the risk of disease (Early AMD vs No AMD) in the 
common reference group (R). HRs are estimated with Cox regression analyses and included age, sex, smoking 
status, and atherosclerosis.
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When lutein or lutein/zeaxanthin were supplemented in participants with early or even advanced 
AMD, these studies reported improvement of visual functions (e.g. visual acuity and contrast 
sensitivity), increase in serum lutein and zeaxanthin levels, and MPOD.23,27 Since most carotenoids 
are lipid-soluble pigments, adding fatty acids to the oral supplementation could improve uptake 
of lutein/zeaxanthin in the gut. However, one study investigated this hypothesis and did not find 
a change of serum levels of lutein and zeaxanthin if omega-3 fatty acids were added to lutein/
zeaxanthin supplementation.28
Only one randomized controlled trial compared supplementation of zeaxanthin (8 mg) to 
supplementation of lutein (9 mg), and to supplementation of zeaxanthin (8 mg) and lutein (9 
mg) combined, versus placebo. MPOD was elevated in all supplementation groups, but was only 
significant in the groups supplemented with zeaxanthin or lutein alone. Zeaxanthin improved foveal 
cone-based visual parameters, while lutein enhanced those associated with gross detailed rod-based 
vision. In the lutein/zeaxanthin group, the two carotenoids were dosed equally rather than 10:1-2 
which is the natural ratio. This may have led to duodenal, hepatic-lipoprotein or retinal competition 
between these nutrients, prohibiting efficient uptake and activity. 29
Several design issues of the studies should be discussed. The majority of the studies on advanced 
cases of AMD investigated geographic atrophy (GA) and focused on visual acuity as the outcome 
event. An outcome as enlargement of surface area of the atrophic lesions would have been more 
objective. Another issue is the size of the studies. Most case-series and trials were very small (N= 
5-136 participants). Contrary to other nutrients, there is no recommended daily allowance or upper 
level of intake (Table 2) for lutein/zeaxanthin, and harmful effects with unnatural high dosages are 
currently unknown.
Lycopene
This carotene can be found in tomatoes and other red vegetables (Table 1); it has no retinal activity. 
In most studies, dietary intake of lycopene was not associated with early or advanced AMD.5,9,10 
However, Morris et al. (2007) did find a trend for lycopene and pigmentary abnormalities; a history of 
higher intake of lycopene decreased the risk of pigmentary abnormalities (P trend = 0.02).
Serum levels of lycopene were inversely correlated with early and advanced AMD (RR 0.49; 95% CI 
0.28-0.86 and RR 0.22; 95% CI 0.1-0.48 respectively).8 A few small serum studies reported similar 
results for early, late and any AMD.20,21,30
TRACE ELEMENTS
Trace elements are dietary minerals and are needed in small amounts for normal cell function. Often 
a trace element is the core of enzymes. However, in large amounts trace elements are toxic.
Zinc
The retina contains high amounts of zinc suggesting a crucial role for this trace element. 31 Zinc has 
antioxidant functions and also acts as a cofactor in several enzymes including retinol dehydrogenase, 
an important enzyme in the vitamin A visual cycle.
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Dietary zinc
Several observational studies have investigated the role of dietary zinc and early AMD. Two studies 
reported an inverse trend for dietary and supplementary intake of zinc approximately ten years 
before ophthalmic examination and pigmentary abnormalities.6,7 However, no association was found 
for early AMD (OR 0.91; 95% CI 0.74-1.11). A significant interaction was found between dietary zinc 
intake and the major susceptibility genes: CFH (Y402H) and AMRS2 (A69S), respectively. Carriers of 
risk variants had a higher risk of AMD in the lower tertile of zinc intake, but risks lowered dramatically 
when intakes increased (Figure 1).15
Supplementation of zinc
Zinc supplementation had an inverse effect on developing advanced AMD in participants with 
signs of early AMD in a meta-analysis (OR 0.73; 95% CI 0.58-0.93). Zinc was supplemented as zinc 
oxide (80mg/day; together with cupric oxide, 2 mg/day) in the Age-related Eye Disease Study 
(AREDS) trial, and as zinc sulphate (200 mg/day) in the other trials. These dosages are highly above 
the recommended upper level of zinc intake (Table 2). 32 Zinc sulphate is the most common zinc 
salt in diet and supplements; zinc oxide has the longest history as a medicine, especially for skin 
irritations and wounds. Supplements versus AMD genotype appeared less significant than diet 
versus genotype. In the AREDS trial, non-carriers of CFH (Y402H) showed a more decreased risk after 
zinc supplementation than carriers, contradicting the findings with diet. 33
Zinc also has the capability to interact with the complement cascade, it is known to downregulate 
complement activation. Compliment activation is an established mechanism of AMD pathogenesis, 
hence, this explains the positive effect of high zinc intake. ARMS2 (A69S) may influence mitochondrial 
function leading to increased complement activation, which again can be counteracted by zinc.15 Zinc 
supplementation at high levels may lead to side effects and complications, including gastrointestinal 
symptoms, anemia and more severe genitourinary causes, therefore, caution is warranted.32,34
Selenium
Selenium has antioxidant and inflammatory capacities and has therefore been investigated in 
AMD. No positive associations have been found. 35 Selenium has been supplemented, but always in 
combination with other antioxidants, prohibiting the study of the single effect.
VITAMINS
Historically, all vitamins were thought to be amines, hence, in 1921 Kazimierz Funk put together the 
words ‘vital’ and ‘amine’, and composed ‘vitamine’. Vitamins are needed only in limited amounts.
Vitamin A
This fat-soluble vitamin was discovered in the beginning of the 20th century in butterfat, and it 
appeared to be associated with yellow-plant pigments, the carotenoids. Later, vitamin A was 
found in the retinal tissue of rats, and was named ‘retinol’ after the retina.36 Total vitamin A includes 
carotenoids, originating from plants, as well as retinol, derived from animals. Foods containing high 
levels of retinol are liver and butter (Table 1). Carotenoids have been discussed earlier in this chapter.
The influence of vitamin A on ophthalmological health has long been known; a vitamin A deficient 
diet leads to diseases of the cornea, i.e., xerolphthalmia and keratomalacia, and also to diseases of 
the retina causing nyctalopia and hemeralopia. Retinal, the active form of retinol, bonds with ‘opsine’ 
to form ‘rhodopsine’, the photosensitive molecule of rod photoreceptors. Aside from the visual 
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function, vitamin A is also needed for growth, survival, and immunity. Supplementation of vitamin 
A has been investigated since the 1920s and has been associated with a reduction of mortality and 
morbidity in different infectious diseases. 37,38
Total vitamin A and retinol
Goldberg et al (1988) investigated the data from NHANES-I and suggested a negative association 
between dietary vitamin A and AMD (P trend = 0.058). Since then vitamin A has been investigated by 
others. A meta-analysis included three prospective cohort studies and could not find an association 
of dietary vitamin A intake and incident early AMD (OR 0.98; 95% CI 0.81-1.18).5 Nevertheless, total 
vitamin A intake including supplement use appeared to be associated with a decrease of pigmentary 
abnormalities (P trend = 0.01).7
For advanced AMD, a trend for total vitamin A intake without supplements was found in a case 
control study (P trend = 0.05).10 Inclusion of supplement use increased the association (P trend = 
0.02). In this study, retinol per se did not have a significant effect. In the AREDS study, dietary Vitamin 
A intake including retinol had a beneficial effect on advanced AMD.9
Vitamin C
L-ascorbid acid, or vitamin C, is a powerful water-soluble antioxidant. Most mammals can synthesize 
vitamin C from glucose in their liver, except for some species like humans. These species lack the 
enzyme gulonolactone oxidase; as a consequence, diet is their only source for vitamin C. When diet 
does not include vitamin C, this can lead to scurvy, a lethal condition if not treated appropriately. 
Thus, vitamin C is needed to survive.39
Vitamin C may play a role in the pathogenesis of AMD. This potent antioxidant could potentially 
inhibit cellular damage from free radicals provoked by ultraviolet exposure in the retina. This 
hypothesis has been tested in many different study designs.
Dietary vitamin C
A meta-analysis has pooled the point estimates from four large, high quality cohort studies. The 
meta-analysis results, just like the single study results, showed no association vitamin C with incident 
early AMD (OR 1.11; 95% CI 0.84-1.46). No meta-analysis was carried out for advanced AMD, since not 
every study had investigated advanced AMD. Those studies that did, did not find an association of 
vitamin C with incident advanced AMD.5 A case-control study found a trend for intake of vitamin C 
versus a lower risk of neovascular AMD (P trend = 0.03).10
Supplementation of vitamin C
There are almost no studies which investigated vitamin C as the only supplement use. Most studies 
combined vitamin C together with other antioxidants.34 Recently, findings from a randomized 
double-masked, placebo-controlled trial showed that there was no association of 500 mg vitamin C 
supplementation with incident AMD (Hazard Ratio (HR), 0.99; 95% CI 0.75-1.31).40 Supplementation 
of vitamin C mostly included 500 mg. Experiments have shown that plasma of subjects is saturated 
at doses of 400 mg daily.39 Increasing the administered dose will probably provide the same results.
In conclusion, no strong association with AMD has been found for vitamin C, nor in diet, nor as 
supplementation.
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Vitamin D
Vitamin D does not only play a role in bone mineralization, but also has anti-inflammatory and 
antiangiogenic properties.41 Hence, a role for vitamin D has been suggested.
There are different forms of vitamin D. The two main forms are vitamin D2 (ergocalciferol) and 
vitamin D3 (cholecalciferol), which only differ from each other by one methyl-group.42,43 Vitamin D2 
is a plant-derived form and can be produced through ultraviolet exposure of foods. A food source 
naturally rich in vitamin D3 is fatty fish (Table 1).42 Diet, however, only contributes 10% of total 
serum level of vitamin D.44 The majority of vitamin D3 is from endogenous produced vitamin D3, 
which is synthesized in the skin under influence of ultraviolet light of the sun. In the liver, vitamin 
D3 is hydroxylated into 25-hydroxyvitamin D3 (25(OH)D), and in the kidney, it is hydroxylated to 
1,25-dihydroxyvitamin D3 (1,25(OH)D), the active metabolite of vitamin D.42
Several studies investigated the role of vitamin D with any form of AMD, as well as early and advanced 
AMD, and studied the nutrient intake as sunlight exposure, serum levels 25(OH)D, and intake of 
vitamin D via diet or supplements.
Vitamin D through sunlight exposure
The majority of vitamin D is produced through sunlight exposure of the skin. This environmental 
factor has been analyzed since the beginning of AMD research, with contradicting results. The 
combination of a potential harmful effect by DNA damage as well as a beneficial effect through 
Vitamin D may be an explanation.
Serum levels 25(OH)D
Parekh et al. (2007) was the first to report an association of serum levels of 25(OH)D with AMD in 
white non-Hispanics. The three highest quintiles of serum level 25(OH)D were inversely associated 
with early AMD after adjustment for age and serum cotinine, a biomarker for exposure to tobacco (P 
trend = 0.003).41 Among non-Hispanic Blacks and Mexican American individuals a similar, albeit non-
significant, effect was found. This study also analyzed the different characteristics of early AMD, soft 
drusen and pigmentary changes on the entire population. Soft drusen, but not pigmentary changes 
were associated with 25(OH)D serum levels; P trend = 0.006 and 0.40 respectively. An association 
with advanced AMD was not found, most likely due to the small number of advanced cases.
An inverse association of 25(OH)D levels with early AMD, but not with advanced AMD, was found in 
postmenopausal women < 75yrs (P trend = 0.01).44
A few studies have analyzed hypovitaminosis D as a marker for AMD. No associations within these 
analysis has been found for neovascular AMD 45, but a significant association was reported for 
hypovitaminosis with any form of AMD.46 Serum level of 25(OH)D lower than 50nmol/L increased 
the risk of AMD 3 times (OR 3.03; 95% CI 1.04-8.80). Although interesting, these results need to be 
interpreted carefully since the number of cases and controls was small (N=65), and the study has not 
yet been replicated.
Dietary vitamin D
 A positive association with decreased intake was found by a twin study, which selected 28 discordant 
twin pairs: one twin was diagnosed with advanced AMD; the other twin had no or only signs of early 
AMD. Vitamin D intake appeared significantly higher in twins with no or only early AMD (P = 0.048).47 
In some countries, dairy products are enriched with vitamin D, such as liquid milk in the United States 
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of America. One study showed that milk consumption was positively correlated with serum vitamin 
D levels (Pearson correlation coefficient, 0.2; P<0.001), and more than weekly milk consumption was 
associated with lower odds for early AMD. But only soft drusen were significantly inversely associated 
with the consumption of milk. No association of advanced AMD with milk consumption was found.41 
Fatty fish is another food which is rich in vitamin D, and this may also attribute to the protective effect 
that has been found for fatty fish.48,49
Supplementation of vitamin D
Results of supplement use are inconclusive.41,44 Most supplements contain vitamin D2, which is almost 
ten times less active than vitamin D3.43 This may explain the difficulty in finding a strong association. 
Parekh et al. (2007) did not find an association in the total population, but, after excluding those with 
high intake due to milk consumption, he did. To disentangle the effects, it would have been more 
interesting if he analyzed the use of vitamin D supplements in the population not consuming any 
milk.
Vitamin E
Vitamin E refers to a group of tocopherols and tocotrienols, of which the former is the most profuse 
form in nature and has the highest biological activity. Vitamin E deficiency therefore mainly refers to 
α-tocopherol. Vitamin E is a fat-soluble chain-breaking antioxidant, and may protect the retina from 
damage caused by free-radicals. High levels of this nutrient can be found in corn and soybean oil 
(Table 1).50
Plasma levels α-tocopherol
In the POLA study, no significant association was found between plasma levels of α-tocopherol and 
advanced AMD (P = 0.08). When α-tocopherol plasma levels were standardized to plasma lipids like 
cholesterol and triglycerides, the ratio was negatively associated with advanced AMD (P=0.004). The 
ratio was also associated with any signs of early AMD, drusen or pigmentary changes, in subjects free 
of advanced AMD (P=0.04). All associations were adjusted for potential confounding factors.51
Dietary vitamin E
Several prospective cohort studies have investigated the role of dietary vitamin E and the risk of 
developing AMD. Of these studies, three were of high quality and results were pooled quantitatively 
using meta-analytic methods. An almost significant association was found for vitamin E and incident 
early AMD (OR 0.83; 95% CI 0.69-1.01).5 For advanced AMD, an association was found in the long-
term follow-up of one study; higher intakes of total vitamin E (including supplement use) predicted 
advanced AMD. 11 This was not confirmed by the other studies.
Supplementation of vitamin E
Recently, a meta-analysis was published concerning three large trials supplementing vitamin E to 
healthy subjects.12 Vitamin E had been supplemented in different dosages of α-tocopherol, 50-402 
mg = 75-600IU versus placebo for 4-10 years. The complete sample consisted of 40,887 participants 
of which 20,438 had received α-tocopherol supplementation; 20,449 had been assigned to placebo. 
In the supplemented group, 405 individuals developed early AMD, and 42 advanced AMD. In the 
placebo group, 458 progressed to early AMD; 31 to advanced AMD. Thus, no associations were found 
(any type of AMD RR 0.98; 95% CI 0.89-1.08; advanced AMD RR 1.05; 95% CI 0.80-1.39).
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Many studies have investigated the role of vitamin E in chronic diseases. High-dose vitamin E 
supplements (≥ 268 mg=400 IU) have been linked to an increased risk of heart failure in people 
with vascular disease and diabetes. Supplements given in these trials were up to 15-fold higher 
than the maximum dietary intake in the cohort studies. Since a protective effect against AMD is 
dubious for vitamin E,52 extra care should be taken not to prescribe supplementation to those with 
cardiovascular risk factors.
LIPIDS
Almost 20% of the dry weight of the retina is accountable to lipids. Over half of all the retinal fatty 
acids are unsaturated; the majority of these are polyunsaturated fatty acids (PUFAs). Docosahexaenoic 
acid (DHA) is a PUFA which can be found in the photoreceptor outer segments, and which has been 
shown to be a survival factor for photoreceptors. The high concentrations of this lipid in the retina 
and its anti-inflammatory properties 53 suggests a potential role for omega-3 fatty acids in retinal 
disease.
Dietary intake lipids
Reported outcomes of dietary omega-3 fatty acids, fish consumption (rich of omega-3 fatty acids) 
and nut consumption have all been shown to be protective against early and late AMD.53 A meta-
analysis showed an inverse effect of high intake of omega-3 fatty acids and late AMD (OR 0.62; 95% 
CI 0.48-0.82).54 In contrast to omega-3 fat, high levels of trans-fat may potentially increase the risk of 
AMD, but consistent evidence on this notion is lacking.53
A large multi-centered case-control study found a link between the positive effect of omega-3 fatty 
acids and linolic acid, an omega-6 fatty acid. The beneficial effect of high intake of omega-3 fatty 
acids was particularly found in persons with a low intake of linolic acid.55 Similar results have been 
described for fish intake.48 This indicates that the ratio of omega-6/omega-3 fatty acids needs to be 
of the right balance. The most ideal ratio is 3:1 or 4:1, while in reality this is 10-50:1 for the average 
American.56
Interaction between AMD genes and intake of DHA and the other omega-3 lipid, eicopentaenoic 
acid (EPA), was studied in the Rotterdam Study. Homozygous carriers of the CFH variant Y402H could 
lower their risk of developing early AMD with high intake of DHA/EPA (P trend = 0.03). A same effect 
was found for carriers of the risk variant ARMS2 A69S (P trend= 0.01).
A similar effect was found for fish intake and CFH Y402H carriers. Weekly consumption of fish was 
associated with reduced risk of late AMD for carriers of the risk variant.49
Supplementation of omega-3 fatty acids
Very little is known on supplementation of omega-3 fatty acids as a single nutrient and AMD. A pilot 
trial was carried out in 38 patients with drusenoid pigment epithelial detachment in one eye, and 
the effect of oral supplementation with EPA 720mg/day and DHA 480 mg day was compared to 
no treatment (control group). After 6 months of supplementation, a significant increase of serum 
levels and red blood cell membranes of EPA and DHA was found, while no change was found in 
the control group. Since no exudative AMD occurred during the short follow up time, no inferences 
on supplementation of EPA/DHA can be made.57 Before long, the results of the AREDS2 trial are 
expected. In this trial the supplementation of lutein/zeaxanthin and/or omega-3 fatty acids and the 
risk of advanced AMD are being studied.58
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EPIGENETICS AND NUTRIENTS
Epigenetics refers to functional changes of the genome without a change in DNA nucleotide 
sequence. This could explain phenotypical differences in diseased monozygotic twins.59 Various 
nutrients may cause epigenetic changes. Among those reported to have this capacity, betaine (a 
choline derivate) and methionine have been associated with advanced AMD.47 In the US Twin Study 
of Age-Related Macular Degeneration, Seddon et al. (2011) found high dietary intake of betaine to 
be inversely associated with grade of AMD (P = 0.009; adjusted for age, smoking and differences 
between twins), but not with drusen size, drusen area or pigment area. She found an inverse 
association for dietary methionine and drusen area (P =0.033; but not with AMD grade, drusen size 
or pigment area. There was no significant association for dietary choline intake with the macular 
phenotype.
Betaine, choline, methionine and homocysteine are involved in the one-carbon metabolism pathway, 
which occurs in DNA methylation. Choline is oxidized to betaine, which, together with homocysteine, 
will produce methionine under the influence of vitamin B12. Methionine is an essential amino acid 
for DNA methylation.59 Dietary choline, betaine and methionine influence DNA methylation; higher 
intakes of choline and betaine showed lower plasma levels of homocysteine, and a reduction of 
inflammatory markers in serum.59,60 Higher levels of homocysteine or inflammatory markers were 
found to be risk factors for AMD.47 Further studies are needed to confirm these associations with 
AMD.
RESVERATROL
Resveratrol is a natural phenol produced by plants which may have anticancer and anti-inflammatory 
effects. It can be found in the skin of red grapes, and is also present in red wine, although in very low 
concentrations. Experiments have indicated that resveratrol may protect retinal pigment epithelial 
cells from oxidative stress in culture.61 This nutrient could have a beneficial effect on eye health 
and help protecting the macula against AMD. We are not aware of any ongoing trials investigating 
resveratrol supplementation and AMD.
SUPPLEMENTATION WITH COMBINED NUTRIENTS
Many nutrients have been supplemented together, making it impossible to investigate the role 
of the individual nutrients and risk of AMD. Studies supplemented different combinations and 
dosages, further hampering comparison. Nevertheless, it appears that supplementation of several 
nutrients combined can be beneficial; they could enforce each other. In the AREDS trial, a double-
masker clinical trial, participants were randomly subscribed to oral use of (1) antioxidant (vitamin C 
500 mg; vitamin E 400 IU; ß-carotene 15 mg), (2) zinc (zinc oxide 80 mg and cupric oxide 2 mg), (3) 
antioxidants plus zinc or (4) placebo. Estimates of RR show that those who were taking antioxidant 
and zinc had a 25% risk reduction of advanced AMD, while the groups that were taking antioxidant 
alone or zinc alone had a reduction of 17% and 21%, respectively.34
However, the more the merrier does not account for al nutrients. Nutrients that are alike mostly use 
the same uptake and transportation routes throughout the body. High levels of supplementation 
could then lead to competition between these nutrients, and this could even lead to deficiencies. An 
example of this is cupper deficiency caused by increased zinc consumption.32,34
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CONCLUSION
Nutrients and AMD have been widely studied. Not all prior questions have been answered, and 
new questions have already been launched. Nonetheless, from the current findings we conclude 
that a healthy diet for instance, as recommended by the United States Department of Agriculture 
in the food pyramid may help lower the risk of AMD with a special focus on carotenoids (lutein, 
zeaxanthin, lycopene), zinc, and omega-3 fatty acids (Table 3; Figure 2). Less firmly established, but 
also promising, appear a high intake of vitamin D and nutrients influencing epigenetics. Beneficial 
effects may be particularly present in those carrying a genetic risk of AMD.
A word of concern is at place. We need to keep in mind that the nutrients mentioned in this chapter 
are generally not consumed as single items, but accompanied by other nutrients. Furthermore, a 
healthy diet is correlated with other lifestyle factors, which makes it difficult to interpret the positive 
effect of a healthy diet by itself.
TABLE 3 - Overview of nutrients and risk of AMD 
Nutrient
Early 
AMD
Late 
AMD References
Astaxanthin NA NA
Betaine NA Ż? Seddon et al. 2011
α Carotene ~ Ź? Chong et al. 2007; Zhou et al. 2011
β Carotene Ż? ~ Chong et al. 2007; Evans 2012; Ho et al. 2011
β Cryptoxanthin ~ ~ Seddon et al. 1994; Chong et al. 2007
Lutein/zeaxanthin ŻŻ ŻŻ Ma et al. 2012; Sabour-Pickett et al. 2012
Lycopene ŻŻ ŻŻ Mares-Perlman et al. 1995 Simonelli et al. 2002; Cardinault et al. 2005; Morris et al. 
2007
Methionine NA Ż? Seddon et al. 2011
Omega-3 fatty acids ŻŻ ŻŻ Chong et al. 2008; Kishan et al. 2011
Omega-6 fatty acids NA Ź? Kishan et al. 2011
Resveratrol NA NA
Selenium NA NA
Vitamin A (total) ~ Ż? Seddon et al.1994; Chong et al. 2007; San Giovanni et al. 2007
Vitamin A (retinol) ~ ~ Seddon et al. 1994; San Giovanni et al. 2007
Vitamin C ~ Ż? Seddon et al. 1994; Chong et al. 2007
Vitamin D Ż? Ż? Parekh et al. 2007; Millen et al. 2011; Seddon et al. 2011; Graffe et al. 2012
Vitamin E* ~ ~ Chong et al. 2007; Evans 2012
Zinc Ż? ŻŻ Chong et al. 2007; Evans 2008; Ho et al. 2011
* There are many different forms of vitamin E, the most common is α-tocopherol
ŻŻ lowering
Ż? possible lowering
~ questionable
Ź? possible increase
ŹŹ increase
NA Not able; no results available
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2 times per day
Limited intake
0-2 times per day
Butter
Dairy products: milk, cheese 
etc. or soy products
Poultry, eggs
Nuts, seeds, beans, lentils
1-3 times a day
Vegetables
Unlimited; At least 200 g/day 2-3 times a day
Fruits
Rice, potatoes, whole cereal products; bread, pasta
Vegetable oils
Every day, small amounts
Every meal
Fatty Fish
2 times per week
Red meat
FIGURE 2 - Nutritional advice for lowering risk on AMD
This food pyramid gives a nutritional advice for lowering risk on AMD. All the foods in bold contain nutrients 
which have been associated with a lower risk on developing AMD.
Take-home messages
• Vitamins and minerals are essential for normal retinal physiology. Supplementation of these 
nutrients mostly has a dosage outside the recommended daily allowance, and therefore should 
be prescribed with thought.
• We consume foods, not nutrients.
• Dietary intake of carotenoids (lutein, zeaxanthin, lycopene) zinc and omega-3 fatty acids can 
help lower the risk of AMD
• Supplementation of lutein, zeaxanthin and zinc can help lower the risk of AMD.
• Vitamin D and nutrients influencing epigenetics are promising new topics for more in-depth 
research.
• Those at genetic risk should be made aware of their potential to lower the risk of AMD through 
diet.
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ABSTRACT
Purpose Many studies have shown that various micronutrients reduce risk of age-related macular 
degeneration (AMD). However, what a diet offering protection should entail is not clear. We 
investigated whether general dietary guidelines for an overall healthy lifestyle is beneficial for AMD.
Design Prospective population-based Rotterdam Study
Participants 3448 persons aged 55+ years with gradable fundus photographs, no AMD at baseline, 
follow-up data, and reliable data on food consumption.
Methods Fundus photographs from 5 examination rounds were graded for the presence of any AMD. 
Dietary data were collected at baseline using a validated 170-item food frequency questionnaire and 
food categories based on Dutch Dietary Guidelines were categorized into food patterns. Associations 
of food patterns with incident AMD were analyzed using Cox-proportional hazards models. Risk 
profiles were analyzed for those adhering to recommended food patterns. Analyses were adjusted 
for age, sex, total energy intake, smoking, body mass index, hypertension, education and net year 
income.
Main Outcome Measures Incident early and late AMD determined per visit during a mean follow-up 
period of 9.1±5.8 years.
Results A total of 754 persons developed incident AMD. Intake of fish (2x/week) decreased the risk 
of incident AMD; hazard ratio (HR) 0.76 [95% Confidence Interval (CI) 0.60-0.97]). Combined intake 
of the recommended proportions of fish, vegetables and fruit showed a further reduction of the risk 
of incident AMD (HR 0.58 [95%CI 0.36-0.93]). Individuals adhering to this food pattern were younger, 
had higher net income, and were less likely to smoke, but risk lowering effects remained significant 
after additional adjustment for these factors. Intake of food categories vegetables (≥200gr/day), fruit 
(2x/day), and fish(2x/week) was 30.6%, 54.9% and 12.5%, respectively. Combined intake of these 
three food categories was consumed by 3.7% of the population. Only 0.3% adhered to the food 
pattern including all food categories.
Conclusion Only a small portion of the population adheres to dietary recommendations for 
an overall healthy lifestyle. However, a diet of 200 grams of vegetables/day, 2x fruit/day, and 2x 
fish/week is associated with a significantly reduced risk of AMD. This suggests that these dietary 
recommendations are useful for counseling persons at risk of AMD. 
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INTRODUCTION
Despite recent therapeutic developments, age-related macular degeneration (AMD) is still the 
leading cause of visual impairment in the elderly of industrialized countries. In Europe, the number 
of affected persons is expected to increase with the aging population to 18.8 million in 2040.1,2 As 
current therapeutic options are still unable to improve the long term visual prognosis, unraveling the 
etiology of AMD has become a strong research focus. The disease is caused by a complex interplay of 
many genetic and nongenetic factors,3 and nutrition is a key player among the amendable lifestyle 
factors.
Nutrients with anti-oxidative properties, in particular lutein and zeaxanthin, zinc, vitamins C and E, 
and the polyunsaturated omega-3 fatty acids, have been shown to reduce risk of developing AMD. 
Evidence for these beneficial effects stems from trials with high dose supplementation,4,5 as well 
as from reports on dietary intake.6-13 A diet which combines multiple beneficial nutrients appears 
to be more protective against AMD than an unvaried diet.10,14-16 Possible explanation is that the 
bioavailability and nutritional value of a nutrient depends on the concomitant uptake of other 
nutrients.
Although it is clear which micronutrients are important for AMD, clinicians and patients are 
still doubtful about the diet pattern which is beneficial for persons at risk of AMD. Several 
studies evaluated dietary patterns,14-16 nevertheless, how to translate their findings into clinical 
recommendations remains challenging. In this study, we aimed to assess whether simple dietary 
guidelines are associated with a reduced the risk of AMD.17 We therefore defined and analyzed 
recommended minimum intake values for different food categories and food patterns based 
on Dutch Dietary Guidelines and recommendations by the National Food Center (NFC). We also 
calculated the proportion of the population who adhered to these recommendations, characterized 
their profile, and investigated their risk of AMD.
METHODS
Study Population
The Rotterdam Study is a prospective, population-based cohort study investigating the frequencies 
and determinants of cardiovascular, neurological, ophthalmological, and locomotor diseases. The 
rationale and design have been described in detail elsewhere.18 In brief, all inhabitants’ aged 55 
years and older living in Ommoord, a city district of Rotterdam, The Netherlands, were invited to 
participate in the study (99% were from European descent). The ophthalmologic part of the study 
became operational after the pilot phase of the study had started, and included 6780 participants. 
A baseline home interview and examinations at the study center were performed from 1990 to 
1993 and 4 follow-up examinations were performed in 1993-1995, 1997-1999, 2002-2004, and 
2009-2011. The Rotterdam Study was approved by the Medical Ethics Committee of the Erasmus 
MC and by the Ministry of Health, Welfare, and Sport of the Netherlands, implementing the ‘‘Wet 
Bevolkingsonderzoek: ERGO (Population Studies Act: Rotterdam Study).’’ All participants provided 
written informed consent to participate in the study and to obtain information from their treating 
physicians.
For the current analysis, participants were eligible if they had gradable fundus photographs 
(N=6419) at baseline, at least one follow-up eye examination, and valid dietary assessments, which 
resulted in a study population of N=4201 persons (62% of persons with eye data (Figure 1: Diagram 
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showing selection of participants at risk of any AMD of the Rotterdam Study)). Of these, persons with 
a diagnosis of dementia were excluded because of unreliable dietary recall, persons with macular 
pathology other than AMD hindering appropriate grading of the macula, and persons with AMD 
(early or late) at baseline. Hence, only persons at risk of incident AMD were included in the analysis.
Reliable eye and  
diet data at baseline 
n = 5185
Excluded:  
x missing diet data n = 1234 
R not attending study center for dietary 
assessment  
R pilot phase  
R suspected dementia  
R unreliable intake data  
R logistical reasons  
Excluded:  
x died before first follow up visit n = 107 
x prevalent AMD n = 386 
x no follow-up visits n= 543 
x missing data = 197 
Excluded:  
x no gradable fundus photographs n = 361 
 
Reliable eye  
n =6419
 
Rotterdam Study 
 participants with eye 
examination 
N = 6780 
Eligible for incident AMD 
N= 4201 
FIGURE 1 - Selection of participants at risk of any AMD of the Rotterdam Study
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Assessment of AMD
Each participant underwent a comprehensive ophthalmic examination, including color fundus 
photography. Fundus photography of the macular area was performed after pupil dilation using a 35° 
fundus camera (Topcon TRV-50VT; Topcon Optical Company). This was replaced by a Topcon digital 
35° color fundus camera (Topcon TRC 50EX with a Sony DXC-950P digital camera; 0.44 megapixel, 
Minato, Japan) during the third and fourth follow-up exam.
Grading procedures and graders were identical at baseline and follow-up. Graders were masked to 
non-ocular determinants, including dietary intake. Each eye was graded according to the Wisconsin 
Age-related Maculopathy Grading19 and classified using the Rotterdam classification.20 Classification 
of the person was based upon the eye with the most severe AMD stage. The outcome was incident 
AMD, i.e., persons who developed signs of early or late AMD during the study period; no AMD was 
used as the reference. Early AMD was defined by presence of soft distinct drusen with pigmentary 
changes, soft indistinct drusen with or without pigmentary changes or reticular pseudodrusen with 
or without pigmentary changes. Late AMD was defined by presence of geographic atrophy and/or 
neovascular AMD. No AMD was defined as no signs of early or late AMD.
Dietary Assessment
At baseline, dietary intake was assessed using a two-stage approach: 1) Self-administered checklist 
at home in which subjects were asked which foods were consumed weekly, or at least twice a month 
during the preceding year. 2) Structured interview with a trained dietician at the research center 
reviewing self-administered checklists for frequencies and amounts. The interview included a 170-
item, validated semi-quantitative Food Frequency Questionnaire. This questionnaire was validated 
and adapted for use in the elderly.17,18 Frequency of each intake was recorded as times per day, per 
week, or per month. The portion sizes in grams per day (gr/day) were estimated using standardized 
household measures.19 Using the computerized Dutch Food Composition Table of 1993, these 
dietary data were converted to macronutrient intakes.20
Stratification into food categories and food patterns
We defined food categories and patterns with recommended minimum intake values based on 
recommendations by the NFC, which were published as the Dutch Dietary Guidelines in 200617 
(Supplementary Table 1).25 Intake of each food category was coded as ‘below recommended 
minimum intake values’ and ‘equal to and above ‘recommended minimum intake values’ in grams 
per day. NFC did not provide maximum intakes for the different food categories except for ‘meat’; for 
which a maximum of 500 grams per week was taken into account. For the analysis, we calculated the 
equivalent intake per day (500 gr / 7=71 gr/day). Minimal amount of meat per day (224 gr / 7 = 32 
gr/day) was based on 2 portions of meat per week. The recommended intake of ‘vegetables’ was 200 
grams per day; we further stratified this category according to those rich in anti-oxidants associated 
with a reduced risk of AMD..4,5,10 ‘Fruit’ intake was advised as 2 large pieces of fruit per day, which is 
equivalent to approximately 200 grams of fruit per day. The recommended ‘fish’ intake was 2 potions 
a week, however, for our analysis, we calculated the equivalent intake of fish per day (224 gr / 7 = 32 
gr/day). For the intake of ‘eggs’, 2 pieces a week was recommended and the equivalent per day was 
used in our analysis. We did not consider the recommended category ‘beverages’, as data on this 
category were unreliable.
We based the design of food patterns on various food categories (Table 2). Particularly focusing on 
foods with well-established relationships with AMD (i.e., lutein, zeaxanthin, omega-3 fatty acids). 
According to the Nevo tables, these nutrients can be found in vegetables, fruits, and fish. Beside 
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fish, we also studied the effect of poultry and meat as an alternative animal protein source. We first 
analyzed a pattern containing all food categories (#1, includes: ‘vegetables’, ‘fruit’; ‘fish’, ‘eggs’, ‘poultry’, 
‘meat’, ‘dairy’, ‘potatoes’, ‘legumes’, ‘grains’ and ‘fat products’ like butter and margarine). Subsequent, 
food patterns (2-9) each contained a more limited set. Persons adhering to a food pattern were 
defined as those with intakes equal to and above the recommended minimum intake values in 
grams per day; persons with intakes below the recommended minimum intake were considered the 
reference group.
TABLE 2 - Food patterns based on Dutch Dietary Guidelines
Food pattern 1: Vegetables ≥ 200gr; fruit ≥ 200gr; fish ≥ 32gr; [egg, and/or poultry, and/or meat] ≥ 80gr; and dairy 150 
gr;[potatoes, and/or legumes, and/or grains] ≥ 319gr; fat products ≥ 15gr
Food pattern 2: Vegetables ≥ 200gr; fruit ≥ 200gr; fish ≥ 32gr; [egg and/or poultry and/or meat] ≥ 80gr
Food pattern 3: Vegetables ≥ 200gr; fruit ≥ 200gr; fish ≥ 32gr; [egg and/or poultry] ≥ 48gr
Food pattern 4: Vegetables ≥ 200gr; fruit ≥ 200gr; fish ≥ 32gr; poultry ≥ 16gr
Food pattern 5: Vegetables ≥ 200gr; fruit ≥ 200gr; fish ≥ 32gr; 32gr ≤ meat ≤ 71gr
Food pattern 6: Vegetables ≥ 200gr; fruit ≥ 200gr; poultry ≥ 16gr
Food pattern 7: Vegetables ≥ 200gr; fruit ≥ 200gr; egg ≥ 32gr
Food pattern 8: Vegetables ≥ 200gr; fruit ≥ 200gr; 32gr ≤ meat ≤ 71gr
Food pattern 9: Vegetables ≥ 200gr; fruit ≥ 200gr; fish ≥ 32gr
Abbreviations: gr = gram
Assessment of covariates
Information on covariates was collected through face-to-face, standardized interviews and physical 
examinations performed at baseline. Smoking was categorized in never, past, current. Education 
variable was divided in two groups < = 12 years of education versus 13+ years. Body mass index (BMI) 
was calculated as weight in kilograms divided by height squared in meters. Blood pressure, systolic 
and diastolic, was calculated as the average of two consecutive measurements, using random-zero 
mercury sphygmomanometers. Hypertension was defined as a systolic blood pressure ≥ 140 mmHg 
or a diastolic blood pressure ≥ 90 mmHg or use of anti-hypertensive medication. Net year income 
at baseline was classified low (≤ 35,999 Dutch guilders), average (36,000 thru 48,999 Dutch guilders) 
and high (≥49,000 Dutch guilders). Registration of deceased persons during follow up was complete 
until January 1st, 2016.
Statistical Analysis
Characteristics of participants with and without incident AMD were compared using analysis of 
covariance (ANCOVA) for continuous variables and logistic regression analysis for discrete variables, 
adjusted for age and sex. Effect estimates for the food categories were adjusted for total energy 
intake (TEI), age, and sex. We investigated adherence of the daily food intake for each food category 
in our population and calculated the frequencies. The association of food categories and food 
patterns with incident AMD was analyzed using Cox-proportional hazards models. Intake below 
recommended minimum intake values was defined as the reference. All analyses were initially only 
adjusted for age and sex, and subsequently also for TEI, smoking, BMI, hypertension, education and 
net year income.
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Profiles of persons who adhered to the beneficial food pattern and those who did not were 
further investigated. To this end, the variables age, sex, smoking, hypertension, BMI, mortality and 
total energy intake were compared between those adhering to food pattern 9 (intake per day for 
vegetables ≥ 200gr and fruit ≥ 200gr and fish ≥ 32gr) and those not meeting these criteria using 
ANCOVA for continuous variables and logistic regression analysis for discrete variables. All these 
analyses were adjusted for age and sex.
We used P <0.05 to denote statistical significance, and all tests were 2-sided. The proportional 
hazards assumption was checked using statistical  tests  and graphical diagnostics with scaled 
Schoenfeld residuals. All analyses were performed using SPSS version 21.0 (IBM Corp. Released 
2012. IBM SPSS Statistics for Windows, Version 21.0. Armonk, NY: IBM Corp), except for the tests and 
graphical diagnostics with scaled Schoenfeld residuals which were performed in R (survival package, 
R-project, Institute for Statistics and Mathematics, R Core Team (2013), Vienna, Austria, version 3.0.2).
RESULTS
During a mean follow-up of 9.1±5.8 years, 754 participants developed incident AMD: 681 early and 
73 late AMD. Baseline characteristics for those with and without incident AMD are described in Table 
3. Participants with incident AMD were less frequently diagnosed with hypertension (49.5% vs 52.8%; 
adjusted P = 0.03) and fish intake was lower compared to those without AMD (median intake fish, 7.4 
grams per day versus 6.6 grams per day, adjusted P = 0.03). Other baseline characteristics were not 
significantly different between the two groups.
First, we calculated the risk of incident AMD for food categories and patterns (Table 4). Intake of fish 
was associated with a reduced risk of incident AMD by 24% (Hazard ratio (HR) 0.76 (95% confidence 
Interval (CI) 0.60-0.97) adjusted for age and sex), which remained significant after additional 
adjustment for smoking, body mass index, hypertension, education, net year income and total 
energy intake (HR 0.77 (95% CI 0.60-0.97). Associations with other food categories did not reach 
statistical significance. With respect to food patterns, food pattern 9 (vegetables, fruit and fish) was 
significantly associated with a reduced risk of incident AMD (HR 0.56 (95%CI 0.35-0.89); an association 
which remained significant in the full model (HR 0.58 (95% CI 0.36-0.93). Other food patterns did not 
show a significant association with AMD.
Second, we assessed adherence to the previously defined food categories with recommended 
minimum intake values based on Dutch Dietary Guidelines. Daily food intake according to these 
food categories showed that only 2.0% of the population met the recommended intake of eggs, 
while a high of 82.6% met the recommendations for legumes. For vegetables, fruit, and fish, the 
proportion of participants with minimum intakes was 30.6%, 54.9% and 12.5%, respectively (Table 4). 
For the food patterns, only 0.3% of our population adhered to the complete pattern (Food pattern 1); 
the most commonly followed (7.1%) food pattern was food pattern 6 (vegetables, fruit, poultry). The 
food pattern which met the recommended minimal intake of vegetables, fruit and fish (Food pattern 9) 
was followed by only 3.7%.
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TABLE 3 - Baseline characteristics of the study population
Variables*
No AMD
N=3448
Incident AMD
N=754 P-Value**
Age at baseline, yrs 66.5 (7.2) 67.0 (6.9) 0.06
Sex, % males 40.7 41.0 0.81
Smoking, % 0.44
Past 42.69 45.5
Current 22.9 22.3
BMI, kg/m2 26.4 (3.6) 26.2 (3.5) 0.19
Hypertension, % 52.8 49.5 0.03
Education, % more than 12 yrs 66.2 68.0 0.18
Net year income, % 0.24
Low 25.8 23.9
Average 44.6 46.6
High 29.6 29.6
Total energy intake, Kcal 1970 (499) 2000 (522) 0.08
Food Categories, median (IQR)
Vegetables g/d 164.7 (92.0) 167.3 (81.6) 0.49
Cruciferous & Green Leafy, g/d 45.5 (31.7) 46.4 (29.5) 0.84
Red & Yellow g/d 22.2 (18.7) 22.0 (19.0) 0.78
Other Vegetables g/d 92.5 (61.6) 96.1 (59.8) 0.25
Fruit, g/d 213.7 (160.1) 220.1 (159.5) 0.06
Fish, g/d 7.4 (21.4) 6.6 (21.4) 0.03
Fat products, g/d 24.9 (18.0) 25.4 (18.0) 0.43
Meat, g/d 92.1 (56.5) 93.6 (52.1) 0.77
Grains, g/d 140.0 (74.4) 142.8 (76.3) 0.60
Whole grains, g/d 120.0 (82.0) 120.6 (81.7) 0.51
Refined grains, g/d 10.0 (29.6) 9.9 (24.9) 0.69
Poultry, g/d 8.9 (15.2) 8.6 (13.6) 0.24
Eggs, g/d 14.3 (7.1) 14.3 (7.1) 0.64
Potatoes, g/d 121.8 (85.7) 117.5 (85.5) 0.97
Legumes, g/d 38.1 (28.5) 39.3 (27.3) 0.70
Dairy, g/d 351.8 (298.0) 369.4 (324.9) 0.13
* Values are means and SD unless otherwise specified.
**P-values were calculated using analysis of covariance for continuous variables and logistic regression for discrete variables, 
and adjusted for age and sex. P-values for foods were beside adjustment for age and sex, also adjusted for total energy intake.
Abbreviations: AMD = age-related macular degeneration, SD = standard deviation, Kcal = kilo calorie, yrs = years, g/d = grams 
per day, IQR = interquartile range
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TABLE 4 - Risk of AMD for those following the recommended intakes of food categories and patterns versus 
those who with lower intakes
Variables
Following at least RMIV n (%) Model 1 Model 2
+ - HR (95% CI) HR (95% CI)
Food categories
Vegetables 1286(30.6) 2916(69.4) 0.99 (0.85-1.16) 1.01(0.86-1.18)
Cruciferous & Green Leafy 1376(32.7) 1826(67.3) 0.99(0.85-1.15) 0.98(0.84-1.14)
Red & Yellow 1371(32.6) 2831(67.4) 1.01(0.87-1.17) 1.02(0.87-1.19)
Other 1415(33.7) 2787(66.3) 0.99(085-1.16) 1.00(0.86-1.17)
Fruit 2305(54.9) 1897(45.1) 1.03(0.89-1.19) 1.03(0.89-1.20)
Fish 525(12.5) 3678(87.5) 0.76 (0.60-0.97) 0.76(0.60-0.97)
Fat products 3521(83.8) 681(16.2) 1.08(0.88-1.32) 1.00(0.81-1.23)
Meat
<32 gr 1 1
32 - 71 gr 920(21.9) 3282(78.1) 0.99 (0.71-1.38) 0.91 (0.65-1.28)
>71 gr 1.11 (0.82-1.51) 1.11 (0.81-1.52)
Grains 1188(28.3) 3014(71.7) 1.06(0.89-1.25) 1.00(0.83-1.20)
Poultry 1155(27.5) 3014(72.5) 0.91(0.77-1.07) 0.92(0.78-1.09)
Eggs 83(2.0) 4119(98.0) 1.19(0.74-1.93) 1.10(0.67-1.78)
Potatoes 2217(52.8) 1985(74.8) 0.96(0.83-1.11) 0.91(0.78-1.06)
Legumes 3471(82.6) 731(17.4) 1.13 (0.92-1.38) 1.11(0.90-1.36)
Dairy 870(20.7) 3332(79.3) 1.17 (0.99-1.39) 1.13 (0.95-1.35)
Food patterns
Pattern 1 11(0.3) 4178(99.4) 0.90(0.23-3.62) 0.90(0.22-3.64)
Pattern 2 24(0.6) 4178(99.4) 0.95(0.36-2.54) 0.96(0.36-2.57)
Pattern 3 25(0.6) 4177(99.4) 0.95(0.35-2.53) 0.95(0.35-2.56)
Pattern 4 84(2.0) 4118(98.0) 0.64(0.35-1.16) 0.65(0.36-1.18)
Pattern 5 40(1.0) 4162(99.0) 0.72 (0.32-1.60) 0.74 (0.33-1.66)
Pattern 6 299(7.1) 3903(92.9) 0.81(0.60-1.09) 0.81(0.60-1.10)
Pattern 7 18(0.4) 4184(99.6) 1.68(0.70-4.10) 1.62(0.67-3.92)
Pattern 8 195(4.6) 4007(95.4) 0.97 (0.69-1.36) 1.01 (0.72-1.41)
Pattern 9 155(3.7) 4047(96.3) 0.56 (0.35-0.89) 0.58(0.36-0.93)
Model 1: adjusted for age and sex
Model 2: model 1 + smoking, body mass index, hypertension, education, total energy intake, net year income
Abbreviations: AMD = age-related macular degeneration, CI = confidence interval, HR = hazard ratio, RMIV = recommended 
minimum intake values, gr = gram
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TABEL 5 - Risk profiles of persons who consume the recommended amount of fish, vegetables and fruit (Food 
pattern 9)
Variables* No intake FVF (N=4047) Intake FVF (N=155) P-Value**
Characteristics
Age at baseline, yrs 66.7 (7.2) 64.9 (6.6) <0.001
Sex, % males 40.8 39.4 0.65
Total energy intake, Kcal 1972 (501) 2060 (546) 0.02
Total protein intake 81.2 (19.2) 94.4 (24.0) <0.001
Intake vegetable protein 28.2 (8.2) 31.6 (9.7) <0.001
Total carbohydrates intake 212.1 (61.1) 219.3 (68.4 0.13
Total fat intake 80.4 (27.2) 80.3 (28.5) 1.00
Smoking, % <0.001
Past 43.2 47.7
Current 23.1 14.2
Hypertension, % 52.4 54.8 0.16
BMI, kg/m2 26.3 (3.6) 26.7 (3.3) 0.12
Education, % more than 12 yrs 67.3 73.0 0.29
Net year income, % 0.05
 Low 25.7 20.0
 Average 45.1 39.4
 High 29.2 40.6
Deceased during follow up, % 51.5 40.6 0.29
Food Categories, median (IQR)
Vegetables g/d 162.54 (86.2) 246.5 (62.2) <0.001
Cruciferous & Green Leafy, g/d 45.1 (30.8) 65.1 (32.3) <0.001
Red & Yellow g/d 21.9 (18.2) 35.2 (25.0) <0.001
Other Vegetables g/d 91.6 (58.9) 148.0 (51.9) <0.001
Fruit, g/d 209.6 (157.8) 311.6 (138.3) <0.001
Fish, g/d 6.6 (20.1) 42.7 (21.4) <0.001
Butter & Margarine, g/d 25.1 (18.0) 22.5 (18.9) <0.001
Meat, g/d 92.6 (55.2) 85.2 (64.7) 0.005
Grains, g/d 140.0 (74.4) 137.7 (78.0) 0.47
Whole grains, g/d 120.0 (81.7) 123.1 (96.3) 0.56
Refined grains, g/d 10.0 (29.9) 5.0 (19.9) 0.02
Poultry, g/d 8.9 (15.7) 17.9 (15.0) <0.001
Eggs, g/d 14.3 (7.1) 14.3 (7.1) 0.75
Potatoes, g/d 121.8 (85.5) 106.9 (73.4) 0.01
Legumes, g/d 38.2 (28.3) 43.8 (28.1) 0.05
Dairy, g/d 352.9 (301.0) 374.7 (292.6) 0.30
 * Values are means and SD unless otherwise specified.
**P-values were calculated using analysis of covariance for continuous variables and logistic regression for discrete variables, 
and adjusted for age and sex.
Abbreviations: FVF = recommended minimum intake values, of fish, vegetables & fruit (Food pattern 9), yrs = years, BMI = 
body mass index, Kcal = kilo calorie, SD = standard deviation, IQR = interquartile range, g/d = grams per day
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Third, we aimed to investigate the characteristics of those who managed to adhere to Food pattern 9, 
and studied the risk profiles of these individuals (Table 5). Persons who consumed the recommended 
intake of fish, vegetables and fruit were younger than those who did not (adjusted P<0.001), less 
likely to smoke (adjusted P<0.001), had higher intake of total calories (adjusted P=0.02), and higher 
intake of protein (adjusted P<0.001), in particular vegetable protein (adjusted P<0.001. Persons who 
adhered to Food pattern 9 also had a lower intake of fat products (22.5 (18.9) compared to 25.1 (18.0) 
adjusted P<0.001), a lower intake of meat (85.2 (64.7) - 92.6 (55.2) adjusted P = 0.005), a lower intake 
of refined grains (5.0 (19.9) – 10.0 (29.9) adjusted P=0.02) and a lower intake of potatoes (106.9 (73.4) 
- 121.8 (85.5) adjusted P = 0.01). But had a higher intake of poultry (17.9 (15.0) - 8.9 (15.7) adjusted 
P<0.001), and a higher intake of legumes (43.8 (28.1) - 38.2 (28.3) adjusted P = 0.05). We conducted an 
additional risk analysis for food pattern 9 adjusting for these potential confounders. The associations 
between food pattern 9 and AMD risk remained significant in both models (full model: HR 0.58 (95% 
CI 0.36-0.93).
The proportional hazards assumption was checked using statistical tests and graphical diagnostics 
with scaled Schoenfeld residuals and was met for all food patterns. Schoenfelds rho ≤ 0.057 and P≤ 
0.163. For food pattern 9: rho = 0.04 and P = 0.775.
DISCUSSION
Our data showed that recommended minimal intake values based on Dutch Dietary Guidelines of 
200 gr vegetables per day, 2 portions of fruit per day and two times fish per week, was associated 
with a reduced risk of AMD by 42%. Only following the recommendations for fish intake (twice a 
week) was sufficient for a risk reduction of 24%. The dietary recommendations from the NFC have 
been established by nutritional researchers and dieticians with the aim to improve general health. 
These Dutch Dietary Guidelines are not extraordinary, but closely correspond to recommendations 
by health councils from other countries, such as the United States, Germany, France, United 
Kingdom, and Japan. All recommend one to two portions of (particularly fatty) fish per week. The 
NFC recommendations for vegetables and fruit correspond to those from the United States, France, 
United Kingdom, and Japan. Germany recommends even higher minimum dosages: 400 gr/day of 
vegetables and 250 gr/day of fruit.26
Of the 10 food categories, only the category ‘fish’ reached statistical significance for association 
with AMD. Fish was not a frequently consumed food in our population, only 12.5% had regular 
intake of fish. Data from the NFC show that the most commonly eaten fish in the Netherlands are 
smoked salmon, salted herring, and canned salmon with an average consumption of 3.6 kg/year.17 
In comparison, the average fish consumption per person in the rest of Western Europe was 26.0 
kg/year, and in Japan up to 66.0 kg/year.27 Investigators of the Australian Blue Mountain Eye Study 
also reported a protective effect of fish.7,28 Fish is a natural source of omega-3 poly unsaturated fatty 
acids, of which the highest concentrations are found in squid, cod, and tuna.24 Almost 20% of the dry 
weight of the retina is accountable for lipids, mainly consisting of polyunsaturated fatty acids. These 
are highly present in photoreceptor outer segments, which improves fluidity of the photoreceptor 
membranes that results in a faster response to stimulation.29 There is now ample evidence that 
these fatty acids may protect against ischemia, as well as against light-, oxygen-, and inflammatory 
damage contributing to AMD.29,30
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Vegetables and fruit contain carotenoids, which have antioxidant properties. In literature, many 
different types of carotenoids have been analyzed in association with AMD. The most frequently 
studied carotenoids are lutein and zeaxanthin. These carotenoids form the major components of 
macular pigment and are involved in maintenance of the morphologic and functional integrity of 
the retina.31 Lutein and zeaxanthin concentrate in the macula and have the capacity to filter blue 
light and quench reactive oxygen species, thereby reducing light-induced oxidative damage30,31 as 
well as lowering inflammation and protecting neural membranes.32 For the single food categories 
‘vegetables’ and ‘fruit’, no significant association with incident AMD was found. Although intake was 
reasonable, the type of vegetables and fruit consumed in the Netherlands may not contain sufficient 
beneficial nutrients for AMD. Abundantly eaten vegetables in the Netherlands are lettuce, tomatoes, 
cucumber, red bell pepper, and leek. Vegetables containing the highest concentrations of lutein 
and zeaxanthin such as kale, endive, spinach, and orange bell pepper are not consumed in great 
amounts.24 Similarly, the most commonly eaten fruit are apple, pear, orange, and banana, while the 
less consumed blackberry, khaki, and raspberry contain the highest concentration of lutein and 
zeaxanthin.17,24 Other carotenoids, like α-carotene, β-carotene, β-cryptoxanthin and lycopene have 
been studied less thoroughly than lutein and zeaxanthin in association with AMD. Unfortunately, 
there is no clear evidence that dietary intake of these carotenoids lower risk of AMD,33 except for 
dietary intake of β-carotene, which reduces the risk of AMD in particular in those at high genetic 
risk.34 β-carotene can be found in dark-leafy vegetables like spinach and kale, and in yellow and 
orange vegetables like carrots and bell peppers.24
Our findings are consistent with recent studies on dietary patterns and AMD. The Melbourne 
collaborative cohort study showed that higher intake of grains and fish reduced the risk of late AMD 
considerably.14 Intake of vegetables and fruit alone did not associate with late AMD; the combined 
intake of these foods was not studied. Merle et al. investigated the Mediterranean diet which is 
characterized by high intake of vegetables, fruit, whole grains, legumes, nuts and fish, and limited 
intake of red and processed meat. This diet significantly reduced the risk of progression to late AMD by 
one fourth.16 Chiu et al. studied an ‘Oriental’ food pattern, typified by a high intake of vegetables and 
fish, and also found protection against AMD. By contrast, the ‘Western’ diet which was characterized 
by a high intake of processed food and red meat, increased the risk up to 50% for late AMD.15
It is well established that combined intake of foods influences bio-availability and nutritional value 
of individuals nutrients. In our study, we observed that the combined intake of vegetables, fruit, and 
fish performed better than each item by itself. Carotenoids, nutrients in vegetables and fruits, are 
fat-soluble nutrients and their uptake by the intestine is better and more consistent when they are 
delivered via a lipid matrix, for instance from fish intake.35-37 In addition, combined intake of foods can 
lead to competitive processing. For instance, meats and egg yolk are the major source of the omega-6 
fatty acidarachidonic acid (AA),35,38 and excessive intake of AA interferes with omega-3 processing 
through competition via enzymes in the eicosanoid pathway.29,39 A high omega-6:omega-3 ratio 
has been associated with cardiovascular disease and a variety of inflammation-related diseases.29 
This exemplifies the complexity of dietary effects, and indicates that single nutrient studies tend to 
overlook the entire context.
The type of persons consuming the recommended daily intake of fish, vegetables and fruit (food 
pattern 9) were younger and less likely to smoke. Their total energy intake was higher, which seemed 
to come from a higher intake of vegetable proteins. Net household income was higher in the group 
adherent to food pattern 9. However, this did not explain the relationship with diet as income was 
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not significantly associated with AMD. Nevertheless, individuals with higher standards of living and 
education generally have healthier dietary eating patterns, and we cannot exclude that residual 
confounding may play a role.40,41
Strengths of our study were the prospective design and large study population, the extensive 
170-item Food Frequency Questionnaire ascertained before the onset of disease, the detailed 
and consistent diagnosis of AMD features throughout the study, and the availability of large set 
of covariates for analysis. Potential weaknesses were selective nonresponse of the more diseased 
eligible, the imprecision of dietary data, missing data on physical exercise, and the lack of power to 
assess risks in small subgroups, especially for the late AMD cases. Only 62% of the persons with an eye 
exam, reliable diet data at baseline and at least one follow-up entered the analysis due to missing data 
(Figure 1). Participants with missing data tended to be older; included more women; had less than 12 
years of education; and had a higher income. They did not differ in their total energy intake. During 
the extensive follow up, we lost a considerable proportion of participants mostly due to death. Taken 
together, those not fully participating in the analysis tended to be older, which most likely led to an 
underestimation of the true effect. The baseline phase of this study was performed almost 3 decades 
ago, therefore, the studied intakes may not reflect current eating habits. Nevertheless, as knowledge 
of beneficial AMD foods and supplements was limited at the time, we expect associations to be 
genuine and not biased by preventative recommendations.
What are the clinical implications? Notwithstanding all limitations, a good advice that 
ophthalmologists and other eye care providers can give to patients at risk of AMD is a diet consisting 
of a large variety of vegetables, fruit, and fish. The amount advised by NFC is a minimum, but this 
consumption will still be a challenge to the average elderly person. A recommendation of a healthy 
lifestyle including a healthy diet, refrainment from smoking, and regular exercise42 should be part of 
any counseling session for those at risk of AMD progression.
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SUPPLEMENTARY TABLE 1 - Recommended minimum intake values based on Dutch Dietary Guidelines
Food categories 
RMIV per day
Men Women Average Servings per day
Total vegetables 200gr 200gr 200gr (1 1/3 cups)
Cruciferous & Green Leafy Veg. 56gr 56gr 56gr (3/8 cups)
Red & Yellow Veg. 25gr 25gr 25gr (1/6 cups)
Other Vegetables 118gr 118gr 118gr (3/4 cups)
Fruit 200gr 200gr 200gr (2 large pieces)
Fish* 32gr 32gr 32gr (1.13 oz)
Fat products 15gr 15gr 15gr (1 tbsp)
Meat - minimal 32gr 32gr 32gr (1.13 oz)
Meat - maximal 71gr 71gr 71 gr (2.5 oz)
Grains 210gr 175gr 175gr (6.17 oz)
Poultry 16gr 16gr 16gr (0.56 oz)
Eggs** 16gr 16gr 16gr (0.56 oz)
Potatoes 143gr 114gr 114gr (3-5 pieces)
Legumes 21gr 21gr 21gr (1/7 cups)
Dairy 150gr 150gr 150gr (2/3 cups)
* Calculation based on weekly intake of 2 times fish per week
**Calculation based on weekly intake of 2 eggs per week
Abbreviations: RMIV = recommended minimum intake values, gr=gram, oz=ounce, tbsp = table spoon.
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ABSTRACT
Background In animal models, lack of thyroid hormone is associated with cone photoreceptor 
preservation while administration of high doses of active thyroid hormone leads to deterioration. 
The association between thyroid function and age-related macular degeneration (AMD) has not 
been investigated in the general population.
Methods Participants ≥55 years from the Rotterdam Study with thyroid-stimulating hormone (TSH) 
and/or free thyroxine (FT4) measurements and AMD assessment were included. We conducted 
age- and sex-adjusted Cox-proportional-hazards models to explore the association of TSH or FT4 
with AMD, in the full range and in those with TSH (0.4-4.0 mIU/L) and/or FT4 in normal range (11-
25 pmol/L). Cox-proportional-hazards models were performed for the association of TSH or FT4 
with Retinal Pigment Alterations (RPA), as an early marker of retinal changes. Multivariable models 
additionally included cardiovascular risk factors and thyroid peroxidase antibodies positivity. We also 
performed stratification by age and sex. A bidirectional look-up in Genome-Wide Association Studies 
(GWAS) data for thyroid parameters and AMD was performed. Single Nucleotide Polymorphisms 
(SNPs) that are significantly associated with both phenotypes were identified.
Results We included 5573 participants with a median follow-up of 6.9 years (interquartile range 
4.4-10.8 years). During follow-up 805 people developed AMD. TSH levels were not associated with 
increased risk of AMD. Within normal range of FT4, participants in the highest FT4 quintile had a 
1.34-fold increased risk of developing AMD, compared to individuals in the middle group (95% 
confidence interval [CI] 1.07-1.66). Higher FT4 values in the full range were associated with a 
higher risk of AMD (Hazard Ratio 1.04, CI, 1.01-1.06 per 1 pmol/L increase). Higher FT4 levels were 
similarly associated with a higher risk of RPA. Restricting analyses to euthyroid individuals, additional 
multivariable models and stratification did not change estimates. We found a SNP (rs943080) in the 
VEGF-A gene, associated with AMD, to be significant in the TSH GWAS (p=1.2x10-4). Adding this SNP 
to multivariable models did not change estimates.
Conclusion Higher FT4 values are associated with increased risk of AMD -even in euthyroid 
individuals- and increased risk of RPA. Our data suggest an important role of thyroid hormone in 
pathways leading to AMD.
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BACKGROUND
Age-related macular degeneration (AMD) is a disease of the retina in the elderly which can 
lead to irreversible blindness and is characterized by drusen, pigmentary changes, choroidal 
neovascularization and geographic atrophy. While AMD is one of the leading causes of visual 
impairment worldwide and increasing in prevalence 1-7, the exact pathophysiology and pathways 
leading to AMD are not entirely understood.
Thyroid hormones are known to regulate various visual functions in experimental and human 
studies 8-10. Human retinal pigment epithelial (RPE) cells express thyroid hormone receptors and 
seem to be a direct target for thyroid hormones 11. Recently it has been shown that suppression 
of thyroid hormone signaling resulted in preservation of cone photoreceptors in mouse models of 
retinal degeneration 12. In contrast, administration of active thyroid hormone leads to deterioration 
of cones. Thyroid dysfunction and subclinical thyroid dysfunction are common in the general 
population, with a prevalence up to 10% 13-16. These thyroid disorders are associated with various 
cardiovascular risk factors, including alterations in lipid levels, atherosclerosis and hypertension 17-19, 
which are known predisposing factors for development and progression of AMD 20,21. However, there 
are no studies in the general population assessing the association between thyroid function and the 
risk of AMD. Therefore, we aimed to assess the relation between thyroid-stimulation hormone (TSH), 
free thyroxine (FT4) and the risk of incident AMD in a prospective population-based cohort study and 
to study possible underlying genetic pathways through investigating an overlap in genome-wide 
significant hits (i.e. bidirectional genetic look-up).
METHODS
The Rotterdam Study
The Rotterdam Study is a prospective population-based cohort study that addresses determinants 
and occurrence of cardiovascular, neurological, ophthalmologic, psychiatric, and endocrine 
diseases in the elderly living in Ommoord, a suburb of Rotterdam. The aims and design of the 
Rotterdam study have been described elaborately elsewhere 22. For this analysis we included 
participants from two independent cohorts from the Rotterdam Study. The Rotterdam Study 
Cohort I (RSI) started in 1989 and included a total of 7,983 participants (response rate 78 
percent) aged 55 years and older. Baseline data were collected from 1990 until 1993 and four 
follow-up examinations were performed in 1993-1995, 1997-1999, 2002-2004 and 2009-2011. 
The second cohort is the Rotterdam Study Cohort II (RSII) and includes a total of 3,011 participants 
(response rate 67 percent) aged 55 years and older. Baseline data were collected from 2000-2001 and 
follow-up examinations were performed in 2004-2005 and 2011-2012.
Study Population
Participants from baseline study cohorts RSI (RSI-1) and RSII (RSII-1) were eligible for these analyses 
if they had TSH and/or FT4 measurements and had gradable fundus photographs at baseline and at 
least one follow-up eye examination. Since not all participants from RSI had thyroid measurements 
at baseline, additional baseline samples were drawn from RSI visit 3 (RSI-3). Participants with AMD 
at baseline (N=567) were excluded from further analyses. In total 5573 participants from these two 
cohorts were eligible to be included in our analyses (Supplementary Figure 1). The Medical Ethics 
Committee of the Erasmus University had approved the study protocols, and participants had given 
a written informed consent in accordance with the Declaration of Helsinki.
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Assessment of thyroid function
For RSI-1, serum TSH (TSH Lumitest; Henning, Berlin, Germany), anti-TPOAb (ELISA; Milenia; 
Diagnostic Products Corp, Los Angeles, CA, USA) and free T4 levels (FT4; Vitros, ECI Immunodiagnostic 
System; Ortho-Clinical Diagnostics, Amersham, UK) were determined in a random subset of the 
baseline serum samples (n=1855). Thyroid function assessment was also performed in baseline 
serum samples for TSH and FT4 (The electrochemiluminescence immunoassay for thyroxine and 
thyrotropine, “ECLIA”, Roche) for RSI-3 and RSII-1. The tests’ TSH reference ranges did not differ 
substantially and had a good Spearman correlation co-efficient (0.96 for TSH, p < 0.0001and 0.81 for 
FT4, p < 0.0001). We determined the cut-off values for normal range TSH as 0.4-4.0 mIU/L according 
to national guidelines. The reference range for FT4 was 11-25 pmol/L and anti-TPOAb levels greater 
than 60 kU/mL were regarded as positive.
Diagnosis of age-related macular degeneration
All eligible participants underwent fundus photography after pharmacologic mydriasis. For visits RSI-
1 to RSI-3 and RSII-1 a 35° film fundus camera was used (Topcon TRV-50VT, Topcon Optical Company, 
Tokyo, Japan) after which a 35° digital color fundus camera (Topcon TRC-50EX, Topcon Optical 
Company, Tokyo, Japan with a Sony DXC-950P digital camera; 0.44 megapixel, Sony Corporation, 
Tokyo, Japan) followed for visits RSI-4, RSI-5, RSII-2 and RSII-3. Fundus transparencies were graded 
according to the Wisconsin Age-Related Maculopathy Grading 23 and the modified International 
Classification System 24 by trained graders under the supervision of senior retinal specialists ( J.R.V., 
C.C.W.K.). The eyes of each participant were graded and classified separately, and the eye with the 
more severe grade was used to classify the person. In the analyses incident early and late AMD 
combined was used as outcome variable. In the manuscript this is referred to as AMD. Besides AMD 
we also investigated AMD specific lesions as a separate outcome variable. These lesions included 
retinal pigmentary alterations, large drusen (≥125μm) and large drusen area (≥ 5331,820 μm2) 25.
Baseline measurements
Smoking was derived from computerized baseline questionnaires and categorized in current or 
non-current smokers. Blood pressure, systolic and diastolic, was calculated as the average of two 
consecutive measurements, using random-zero mercury sphygmomanometers. Hypertension was 
defined as having a systolic blood pressure ≥ 140 mmHg or a diastolic blood pressure ≥ 90mmHg 
or using anti-hypertensive medication at baseline. Cholesterol was measured at baseline by the 
CKCL (Centra Clinical Chemical Laboratory) of the Erasmus University Medical Center. A subgroup of 
measurements was carried out in the laboratory of the Department of Epidemiology & Biostatistics 
(Erasmus University Medical School). History of diabetes was defined by a repeated impaired fasting 
glucose ≥ 7 or use of anti-glycemic medication at baseline. Body-mass index (BMI) was calculated as 
weight kilograms divided by height squared in meters.
Statistical analysis
Participant baseline characteristics were compared using a χ2 or t-test. Due to a skewed distribution, 
TSH was log-transformed for the statistical analyses. We used cox-proportional hazards model 
to calculate the relationship between TSH and FT4 at baseline and the risk of incident AMD, first 
including all participants and then including only those with normal range TSH and/or FT4 values. 
We performed a crude cox-model including only thyroid parameters after which we also included 
quadratic and cubic terms to explore possible non-linear relationships. We then performed 
additional models adjusting first for age and sex and second also adding smoking, hypertension, 
cholesterol, diabetes and BMI to the model. Hypertension, cholesterol, diabetes and BMI could act as 
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confounders and possible mediators depending on the presumed pathway through which thyroid 
function is related to AMD. These variables were included in the multivariable model as possible 
confounders of non-vascular pathways. We looked at the association between AMD and TSH or FT4 
both continuously and in quintiles, as well as overall and within the normal range of TSH. The middle 
quintile was used as reference group as biologically it is expected to represent the subgroup with 
the most thyroid function within the euthyroid group. We performed pre-defined stratification by 
sex and age categories, using a cutoff 65 years as this is the median of the current population and 
the treatment threshold for subclinical thyroid dysfunction according to the European guidelines26. 
Further interaction terms were introduced to the model to explore possible differential risk 
patterns. We performed a sensitivity analysis excluding those using thyroid medication at baseline 
(levothyroxine and anti-thyroid drugs) and those with prior self-reported thyroid disease at baseline. 
We also performed FT4 and TSH analyses with specific AMD lesions defined as retinal pigment 
alteration, large drusen and large drusen area as separate outcome variable to examine possible 
early changes in underlying pathways. To address the issue of drop-out of individuals during follow-
up that could possibly be not completely at random, we adjusted the model for inverse probability 
weights (IPW”s). These were calculated using possible baseline explanatory variables for drop-out 
such as smoking, BMI and medication use. Proportional hazards assumption was checked statistically 
using the Schoenfeld test and assessing the Schoenfeld plot. All statistical analyses were performed 
using SPSS version 21 (SPSS IBM, New York, U.S.A) except for the Schoenfeld tests and (Schoenfeld) 
plots which were performed in R (survival package, R-project, Institute for Statistics and Mathematics, 
R Core Team (2013), Vienna, Austria, version 3.0.2).
Bidirectional genetic look-up
Genome-Wide Association Studies (GWAS) have been performed for AMD 27 and thyroid function (TSH 
and FT4) 28,29. These studies identified several single-nucleotide polymorphisms (SNPs) associated to 
these two phenotypes. Some of the genome-wide significant SNPs in the AMD GWAS might also 
play a role in thyroid function and vice versa. Overlap between common genetic polymorphisms 
can provide insight into possible shared genetic pathways. It might also elucidate a mediation effect 
between the two phenotypes, i.e. identify and explicate the process that underlies a possible observed 
relationship between thyroid function and AMD. To evaluate these potential genetic pathways, we 
conducted a bidirectional genetic look-up using the results of the above mentioned GWA Studies 
for AMD and thyroid function. We first extracted SNPs that reached genome-wide significance from 
the AMD GWAS performed by the AMD Gene consortium 27. We then checked whether these were 
significantly associated with TSH or FT4 in the thyroid function GWAS performed by Porcu et al. 28. 
Hereafter we extracted the genome-wide significant SNPs for TSH or FT4 from the thyroid function 
GWAS and checked whether they were associated with AMD in the AMD GWAS. For the significance 
level, we applied a multiple testing correction (Bonferroni Correction), using a p-value threshold of 
0.05 divided by the amount of significant SNPs per GWAS. In case of a significant finding, we added 
the SNP to the multivariable model to evaluate a possible mediation effect.
RESULTS
We included 5573 participants with TSH and/or FT4 measurements at baseline and incident AMD 
data, with a median follow-up of 6.9 years (interquartile range [IQR] range of 4.4-10.8 years). Of these, 
5572 had TSH and 5504 had FT4 baseline measurements. A total of 805 people developed AMD 
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(Early AMD N=725, Late AMD N=80) during follow-up with an incidence rate of 18 per 1000 person-
years. The baseline characteristics for those with and without incident AMD during follow-up were 
comparable, except for proportion of diabetes (Table 1).
TABLE 1 - Baseline Characteristics of Included Participants from the Rotterdam Study Evaluating the Association 
between Thyroid Function and AMD* 
Variable 
No incident AMD
N=4768
Incident AMD
N=805 P-value**
Age, years 67.6 (7.6) 67.9 (7.1) 0.29
Sex % female 57.6 57.8 0.94
History of Diabetes % 10.8 8.4 0.04
BMI kg/m2 26.9 (3.9) 26.6 (3.7) 0.07
Cholesterol mmol/L 6.1 (1.2) 6.1 (1.1) 0.23
Smoking % current 20.7 21.0 0.85
Hypertension % 63.0 58.7 0.17
TSH mIU/L median (IQR) 1.78 (1.15-2.69) 1.73 (1.17-2.67) 0.78
FT4 pmol/L 15.8 (2.6) 16.0 (3.2) 0.13
TPOAb kU/L 30.5 (95.1) 30.8 (96.2) 0.93
*Values are means and SD unless otherwise specified.
** For comparison a t-test was conducted, for TSH the log-transformed values were used.
Abbreviations: AMD = Age-related Macular Degeneration; BMI = body-mass index; TSH = thyroid-stimulating hormone, FT4 = 
free thyroxine; SD = Standard deviation; IQR = inter-quartile range; TPOAb = thyroid peroxidase antibodies.
Association between thyroid function and AMD
Although there was no association between TSH and AMD (hazard ratio [HR] 0.99; 95% confidence 
interval [CI] 0.91-1.07, Table 2), the risk of AMD was significantly increased in those with higher FT4 
levels (Table 2). When categorizing the FT4 values within normal range quintiles, those in the highest 
FT4 quintile had an increased risk compared to the middle group with a HR of 1.34 (95% CI, 1.07-1.66) 
and a non-significant p for interaction (p=0.066) (Table 2). This association remained similar after 
additional adjustments for smoking, diabetes, hypertension, cholesterol, BMI, and TPOAb positivity 
(Figure 1). This association also remained similar after analyzing only those within the normal range 
of TSH and FT4, that is, those with normal thyroid function.
Excluding those with thyroid medication or thyroid disease at baseline as a sensitivity analysis, did 
not alter the association (Table 3). Stratifying for age and sex did not reveal any significant differential 
risk (Supplementary Table 1). The association between thyroid function and retinal pigment 
alterations for FT4 showed similar significant hazard ratios, with the exception of the risk estimates 
when looking at FT4 only in the normal range of TSH (Table 4). TSH and FT4 were not associated with 
large drusen or large drusen area (data not shown). Introducing quadratic and cubic terms for TSH 
and FT4 to the crude model, as an exploration of non-linearity, did not improve model performance. 
Taking possible non-random follow-up using IPW’s did not change risk estimates. The proportional 
hazards assumption was checked statistically with the Schoenfeld test and Schoenfeld plot and met 
for both the TSH (p = 0.232) and FT4 (p = 0.154) analyses.
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TABLE 2 - Association between TSH, FT4 and risk of AMD 
Incident AMD vs no AMD AMD N Total N
HR (95% CI), 
model 1
HR (95% CI), 
model 2
HR (95% CI), 
model 3
TSH mIU/L 805 5572 0.99 (0.91-1.07) 0.99 (0.91-1.07) 0.99 (0.91-1.07)
TSH in normal rangea 696 4756 1.06 (0.91-1.23) 1.09 (0.93-1.27) 1.08 (0.93-1.26)
Normal range TSHa          
Q1 0.40-1.10 148 1082 1.04 (0.82-1.32) 1.00 (0.79-1.28) 1.00 (0.79-1.28)
Q2 1.11-1.54 167 990 1.32 (1.04-1.66) 1.29 (1.02-1.62) 1.29 (1.02-1.62)
Q3 1.55-1.99 128 962 1 1 1
Q4 2.00-2.61 117 851 1.09 (0.85-1.40) 1.07 (0.83-1.37) 1.07 (0.83-1.38)
Q5 2.62-3.97 136 871 1.22 (0.96-1.56) 1.22 (0.95-1.55) 1.21 (0.94-1.54)
P interaction     0.648 0.485 0.517
Total 696 4756      
FT4 pmol/L 791 5504 1.04 (1.01-1.06) 1.04 (1.01-1.06) 1.04 (1.01-1.06)
FT4 in normal rangeb 765 5382 1.04 (1.01-1.07) 1.04 (1.01-1.07) 1.04 (1.01-1.07)
Normal range FT4b          
Q1 11.0-14.0 149 1090 1.03 (0.82-1.29) 1.04 (0.82-1.31) 1.04 (0.82-1.31)
Q2 14.0-15.1 152 1001 1.12 (0.89-1.41) 1.17 (0.92-1.47) 1.16 (0.92-1.47)
Q3 15.1-16.2 144 1094 1 1 1
Q4 16.2-17.5 134 1060 1.01 (0.80-1.28) 1.03 (0.81-1.30) 1.03 (0.81-1.31)
Q5 17.5-24.9 186 1137 1.34 (1.07-1.66) 1.35 (1.08-1.69) 1.35 (1.09-1.69)
P interaction 765 5382 0.066 0.088 0.08
Normal range FT4b in normal range TSHa 673 4658 1.04 (1.01-1.08) 1.04 (1.01-1.08) 1.04 (1.01-1.07)
a normal range of TSH defined as 0.4-4.0 mIU/L.
b normal range of FT4 defined as 11-25 pmol/L.
Model 1: Adjusted for sex and age.
Model 2: Model 1 + smoking, hypertension, cholesterol, diabetes, BMI.
Model 3: Model 2 + thyroid peroxidase antibodies positivity.
Abbreviations: AMD Age-related Macular Degeneration ; BMI body-mass index; CI confidence interval; FT4 free T4; HR hazard 
ratio; Q quintile; TSH Thyroid-Stimulating Hormone.
FT4 pmol/L quintiles AMD N Total N
HR Ratio
(95% CI)a
11.0 - 14.0 149 1090 1.04 (0.82-1.31)
14.0 - 15.1 152 1001 1.16 (0.92-1.47)
15.1 - 16.2 144 1094 [REFERENCE]
16.2 - 17.5 134 1060 1.03 (0.81-1.31)
17.5 - 24.9 186 1137 1.35 (1.09-1.69)
Decreased risk          Increased risk
0.50 1.00 2.50
FIGURE 1 - Quintiles of FT4 within the normal range and risk of AMD.
The normal range of FT4 was defined as 11-25 pmol/L (Conversion 1 pmol/L=0.0777 ng/dL).
a Analyses were adjusted for sex, age, smoking, hypertension, cholesterol, diabetes, body-mass index and thyroid peroxidase 
antibodies positivity.
Abbreviations: AMD Age-related Macular Degeneration; FT4 free thyroxine; HR hazard ratio
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Bidirectional genetic look-up
In the thyroid function GWAS, 20 SNPs were associated with TSH and 6 with FT4 28. The AMD GWAS 
revealed 19 genome-wide significant SNPs related to the phenotype. None of the SNPs from the 
thyroid function GWAS were significant in the AMD GWAS. One SNP (rs943080) in the Vascular 
Endothelial Growth Factor A (VEGFA) gene that is related to AMD, was also significantly associated 
with TSH (p=1.2x10-4, significance threshold =0.0026) (Supplementary Table 2). Within our study 
population, GWAS data were available for a total 4646 participants. Additionally correcting for the 
rs943080 SNP in the most adjusted model in these participants, resulted in similar risk estimates for 
the FT4 analysis (HR 1.04, CI 95% 1.01-1.07). Stratifying for this SNP did show risk differences between 
the different genotypes but not significantly (Supplementary Table 1).
TABLE 3 - Sensitivity Analyses excluding participants with Thyroid Medication or Thyroid Disease at baseline
Incident AMD vs no AMD AMD N Total N
HR (95% CI), 
model 1
HR (95% CI), 
model 2
HR (95% CI), 
model 3
Excluded medication thyroida
Free T4 752 5225 1.03 (1.01-1.06) 1.03 (1.01-1.06) 1.03 (1.01-1.06)
TSH mIU/L 778 5417 0.99 (0.91-1.08) 1.00 (0.92-1.09) 1.00 (0.91-1.09)
Excluding baseline thyroid diseaseb
Free T4 751 5237 1.04 (1.01-1.08) 1.04 (1.01-1.07) 1.04 (1.01-1.08)
TSH mIU/L 764 5300 0.98 (0.89-1.07) 0.98 (0.89-1.07) 0.97 (0.89-1.07)
a 155 participants had thyroid medication (ie. thyroid hormone use) at baseline
b 272 participants had self-reported thyroid disease at baseline
Model 1: Adjusted for sex and age.
Model 2: Model 1 + smoking, hypertension, cholesterol, diabetes, BMI.
Model 3: Model 2 + thyroid peroxidase antibodies positivity
Abbreviations: BMI body-mass index; CI confidence interval; FT4 free thyroxine; HR hazard ratio; TSH thyroid-stimulating 
hormone
TABLE 4 - Association between FT4 and TSH with Retinal Pigment alterationsa 
Incident pigment alterations vs no 
pigment alterations Cases N Total N
HR (95% CI), 
model 1
HR (95% CI), 
model 2
HR (95% CI) , 
model 3
TSH mIU/L 729 5401 0.98 (0.90-1.06) 0.97 (0.90-1.06) 0.96 (0.88-1.04)
Normal range TSHb 618 4591 1.02 (0.87-1.20) 1.05 (0.89-1.23) 1.04 (0.88-1.22)
FT4 pmol/L 720 5338 1.04 (1.01-1.07) 1.04 (1.01-1.07) 1.04 (1.01-1.07)
Normal range FT4c 697 5226 1.04 (1.01-1.07) 1.04 (1.01-1.07) 1.04 (1.01-1.07)
Normal range FT4c in normal range TSHb 601 4500 1.03 (1.00-1.07) 1.03 (0.99-1.06) 1.03 (0.99-1.06)
a participants with late AMD were excluded from this analysis
b normal range of TSH defined as 0.4-4.0 mIU/L.
c normal range of FT4 defined as 11-25 pmol/L.
Model 1: Adjusted for sex and age.
Model 2: Model 1 + smoking, hypertension, cholesterol, diabetes, BMI.
Model 3: Model 2 + thyroid peroxidase antibodies positivity
Abbreviations: BMI body-mass index; CI confidence interval; FT4 free thyroxine; HR hazard ratio; TSH thyroid-stimulating 
hormone
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DISCUSSION
In this prospective cohort study we investigated the association between thyroid function and 
incidence of AMD. Higher FT4 values were associated with an increased risk of developing AMD, 
even within the normal range of TSH and FT4 (i.e. euthyroid subjects), while there was no association 
between TSH and AMD. The similar findings between higher levels FT4 and retinal pigment alterations 
might suggest that thyroid hormone plays a role in the development of AMD rather than just act as 
a promoter of disease. To our knowledge, this is the first prospective population-based cohort study 
to look at the association between thyroid function and AMD.
A limited number of studies investigating thyroid disease and AMD have been published, all lacking 
laboratory assessment of thyroid function. Bromfield et al. reported an increased risk of AMD in 
subjects with self-reported hypothyroidism 30. A case-control study by Anand et al. reported an 
association between thyroid hormone use and a higher risk of AMD with geographic atrophy 31, 
but no data were reported on the number of patients that were over- or undertreated. Similarly, the 
Beaver Dam Eye study also reported an association between thyroid hormone use and early AMD 32, 
but this was not confirmed by Douglas et al. 33. As mentioned previously, none of these studies had 
laboratory assessment of thyroid function nor did they investigate the association in a time-to-event 
analysis. In our study, excluding all subjects using thyroid medication did not alter risk estimates, 
supporting a potential intrinsic effect of thyroid hormone.
There are several pathophysiological explanations for the relationship between thyroid hormones 
and AMD. In a mouse model of retinal degeneration, suppression of thyroid hormone signaling 
resulted in preservation of cone photoreceptors 12. The same study found that stimulating thyroid 
hormone signaling, by administering the active thyroid hormone triiodothyronine, deteriorates 
cones in mouse models with a slow progressive and moderate degeneration phenotype 12. In 
addition, mice lacking type 3 deiodinase, the enzyme responsible for the degradation of thyroid 
hormones, have decreased survival and disturbed maturation of cone photoreceptors 34. The findings 
of these studies suggest that thyroid hormone may lead to a higher turnover of photoreceptors 
and in retinal degeneration this leads to deterioration of photoreceptors. Beside photoreceptors, 
thyroid hormone might also have an influence on the retinal pigment epithelial cells 11. In the healthy 
retina the turnover of photoreceptors is extremely high. Every day the photoreceptors shed the ends 
of their outer segments resulting in full renewal every ten days. These shedded parts of the outer 
segments are fagocytosed by the retinal pigment epithelium (RPE) cell 35. Increase of the turnover 
of the photoreceptors by thyroid hormone may bring additional stress to the process. RPE cells at 
distress may change resulting in pigmentary alterations in the macular area. The RPE cells may also 
be targeted directly by the thyroid hormone resulting in these changes 11. These results may provide 
an explanation for the findings in our study.
Thyroid dysfunction has been linked to cardiovascular risk factors and disease, including effects on 
the vascular function, lipids and atherosclerosis 36. As some of these risk factors are also linked to 
AMD 20,21, one could speculate about a joint vascular pathway leading to both thyroid dysfunction 
and AMD or perhaps that the relation between thyroid dysfunction and AMD could be mediated 
through this pathway. We were not able to confirm these hypotheses. First of all, these cardiovascular 
risk factors are mainly seen in hypothyroidism, (i.e. high TSH and low FT4), whereas our data show an 
association between high FT4 and AMD. Also, correcting for some of these risk factors (for example 
hypertension) that could act as confounders and possible mediators did not change risk estimates, 
suggesting that the effect of thyroid function is not through these pathways. Lastly, VEGFA gene was 
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found to be significant in the look-up for the TSH GWAS and not the FT4 GWAS. However, our results 
suggest a higher risk of AMD in higher levels of FT4 and not in TSH. Furthermore, the association did 
not change by adding this SNP to the multivariable model.
We find an effect with FT4 but not with TSH. This however does seem to be in line with previous 
literature from cohort studies in elderly populations investigating the relation between thyroid 
function and several other endpoints 37,38. Regulation of serum thyroid hormone levels is controlled 
by the hypothalamus-pituitary-thyroid axis. The set point of this feedback mechanism is defined 
individually, with thyroid hormone levels showing a much greater inter-individual than intra-
individual variability 39. The individual set point can be modulated by several pathophysiological (for 
example critical illness) and physiological (for example ageing) mechanisms40. This could be one of 
the explanation why in this elderly and ageing population we do find an association with FT4 but 
not with TSH, especially in the euthyroid range. Furthermore, previous literature showed an increase 
in TSH with increasing age, suggesting higher TSH levels are needed to keep thyroid hormone levels 
within the desired range38. We only have thyroid function measures at baseline and are therefore 
not able to investigate whether changes in thyroid function over time is an explanation for the 
discordant association between TSH, FT4 and AMD.
Important strengths of our study are the assessment of thyroid function at baseline through laboratory 
testing as well as the elaborate assessment of AMD at baseline and follow-up. Also, we were also able 
to investigate the association between thyroid function and specific AMD lesions like retinal pigment 
alterations to examine possible early changes in underlying pathways. The availability of genetic 
data gave us the opportunity to explore possible genetic pathways. The bidirectional genetic look-
up, revealed one SNP in the VEGFA gene to be significant in the TSH GWAS but not for FT4. Adding 
this SNP to the multivariate model did not alter risk estimates. An explanation for the absence of 
overlapping genome-wide significant SNP’s could be that these GWA studies were underpowered 
for this association.
A limitation of our study is that thyroid parameters were measured once at baseline. Therefore, the 
evolution of thyroid hormone levels could not be taken into account. Also, residual confounding 
cannot be excluded, even with the large number of covariates included in these analyses. Lastly, 
this study is conducted in a mainly Caucasian population of 55 years and older and may not be 
generalizable to other populations.
CONCLUSION
We find an increased risk of incident AMD in subjects with higher FT4 levels, even in those with 
a normal thyroid function and when excluding thyroid medication users. This implies an intrinsic 
(that is. not exogenous) deleterious effect of thyroid hormone on AMD. We also find an association 
between higher FT4 levels and retinal pigment alterations, suggesting that thyroid hormone could 
even play a role in the early stage of development of AMD. Functional and clinical studies could 
provide more evidence for a true causal relationship.
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ABSTRACT
Purpose To determine if use of antiplatelet or anticoagulant (AP/AC) medication influences visual 
acuity in patients with active neovascular age-related macular degeneration (N-AMD).
Design Retrospective analysis of data from a randomized controlled trial
Methods
Setting: Multi-center
Study Population: 330 patients with active N-AMD from the BRAMD study, a comparative trial 
between bevacizumab and ranibizumab in the Netherlands.
Observation Procedures: Patients underwent an extensive ophthalmic examination. Visual acuity 
was categorized into functional vision (best corrected visual acuity (BCVA) >=0.5), visual impairment 
(BCVA < 0.5), and severe visual impairment (BCVA<0.3). Fundus photographs were graded for 
presence of retinal or subretinal hemorrhages. Information on AP/AC medication was obtained 
through interview. Logistic regression analysis was used to determine associations between AP/AC 
medication and outcomes. Frequency of hemorrhages in users and non-users stratified for visual 
acuity categories was analyzed with ANCOVA.
Main Outcome Measures: BCVA and presence of hemorrhages.
Results In total, 40.9% of the patients used AP/AC medication, of which 73.3% was aspirin. AP/AC use 
was not associated with visual impairment (adjusted odds ratio (OR) 0.79 (95% confidence interval 
(CI) 0.43-1.44), or severe visual impairment (adjusted OR 0.75 (95% CI 0.40-1.43). Patients on AP/
AC presented with comparable frequencies of hemorrhages (27% versus 32%, P=0.32, respectively). 
Similar results were found when analyses were restricted to aspirin users only.
Conclusion In our study, use of AP/AC medication was neither associated with visual decline nor 
with the occurrence of hemorrhages in patients with active N-AMD.
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INTRODUCTION
Recently, several population based-studies have shown an association of aspirin use with an 
increased risk of choroidal neovascularization (CNV) in age-related macular degeneration (AMD).1-3 
These findings were not unequivocal as randomized controlled trials4,5 and meta-analyses were 
inconclusive.6-9 These contrasts have renewed the discussion on the use of aspirin and other 
antiplatelet or anticoagulant drugs in persons with neovascular AMD. While these therapies are 
mostly prescribed for their cardiovascular and cerebrovascular protective effects, they may have 
adverse events due to an increased risk of bleeding.10-12 The antithrombotic characteristics may 
deteriorate the outcome of neovascular AMD, leading to more severe hemorrhages and increased 
fibrovascular scarring, both jeopardizing visual acuity.13 At this time, it is still unclear whether 
antiplatelet or anticoagulant medication should be discontinued for patients with neovascular AMD.
We investigated the effect of antiplatelet and anticoagulant medication on visual acuity in patients 
with active CNV. We studied visual acuity, presence of retinal and subretinal hemorrhages, total CNV 
lesion size and retinal thickness in relation to the use of antiplatelet and anticoagulant medication 
before and after anti-vascular endothelial growth factor (anti-VEGF) therapy.
METHODS
BRAMD Study participants
BRAMD is a Dutch comparison study investigating Bevacizumab versus Ranibizumab in AMD, and 
was designed as a triple masked, randomized, clinical non-inferiority multicenter trial. Details on the 
study design have been described elsewhere.14 In short, 330 patients aged 60 years or older from 
five academic medical centers in the Netherlands were included in the study. Inclusion criteria was 
a diagnosis of primary or recurrent active sub- or juxtafoveal choroidal neovascularization (CNV) 
secondary to AMD with a total area of CNV <12 disc areas and a best corrected visual acuity (BCVA) 
score between 20 and 78 letters on an Early Treatment Diabetic Retinopathy Study like chart (ETDRS) 
in the study eye. Further details on in- and exclusion criteria of this study are provided in Supplemental 
Table 1. After baseline assessment, all patients received monthly injections with bevacizumab or 
ranibizumab for 12 months. The institutional ethical review boards from the participating medical 
centers approved the BRAMD study. The study adhered to the tenets of the Declaration of Helsinki 
and was registered at the Dutch trial register (Nederlands trial register) (NTR1704). Participants 
who had a full ophthalmic examination including imaging, disclosed medication use, and a signed 
informed consent were included in the current analysis. In total, 330 eyes from 330 participants were 
included.
Ophthalmic data collection
All participants underwent a standardized full ophthalmic examination and imaging including, 
fluorescein angiogram, 30° color digital fundus photographs and spectral domain optical coherence 
tomography (SD-OCT). Diagnosis, size of lesion quantified as optic disc area (DA), and presence of 
active choroidal neovascularization due to AMD was confirmed by trained independent graders, 
masked for patient information such as the use of antiplatelet or anticoagulant drugs, at the UK 
Network of Ophthalmic Reading Centers. The presence of retinal or subretinal hemorrhage in the 
posterior pole was determined on fundus photographs. Retinal thickness was measured in the fovea 
using a built-in caliper on SD-OCTs at baseline and during last visit. Presence of pseudophakia was 
determined using slit lamp observation.
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Best corrected visual acuity (BCVA) was assessed using an ETDRS chart and categorized in 3 groups:
ETDRS chart letters Snellen decimal equivalent Snellen Foot equivalent
Functional vision BCVA ≥ 70 BCVA ≥ 0.50 BCVA ≥ 20/40
Moderate visual impairment 70 > BCVA ≥ 59 0.50 > BCVA ≥ 0.30 20/40 > BCVA ≥ 20/66
Severe visual impairment 59 > BCVA ≥ 20 0.30 >BCVA ≥ 0.05 20/66 > BCVA ≥ 20/400
Assessment of variables
At baseline, detailed information was obtained from the participants concerning demographic 
characteristics, medical history, and medication use. Medical history included information about 
cardiovascular diseases such as myocardial infarction, congestive heart failure, stroke, transient 
ischemic attack and hypertension. Information on use of antiplatelet and anticoagulant (AP/AC) 
drugs including name of the drug, dosage, frequency and start date was obtained at baseline. Blood 
pressure was measured at baseline. Hypertension was defined as systolic blood pressure ≥ 140 
mmHg or a diastolic blood pressure ≥90 mmHg or if the participant was using anti-hypertensive 
medication at baseline. Smoking habits were assessed by interview and categorized into never/past/
current smoking.
Statistical analysis
Primary study outcomes were visual impairment (moderate and severe visual impairment combined) 
and severe visual impairment. Secondary outcomes were presence of retinal hemorrhages, foveal 
retinal thickness, and CNV lesion size in the study eye. Several determinants had missing values. 
Lens data were missing in 16% of study subjects, smoking data in 18.8%. Missing data were 
randomly distributed, and not significantly associated with visual impairment (analysis of covariance 
(ANCOVA) adjusted for age, sex P=1.00 for lens; P=0.47 for smoking). We used the iterative Markov 
chain Monte Carlo algorithm (5 steps) for multiple imputations. These were calculated using possible 
predictable baseline values such as age, sex, diabetes, and smoking for lens data; age, sex, history 
of cardiovascular disease, hypertension, and CNV presence in the fellow eye for smoking data. 
Analyzing the dataset excluding the multiple imputations for the variables lens status and smoking 
did not change risk estimates or associations observed in this study.
We first analyzed baseline characteristics between users of AP/AC and nonusers; continuous variables 
were compared using ANCOVA and categorical variants using logistic regression. After this we 
plotted users and nonusers of AP/AC with visual acuity and with retinal hemorrhages. Groups were 
compared using ANCOVA adjusted for age, sex, and study center. We then performed binary logistic 
regression analysis for the use of AP/AC and visual impairment, severe visual impairment, retinal 
hemorrhages, and CNV lesions size. Foveal retinal thickness measurements were also analyzed using 
ANCOVA. All analyses were adjusted for age, sex, and study center, and subsequently for smoking, 
medical history cardiovascular diseases, diabetes, hypertension, choroidal neovascularization in the 
fellow eye, lens status. All statistical analyses were performed using SPSS version 21 (SPSS IBM, New 
York, U.S.A.).
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RESULTS
General characteristics of the 330 study participants from the BRAMD study are presented in 
Table 1. AP/AC users were slightly older (mean age 79.4 years for AP/AC users versus 76.4 years for 
nonusers; P = 0.001) and presented more often with diabetes mellitus (17.0% versus 8.7%; P = 0.01). 
Although users were more often diagnosed with hypertension (81.9% versus 52.0%; P <0.0001), no 
significant differences were found for blood pressure measurements (P = 0.37 for systolic and P = 
0.54 for diastolic blood pressure). History of cardiovascular diseases was more common in users 
(34.1% versus 4.6%; P <0.0001). 40.9% of the study participants used any type of AP/AC drug. In those 
using AP/AC medication, antiplatelet drugs, with aspirin in particular, were the type of medication 
mostly used; 76.3% and 73.3%, respectively. Other baseline characteristics did not differ significantly 
between both groups.
We investigated use of AP/AC drugs and risk of visual impairment (Table 2). Use of AP/AC was not 
associated with visual impairment (Odds’ Ratio (OR) 0.74 (95% Confidence Interval (CI) 0.44-1.24), 
adjusted for age, sex, and study center) and (OR 0.79 (95% CI 0.43-1.44), additional adjustment 
for smoking, lens status, medical history for cardiovascular diseases, diabetes, hypertension and 
presence of CNV in the fellow eye). AP use was significantly associated with a lower risk of visual 
impairment (OR 0.58 (95% CI 0.34-0.99). After adjustment for additional confounders, the association 
was no longer significant (OR 0.61 (95% CI 0.34-1.09)). For aspirin use, estimates were in the same 
direction, but no significant association was found. Associations with AC drugs were not significant 
in either model. The analyses with severe visual impairment as outcome showed similar effects, 
but none of the associations were significant. We also analyzed visual acuity from the last visit of 
the BRAMD study. Estimates were in the same direction, but no significant association was found 
(Supplemental Table 2).
The distribution of baseline functional vision and visual impairment was plotted for the presence of 
retinal or subretinal hemorrhages in users and nonusers of AP/AC medication (Supplemental Figure 
1). Visual acuity was significantly lower in those with retinal or subretinal hemorrhages (P = 0.008). 
However, users or nonusers of AP/AC with hemorrhages did not differ in visual acuity (P=0.77).
The association between AP/AC use and the presence of retinal or subretinal hemorrhages is shown 
in Table 3. Users of AP/AC medication had a lower risk of hemorrhages. The association became 
significant after additional adjustment for covariates, OR 0.76 (95% CFI 0.46-1.25) and OR 0.47 (95% 
CI 0.26-0.83), respectively. This trend was also observed for AP; OR 0.52 (95% CI 0.30-0.90) and OR 
0.34 (95% CI 0.18-0.62), respectively. Aspirin use became significantly associated with a lower risk of 
hemorrhages after additional adjustment; OR 0.61 (95% CI 0.34-1.08) and OR 0.36 (95% CI 0.18-0.71), 
respectively. No association was found between AC and hemorrhages.
Foveal retinal thickness differed significantly between aspirin users and nonusers at baseline 
(P = 0.04). This was not observed during the last visit (P =0.84). With respect to other groups, no 
significant difference was found between users and nonusers at baseline (Supplemental Table 3) 
or during their last visit (Supplemental Table 4). AP/AC was not associated with CNV lesions size at 
baseline (Supplemental Table 5).
140 Chapter 4.4
TABLE 1 - Baseline characteristics of the study population
BRAMD study N=330
P Valuea
Nonusers
N=195
AP/AC users
N=135
Age, yrs (sd) 76.4 (8.9) 79.4 (6.5) 0.001
Sex, % males 42.1 47.4 0.29
Smokers, % former and current 65.6 68.4 0.47
Retinal or subretinal hemorrhage, % 32.3 26.7 0.32
Best corrected visual acuity study eye, %     0.35
Functional vision 25.1 28.1  
Moderate visual impairment 32.3 28.9  
Severe visual impairment 42.6 43.0  
Pseudophakic eyes, % 37.0 21.5 0.49
CNV in the fellow eye, % 22.6 23.8 0.63
Retinal foveal thickness, μm (sd) 380 (123) 396 (120) 0.27
CNV lesion size, %     0.36
0-1 disc area 36.6 32.6  
≥2 disc area 63.4 67.4  
Diabetes Mellitus, % 8.7 17.0 0.01
Hypertension, % 46.2 83.7 <0.0001
Systolic blood pressure, mmHg (sd) 153 (21) 151 (25) 0.37
Diastolic blood pressure, mmHg (sd) 81 (10) 80 (12) 0.54
History of cardiovascular diseases, % 4.6 34.1 <0.0001
Myocardial infarction 3.1 11.9 <0.0001
Congestive heart failure 1.0 4.4 0.16
Stroke 1.0 3.7 0.26
Transient ischaemic attack 1.0 18.5 <0.0001
Antiplatelet or anticoagulant drugs, % 0 100  
Antiplatelet drugs, % - 76.3  
Aspirin - 73.3  
Clopidogrel - 5.7  
Anticoagulant drugs, % - 27.4  
Acenocoumarol - 21.0  
Fenprocoumon - 4.8  
For continuous variables means were calculated
a P values were calculated using analysis of covariance for continuous variables and logistic regression for discrete variables, 
adjusted for age, sex and study center
Abbreviations: AP/AC = antiplatelet or anticoagulant, CNV = choroidal neovascularization, sd = standard deviation, yrs = years 
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TABLE 2 - Association between antiplatelet or anticoagulant medication and risk of visual impairment at baseline 
Risk of visual impairment 
Functional
vision eyes
(N=87)
Visual
impaired eyes
(N=243)
OR (95% CI) 
Model 1 
OR (95% CI) 
Model 2
Use of antiplatelet or anticoagulant drug        
 No 49 146 1 1
 Yes 38 97 0.74 (0.44-1.24) 0.79 (0.43-1.44)
Use of antiplatelet drugs      
 No 54 173 1 1
 Yes 33 70 0.58 (0.34-0.99) 0.61 (0.34-1.09)
Use of anticoagulant drugs        
 No 81 212 1 1
 Yes 6 31 1.88 (0.75-4.70) 2.00 (0.77-5.18)
Type of antiplatelet or anticoagulant drugs        
 None 49 146 1 1
 Aspirin 31 68 0.64 (0.37-1.12) 0.76 (0.40-1.44)
 Acenocoumarol 5 24 1.42 (0.51-3.98) 1.26 (0.40-3.99)
Risk of severe visual impairment 
Functional
vision eyes 
(N=87)
Severe visual 
impaired eyes 
(N=141)
OR (95% CI) 
Model 1 
OR (95% CI) 
Model 2 
Use of antiplatelet or anticoagulant drug        
 No 49 83 1 1
 Yes 38 58 0.74 (0.42-1.30) 0.75 (0.40-1.43)
Use of antiplatelet drugs    
 No 54 97 1 1
 Yes 33 44 0.64 (0.36-1.15) 0.66 (0.35-1.26)
Use of anticoagulant drugs        
 No 81 124 1 1
 Yes 6 17 1.63 (0.61-4.41) 1.57 (0.57-4.33)
Type of antiplatelet or anticoagulant drugs        
 None 49 83 1 1
 Aspirin 31 44 0.71 (0.39-1.30) 0.75 (0.38-1.50)
 Acenocoumarol 5 14 1.34 (0.44-4.09) 1.18 (0.36-3.85)
Model 1: adjusted for age, sex and study center
Model 2: model 1 including smoking, lens status, medical history cardiovascular diseases, diabetes, hypertension, choroidal 
neovascularization fellow eye
Abbreviations: CI = confidence interval, OR = Odds' ratio
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TABLE 3 - Association between antiplatelet or anticoagulant medication and the risk of retinal or subretinal 
hemorrhage at baseline
 
No 
hemorrhage
(N=231)
retinal or subretinal 
hemorrhage
(N=99)
OR (95% CI) 
Model 1 
OR (95% CI) 
Model 2 
Use of antiplatelet or anticoagulant drug        
No 132 63 1 1
Yes 99 36 0.76 (0.46-1.25) 0.47 (0.26-0.83)
Use of antiplatelet drugs      
No 150 81 1 1
Yes 77 22 0.52 (0.30-0.90) 0.34 (0.18-0.62)
Use of anticoagulant drugs        
No 210 83 1 1
Yes 21 16 2.07 (1.02-4.20) 1.71 (0.82-3.58)
Type of antiplatelet or anticoagulant drugs
None 132 63 1 1
Aspirin 77 22 0.61 (0.34-1.08) 0.36 (0.18-0.71)
Acenocoumarol 14 15 2.37 (1.06-5.31) 1.28 (0.51-3.20)
Model 1: adjusted for age, sex and study center
Model 2: model 1 including smoking, medical history cardiovascular diseases, diabetes, hypertension,
choroidal neovascularization fellow eye
Abbreviations: CI = confidence interval, OR = Odds' ratio
DISCUSSION
In the BRAMD study, we showed that AP/AC use did not increase the risk of visual impairment in 
patients with neovascular AMD, nor did this medication increase the risk of retinal hemorrhages. 
Subgroup analysis identified aspirin as the major contributor to these associations. AP/AC use was 
not associated with CNV lesion size. For foveal retinal thickness, however, aspirin use was borderline 
significantly associated with a thicker retina. After monthly anti-VEGF injections given for one year, 
no differences were observed between users and nonusers for the different outcomes.
This study has strengths and limitations. An important benefit was that our study was a case only 
study of neovascular AMD, resulting in a larger similarity of disease characteristics than population-
based studies, which compare AMD versus no AMD. Factors such as smoking, visual acuity in the 
study eye, disease activity in the fellow eye, and pseudophakia were comparable between users and 
non-users. Other strengths are the strict inclusion criteria of the BRAMD trial requiring multimodal 
imaging to diagnose active CNV, homogenizing the CNV cases entering the study. Among the 
limitations are the lack of data on medication use prior to the onset of CNV, the exclusion of severe 
cases, and the relatively small sample size. This limited our ability to perform detailed subgroup 
analyses, and may hamper extrapolation of findings. We observed a higher age and frequency of 
diabetes and cardiovascular disorders among users of AP/AC in concordance with the indication for 
these medications. Nevertheless, true confounding by indication is unlikely: the beneficial effect for 
AP/AC users found in our study is not in line with the higher risk of AMD for cardiovascular disorders 
suggested by some studies.15,16
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Our study investigated the effect of AP/AC medication on visual acuity, while most other studies 
focused on onset of early and late stages of AMD, or on the occurrence of hemorrhages only. With 
respect to AMD, the majority of population-based studies found an increased risk of CNV. The 
cross-sectional EUREYE study observed a two times increased risk of CNV for aspirin users, which 
sustained after correction for indication.1 The Beaver Dam Eye Study (BDES) and Blue Mountains Eye 
Study (BMES) found a similarly increased risk of CNV, however, BDES observed this increase only 
for those with at least 10-year intake.2 The association found by BMES was no longer significant 
after adjustment of additional cardiovascular risk factors.3 Case studies and clinical trials did not 
support an increased risk of AMD. The Women’s Health Study found a lower, albeit nonsignificant, 
risk of visually significant AMD for those randomized to aspirin.5 The Physician Health Study found 
a similar trend for the entire group of aspirin users, and a significantly protective effect in men with 
hypertension.4 A case study performed by Wilson et al. also found a protective effect of aspirin: fewer 
AMD patients on this medication developed CNV.17 The Age-Related Eye Disease Study 2 reported 
this trend as well. This study observed a protective effect of aspirin use with the presence of AMD, 
including CNV, and with progression of AMD.18,19 Meta-analyses and reviews have been published 
evaluating studies of various designs.6-9,20-23 Overall risk estimates varied from no to a small increased 
risk (overall risk ratio < 2) for CNV as well as for other forms of AMD. Nevertheless, the inconsistency 
of study results was striking.
To evaluate whether AP/AC medication influenced the macular anatomy, we compared foveal retinal 
thickness and CNV lesion size between users and nonusers. We found a borderline significantly 
thicker foveal retinal thickness for aspirin users, compared to non-users. This association was found 
after additional adjustment for frequency of diabetes, hypertension, cardio vascular history and 
CNV in the fellow eye, all variables which could influence foveal retinal thickness. Unfortunately, 
we did not have morphology on OCT images to our disposal, which may have helped to explain 
the observed differences. Foveal retinal thickness was comparable between the aspirin users and 
the nonusers after treatment with anti-VEGF medication. For the other AP/AC groups, no significant 
association as found for both foveal retinal thickness and CNV lesions size at baseline and after anti-
VEGF treatment. Animal studies showed equivalent results: aspirin treated mice did not differ in laser 
induced CNV lesion size from the control group.24
AP/AC use has been associated with an increased risk of bleeding, such as cerebral and 
gastrointestinal bleeding.10 Whether this also accounts for ocular hemorrhages is still unclear. This 
study provides evidence that in particular aspirin users do not have an increased risk of retinal or 
subretinal hemorrhages. Several other studies focused on AP/AC and hemorrhages in CNV.25-35 None 
of these studies found a protective effect. Tilanus et al.29 found a higher risk of large hemorrhages, 
in particularly for AC users, while Kuhli-Hattenbach et al.27,33 and Kiernan et al.25 found an increased 
risk of large hemorrhages for all AP/AC users. By contrast, the Macular Photocoagulation Study26 
did not find a significant association between aspirin use and hemorrhages, and the Comparison of 
AMD Treatment Trials (CATT) study30 only found a significant association for aspirin and clopidogrel 
bisulfate after stratification for hypertension. Stratification for hypertension did not influence our 
results (Supplemental Table 6). What could explain these differences in results, in particularly those 
from the CATT Study? The BRAMD study used very similar inclusion criteria as CATT, however, patients 
with >70% lesion area covered by blood were excluded in our study. We do not think that this is an 
explanation to the data, as the proportion of patients with >2 DA of hemorrhage in CATT was small 
(<5%). A factor that could be held accountable is the eligibility of patients with past treatments for 
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AMD in BRAMD (13.3%). In CATT, only naïve patients were eligible and hemorrhages had therefore 
not undergone prior treatment. Reports on patients treated with anti-VEGF reported only 0.6% 
macular hemorrhages and these hemorrhages were not associated with AP/AC use.36
Aspirin appeared to be the major driver of the beneficial effect of AP/AC in our study. Fourty 
percent of the population used AP/AC medication, of which three fourth was aspirin. Aspirin is a 
nonsteroidal anti-inflammatory drug (NSAID) and the only NSAID that irreversibly inactivates both 
isoforms of the cyclooxygenase (COX) enzymes.12,23 It can suppress the production thromboxanes 
and prostaglandins by inhibiting the catalytic activity of COX-1 and COX-2, thereby reducing platelet 
aggregation, inflammation, and angiogenesis, and promoting apoptosis.23,24,37 A recent study in mice 
showed that inhibition of COX-2 reduced angiogenesis and subretinal fibrosis in CNV.38 Mechanisms 
independent of COX can also induce cell apoptosis.37 Aspirin has antioxidant properties and 
provides a protective effect against lipid peroxidation, upregulates other antioxidants, and inhibits 
mitochondrial oxidative phosphorylation reducing reactive oxygen species.24,37,39 Finally, aspirin 
modulates DNA transcription through inhibition of nuclear factor kappa B, thereby influencing many 
biological processes, including inflammation and apoptosis.23,37 Taken together, aside from the anti-
platelet aggregation and apoptosis, these actions of aspirin are in line with a favorable effect on 
AMD.
In summary, the BRAMD trial suggests that AP/AC use did not increase the risk of visual impairment 
or the occurrence of hemorrhages. Validation of our data is expected from the large-scale ‘ASPirin in 
Reducing Events in the Elderly’ (ASPREE) trial, an ongoing study which investigates the use of low-
dose daily aspirin on AMD phenotype.40 Our findings are of clinical importance, because they imply 
that patients with neovascular AMD can continue their prescribed use of AP/AC medication without 
negative effects on AMD outcome.
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SUPPLEMENTAL TABLE 1 - In- and exclusion criteria of the BRAMD study
Inclusion criteria
Patients 60 years of age or higher.
Patients with primary or recurrent sub-, juxta- or extrafoveal CNV secondary to AMD, including those with RAP, that may 
benefit from anti-VEGF treatment in the opinion of the investigator.
The total area of CNV (including both classic and occult components) encompassed within the lesion must be more or equal 
to 30% of the total lesion area.
The total lesion area should be < 12 disc areas.
A best corrected visual acuity (BCVA) score between 78 and 20 letters (approximately 0,63–0,05 Snellen equivalent) in the 
study eye.
Exclusion criteria
Ocular treatment with anti-angiogenic drugs in the last 2 months or Triamcinolone in the last 6 months.
Laser photocoagulation (juxtafoveal or extrafoveal) in the study eye within one month preceding baseline.
Patients with angioid streaks or precursors of CNV in either eye due to other causes, such as ocular
histoplasmosis, trauma, or pathologic myopia.
Spherical equivalent of refractive error in the study eye demonstrating more than– 8 diopters of myopia.
Cataract extraction within three months preceding baseline.
IOP >25 mm Hg.
Active intraocular inflammation in the study eye.
Vitreous hemorrhage obscuring view of the posterior pole in the study eye.
Presence of a retinal pigment epithelial tear involving the macula in the study eye.
Subretinal hemorrhage in the study eye if the size of the hemorrhage is > 70% of the lesion.
Subfoveal fibrosis or atrophy in the study eye.
History of hypersensitivity or allergy to fluorescein.
Inability to obtain fundus photographs, fluorescein angiograms or OCT’s of sufficient quality to be analyzed and graded by 
the Central Reading Centre.
Systemic disease with a life expectancy shorter than the duration of the study.
Inability to adhere to the protocol with regard to injection and follow-up visits.
Legally incompetent adult.
Refusal to give written informed consent.
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SUPPLEMENTAL TABLE 2 - Association between antiplatelet or anticoagulant medication and risk of visual 
impairment during last visit
Risk of visual impairment
Functional 
vision eyes 
(N-178)
Visual 
impaired eyes 
(N=148)
OR (95% CI) 
Model 1 
OR (95% CI) 
Model 2
Use of antiplatelet or anticoagulant drug        
 No 105 87 1 1
 Yes 73 61 0.90 (0.57-1.42 0.97 (0.58-1.65)
Use of antiplatelet drugs        
 No 117 106 1 1
 Yes 61 42 0.69 (0.42-1.12) 0.71 (0.42-1.19)
Use of anticoagulant drugs        
 No 163 127 1 1
 Yes 15 21 1.69 (0.83-3.45) 1.81 (0.86-3.82)
Type of antiplatelet or anticoagulant drugs        
 None 105 87 1 1
 Aspirin 57 42 0.80 (0.48-1.32) 0.92 (0.52-1.63)
 Acenocoumarol 11 17 1.63 (0.71-3.74) 1.90 (0.73-4.96)
Risk of severe visual impairment 
Functional 
vision eyes 
(N-178)
Severe visual 
impaired eyes 
(N=94)
OR (95% CI) 
Model 1 
OR (95% CI) 
Model 2 
Use of antiplatelet or anticoagulant drug        
 No 105 52 1 1
 Yes 73 42 1.02 (0.60-1.71) 1.04 (0.57-1.88)
Use of antiplatelet drugs        
 No 117 64 1 1
 Yes 61 30 0.81 (0.47-1.39) 0.81 (0.45-1.48)
Use of anticoagulant drugs        
 No 163 80 1 1
 Yes 15 14 1.78 (0.81-3.92)  1.73 (0.76-3.91)
Type of antiplatelet or anticoagulant drugs       
 None 105 52 1 1
 Aspirin 57 30 0.96 (0.54-1.70) 1.23 (0.53-1.94)
 Acenocoumarol 11 12 1.96 (0.80-4.83) 2.04 (0.72-5.75)
Model 1: adjusted for age, sex and study center
Model 2: model 1 including smoking, lens status, medical history cardiovascular diseases, diabetes, hypertension, choroidal 
neovascularization fellow eye
Abbreviations: CI = confidence interval, OR = Odds' ratio
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SUPPLEMENTAL TABLE 3 - Association between antiplatelet or anticoagulant medication and foveal retinal 
thickness on OCT at baseline 
 
 
User Nonuser
 
P value*
 
P value**N FRT N FRT
Antiplatelet or anticoagulant drug 135 396 (120) 195 380 (123) 0.27 0.08
Antiplatelet drugs 103 401 (128) 227 380 (118) 0.19 0.06
Anticoagulant drugs 37 390 (95) 293 386 (125) 0.73 0.73
Type of anticoagulant            
 Aspirin 99 405 (129) 195 380 (123) 0.15 0.04
 Acenocoumarol 29 399 (96) 195 380 (123) 0.37 0.29
FRT is in μm and values are mean (SD)
P values obtained using ANCOVA
* adjusted for age, sex and study center
** adjusted for age, sex, study center, smoking, medical history cardiovascular diseases, diabetes, hypertension, choroidal 
neovascularization fellow eye
Abbreviations: FRT = foveal retinal thickness, OCT = optical coherence tomography, SD = standard deviation 
SUPPLEMENTAL TABLE 4 - Association between antiplatelet or anticoagulant medication and foveal retinal 
thickness on OCT during last visit
 
 
User Nonuser
 
P value*
 
P value**N FRT N FRT
Antiplatelet or anticoagulant drug 133 247 (67) 193 248 (61) 0.73 0.91
Antiplatelet drugs 103 247 (70) 223 248 (60) 0.77 0.98
Anticoagulant drugs 35 247 (62) 291 248 (64) 0.99 0.98
Type of anticoagulant            
 Aspirin 99 246 (71) 193 248 (61) 0.61 0.84
 Acenocoumarol 28 248 (67) 193 248 (61) 0.91 0.56
FRT is in μm and values are mean (SD)
P values obtained using ANCOVA
* adjusted for age, sex and study center
** adjusted for age, sex, study center, smoking, medical history cardiovascular diseases, diabetes, hypertension, choroidal 
neovascularization fellow eye
Abbreviations: FRT = foveal retinal thickness, OCT = optical coherence tomography, SD = standard deviation
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SUPPLEMENTAL TABLE 5 - Association between antiplatelet or anticoagulant medication and CNV lesion size at 
baseline
 
Lesion size < 2 DA
 (N=109)
Lesion size ≥ 2 DA 
(N=203)
OR (95% CI) 
model 1
OR (95% CI) 
model 2
Use of antiplatelet or anticoagulant drug        
 No 67 116 1 1
 Yes 42 87 1.26 (0.77-2.06) 1.47 (0.83-2.60)
Use of antiplatelet drugs        
 No 75 138 1 1
 Yes 34 65 1.09 (0.65-1.82) 1.18 (0.67-2.06)
Use of anticoagulant drugs      
 No 100 178 1 1
 Yes 9 25 1.58 (0.70-3.55) 1.66 (0.72-3.86)
Type of drugs        
 None 67 116 1 1
 Apirin 30 65 1.37 (0.79-2.35) 1.68 (0.90-3.15)
 Acenocoumarol 7 20 1.67 (0.65-4.25) 1.83 (0.64-5.20)
Model 1: adjusted for age, sex and study center
Model 2: model 1 including smoking, medical history cardiovascular diseases, diabetes, hypertension, choroidal 
neovascularization fellow eye
Abbreviations: CI = confidence interval, CNV = choroidal neovascularization, DA = disk area, OR = Odds' Ratio
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SUPPLEMENTARY FIGURE 1 - Distribution of visual acuity in those with or without retinal or subretinal hemorrhage 
for antiplatelet or anticoagulant medication
On the x-axis the frequency in percentages is plotted, on the y- axis the groups indicating the users and nonusers of antiplatelet 
or anticoagulant medication and these group were further stratified for presence of retinal or subretinal hemorrhage (+) or no 
presence hemorrhage (-).
Abbreviations AC = anticoagulant, AP = antiplatelet.
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SUMMARY
The genetics of age-related macular degeneration (AMD) has been an exciting research area during 
the last decade. The advances in molecular genetic techniques paved the way for great progress 
in the discovery of genes and led to identification of many disease-associated risk variants. Several 
genes have been associated with AMD and the two major AMD genes are CFH and ARMS2-HTRA1 
. Other genes associated with AMD are complement (CFB/C2, C3, CFI), lipid (APOE, LIPC, CETP, 
suggested genes LPL and ABCA1), and collagen genes (COL8A1 and COL10A), implicating a role for 
these in the pathogenesis of AMD.
Interactions of AMD genes with life style factors such as smoking and anti-oxidant intake have been 
reported and are of interest to manage AMD risk.
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GENETIC FACTORS
Although familial occurrence had been known for many years, major advances in the identification 
of genetic factors for AMD were achieved after the start of Genome Wide Association Studies (GWAS). 
We will discuss the currently known AMD-associated genes and their importance to the disease. A 
summary of the genes can be found in Table 1.
The Complement Pathway Genes
Complement Factor H (CFH)
CFH is one of the two major AMD genes. The CFH protein is a key regulator of the complement 
pathway – it inhibits the activation of complement component C3 to C3b and degrades C3b, thereby 
limiting the amplification phase of the alternative complement cascade.1 CFH is present in serum, 
not membrane-bound, expressed in the retinal pigment epithelium and can be found in drusen.2,3
First reports on an association between CFH and AMD stem from 2005,4,5,6 and since then this finding 
has been replicated by numerous studies in different populations.7-38 The well-known risk allele Y402H 
is common in Caucasians and Africans (~36%), but much less so in Asians (~7–15%) and Hispanics 
(~17%).39 Functionally, this and other risk alleles have been shown to alter CFH binding, thereby 
impairing the regulatory function of CFH, increasing complement activation, and subsequently 
causing an inflammatory response and cell death.3-6,13,40-42
CFH is located in a large region of linkage disequilibrium. Apart from Y402H, many other variants 
have been shown to be associated with increased risk of AMD. A non-coding variant (rs1410996) 
was found to have an even stronger association than Y402H.43-44 In particular in Asian populations, 
the Y402H variant was not significantly associated with AMD, whereas other variants including 
rs1410996 were.24,35 The genes in the vicinity of CFH, such as CFHR1-5, have gene functions similar to 
CFH, and have also been associated with AMD. A haplotype carrying a deletion of CFHR1 and CFHR3 
(delCFHR1/3) was reported to have a protective effect, and occurred in 20% of controls and 8% of 
cases.45-46 The proteins encoded by these genes are absent in serum of persons who are homozygous 
for delCFHR1/3. 45 CFHR1 and CFHR3 contain a C3-binding site and deletion of these genes may 
reduce competition for the binding of CFH to C3b, enhancing inhibitory activity by CFH. DelCFHR1/3 
was more frequent in African Americans (16%), and less common in Hispanics (6.8%) and European 
Americans (4.7%).47
Complement Factor B (CFB)/Complement Component 2 (C2)
Complement factor B (CFB) and complement component 2 (C2) are activators of the alternative and 
classical pathways, respectively. Four variants in the CFB and C2 gene located on chromosome 6p21 
have been shown to have a strong protective effect: CFB R32Q, which is in nearly complete linkage 
disequilibrium with C2 IVS10, and CFB L9H, which is in nearly complete linkage disequilibrium with 
C2 E318D.44,48-54
Genetic and functional data suggest that CFB variants rather than C2 variants are likely to have 
caused the observed protection. Only the CFB R32Q variant results in inferior C3b binding affinity, 
leading to a lower potential to amplify complement activation.55-56 Moreover, the majority of proteins 
of the alternative pathway (e.g., CFH, CFB) are present in drusen, whereas proteins from the classical 
pathway (e.g., C2) are not.57-58 Good epidemiologic analysis with adjustment for confounders showed 
that the association with C2 R32Q was robust (OR, 0.21; 95% CI, 0.11–0.39), while the association 
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with C2 E318D became insignificant (OR, 0.60; 95% CI, 0.25– 1.47).49 These data suggest that the C2 
variants show residual association with AMD originating from their high linkage disequilibrium with 
CFB.
Complement Component 3 (C3)
Complement component C3 is the convergence point of all complement pathways (classical, lectin, 
and alternative). Activation of C3 is crucial for the formation of membrane attack complexes that 
leads to cell lysis.59 The C3 gene is located on chromosome 19p13.3–13.2. The amino acid changes 
caused by the C3 variants R102G and P314L may alter the binding capacity of C3 to pathogenic cell 
surfaces or other complement proteins.59-61 A causal relation with AMD is plausible, since C3 mRNA 
is present in neural retina, choroids, and retinal pigment epithelium57; its cleavage product C3a is 
present in drusen,1,62 and C3a can induce vascular endothelial growth factor expression and promote 
choroidal neovascularization.63
The two functional variants, R102G (rs2230199) and P314L (rs1047286), are in high linkage 
disequilibrium. They have both been identified as genetic risk factors for AMD.64-72 R102G has also 
been implicated in the progression from the earlier stages of AMD to late AMD.51 The two initial 
investigations as well as later studies concluded that R102G is more significant in AMD causality than 
P314L.64-65,67-69,72-73
An allele-dose effect for R102G was observed in the various Caucasian studies with an increased risk 
of 1.4–1.7 for heterozygotes and 1.8–3.3 for homozygotes. The Rotterdam Study found associations 
of the C3 variants with early as well as late AMD, and reported that the risk increase was most 
prominent for the mixed type of AMD (both geographic atrophy and neovascular AMD present).68 
The effect of the C3 alleles is independent from CFH Y402H and ARMS2 A69S.68-69
Complement Factor I (CFI)
The CFI protein is regulated by CFH and functions as a cofactor for the cleavage and inactivation of 
C3b. Recently, several variants near the CFI gene have been associated with risk of AMD in Caucasian 
as well as Asian populations74-79 In a Japanese study, rs10033900 had a protective effect with OR 
0.28 (95% CI, 0.11–0.69) for homozygous carriers of the minor allele. No association was found for 
heterozygous carriers (OR, 0.99; 95% CI, 0.61–1.62). A recent genome-wide association study found 
that the major allele of rs2285714 was associated with an increased risk of 1.31 (95% CI, 1.18–1.45). 
Ennis et al. reported significantly (P < 0.05) protective effects for rs11728699, rs6854876, rs7439493, 
and rs13117504 with ORs ranging from 0.68 to 0.74 (P < 0.05), and these SNPs also tagged significant 
protective (GCAG, OR 0.69) and causative (TGGC, OR 1.34) haplotypes.75-77
The ARMS2-HTRA1 (10q26) Locus
Linkage studies had already identified a susceptibility locus at chromosome 10q26. GWA studies 
conformed this locus as the second major contributor to the pathogenesis of AMD.7,81-98 As this region 
contains many genes in high linkage disequilibrium (Pleckstrin Homology Domain-containing Protein 
family A member 1 (PLEKHA1), LOC387715 (or Age-related maculopathy susceptibility gene 2, ARMS2) 
and high temperature requirement factor A1 (HTRA1) gene), controversy exists about which gene is 
the AMD susceptibility gene.
In the ARMS2 gene, rs10490924 has repeatedly been reported to increase risk of AMD up to 15 
times.7,85-86,89-92,94,98-97 This functional SNP causes an A69S change, and has been described as the 
causal SNP that by itself could explain the bulk of the association between the 10q26 region and 
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AMD.91 The precise function of ARMS2 in AMD remains to be elucidated. Disorganized mitochondrial 
membranes, as well as decreased number of mitochondria in retinal pigment epithelium cells of 
AMD donors have provided evidence of mitochondrial dysfunction in AMD.99-100 This suggests that 
ARMS2 may jeopardize mitochondrial function, and consequently lead to the formation of reactive 
oxygen species, apoptosis, and AMD.94,99-103 Moreover, immunohistochemical studies located the 
ARMS2 protein to the mitochondrial outer membrane, in particular of rods and cones.91,94 However, 
its presence has also been reported in the cellular cytosol104 and the extracellular matrix.105
Meta-analyses of the HTRA1 gene reported an increased risk of AMD for homozygous (OR, 9.26; 
95% CI, 7.27–11.91) as well as heterozygous (OR, 2.33; 95% CI, 2.01–2.71) carriers of the rs11200638 
risk allele.106 Stratified analyses revealed that rs11200638 was significantly associated with CNV but 
not with GA, and that the causative effect was stronger in Caucasians than in Asians.107-108 Also for 
this gene, various lines of evidence support involvement in AMD. The rs11200638 risk allele has 
been associated with higher levels of HTRA1 mRNA and protein in some studies,87,98,109-110 although 
two other studies with larger datasets could not validate this finding in heterologous expression 
systems.91,111 Furthermore, HTRA1 may inhibit signaling of TGF-ß proteins, which have been reported 
to act as negative growth regulators in the retina and RPE.112-114 In addition, HTRA1 may stimulate 
the degradation of extracellular matrix through enhanced expression of matrix metalloproteases. 
Consequently, overexpression of HTRA1 may affect the integrity of Bruch’s membrane and RPE 
contributing to AMD development. Recently, Richardson et al. found rs3793917 (located between 
ARMS2 and HTRA1) to be most associated with AMD (OR, 3.45; 95% CI, 2.36–5.05), and indicated 
that the intergenic region between this SNP and HTRA1 rs11200638 was most likely to confer AMD 
risk.96 However, they could not distinguish rs3793917 from rs11200638 and rs10490924 to explain 
causality since they were all in high linkage disequilibrium.
Common haplotypes encompassing both the ARMS2 and the HTRA1 genes have also been linked 
to AMD. Gibbs et al. described a common haplotype TAT tagged by rs10490924, rs11200638, and 
rs2293870 that significantly predisposed to AMD (P = 2.70 × 10−9), and a haplotype GGG that was 
significantly protective against AMD (P = 0.003).95 Yang et al. also found a haplotype T-G-Wt-G tagged 
by rs2736911, rs10490924, in/del/Wt, and rs11200638, which was protective in Caucasian as well as 
Chinese populations (P < 0.007).98 They also observed that the in/del or the rs11200638 risk allele 
by itself was insufficient to alter HTRA1 expression, and found that a common disease haplotype 
including both the in/del and rs11200638 leads to upregulation of HTRA1. Hence, they proposed 
a binary model where downregulation of ARMS2 and concomitant upregulation of HTRA1 best 
explained the risk associated with the 10q26 locus. Further functional analyses in larger datasets are 
warranted to conclude what the key genetic contributors in the 10q26 locus are.
The Lipid-Related Genes
Apolipoprotein E (APOE)
Apolipoprotein E is a key regulator of lipid and cholesterol transport in the central nervous system,115 
and has been linked to various neurodegenerative and cardiovascular diseases (e.g., Alzheimer’s 
disease and stroke).116-118 In the eye, APOE is expressed in photoreceptor cells, retinal ganglion cells, 
Müller cells, retinal pigment epithelium, Bruch’s membrane, choroid, and in the disease-associated 
lesions: drusen and basal laminar deposits.57,58,119-123 There are three common allelic variants of the 
APOE gene: ε2, ε3, and ε4, with ε3 being the most prevalent.124-125 The majority of studies support 
a protective effect of the APOE ε4 allele against AMD,119,126-138 though in some reports, this inverse 
association failed to reach statistical significance.127,131,133,137-138 Stratification of late AMD into GA and 
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CNV showed that the greatest protective effect for the ε3ε4 genotype was in individuals with GA (OR 
0.35, 95% CI 0.13–0.92).132 The APOE ε2 allele has mainly been associated with a non-significant but 
increased risk of AMD.119,126,129-132,134,137
Several studies reported that ε4 carriers have significantly lower CRP levels than noncarriers, especially 
compared to ε2 carriers. CRP level reportedly decreases in a dose-dependent order of ε2/ ε2, ε2/ε3, 
ε3/ε3, ε2/ε4, ε3/ε4, and ε4/ε4.140-145 In addition, APOE ε2 appears to enhance expression by RPE cells 
of the vascular endothelial growth factor and fibroblast growth factor,146 whereas their expression 
is reportedly suppressed by APOE ε4.136,147 This indicates that APOE ε2 induces neovascularization by 
altering angiogenic cytokines, whereas APOE ε4 limits this process. And in contrast to ε2, APOE ε4 has 
positive charges which diminish hydrophobicity of Bruch’s membrane, and results in better clearance 
of debris. Moreover, ε4 carriers reportedly have 36% lower risk of hypertension than noncarriers.148 
Another interesting finding is that APOE ε4 levels seem to decrease with advancing age,145 which 
may reduce transport of lipids and cell debris, culminating in a higher rate of AMD in older age. 
APOE also plays an important role in the maintenance of retinal membrane cell: Lipids are released 
from the degenerating cell membrane and astrocytes react by synthesizing APOE to bind the free 
cholesterol and lipids and to distribute them for reuse in cell membrane biosynthesis.149-151 Based 
on the cumulative empirical evidence and pooled data outlined above, it can be proposed that the 
APOE ε4 offers a reduced risk for onset, severity, and progression rate of AMD, in contrast to APOE ε2.
Hepatic Lipase (LIPC)
Two parallel published genome-wide association studies (GWAS) reported causative variants for the 
LIPC gene.76,152 LIPC has been associated with high-density lipoprotein cholesterol (HDL-c) levels in 
blood153-154 and is involved in mediating the uptake of HDL-c at the cell surface.155 LIPC is expressed 
in the retina and modification of HDL-related efficiency could influence the risk of AMD, because 
HDL is an important transporter of lutein/zeaxanthin.152,156-157 The common allele of rs493258 near 
the LIPC gene on chromosome 15q22 (OR, 1.14; 95% CI, 1.09-1.20; frequency in controls ~0.56; P = 
1.3 × 10-7) increased the risk of AMD, whereas the minor allele of rs10468017, a functional promoter 
variant, (OR, 0.82; 95% CI, 0.77-0.88; frequency in controls ~0.30; P = 1.34 × 10-8) had a protective 
effect. However, confirmation of the protective variant was achieved after targeted examination of 
the suggestive markers of the GWAS peformed by Neale et al.152
Cholesterylester Transfer Protein (CETP)
The rare allele of rs3764261 at the CETP gene on chromosome 16q21 (OR, 1.19; 95% CI, 1.12-1.27; 
frequency in controls ~0.32; P = 7.4 × 10-7) in associated with an increased risk of AMD76 and has 
recently been replicated by Yu et al.158 CETP plays an important role in the production and degradation 
of HDL-c and is expressed in the retina.152,156
Lipoprotein Lipase (LPL)
Chen et al. (2010) reported also the variant rs12678919 at LPL on chromosome 8p22 (OR, 1.38; 95% 
CI, 1.11-1.43; P = 3 × 10-3). This variant was not significant but consistent with the hypothesis that 
HDL metabolism is associated with AMD pathogenesis; LPL plays, like CETP, an important role in 
the production and degradation of HDL-c.152,156 Recently, an association, although not significant, 
between LPL rs12678919 and late AMD was suggested by Peter et al.(OR, 0.5, 95% CI, 0.2—1.2, P = 
0.10) for carriers of 1 or 2 G alleles compared to non-carriers.79 The G allele increases serum HDL levels 
(P < 10-10, 2.44 mg/dl increase per G allele), confirming the role of LPL in the HDL metabolism.153
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ATP-Binding Cassette Subfamily A Member 1 (ABCA1)
ABCA1 is involved in mediating the uptake of HDL-c at the cell surface and have been shown to 
be expressed in the retina.152,155-156 The variant rs1883025 near ABCA1 on chromosome 9q22 (OR, 
1.15; 95% CI, 1.07-1.23; P = 5.6 × 10-4) has been suggested by Chen et al. to be associated with 
AMD.76 Several other studies confirmed this suggestion and showed a significantly higher risk allele 
frequency in AMD patients compared with control individuals (P = 0.00027).152,158-160
With increasing age, lipids and cholesterol accumulate underneath the RPE and are constituents of 
drusen.57,161 The HDL-c associated variants might affect the formation of drusen and subsequently 
the development of AMD. The ‘non risk’ TT-genotype of ABCA1 rs1883025 had a significant protective 
effect for intermediate and large drusen; (OR, 0.48; 95% CI; 0.27-0.85), (OR, 0.41; 95% CI, 0.23-0.74), 
respectively.160
Collagen related genes
Alpha chain of type VIII collagen (COL8A1)
The COL8A1 gene on chromosome 3 encodes for one of the alpha chains of type VIII collagen, a major 
component of the multiple basement membranes in the eye, including Bruch’s membrane and the 
choroidal stroma.152 The intronic variant rs13095226 was associated with a slight increased risk of 
AMD (OR, 1.24; 95% CI, 1.13-1.35; P = 2.50 × 10-6).162
Alpha chain of type X collagen (COL10A1)
Recently, a genome-wide association study (GWAS) has published a novel loci, rs1999930 near the 
COL10A1 gene (OR, 0.87; 95% CI, 0.83-0.91; P = 1.1 × 10-10).158 COL10A1 is a short-chain collagen 
expressed by hypertrophic chondrocytes during endochondral ossification. Although no relation 
of COL10A1 with the retina has been found, the previous finding of the collagen gene COL8A1, 
implicates a role for collagen in a causal pathway for AMD.
Other genes
Tissue Inhibitor of Metalloproteinases-3 (TIMP3)
Candidate gene analyses initially found no evidence of linkage or association between AMD and 
TIMP3 on chromosome 22q12.1–13.2.163,164 Recently, a genome-wide association study (GWAS) 
found the region near TIMP3 to be a susceptibility locus,76 which was previously reported by one 
linkage study.165 TIMP3 is a metalloproteinase involved in degradation of the extracellular matrix in 
the retina,166 and is mutated in Sorby’s fundus dystrophy.167 The common variant rs9621532, nearby 
TIMP3 was associated with increased risk of AMD (OR, 1.41; 95% CI, 1.27-1.57; frequency in controls 
~0.95; P = 1.1 × 10-11).76
Vascular Endothelian Growth Factor A (VEGFA)
VEGFA is a member of the VEGF family and functions to increase vascular permeability, angiogenesis, 
cell growth and migration of endothelial cells. VEGFA is also a target in the treatment of CNV with 
anti-VEGF therapy. Haines et al found a strong association for the variant rs2010963 with linkage-
analysis (LOD score = 1.32, P= 0.0001) in early and late AMD, but a moderate result in a later case-
control setting (P = 0.02).168 Recently a new variant near the VEGFA gene was published.158 The variant 
rs4711751 on 6p12 near VEGFA (OR, 1.15; 95% CI, 1.10-1.21; P=8.7 × 10-9) was not in LD with the 
earlier found variant, indicating a novel region associated with AMD. Unfortunately the variant found 
by Haines et al could not be replicated.
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Tumor necrosis factor receptor superfamily 10 a (TNRSF10A)
TNRSF10A encodes for TRAILR1, a TRAIL receptor, which is broadly expressed in human adult RPE.166 
Arakawa et al reported a variant, rs13278062 near TNRSF10A on chromosome 8p21 (OR, 0.73; 95% 
0.67-0.80; P = 1.03 × 10-12) to be associated with exudative AMD in a Japanese population.169
GENE-GENE AND GENE-ENVIRONMENT INTERACTIONS
CFH Y402H
The Rotterdam Study (RS) reported interaction between CFH Y402H and smoking, C-reactive protein 
level, and erythrocyte sedimentation rate (ESR),13 meaning that the joint effect of each determinant 
with Y402H was significantly greater than the sum of the independent effects. Compared to persons 
with the homozygous non-risk (TT) genotype and normal ESR levels, persons with the homozygous 
risk (CC) genotype and elevated ESR levels had a risk of 20.2 (95% CI, 9.5–43.0) for late AMD. Higher 
serum CRP levels in persons with the CC-genotype augmented AMD risk to 27.7 (95% CI, 10.7–72.0) 
compared to persons with the lowest CRP levels and the TT-genotype.
Current smokers with the CC-genotype had an OR of 34.0 (95% CI, 13.0–88.6) for late AMD relative to 
individuals with the TT-genotype who never smoked. Other studies also observed stronger effects 
of CFH Y402H among smokers.18,20,22,170-172 DeAngelis et al. (2007) further specified that smoking ten 
pack-years or more and having the CC-genotype was estimated to increase risk of CNV 144-fold 
compared with smoking less than ten pack-years and having the CT- or TT-genotype.22
AREDS reported a significant interaction between CFH Y402H and BMI.18 Higher BMI (≥25) did not 
increase the risk of AMD for persons with the TT-genotype (OR 0.7; 95% CI 0.4–1.2), whereas it did 
increase risk for those with the CT- (OR 2.2; 95% CI 1.3–4.0) and CC-genotype (OR 5.9; 95% CI 3.1–11.4).
Gold et al. reported that the protection conferred by C2 and/or CFB was strongest in persons with 
the CFH CC-genotype (OR = 0.27), intermediate in persons with the CT-genotype (OR = 0.36), and 
weakest in persons with the TT-genotype (OR = 0.44).48 However, the confidence intervals of all these 
estimates overlapped.
Two studies have examined interaction between genetic variants and antioxidants in the 
development of late AMD.173,174 AREDS calculated the risk of progression to late AMD for the CFH 
Y402H and ARMS2 A69S genotypes in various antioxidant treatment arms.173 A high zinc dosage was 
most protective against AMD in persons with the homozygous non-risk CFH genotype, but produced 
the greatest, albeit non-significant, protection in persons carrying the risk variant of ARMS2. The Blue 
Mountains Eye Study (BMES) found that high fish intake resulted in greater protection against late 
AMD in homozygous carriers of Y402H than in non-carriers.174 In addition, the RS showed that higher 
dietary intake of zinc, w-3 fatty acids, b-carotene, and lutein/zeaxanthin can attenuate the incidence 
of early AMD in those carrying these genetic risk variants (Figure 1).175
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FIGURE 1 - Risks for AMD stratified for genotype and nutrient intake
A - D. Joint effect of dietary nutrient intake and CFH Y402H genotype on the risk of Early AMD.
E – F. Joint effect of dietary nutrient intake and LOC387715 (ARMS2) A69S genotype on the risk of Early AMD.
R is the common reference group.
HRs are estimates of the relative risk of Early AMD, and represent the risk of disease (Early AMD vs No AMD) 
in the various genetic-environmental risk groups divided by the risk of disease (Early AMD vs No AMD) in the 
common reference group (noncarriers - 1st tertile of nutrient intake). HRs are estimated with Cox regression 
analyses and included age, sex, smoking status, and atherosclerosis.
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ARMS2-HTRA1
Although not all studies reported statistical interaction, the majority supported a strong combined 
effect of smoking and ARMS2 A69S in AMD susceptibility.84,170,176-182 Interaction analyses by Schmidt et 
al. between number of pack-years of smoking and A69S genotypes revealed that in affected persons, 
the frequency of the homozygous risk (TT) genotype linearly increased with increasing pack-years 
irrespective of age and gender, with a corresponding decrease in the homozygous non-risk (GG) 
genotype frequencies (P < 0.05).181 When comparing current smokers to never smokers, risks for 
heterozygotes (GT) increased 3- to 6-fold, while for the homozygotes (GG), risk increased 10- to 27-
fold.170,176
Combined effects on the likelihood of early or late AMD were demonstrated by the BMES for the A69S 
GT- and TT-genotypes with the marker’s high-sensitivity CRP (ORs, 1.2 for the highest tertile alone, 
1.6 for GT- and TT-genotypes alone, and 2.2 for both GT and TT-genotypes plus the highest tertile, 
compared with the GG-genotype with the two lower tertiles), IL-6 (corresponding ORs, 1.1, 1.6, and 
2.2), sICAM-1 (ORs, 1.0, 1.5, and 2.3, respectively), and PAI-1 (ORs, 1.3, 1.7, and 2.3, respectively), but 
not with WCC, fibrinogen, homocysteine, and von Willebrand factor.179
Interaction with anti-oxidants and ARMS2 was studied within the same settings as CFH, and resulted 
in similar effects (Figure 1).
Risk of AMD due to the Combined Effect of CFH and ARMS2/HTRA1 SNPs
Several studies have investigated the combined effect of CFH Y402H and ARMS2 A69S/HTRA1 
rs11200638.7,38,87,170,178,183-185,188 Persons with homozygous risk genotypes at both loci (CFH CC –ARMS2 
TT) compared to the non-risk genotype (TTGG) had ORs ranging from 27 in a Finnish case-control 
study178 to 228 in the Caucasian clinic-based AREDS.176 For persons with the homozygous risk genotype 
for both CFH Y402H and HTRA1 rs11200638, the combined ORs ranged from 8 in a Japanese case-
control study184 to 193 in AREDS relative to persons with no risk alleles at either locus.184 In addition 
to the combined risk conferred by CFH Y402H and ARMS2 A69S, Schmidt et al. also observed an extra 
risk of AMD caused by smoking.181 Compared to the nonsmoker/TT(Y402H)/GG(A69S) combination, 
the OR for individuals with the CC-genotype at Y402H and the TT-genotype at ARMS2 increased from 
10.2 for nonsmokers to 34.5 for smokers. Seitsonen et al. also found that smoking caused an extra 
risk for AMD, but only in connection with sex and C3 genotype.178 The univariate ORs for carrying at 
least one risk allele of CFH Y402H was 5.45 (95% CI, 2.18–16.83), of ARMS2 A69S was 4.89 (95% CI, 
1.73–16.43), of C3 R102G was 2.12 (95% CI, 0.52–8.70), and for smoking was 3.22 (95% CI 1.81–6.09), 
while the joint OR for the three loci and smoking was 74.3 (95% CI, 10.81–2123.6).
APOE gene
Debate remains regarding the gender-specific role of the APOE alleles in the development or 
progression of AMD. Schmidt et al. found significant interaction between ε2-carrier status and sex.130 
The ε2-allele conferred a risk of 0.74 (95% CI, 0.52–1.06) in women, and of 1.54 (95% CI, 0.97–2.45) 
in men. Hence, the authors suggested that an increased risk of AMD due to the ε2-allele may only 
be conferred to men. Conversely, Baird et al. found that ε2-carriers had a significant 4.8-fold (95% 
CI, 1.19–19.09) increased risk of AMD progression compared to ε4-carriers and a nearly significant 
2.8-fold (95% CI, 0.96–19.09) increased risk compared to ε3-carriers.132 Since this finding was only 
present in women, the authors suggested that there may be a gender-specific role in progression 
of AMD in persons with an ε2-allele. Fritsche et al. could not corroborate any gender-specific role of 
the APOE-alleles.186
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Schmidt et al.suggested a modifying effect of APOE genotypes on the smoking-associated risk of 
AMD, particularly for CNV.128,187 The effect of smoking was most deleterious for APOE ε2 carriers, 
compared to APOE ε4 carriers and persons with the APOE ε3/ε3 genotype. The increase in CNV risk 
due to smoking was greatest in APOE ε2 carriers, with genotypespecific risks increasing from 1.9 for 
APOE ε4 carriers (P = 0.11) to 2.2 for APOE ε3/ε3 homozygotes (P = 0.007) to 4.6 (P = 0.001) for APOE 
ε2 carriers, compared to non-smoking APOE ε3/ε3 persons. In other studies, the sample sizes of each 
subgroup were too small to determine statistical significance.134,139
CONCLUSION
Since the first assumption of a familial component to AMD, 15 genes associated with the disease 
have been identified. These genes have shed light on the pathogenesis of AMD, and have increased 
our knowledge on the causes of AMD enormously.
Most of the genetic risk is explained by only two genes, CFH and ARMS2/HTRA1. The risk variants in 
these genes occur at a much higher frequency in the general population than the actual disease 
does, provoking the view that life style factors ultimately determine whether these genes will have 
a deleterious effect. Interaction with life style factors such as smoking and BMI has been difficult to 
prove, but the first reports on the complexity of gene-environment modulations have appeared.
Future genetic research will make use of the new molecular methodology such as exome and whole 
genome sequencing. This will undoubtedly lead to finding more risk variants, and more information 
on causal pathways for AMD. Large genetic epidemiologic collaborations will be able to address 
the interaction with environmental factors better than single studies can, and they will also help 
elucidate AMD pathogenesis. It is expected that these developments will open up new avenues for 
long-lasting and successful treatments for AMD.
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ABSTRACT
Age-related macular degeneration (AMD) is a common cause of blindness in older individuals. 
To accelerate understanding of AMD biology and help design new therapies, we executed a 
collaborative genome-wide association study, examining >17,100 advanced AMD cases and >60,000 
controls of European and Asian ancestry. We identified 19 genomic loci associated with AMD with 
p<5x10-8 and enriched for genes involved in regulation of complement activity, lipid metabolism, 
extracellular matrix remodeling and angiogenesis. Our results include 7 loci reaching p<5x10-8 
for the first time, near the genes COL8A1/FILIP1L, IER3/DDR1, SLC16A8, TGFBR1, RAD51B, ADAMTS9/
MIR548A2, and B3GALTL. A genetic risk score combining SNPs from all loci displayed similar good 
ability to distinguish cases and controls in all samples examined. Our findings provide new directions 
for biological, genetic and therapeutic studies of AMD.
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INTRODUCTION, RESULTS AND DISCUSSION
AMD is a progressive neurodegenerative disease that leads to loss of central vision through death of 
photoreceptors1,2. In developed countries, AMD is the leading cause of blindness in those >65 years3. 
Genes in the complement pathway4-11 and a region of chromosome 10 12,13 have now been implicated 
as the major genetic contributors to disease. Association has also been demonstrated with several 
additional loci14-20, each providing an entry-point into AMD biology and potential therapeutic targets.
To accelerate the pace of discovery in macular degeneration genetics, 18 research groups from 
across the world formed the AMD Gene Consortium in early 2010, with support from the National 
Eye Institute (Table 1, Supplementary Table 1, Supplementary Note). To extend the catalog of 
disease associated common variants, we first organized a meta-analysis of genomewide association 
scans (GWAS) – combining data for >7,600 cases with advanced disease (geographic atrophy, 
neovascularization, or both) and >50,000 controls. Each study was first subject to GWAS quality 
control filters (customized taking into account study specific features as detailed in Supplementary 
Table 2) and standardized to the HapMap reference panel and statistical genotype imputation22-25. 
Results were combined through meta-analysis26 and thirty-two variants representing loci with 
promising evidence of association were genotyped in an additional >9,500 cases and >8,200 controls 
(Supplementary Tables 1–3; summary meta-analysis results available online). Our overall analysis of 
the most promising variants thus included >17,100 cases and >60,000 controls.
TABLE 1 - Summary of the samples used in genome-wide discovery and targeted follow-up analyses
For additional details, including a breakdown of the number of cases and controls in individual samples, see 
Supplementary Table 1. Ncases includes only cases with geographic atrophy, choroidal neovascularization, or 
both.
Analysis
Contributing 
study groups Ncases % Female % Neovascular disease Ncontrols % Female
Genome-wide discovery 15 7,650 53.9 59.2 51,844 45.2
Targeted follow-up 18 9,531 56.3 57.8 8,230 53.8
Overall 33 17,181 55.2 58.4 60,074 46.3
Our meta-analysis evaluated evidence for association at 2,442,884 SNPs (Figure 1). Inspection of Q-Q 
plots (Supplementary Figure 1) and the genomic control value (ëGC=1.06) suggest that unmodeled 
population stratification does not significantly impact our findings (Supplementary Table 4 for 
details). Joint analysis of discovery and follow-up studies27 resulted in 19 loci reaching p<5x108 
(Figure 1, Table 2, Supplementary Table 5). These 19 loci include all susceptibility loci previously 
reaching p<5x10-8, except the 4q12 gene cluster for which association was reported in a Japanese 
population. In addition, the set includes seven loci reaching p<5x10-8 for the first time.
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FIGURE 1 - Summary of genomewide association scan results. Summary of genomewide association scan results 
in the discovery GWAS sample. Previously described loci reaching p < 5x10-8 are labeled in blue; new loci 
reaching p < 5x10-8 for the first time after follow-up are labeled in green.
We evaluated heterogeneity between studies using the I2 statistic, which compares variability in 
effect size estimates between studies to chance expectations28. We observed significant (p<.05/19) 
heterogeneity only for loci near ARMS2 (I2=75.7%, p<1x10-6) and near CFH (I2=85.4%, p<1x10-6). 
Although these two loci were significantly associated in every sample examined, the magnitude of 
association varied more than expected. To explore sources of heterogeneity, we carried out a series 
of sub-analyses: we repeated the genomewide meta-analysis adding an age-adjustment, separating 
neovascular (NV) and geographic atrophy (GA) cases, in men and women, and in European- and 
Asian-ancestry samples separately (Figure 2, Supplementary Figure 2). These sub-analyses of the full 
GWAS dataset did not uncover additional loci reaching p<5x10-8; furthermore heterogeneity near 
CFH and ARMS2 remained significant in all sub-analyses (I2>65%, p <0.001). Consistent with previous 
reports17,29,30, separate analysis of NV and GA cases showed ARMS2 risk alleles preferentially associated 
with risk of NV (ORNV=2.97, ORGA=2.50, pdifference=.0008) whereas CFH risk alleles preferentially 
associated with risk of GA (ORNV=2.34, ORGA=2.80, pdifference=.0006). We also observed large differences 
in effect sizes when stratifying by ethnicity, with variants near CFH exhibiting stronger evidence 
for association among Europeans (p=0.0000001) and those near TNFRSF10A among East Asians 
(p=0.002). Potential explanations include differences in linkage disequilibrium between populations 
or differences in environmental or diagnostic factors that modify genetic effects.
Identifying the full spectrum of allelic variation that contributes to disease in each locus will require 
sequencing of AMD cases and controls. To conduct an initial evaluation of the evidence for multiple 
AMD risk alleles in the nineteen loci described here, we repeated genome-wide association analyses 
conditioning on the risk alleles listed in Table 2. We then examined each of the 19 implicated loci 
for variants with independent association (at p<0.0002, corresponding for an estimate of ~250 
independent variants per locus). This analysis resulted in the identification of the previously well 
documented independently associated variants near CFH and C2/CFB8,10,31,32 and of additional 
independent signals near C3, CETP, LIPC, FRK/COL10A1, IER3/DDR1, RAD51B (Supplementary Table 
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6). In four of these loci, the independently associated variants mapped very close (within <60kb) 
to the original signal. This shows each locus can harbor multiple susceptibility alleles, encouraging 
searches for rare variants that elucidate gene function in these regions33,34.
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FIGURE 2 - Sensitivity analysis. The top left panel compares estimated effect sizes for the original analysis and for 
an age-adjusted analysis (where age was included as a covariate and samples of unknown age were excluded). 
The top right panel compares analyses stratified by sex. The bottom left panel evaluates stratification by 
disease subtype. The bottom right panel evaluates stratification by ethnicity. The size of each marker reflects 
confidence intervals (with height reflecting confidence interval along the Y axis and width reflecting confidence 
interval along the X axis). Comparisons reaching p < 0.05 are labeled and colored in red.
To prioritize our search for likely causal variants, we examined each locus in detail (see LocusZoom35 
plots in Supplementary Figure 3) and investigated whether AMD risk alleles were associated with 
changes in protein sequence, copy number variation or insertion deletion polymorphisms. One 
quarter of associated variants altered protein sequence, either directly (N=2) or through linkage 
disequilibrium (r2>.6; N=3) with a nearby non-synonymous variant (Supplementary Table 7). Some 
coding variants point to well-studied genes (ARMS2, C3 and APOE) while others help prioritize nearby 
genes for further study. In chromosome 4q25, index SNP rs4698775 is in strong linkage disequilibrium 
(r2=.88) with a potentially protein damaging variant in CCDC109B36, a coiled coil domain containing 
protein that may be involved in the regulation of gene expression. In chromosome 6q22, index 
SNP rs3812111 is a perfect proxy for a coding variant in COL10A1, a collagen protein that could be 
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important in maintaining the structure and function of the extra-cellular matrix. Interestingly, Y402H 
was not in disequilibrium with rs10737680, the most strongly associated SNP in the CFH region but, 
instead, was tagged by a secondary and weaker association signal (Supplementary Tables 6&7). This 
is consistent with prior haplotype analyses of the locus10,31,32,34,37.
We used publicly available data38,39 to check whether any of our index SNPs might be proxies for copy 
number variants or insertion-deletion polymorphisms (indels), which are hard to directly interrogate 
with genotyping arrays. This analysis identified a single strong association (r2=.99), between 
rs10490924, a coding variant in the ARMS2 gene which is the peak of association in 10q26, and a 3’ 
UTR indel polymorphism associated with ARMS2 mRNA instability40. Because index SNP rs10490924 
is also in strong disequilibrium (r2=.90) with a nearby SNP, rs11200638, that regulates HTRA141, our 
data does not directly answer whether HTRA1 or ARMS2 is the causal gene in this locus. Although 
a common deletion of the CFHR1 and CFHR3 genes has been proposed42,43, there was only modest 
signal in this study which is likely due to linkage disequilibrium with our most significantly associated 
variants in the locus (r2=.31 between rs10737680 and 1000 Genomes Project MERGED_DEL_2_6731) 
as previously suggested34.
Using RNA-sequencing44, we examined mRNA levels of 85 genes within 100 kb of our index SNPs in 
post-mortem human retina (Supplementary Table 8). Of 19 independent risk loci, three had no genes 
with expressed transcripts in either old or young retina. Two genes showed differential expression 
between post-mortem retina of young (ages 17–35) and elderly (ages 75 and 77) individuals: CFH 
(p=0.009) and VEGFA (p=0.003), both with increased expression in older individuals. Using previously 
published data45, we also examined the expression of associated genes in fetal and adult retinal 
pigment epithelium (RPE). This revealed increased C3 expression in adult RPE compared to fetal RPE 
(p=0.0008). CFH, VEGFA and C3 are thus up-regulated with aging, and their role in AMD may indicate 
an accelerated aging process. In addition to C3 and CFH, all the complement genes with detectable 
expression in the retina or RPE experiments showed higher expression levels in older tissue.
To identify biological relationships among our genetic association signals, we catalogued the genes 
within 100kb of the variants in each association peak (r2>0.8 with the index SNP listed in Table 
1). Ingenuity Pathway Analysis (Ingenuity Systems, Redwood, CA) highlighted several biological 
pathways, particularly the complement system and atherosclerotic signaling, to be enriched in the 
resulting set of 90 genes (Table 3, Supplementary Table 9). To account for features of genome-wide 
association studies (such as the different number of SNPs in each gene), we carried out two additional 
analyses. First, we repeated our analysis for 50 sets of 19 control loci drawn from the National Human 
Genome Research Institute (NHGRI) GWAS catalog46. In these 50 control sets, Ingenuity enrichment 
p-values for the complement system and for atherosclerosis signaling genes were exceeded 16% 
and 32% of the time respectively (although these two specific pathways were never implicated in a 
control dataset). Second, we repeated our enrichment analyses using the Interval-based Enrichment 
Analysis Tool for Genome-Wide Association Studies (INRICH)47, which is specifically designed for 
the analysis of GWAS but accesses a more limited set of annotations. The INRICH analyses showed 
enrichment for genes encoding collagen and extra-cellular region proteins (both with p=1x10-
5 and after adjustment for multiple testing padjust=0.0006), complement and coagulation cascades 
(p=0.0002, padjust=0.03), lipoprotein metabolism (p=0.0003, padjust=0.04), and regulation of apoptosis 
(p=0.0009, padjust=0.09) (Supplementary Table 10).
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TABLE 3 - Pathway analysis
Ingenuity canonical pathways
Enrichment analysis
Nominal 
P value
FDR
q value Molecules
Pathway size
(N
genes
)
Complement system 0.000012 0.0015 CFI, CFH, C3, CFBa,C2a, C4Aa, C4Ba 35
Atherosclerosis signaling 0.00014 0.009 PLA2G12A, APOC1b, APOEb, APOC2b, 
APOC4b , TNFS14,COL10A1, PLA2G6
129
VEGF family ligand-receptor interactions 0.0042 0.150 VEGFA, PLA2G12A, PLA2G6 84
Dendritic cell maturation 0.0046 0.150 RELB, ZBTB12, DDR1, COL10A1 185
Phospholipid degradation 0.0058 0.151 PLA2G12A, LIPC, PLA2G6 102
MIF-mediated glucocorticoid regulation 0.0088 0.153 PLA2G12A, PLA2G6 42
Inhibition of angiogenesis by TSP1 0.0093 0.153 VEGFA, TGFBR1 39
FcεRl signaling 0.0098 0.153 VAV1, PLA2G12A, PLA2G6 111
p38 MAPK signaling 0.011 0.153 PL2G12A, TGFBR1, PLA2G6 106
Abbreviations: FDR = false discovery rate.
aAll flank rs429608 and are thus counted as a single hit when determining the significance of enrichment.
bAll flank rs4420638 and are thus counted as a single hit when determining the significance of enrichment.
To explore the connections between our genetic association signals, we tested for interaction 
between pairs of risk alleles – looking for situations where joint risk was different than expected 
based on marginal effects. This analysis resulted in 171 tests of interaction, of which 9 were nominally 
significant (p<0.05, see Supplementary Table 11), consistent with chance expectations. The strongest 
observed interaction involved risk alleles at rs10737680 (near CFH) and rs429608 (near C2/CFB), 
the only association that remained significant after adjusting for multiple testing (p=0.000052, 
<0.05/171=0.00029). Individuals carrying risk alleles at both these loci where at slightly higher risk 
of disease than expected.
The proportion of the variability in the risk of AMD that is due to genes, or heritability, has been 
estimated at 45–70% 2. Estimating the proportion of disease risk explained by the susceptibility loci 
identified48 depends greatly on the disease prevalence, which is difficult to estimate in our sample, 
as it includes cases and controls of different ages and collected through a variety of ascertainment 
schemes. Using a model that assumes an underlying normally distributed but unobserved disease 
risk score or liability49, the nineteen loci described here account for between 10% (if AMD prevalence 
is close to 1%) and 30% (if AMD prevalence is closer to 10%) of the variability in disease risk 
(corresponding to 15–65% of the total genetic contribution to AMD). The variants representing the 
peak of association at loci previously reaching genome-wide significance account for the bulk of this 
variability: the new loci identified here account for 0.5–1.0% of the total heritability of AMD whereas 
secondary signals at novel and known loci account for 1.5–3.0% of the total heritability.
We report here the most comprehensive genetic association study of macular degeneration yet 
conducted, involving 18 international research groups, and a large set of cases and controls. Our data 
reveal 19 susceptibility loci, including 7 loci reaching p<5x10-8 for the first time, nearly doubling the 
number of known AMD loci outside the complement pathway. Our results show some susceptibility 
alleles exhibit different association across ethnic groups and may be preferentially associated with 
specific subtypes of disease. As with other GWAS meta-analysis, differences in genotyping methods, 
quality control steps and imputation strategies between samples might have a minor effect in our 
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results – future studies may document that more uniform approaches across larger sample sizes 
might uncover more signals. A conundrum of macular degeneration genetics remains that the loci 
identified to date contribute to both GA and NV, two different phenotypes of advanced disease. 
In our sample, subtype specific GWAS analyses considering GA or NV cases only did not identify 
additional loci. Consistent with observations for other complex diseases39, the majority of common 
disease susceptibility alleles do not alter protein sequences and are not associated with insertions or 
deletions of coding sequence or with copy number variation. We expect that the loci identified here 
will provide an ideal starting point for studies of rare variation33,34.
In contrast to most other complex diseases, a risk score combining information across our 19 loci, 
can distinguish cases and controls relatively well (Figure 3, area under the ROC curve [AUC]=0.52 
including only new loci or AUC=0.74 including new and previously reported loci; Supplementary 
Figure 4). It may be possible to use similar scores to identify and prioritize at risk individuals so 
they receive preventative treatment prior to the onset of disease50. Monotherapies are increasingly 
utilized to manage neovascular disease, but offer only a limited repertoire of treatment options to 
patients. Identification of novel genes and pathways enables us to pursue a larger range of disease-
specific targets for development of new therapeutic interventions. We expect that future therapies 
directed at earlier stages of the disease process will allow patients to retain visual function for longer 
periods, improving the quality of life for individuals with AMD.
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FIGURE 3 - Risk score analysis. We calculated a risk score for each individual, defined as the product of the number 
of risk alleles at each locus and the associated effect size for each allele (measured on the log-odds scale). The 
plot summarizes the ability of these overall genetic risk scores to distinguish cases and controls. Analyses were 
carried out using 19 SNPs that reached P< 5x10-8 here, the 12 SNPs previously reaching this threshold and the 
7 new variants.
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METHODS
Genome-wide scan for late AMD association including follow-up
Study-speciﬁc association analysis for discovery: Genotyping was performed on a variety of different 
platforms summarized in Supplementary Table 2. Each group submitted results from association 
tests using genotyped and imputed data where the allelic dosages were computed with either 
MACH25, IMPUTE23, BEAGLE24, or snpStats52 using the HapMap2 reference panels. The CEU panel was 
used as a reference for imputation-based analyses for most samples (predominantly of European 
ancestry), with two exceptions: for the JAREDS samples (predominantly of East Asian ancestry), the 
CHB+JPT panel was used as a reference; for the VRF samples (predominantly of South Asian ancestry) 
the combined CEU and CHB+JPT panels were used22,53. For most data sets association tests were run 
under a logistic regression model using either Plink54, Mach2dat25, ProbABEL55, or snpStats52, though 
for one dataset containing related individuals the generalized estimating equations algorithm56 as 
implemented in R57,58. In addition to the primary analysis which tested for SNP associations with 
advanced AMD unadjusted for age, an age-adjusted sensitivity analysis was conducted by each 
group with available age. Each group also provided stratified results by sex or AMD subtype (GA 
or NV) as long as the sample size per stratum exceeded 50 subjects. For all analyses, study-specific 
control for population stratification was conducted (Supplementary Table 4).
Study-speciﬁc association analysis for follow-up: Genotyping of the selected SNPs was performed on 
different platforms; the same models, sensitivity and stratified analyses were computed by each 
follow-up partner, while SNPs with insufficient call rate were excluded based on study-specific 
thresholds. If the index SNP could not be genotyped, a highly correlated proxy was used whenever 
possible (Supplementary Tables 2&3).
Quality control before meta-analysis: Before meta-analysis, all study-specific files underwent quality 
control procedures to check for completeness and plausible descriptive statistics on all variables as 
well as for compliance of allele frequencies with HapMap59. In addition, we excluded SNP results of 
a study into meta-analysis (i) for discovery: if imputation quality measures were too low (MACH & 
PLINK <0.3; SNPTEST <0.4) or if effect sizes (|beta|) or standard errors were too extreme (≥5) indicating 
instability of the estimates, (ii) for follow-up: if Hardy-Weinberg equilibrium was violated (p<0.05/32).
Meta-analyses: For both discovery and follow-up, we performed meta-analyses using the inverse 
variance weighted fixed effect model, which pools the effect size and standard error of each 
participated GWAS. Using an alternative weighted z-score method, which is based on a weighted 
sum of z-score statistics, we obtained a very similar set of test statistics (correlation of –log10(p-
value) >0.98). All analyses were performed using METAL26 and R. For the discovery, we applied two 
rounds of genomic control corrections to each individual GWAS and the combined meta results, 
respectively51. All results were analyzed and validated among four independent teams.
Extended analyses for the identiﬁed AMD loci: Extended analyses were conducted on the identified loci 
and particularly on the top SNP of each locus.
Second signal analysis: To detect potential independent signals within the identified AMD loci, each 
study partner with genotypes for all identified SNPs available re-analyzed their data for all SNPs 
in the respective loci (index SNP ±1Mb) using a logistic regression model containing all identified 
index SNPs. Quality control procedures were performed as before. The beta estimates for each SNP 
were meta-analyzed applying the effective sample size weighted z-score method and two rounds 
of genomic control correction. The significance threshold (p<0.05) for an independent association 
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signal within any of the identified loci was Bonferroni-adjusted using the average effective number 
of SNPs involved across the identified loci determined by SNPSpD60. To this analysis, 13 studies 
contributed including 7,489 cases and 51,562 controls.
Interaction analysis: Utilizing a pre-specified R-scripts (see supplementary material), GWAS partners 
performed 171 logistic regression analyses modeling the pair-wise interaction of the 19 index SNPs 
assuming an additive model for main and interaction effects. Study-specific covariates were included 
to the model if required. Per study, quality control included a check for consistency of SNP main 
effects between discovery and interaction analysis. SNPs with low imputation quality measures 
and pairs with |beta|>5 or standard errors >5 were excluded before meta-analyzing the interaction 
effects with the inverse variance weighted fixed effect model in METAL. To this analysis, 12 studies 
contributed including 6,645 cases and 49,410 controls.
Genetic risk score
The meta-analyzed effect sizes,, for each of the 19 SNPs were calculated in the meta-analysis 
described above and normalized by:
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where j=1,…,19. Using these values as weights, each study partner with data available for all 19 SNPs 
computed the genetic risk score for an individual as a normalized weighted sum of the AMD risk 
increasing alleles among the identified SNPs, with
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where x
ij
 is the phenotype of the ith individual at the jth SNP, so ranges from 0 to 2. Data for these 
calculations were available from 12 studies including 7,195 cases and 49,149 controls.
For each study, we used a leave-one-out cross-validation to access the prediction of the risk score. 
For the kth subject, we fitted a logistic regression model from all subjects in the study excluding the 
kth subjects as:
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where α is the intercept and y is the effect of the genetic risk score. The fitted probability of the kth 
subject was then estimated.
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We sorted the fitted probabilities and calculated sensitivity and specificity by varying the risk 
threshold (the value compared with the fitted probability to dichotomize the subject into case or 
control) from 0 to 1. These were utilized to compute the area-under-the curve (AUC) of the receiver-
operating-curve (ROC).
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Identification of correlated coding variants and tagged non-SNP variation
LD estimates were calculated using genotype data of the identified risk loci (index SNPs ±500kb) 
of individuals with European ancestry from the 1000 Genomes Project (March 2012 release)61 or 
from HapMap (release #28)59. Variants correlated (r²>0.6) with one of the GWAS index SNPs were 
identified using PLINK54. To filter coding variants, all correlated variants were mapped against RefSeq 
transcripts using ANNOVAR62.
Gene expression
We evaluated expression of genes within 100kb of one of the 19 index SNPs, as well as of several 
retina-specific, RPE-specific and housekeeping genes unrelated to AMD for comparison in retina 
(RNA-sequencing data from three young [17–35 yrs age] and two old individuals [75 and 77 yrs age]) 
as well as in fetal and adult retinal pigment epithelium (RPE; published data in the Gene Expression 
Omnibus database45; GSE18811). Expression was analyzed using previously described protocols44 
(Supplementary Table 8).
Pathway analysis
Functional enrichment analysis was performed using the Ingenuity Pathway Analysis software (IPA, 
Ingenuity® Systems). Any gene located within 100kb of a SNP in high LD (r2>0.8) with one of the 
index SNPs was considered a potential AMD risk associated gene and considered for subsequent 
pathway enrichment analysis. LD estimates were calculated as described above. Applying the above 
inclusion filters, 90 genes appear to be implicated by our 19 replicated AMD SNPs (Supplementary 
Table 8). Because genes with related function sometimes cluster in the same locus, we trimmed 
gene lists during analysis so that only one gene per locus was used to evaluate enrichment for each 
pathway. The P-value of the association between our implicated gene list and any of the canonical 
pathways and/or functional gene sets as annotated by IPA’s Knowledge Base was computed using a 
one-sided Fisher’s exact test. The Benjamini-Hochberg method was used to estimate False Discovery 
Rates. To evaluate significance of observed enrichment, we repeated our Ingenuity analysis starting 
with 50 lists of 19 SNPs randomly drawn from the NHGRI GWAS catalog46 and, again, using the 
INRICH tool63. When using INRICH, we used gene sets defined in the Broad’s Molecular Signatures 
database47 (ver3.0) representing manually curated canonical pathway, Gene Ontology biological 
process, cellular component and molecular function gene sets (C2:CP, C5:BP, C5:CC and C5:MF). 
We provided INRICH with our full GWAS SNP list and allowed it to carry out 100,000 permutations, 
matching selected loci in terms of gene count, SNP density and total number of SNPs.
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ABSTRACT
Objective To examine effect modification between genetic susceptibility to age-related macular 
degeneration (AMD) and dietary antioxidant or fish consumption on AMD risk.
Design Pooled data analysis of population-based cohorts
Participants Participants from the Blue Mountains Eye Study (BMES) and Rotterdam Study (RS).
Methods Dietary intakes of antioxidants (lutein/zeaxanthin (LZ), β-carotene and vitamin C), 
long-chain omega-3 polyunsaturated fatty acids and zinc were estimated from food frequency 
questionnaires. AMD genetic risk was classified according to number of risk alleles of CFH (rs1061170) 
and/or ARMS2 (rs10490924) as low (none or 1 risk allele) or high (≥2 risk alleles). Interactions 
between dietary intake and genetic risk levels were assessed. Associations between dietary intake 
and AMD risk were assessed comparing the highest versus the two lower intake tertiles by genetic 
risk subgroups using discrete logistic regression, conducted in each study separately, and next in 
pooled data. Participants without AMD lesions at any visit were controls. We adjusted for age and 
sex in analyses of each cohort sample, and additionally adjusted for smoking status and study site in 
pooled-data analyses.
Main Outcome Measures All 15-year incident late AMD cases were confirmed by chief investigators 
of the Beaver Dam Eye Study, BMES and RS. Inter-grader reproducibility was assessed in an early AMD 
subsample, with 86.4% agreement between BMES and RS graders, allowing for a 1-step difference on 
a 5-step AMD severity scale.
Results In pooled data analyses we found significant interaction between AMD genetic risk status 
and LZ intake (p=0.0009) but non-significant interactions between genetic risk status and weekly fish 
consumption (p=0.05) for risk of any AMD. Among participants with high genetic risk, the highest 
intake tertile of LZ was associated with >20% reduced risk of early AMD, and weekly consumption of 
fish was associated with a 40% reduced risk of late AMD. No similar association was evident among 
participants with low genetic risk. No interaction was detected between β-carotene or vitamin C and 
genetic risk status.
Conclusions Protection against AMD from greater LZ and fish consumption in persons with high 
genetic risk based on two major AMD genes raises the possibility of personalized preventive 
interventions.
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INTRODUCTION
Genetic predisposition for susceptibility to age-related macular degeneration (AMD) has been 
confirmed1 with estimated heritability ranging from 46% to 71% and environmental exposures 
explaining some proportion of risk variance.2
The Age-Related Eye Disease Study (AREDS), a randomized controlled trial (RCT), documented that 
high dose zinc and antioxidant vitamin supplementation slowed AMD progression in advanced 
early AMD cases.3 Another RCT conducted in persons with geographic atrophy demonstrated 
that a lutein supplement over 12 months improved visual function.4 Although evidence about the 
protective association between dietary intake or serum levels of these carotenoids and AMD has 
been inconsistent, findings from a systematic review and meta-analysis support an association of 
dietary lutein/zeaxanthin (LZ) intake and reduced risk of late AMD.5 
Previously, Blue Mountains Eye Study (BMES) and Rotterdam Study (RS) investigators independently 
documented that high dietary intake of LZ was associated with a reduced long-term risk of AMD.6;7 
In addition, in the BMES cohort weekly consumption of fish was associated with reduced risk 
of late AMD only in participants with the CFH risk (CC) genotype.8 In the RS cohort high dietary 
intake of antioxidants reduced the risk of early AMD in persons with high genetic risk for AMD.9 
The apparent protective effect observed in persons with genetic susceptibility to AMD8;9 suggests 
an effect modification between known AMD genetic variants and dietary long-chain omega-3 
polyunsaturated fatty acids (ω-3 PUFAs) or antioxidants.
Joint contributions and interactions between AMD-related genetic variants and other AMD risk 
factors (eg. smoking,10;11 inflammatory markers12;13) have been documented previously, including an 
effect modification of dietary docosahexaenoic fatty acids (DHA, a component of ω-3 PUFAs) on risk 
of geographic atrophy in persons with the risk genotype of the ARMS2 gene.14 The interplay between 
nature and nurture may provide a better understanding of why some, but not all, persons with 
AMD-related genetic risk variants develop this condition. Using pooled longitudinal data from two 
population-based cohorts, we aimed to assess the consistency of the suggested effect modification 
between AMD genetic susceptibility and dietary intake of antioxidants or fish in relation to the 
incidence of early, late and any (early and late) AMD.
METHODS
The BMES and RS are population-based cohort studies with follow-up periods of 15 years. Participants 
were predominantly white.
Blue Mountains Eye Study (BMES)
In 1992-4, 3654 residents (82.4% of those eligible) aged 49+ years, living in two postcode areas 
west of Sydney, Australia, participated in baseline examinations; 2335, 1952 and 1140 were re-
examined after 5 (1997-9), 10 (2002-4) and 15 years (2007-10), respectively. There were 2452 baseline 
participants followed-up at least once. Each study visit was approved by the University of Sydney 
and the Sydney West Area Health Service Human Research Ethics Committees, and written, informed 
consent was obtained.
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After pharmacological mydriasis, 30º stereoscopic color transparencies of the macula and optic disc, 
and non-stereoscopic color transparencies of another four subfields were taken, using a Zeiss FF3 
fundus camera (Carl Zeiss, Oberkochen, Germany) for baseline, 5- and 10-year follow-up visits, and a 
40° digital camera (Canon CF-60 DSi with a Canon EoS 1DS Mark II camera body, Canon Inc., Tokyo, 
Japan) for the 15-year follow-up examination.
Rotterdam Study (RS)
At baseline (1990-93), 7983 (77.7% participation rate) eligible persons aged 55+ years were 
interviewed and examined. Ophthalmological examinations and retinal photography were 
performed on 6419 participants. Of these, 4977, 3637, 2674 and 1452 were re-examined at the 
second (1993-95), third (1997-99), fourth (2002-04) and fifth (2009-11) visits, respectively. Overall, 
3579 participants had genetic and baseline dietary data together with follow-up information, were 
free of late AMD at baseline, and were included. In order to correspond with the BMES follow-up visit 
intervals (each 5 years), participants of the second follow-up visit (1993-95) were excluded, except 
for incident late AMD cases that were included as incident AMD cases at the third visit (1997-99). 
Each visit was approved by the Erasmus Medical Center Ethics Committee and complied with the 
Declaration of Helsinki. All participants gave written informed consent prior to participation.
After pharmacological mydriasis, 35° stereoscopic color transparencies of the macula (Topcon TRV-
50VT fundus camera, Topcon Optical Co, Tokyo, Japan) were taken in each of the first three visits, and 
35° digital images (Topcon TRC 50EX fundus camera with the Sony DXC- 950P digital camera, Topcon 
Optical Co, Tokyo, Japan) were taken in the fourth and fifth visits.
Age-related Macular Degeneration Phenotype Definitions and Harmonization 
In both studies, retinal photographs of both eyes were graded by trained graders of each study 
initially,15;16 following the Wisconsin Age-related Maculopathy Grading System. Phenotype 
harmonization was performed within the Three Continent AMD Consortium.17 In brief, all late AMD 
incident cases detected from each study were initially adjudicated and confirmed by the retinal 
specialists of the corresponding study team, and then were confirmed by chief investigators of the 
BMES, RS and Beaver Dam Eye Study (BDES). A five-step severity scale (levels 10-50) was developed 
(Table 1, available at http://aao.journal.org). A subsample of 60 eyes covering various severity levels of 
early AMD was selected from the BDES and sent to BMES and RS teams to be graded independently. 
Exact agreement on the 5-step severity scale was 61.0% between BMES and RS graders; allowing a 
1-step difference increased agreement to 86.4%.
Assessment of Dietary Intake
In the BMES, a validated18 145-item, semi-quantitative food frequency questionnaire (FFQ), modified 
from an early FFQ by Willett et al19, was used. The FFQ was completed and returned by 3267 baseline 
participants (89.4%), of which 2900 (88.8%) were considered usable.18
The electronic version of the Australian Tables of Food Composition 199020 was used to calculate the 
intake of most nutrients. . The intake of ω-3 PUFA was calculated by adding dietary consumption 
of eicosapentaenoic (20:5, n-3) and docosahexaenoic (22:6, n-3) fatty acids. Information on fish 
consumption was obtained from the FFQ and regular fish consumption was defined as ≥1 serving 
per week, compared to <1 serving per week.
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In the RS, baseline dietary information was collected in 2 stages. First, participants completed 
a checklist at home. Second, a face-to-face interview was conducted by a trained dietitian at the 
research center, using a 170-item validated semi-quantitative FFQ.21 Using the computerized Dutch 
Food Composition Table, these dietary data, including intakes of vitamins and zinc, were converted 
to total energy and nutrient intakes per day.21 Intake of specific fatty acids was based on a food 
composition database derived from the TRANSFAIR Study.22 Beta-carotene and LZ were updated 
using an additional database of the Netherlands Institute of Public Health and Environmental 
Protection (personal communication, YCJ Vollebregt and EJM Feskens, unpublished observations, 
1993).23
Genotyping BMES
In the BMES, genotyping was performed using the Illumina Human 670-Quadv1 custom genotyping 
array at the Wellcome Trust Centre for Human Genetics, Sanger Institute, Cambridge, as part of the 
Wellcome Trust Case Control Consortium 2. After quality checking,24 genotypes of 2534 participants 
(544,802 single-nucleotide polymorphisms (SNPs)) were used for imputation. Genotypes were 
imputed from the 1000 Genomes (Version 1) reference using IMPUTE software (https://mathgen.
stats.ox.ac.uk/impute/impute.html, accessed June 4, 2013).
In addition, genotype data were obtained previously for rs1061170 in CFH, and rs10490924 in ARMS2 
for participants who attended the 5-year follow-up visit.8 We therefore used the genotyped SNPs of 
these two whenever available. The concordance rate between typed and imputed genotypes was 
99.61% for rs1061170 and 99.26% for rs10490924 based on participants who had both typed and 
imputed data of these two SNPs. 
Genotyping RS
In the RS, genotyping was performed using TaqMan assays (Applied Biosystems, Foster City, California, 
USA). The two SNPs (rs1061170 in CFH and rs10490924 in ARMS2) were successfully genotyped 
in 6345 and 6411 participants, respectively, and 6260 had both SNPs typed.9 In addition, for 
participants without genotype data, imputed data of these two SNPs were obtained from a genome-
wide association scan dataset, genotyped using the Illumina Infinium II HumanHap5. Imputation 
was performed using Markov Chain Haplotyping package version 1.0.15 software (http://www.sph.
umich.edu/csg/abecasis/MACH/, Ann Arbor, Michigan, USA, accessed June 4, 2013) and HapMap 
CEU data (NCBI build 36, release 22, The International HapMap Project). There were 6478 participants 
with both SNPs either typed or imputed.
Statistical Analysis
Of the 2534 BMES participants with dietary and genotype data available, 680 participated in the 
BMES Extension Study (1999-2000) who had not been followed, leaving 1854 included in this report. 
Of the 3579 RS baseline participants with follow-up information, dietary and genotype data available, 
2778 were followed at the third, fourth and/or fifth visits and thus included. Characteristics between 
participants who were included and excluded were compared by each study (Table 2, available at 
http://aao.journal.org). Distributions of baseline AMD risk factors by incident AMD categories are 
shown in Table 3.
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We compared dietary intakes between Australian and Netherlandish people using national survey 
data of the two countries (Table 4, available at http://aao.journal.org). The most recent published 
food survey data available are from the 1995 Australian National Survey,25;26 and the Dutch National 
Food Consumption Survey 2007-2010.27 Main macronutrient intakes were also compared between 
BMES and RS baseline populations (Table 5, available at http://aao.journal.org).
We used energy-adjusted dietary intakes of antioxidants (LZ, β carotene, vitamin C), ω-3PUFA, 
zinc and fish consumption as dietary exposures, and incident early, late or any (early and late 
combined) AMD as outcome variables. Controls were participants who had no early or late AMD 
lesions at all visits (level 10 on the severity scale; Table 1, available at http://aao.journal.org). Given 
the substantial differences in estimates for population means of dietary antioxidant intake between 
the two studies, we used population-specific tertiles in analyses, and examined tertile distributions 
of dietary antioxidant intake by incident early, late and any AMD (Table 6). We initially examined the 
associations of these dietary intakes with risk of AMD across three tertiles, and detected a threshold 
between the highest and the two lower intake tertiles. We therefore decided to compare the highest 
vs the two lower tertiles in all models, referenced to controls.
To assess if there were effect modifications between the selected dietary intakes and genetic 
susceptibility to AMD, using the two variants of major AMD-related genes (CFH, rs1061170 and ARMS 
2, rs10490924) we grouped participants’ genetic risk of AMD into three levels: 1) having no risk alleles 
of either CFH (rs1061170) or ARMS2 (rs10490924); 2) having 1 risk allele from either of the two genes; 
and 3) having ≥2 risk alleles from either or both of these genes. We tested for statistical interactions 
between genetic risk status according to the above grouping and the dietary exposures by adding 
product terms of the gene risk levels with one dietary exposure at a time, together with the genetic 
risk status and the dietary exposure in each of the discrete logistic regression models. We adjusted 
for age, sex and smoking in analyses performed within each study, and additionally adjusted for 
study site in analyses of pooled data of the two studies (Table 7, available at http://aao.journal.org).
We further compared the highest intake tertile versus the two lower tertiles in subgroups stratified 
by the three AMD genetic risk levels, with 15-year incident early, late or any AMD as the dependent 
variable and time-to-event as the discrete variable in logistic regression models. We adjusted for 
age and sex in all models, one model for each dietary exposure, in analyses of data from each study 
separately (Table 8), and adjusted for age, sex, smoking status and study indicator in pooled data 
analyses (Table 9).
Risk estimations are presented as odds ratios (OR) and 95% confidence intervals (CIs). SAS (Version 
9.2, SAS Institute, Cary, NC) was used for all analyses. OR above (or below) 1 indicated an increase 
(or decrease) in risk associated with the highest intake tertile relative to the risk associated with the 
lower intake tertiles.
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TABLE 9 - Associations of Dietary Antioxidants with Incidence of Early and Late Age-related Macular Degeneration 
by subgroups of population with none, one, or two or more risk alleles of the CFH and ARMS2 genes
Dietary Factors
Genetic Risk Group = 0 risk allele from CFH or ARMS2
Early AMD (n=215) Late AMD (n=14) Any AMD (n=229)
Fish (≥1 serving/week)† 1.17 (0.87, 1.57) 0.91 (0.29, 2.84) 1.14 (0.85, 1.51)
Lutein/zeaxanthin* 1.47 (1.09, 1.97) 0.65 (0.17, 2.43) 1.40 (1.05, 1.87)
Vitamin C* 0.91 (0.67, 1.24) 0.78 (0.20, 2.95) 0.91 (0.67, 1.23)
Dietary Factors
Genetic Risk Group = 1 risk allele from CFH or ARMS2
Early AMD (n=429) Late AMD (n=74) Any AMD (n=503)
Fish (≥1 serving/week)† 0.87 (0.70, 1.08) 0.98 (0.59, 1.63) 0.90 (0.73, 1.10)
Lutein/zeaxanthin* 0.91 (0.73, 1.13) 1.06 (0.63, 1.79) 0.92 (0.75, 1.13)
Vitamin C* 0.94 (0.75, 1.17) 1.33 (0.79, 2.24) 0.96 (0.78, 1.19)
Dietary Factors
Genetic Risk Group =2+ risk alleles from CFH and ARMS2
Early AMD (n=430) Late AMD (n=112) Any AMD (n=542)
Fish (≥1 serving/week)† 0.89 (0.71, 1.10) 0.54 (0.35, 0.85) 0.84 (0.69, 1.03)
Lutein/zeaxanthin* 0.78 (0.62, 0.99) 0.64 (0.40, 1.03) 0.75 (0.60, 0.93)
Vitamin C* 0.87 (0.70, 1.10) 0.67 (0.43, 1.06) 0.86 (0.70, 1.06)
Pooled data of BMES & RS, adjusting for age, sex, smoking and study site indicator
Abbreviations: AMD = age-related macular degeneration, ARMS2 = age-related maculopathy susceptibility 2, BMES = Blue 
Mountains Eye Study, CFH = complement factor H, LZ = lutein/zeaxanthin, RS = Rotterdam Study 
*Population-specific tertiles with the highest versus the other 2 (middle and lowest) tertiles, adjusted for age, sex, smoking, 
energy intake,  and study site.
† Compared to persons with fish consumption <1 serving/week. 
RESULTS
Comparisons of characteristics between the 1854 included and the 1800 excluded BMES participants, 
and between the 2778 included and the 3641 excluded RS participants, showed that those excluded 
were older, and more likely to have a history of diabetes or cardiovascular conditions, and early 
AMD. After adjusting for age, the significant differences in early AMD and AMD lesion distributions 
between the two groups disappeared (Table 2, available at http://aao.journal.org). In the BMES, 
excluded participants had lower mean intake levels of dietary antioxidants and ω-3 PUFA, compared 
to those who were included. In the RS, excluded and included participants had similar mean intake 
levels of dietary oxidants and ω-3 PUFA (Table 2, available at http://aao.journal.org). Of the 1800 
BMES excluded participants, 32% died before the 5-year follow-up examination. Of the 3641 RS 
excluded participants, 22% died before the 6-year follow-up examination.
Of the 1854 BMES participants, 723 had no AMD at all visits, 467 had incident early AMD and 88 had 
incident late AMD. Of the 2778 RS participants, the corresponding numbers were 2006 without AMD, 
657 with incident early AMD and 115 with incident late AMD.
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As expected, the mean ages of the incident AMD groups were higher compared to controls. In 
addition, crude data comparisons confirmed that in both the incident early and late AMD groups, 
the proportions of participants homozygous for the risk genotypes of CFH and ARMS2 were higher 
compared to controls, as were the proportions of current smokers in the late AMD groups (Table 3).
Comparison of Australian25;26 and Dutch27 national food consumption survey data (Table 4, available 
at http://aao.journal.org) showed that Australian men and women aged 45-64 years consumed more 
fruits, seafood and meat/poultry products than Dutch men and women aged 51-69 years. Although 
vegetable consumption levels were similar between Australian and Dutch men and women of 
similar age groups, Australians consumed less leafy vegetables than the Dutch, and Australian 
men consumed more carrots/root vegetables than Dutch men. Consumption levels of energy and 
other dietary items/food groups, macronutrients and micronutrients were similar, except for iron 
intake, which was substantially lower among Dutch men and women. We could not find data on LZ 
consumption levels from the national surveyreports.25-27
Energy and main macronutrient intake levels were similar between the BMES and RS populations 
(Table 5, available at http://aao.journal.org). While the mean intakes of ω-3 PUFA and zinc were similar 
between the two populations, the mean intakes of LZ (higher in the RS) and β carotene (higher in the 
BMES) differed substantially (Table 6). A consistent pattern was evident in both study samples that 
relatively lower proportions of participants in the incident late AMD group were in the highest intake 
tertile of LZ and ω-3 PUFA (Table 6).
Significant interaction between AMD genetic risk status and LZ intake with respect to risk of early 
or any AMD was evident in the RS but not the BMES. In pooled data analyses of the two cohorts, 
we found a significant interaction between AMD genetic risk status and LZ intake with respect to 
risk of early AMD (p=0.002) or any AMD (p=0.0009), and a marginally non-significant interaction 
between AMD genetic risk status and weekly consumption of fish (p=0.05) (Table 7, available at 
http://aao.journal.org). These interaction p values are smaller than the corresponding significance 
levels required after Bonferroni correction for three interaction tests for the three dietary factors 
(p<0.05/3=0.017). There was no significant interaction found between vitamin C, β-carotene or zinc 
intake and AMD genetic risk status on AMD risk. 
We next stratified the study samples according to their genetic risk levels and investigated the 
associations between baseline weekly consumption of fish, dietary intakes of LZ or vitamin C and 
incidence of early, late or any AMD in each study (Table 8), and then in pooled data of the two studies 
(Table 9). In the subgroup with ≥2 risk alleles of CFH and/or ARMS2, weekly fish consumption and 
the highest tertile intake of vitamin C were associated with reduced risk of any AMD in the BMES but 
not the RS (Table 8). There was a marginally non-significant association between the highest tertile 
intake of LZ and reduced risk of any AMD in both studies, where the association magnitude was 28% 
and 23% risk reduction in the BMES and RS, respectively (Table 8).
In pooled data analysis of the two cohorts, among participants with ≥2 risk alleles of the CFH and/
or ARMS2, a significant association between weekly consumption of fish and a 46% reduction in late 
AMD risk was evident. Similarly, significant associations were evident between the highest tertile 
intake of LZ and 22%-25% risk reduction in early and any AMD. The highest tertile intakes of LZ and 
vitamin C were non-significantly associated with an approximately 35% risk reduction in late AMD 
(Table 9). In the other two subgroups with no or one risk allele, no similar associations were evident 
(Tables 8 and 9).
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DISCUSSION
By using data from two population-based cohorts we showed consistent evidence that participants 
with ≥2 risk alleles of either or both the CFH (rs1061170) and/or ARMS2 (rs10490924) had a significantly 
reduced risk of early or any AMD, if they frequently consumed food items rich in LZ.
Findings from the BMES and RS individually were less consistent for the effect modification of weekly 
consumption of fish or high dietary vitamin C intake with AMD genetic risk level on AMD risk (Table 
8, bottom panel). Pooling data from the two cohorts and incorporating three follow-up visits with 
similar time intervals, we demonstrated a significant association of regular fish consumption with a 
46% reduction in late AMD risk, and a marginally non-significant association between high intake 
of vitamin C and reduced risk of late or any AMD, among participants with high genetic risk of AMD 
(Table 9, botom panel). These two effect modifications, however, appear to be driven by findings 
from the BMES. In contrast, the association between the highest tertile of LZ intake and reduced 
risk of early or any AMD in those with high genetic risk was driven by the findings from the RS, but 
the direction of the protective association was relatively consistent across the two cohorts, with risk 
estimates around 0.7-0.8, although not reaching statistical significance (Table 8, bottom panel). This 
effect modification became significant when data were pooled, with a 22% risk reduction in early 
AMD in participants with high genetic risk (Table 9, bottom panel). 
A recent report from the AREDS2 documented a protective effect of LZ supplement use over 5 years 
compared to no LZ use on AMD progression in persons in the lowest quintile of dietary LZ intake.27 
The relatively short follow-up duration and lack of stratified analyses conducted in genetic risk 
subgroups may explain the non-significant findings in primary analyses.28
A beneficial effect of ω-3 PUFA and fish consumption on AMD 29-31 has been reported previously, 
where the anti-inflammatory property of ω-3 PUFA32 is considered to be one of the underlying 
mechanisms. In addition, there is increasing recognition that a lipid metabolism pathway may be a 
key element in the course of AMD development.33 The outer segments of photoreceptors, subjected 
to high photo-oxidative stress, have high concentrations of PUFAs and high oxygen tension, and 
PUFAs are susceptible to oxidation in the presence of oxygen or oxygen-derived radical species.34 
It is possible that lipid oxidation/ peroxidation products activate or amplify local inflammatory 
processes via the complement system,33;35;36 and that ω-3 PUFA and antioxidants may counteract 
these processes. Evidence on possible mechanisms is emerging.37
Lutein and zeaxanthin are components of macular xanthophylls and dihydroxy-carotenoids. The light 
filtering capability is a passive antioxidant function of LZ, and thus potentially prevents bluelight 
from generating reactive oxygen species.38 LZ may also have an anti-inflammatory property.39 Our 
findings are in keeping with these known functions of ω-3 PUFA and LZ. The effect modification of LZ 
on participants with high AMD genetic risk suggests the possibility that susceptibility to activation 
and amplification of the complement pathways can be compensated by these antioxidants. An 
analogous observation is the significant association between blue light exposure and neovascular 
AMD in persons with low levels of plasma LZ, and vitamins C and E.40
The reliability of dietary data collected in nutritional epidemiology studies may be a concern. We 
compared dietary consumption survey data between two countries25-27 (Table 4, available at http://
aaojournal.org) and between two study samples (Table 5, available at http://aaojournal.org), that 
showed similar intake levels of energy, most main food groups and macronutrients between the 
two countries and the two study populations. The concordance of most dietary intakes between the 
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two populations suggests that the FFQs used and the resulting dietary data are likely to be robust, 
regardless of which specific FFQ was used. Nevertheless, we noticed differences in the intake levels 
of some food items between the two countries. The relatively high intake level of leafy vegetables by 
the Dutch and the relatively high intake level of carrots/root vegetables by Australian men, together 
with higher proportions of Australians eating these vegetables, may partly explain the differences 
in population mean intake levels of LZ and β carotene (Table 4, available at http://aaojournal.org). 
Different LZ intake estimation methods used by the two studies may also contribute to the difference 
in mean intake estimates of this nutrient.
Strengths of this study include long-term follow-up of population-based samples, photographic 
documentation of AMD status with incident late AMD cases cross-validated, and reasonable inter-
grader reproducibility on early AMD detection between study graders. A major limitation of this 
study is a degree of heterogeneity in dietary intake patterns and consumption levels of some 
micronutrients between the two populations. We have used relative measures for dietary intakes and 
adjusted for different study sites in the statistical models. Findings for relative measures are directly 
applicable to populations of specific geographic locations regardless of absolute intake levels. Other 
limitations include survival bias to which our cohorts are subject, non-availability of serum or plasma 
nutrient levels and lack of specific data for oily fish consumption. Misclassification or reduced power 
from these limitations will tend to bias the associations towards the null. There was no evidence 
supporting associations between mortality and the two genotypes or the dietary antioxidants under 
investigation, so survival bias should have only minimal effect on the associations. Even with pooled 
data from two cohorts, we had a limited numbers of late AMD cases and therefore insufficient power 
to detect a significant association between LZ intake and late AMD incidence in the high genetic risk 
subgroup (Table 9).
Caution is needed in interpreting these findings. Nutrients do not work alone but interact with genes 
and the internal environment of the host, which may be influenced by many factors such as lifestyle, 
intestinal microorganisms and the uptake ability of the host, all of which may lead to differences in 
bioavailability of specific nutrients on disease pathways.
In conclusion, we showed that dietary intake of LZ is associated with an approximate 20% reduction 
in risk of developing early AMD among persons with high genetic risk of AMD. The relatively 
consistent pattern of the effect modifications between LZ intake and AMD-related genetic risk levels 
in our two cohorts may have clinical implications in the management of AMD patients. Future studies 
are warranted to confirm this effect modification of major AMD-related genes and dietary intake 
of antioxidants on the risk of AMD. Our findings also highlight the importance of incorporating 
information from both genetic and environmental exposures to capture the complexity of disease 
pathways and pathogeneses of conditions such as AMD.
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ABSTRACT
Purpose Prediction models for age-related macular degeneration (AMD) based on case-control 
studies have a tendency to over-estimate risks. The aim of this study is to develop a prediction model 
for late AMD based on data from population-based studies.
Design Three population-based studies: the Rotterdam Study (RS), the Beaver Dam Eye Study (BDES), 
and the Blue Mountains Eye Study (BMES) from the Three Continent AMD Consortium (3CC).
Participants Persons (n=10,106) with gradable fundus photographs, genotype data, and follow up 
data without late AMD at baseline.
Methods AMD features were graded on fundus photographs using the 3CC AMD severity scale. 
Associations with known genetic and environmental AMD risk factors were tested using Cox 
proportional hazard analysis. In RS, the prediction of AMD was estimated for multivariate models 
by area under receiver operating characteristic curves (AUC). The best model was validated in BDES 
and BMES, and associations of variables were re-estimated in the pooled data set. Betas were used 
to construct a risk score, and risk of incident late AMD was calculated using Cox proportional hazard 
analysis. Cumulative incident risks were estimated using Kaplan-Meier product-limit analysis.
Main Outcome Measure Incident late AMD determined per visit during a median follow up period 
of 11.1 years with a total of 4-5 visits.
Results Overall, 363 participants developed incident late AMD, 3378 early AMD, and 6365 remained 
free of any AMD. The highest AUC was achieved with a model including age, sex, 26 single nucleotide 
polymorphisms in AMD risk genes, smoking, BMI, and baseline AMD phenotype. The AUC of this 
model was 0.88 in RS; 0.85 in BDES and BMES at validation; and 0.87 in the pooled analysis. Individuals 
with low risk scores had a hazard ratio (HR) 0.02 (95% confidence interval [CI] 0.01-0.04) to develop 
late AMD; those with high risk scores had HR 22.0 (95%CI 15.2-31.8). Cumulative risk of incident late 
AMD ranged from virtually 0 to over 65% for those with the highest risk scores.
Conclusion Our prediction model is robust and distinguishes well between those who will develop 
late AMD and those who will not. Estimated risks were lower in these population-based studies than 
in previous case-control studies.
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INTRODUCTION
Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly of 
industrialized countries1,2. Approximately 21 million elderly individuals are affected worldwide, and 
this number is expected to rise dramatically with the aging population3,4. AMD can be divided in 
several stages; early AMD, characterized by subcellular deposits (drusen) and pigmentary changes, 
and late AMD, subdivided into atrophy of the retinal pigment epithelium (dry AMD) and choroidal 
neovascularization (wet AMD). Despite improved treatment options, late AMD can cause irreversible 
blindness, while severe stages of early AMD are mostly asymptomatic they signal a high risk of 
progression to late AMD5.
Age, early AMD phenotype, and genetic and environmental factors play important roles in the 
pathogenesis of late AMD6-11. These factors may be used to predict this end stage and to identify 
high risk individuals. Reasons for assessing predictive values may be risk-dependent (personalized) 
patient care and surveillance strategies for therapy. Future intervention research such as randomized 
controlled clinical trials can use prediction models to select individuals with a high risk of outcome 
events.
Previously reported prediction models were based on selections of cases and non-affected 
controls12-28. Most studies compared only the extreme ends of disease, excluding the majority of the 
population with an intermediate disease risk. This has inherent methodological concerns, because 
the disease risk is overestimated by design. Population-based studies include a whole spectrum of 
risk levels, and therefore findings from these studies would be more generalizable29 and better suited 
for clinical implementation.
In this study, we present a prediction model for late AMD based on population-based cohort studies 
from three continents. We optimized a prediction model in one of the cohorts, and subsequently 
validated this in the other two cohorts. We included established genetic, environmental, and clinical 
risk factors in the model, assessed relative as well as cumulative risks, and provided a risk score which 
can be used to estimate the risk of AMD in individuals.
METHODS
For this paper we followed the guidelines for genetic risk prediction studies (GRIPS)30.
Study Populations
The Three Continent AMD Consortium (3CC) consists of four population-based studies: the European 
Rotterdam Study (RS), the American Beaver Dam Eye Study (BDES) and the Los Angeles Latino Eye 
Study (LALES), and the Australian Blue Mountains Eye Study (BMES). For the purposes of this study, 
LALES was excluded due to absence of genotype and follow up data.
The RS is a prospective population-based cohort study investigating chronic diseases in the elderly. 
All inhabitants aged 55 years and older living in a suburb of Rotterdam, the Netherlands, were invited 
to participate in the study31,32. Of the initial cohort of 10,275 eligible individuals, 7,983 (78% of those 
eligible) participated in the overall study (98% Caucasian). The ophthalmologic part began later, 
and included 6780 participants (78% of those eligible) participated. Baseline examinations took 
place from 1990-1993, and four follow-up examinations were performed in 1993-1995, 1997-1999, 
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2002-2004 and 2009-2011, respectively. The Erasmus Medical Center Ethics Committee approved 
the study, which complies with the Declaration of Helsinki. All participants gave written informed 
consent for participation in the study.
The BDES is a prospective cohort study investigating eye diseases in the population of Beaver Dam, 
Wisconsin (USA)33. To identify all residents in the city or township of Beaver Dam who were 43 to 
84 years of age, a private census was performed from 1987-1988. Of the 5,924 eligible individuals, 
4,926 (83% of those eligible) participated in the baseline examination between 1988-1990 (99% 
Caucasian). There were follow-up examinations every five years; 1993-1995, 1998-2000, 2003-2005, 
2008-2010. BDES was approved by the Institutional review board from the University of Wisconsin-
Madison and adhered to the tenants of the Declaration of Helsinki. All participants provided signed, 
informed consent for participation in the study.
The BMES is a prospective cohort study of eye diseases and other health outcomes in an urban 
population34. All residents aged 49 years or older, living in two postcode areas of the Blue Mountains 
region in West Sydney, Australia, were invited to participate in the study. In 1992-1994 baseline 
examinations were performed in 3,654 participants (82.4% of those eligible). Re-examinations were 
performed after five, ten and fifteen years (in 1997-1999, 2002-2004 and 2007-2009, respectively). 
All BMES examinations were approved by the Human Research Ethics Committees of the Western 
Sydney Area Health Service and the University of Sydney, and complied the Declaration of Helsinki. 
All participants provided written informed consent for participation of the study.
Participants were eligible for the current analysis when genotype data, as well as gradable fundus 
photographs at baseline, and at least one follow-up eye-examination were available (Figure 1, 
available at http://aaojournal.org). Persons with late AMD at baseline were excluded. This resulted in 
4753 (RS), 3542 (BDES) and 1811 (BMES) participants available for analysis, with a median follow-up 
of 10.7 (Interquartile range [IQR] 12.8; RS), 15.6 (IQR 10.4; BDES), 11.8 (IQR 5.6; BMES) years. In total, 
10,106 participants with a median follow-up of 11.1 (IQR 11) years were included in the analysis. To 
investigate possible selection bias, we analyzed whether persons excluded from this study differed 
in baseline level of AMD from those who were included. The two groups did not differ in early AMD 
levels (10-40) after adjustment for age and sex (P=0.95).
Diagnosis of AMD
All participants underwent fundus photography after pharmacologic mydriasis. Fundus 
transparencies of all studies were graded according to the Wisconsin Age-Related Maculopathy 
Grading35,36 by trained graders under the supervision of senior retinal specialists or senior researchers 
(RS: PTVMdJ, JRV, CCWK; BDES: RK, BEK; BMES: JJW and PM). The graded fundus photographs were 
classified using a classification common to all studies: the 3CC AMD severity scale37 (Table 1, available 
at http://aaojournal.org). All prevalent and incident late AMD cases from each of these three studies 
were cross-checked by investigators of the other two studies, with consensus obtained via discussion 
over multiple teleconferences. The eyes of each participant were graded and classified separately; 
and the eye with the more severe grade was used to classify the person.
Genotyping
Genomic DNA was extracted from peripheral blood leukocytes. All eligible study participants in the 
RS were genotyped with the Illumina Infinium II HumanHap550 array, or Taqman assays (Applied 
Biosystems, Foster City, California, USA). HapMap CEU data (release #22) was used for imputation.
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DNA from BDES participants was extracted from the buffy coats of blood obtained at baseline 
examinations or subsequent exams that have been stored frozen at -80ºC. DNA samples arrayed 
in 96-well plates were submitted for genotyping via an Illumina iSelect Custom Genotyping Panel 
(Illumina Inc, CA, USA) at the Genomics Core Facility at Case Western Reserve University, or via the 
KASP Assay at LCG Genomics (Teddington, Middlesex, UK). The data collected was analyzed using 
Illumina’s Genome Studio, or via the KASP SNP Genotyping System. The assays were controlled for 
quality by examining cluster separation values, call frequency, ABR mean values and ABT mean 
values. Untyped SNPs were imputed using HapMap CEU (release #22) as reference.
In the BMES, all participants with DNA available were genotyped using Illumina Human670-Quad 
v1 custom array at the Wellcome Trust Centre for Human Genetics, Sanger Institute, Cambridge as 
part of the Wellcome Trust Case Control Consortium 2 (WTCCC2). A smaller subset of participants (N 
= 1,356) was also independently genotyped using the Illumina 610-Quad genotyping array at the 
Hunter Medical Research Institute, Newcastle, Australia. Following quality control, the genotyped 
data were imputed from the 1000 Genomes (Version 1) reference using IMPUTE software.
Selection of Single Nucleotide Polymorphisms (SNPs)
For selection of AMD genes, we reviewed publications on AMD genetics 38,39 and prediction of AMD 12-28. 
From these, we selected 41 tag SNPs which were available in all three cohorts, and which were not in 
linkage disequilibrium (r2 <0.60). Genotypes of SNPs were coded as 0 for carriers of two major alleles; 
1 for the heterozygous genotype; and 2 for carriers of two minor alleles. When none of the cases were 
carriers of two minor alleles, genotypes of the SNPs were coded as 0 for carriers of two major alleles; 
and 1 for all carriers of at least one minor allele. As a first step, each SNP was tested for association 
with late AMD in all three cohorts.
For each locus with multiple SNPs, we performed a backwards Cox proportional hazard analysis to 
determine the best predictive SNPs for incident late AMD within each locus with data from the RS.
Assessment of non-genetic variables
All non-genetic variables used in the analyses were assessed using baseline data. Information on 
cigarette smoking was obtained in an interview at baseline and categorized as never, former, and 
current for smoking. Height, weight and blood pressure were measured at the beginning of baseline 
examination. Body mass index (BMI) was calculated by dividing weight (kg) by the height squared 
(m2). The BMI variable was categorized as not overweight or obese (BMI=< 25) and overweight or 
obese (BMI> 25). Age (yrs) at baseline was categorized in three categories; <65, 65-75, >75 years. 
Baseline AMD grading was entered into the analysis as categorized variables with levels 10-40.
Statistical analyses
Throughout the entire study, incident late AMD was used as the outcome variable; non-incident late 
AMD, including those persons remaining at an early AMD stage, were used as the reference group. 
All analyses were performed using SPSS version 20.0; SPSS INC, Chicago, Illinois.
Variables were analyzed for association with incident late AMD in the three cohorts using Cox 
proportional hazard analysis, adjusting for age and gender. We constructed five different models 
based on a minimal and a maximal selection of clinical, genetic, and environmental factors. Model 1 
was a minimal model including only age and sex; model 2 was a non-genetic model including age, 
sex, environmental and ocular factors; model 3 was a minimal genetic model including age, sex, 
and major genetic AMD risk variants (CFH Y402H, ARMS2 A69S, C3 R102G, C2 L9H, CB R32Q); model 
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4 was a maximal genetic model including age, sex, and 26 genetic AMD risk variants (see section 
SNP selection above), and model 5 was a maximal gene-environmental model including age, sex, 
environmental, ocular factors, and the 26 genetic AMD risk variants. For each model, we calculated 
the area under the curve (AUC) of incident late AMD in the RS, and validated the best model in BDES/
BMES.
Subsequently, we estimated the association of all variables in the best model using multivariate 
Cox proportional hazard analysis in the pooled dataset of all three cohorts and calculated the AUC. 
Calibration of the model was tested using the Hosmer-Lemeshow test. This goodness of fit test 
shows how well predicted risks match the observed risks. To test whether non-major genetic AMD 
risk variants could be discarded from this model without jeopardizing the AUC, backwards regression 
(eliminating SNPs with P > 0.05) using Cox proportional hazard analysis was carried out and the AUC 
of the new model was calculated within the pooled dataset. In this dataset, we estimated the beta of 
each variable from the best model using multivariate Cox proportional hazard analysis. The estimated 
beta of a variable was the individual risk score of that variable. Next, we created a summary risk score 
based on the sum of the betas from the multivariate Cox proportional hazard analysis. Risk scores 
were rounded off, and frequencies of the risk scores were plotted stratified for incident late AMD and 
no AMD. We calculated risk of incident late AMD with the middle risk score (3) as the reference using 
Cox proportional hazard analysis. Risk scores at the extreme ends were pooled to increase sample 
size due to limited numbers.
We calculated the cumulative risk of incident late AMD per risk score. We assigned the age of onset 
for incident late AMD as the median between the examination at which late AMD was first observed 
and the previous examination. For participants who did not develop late AMD, we used age at last 
examination for censoring. All participants aged 90+ years were censored at age 90 to maintain 
unbiased estimates. Risks were calculated using Kaplan-Meier product-limit analysis. Participants 
who died or were lost to follow-up were censored at the time of the last examination. Cumulative 
risks stratified for the risk score were compared with the overall cumulative risk based on incidence 
of late AMD (prior risk) using log-rank tests of equality (Mantel-Cox).
Missing data were encountered in the analysis of each model. Only participants with data on all 
variables in the model entered the analysis.
RESULTS
In total, 363 persons developed incident late AMD during a median follow-up (fup) time of 11.1 years 
(IQR 11), of which 132 cases in RS (fup 10.7; IQR 12.8), 153 cases in BDES (fup 15.6; IQR 10.4), and 
78 cases in BMES (fup 11.8; IQR 5.6). Incidence rates for the three studies were 2.89/1000 person-
years (PY), 2.96/1000 PY, and 3.66/1000 PY for RS, BDES and BMES respectively. The distribution of 
demographic characteristics and environmental risk factors differed slightly among the three cohorts 
(Table 2). Since the inclusion criteria for age were higher than for the other studies, participants in 
the RS were older. Early AMD (level 20-40) at baseline was more frequent in RS participants; BMI 
was higher in BDES participants; and current smokers were less frequent in BMES participants. The 
frequency of genetic risk alleles was not significantly different among the three studies, although 
there were slight differences in genotype distributions. Visual inspection of a principle component 
analysis of all genetic data against HapMap CEU data (NCBI build 36, release 22) as reference showed 
similar plots for the three cohorts (data not shown).
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Risk factors were tested separately for association with incident late AMD in all cohorts, adjusting for 
age and sex. (Table 3, available at http://aaojournal.org). Most SNPs in the genes CFH, ARMS2, CFHR5 
were significant in all three cohorts (P<0.05). SNPs in the genes LIPC, TIMP3, ADAMTS9, IER3/DDR1, 
TNFRSF10A, TGFBR1, and B3GALTL were not significant in any single cohort. In all other genes, SNPs 
were significant in at least one of the cohorts. In all three studies, increasing severity levels of early 
AMD stages at baseline, based on the 3-CC AMD severity scale (Table 1, available at http://aaojournal.
org) was associated with a highly significant risk of incident late AMD. Of the environmental risk 
factors, current smoking showed a significant association in the RS and BMES, BMI showed no 
significant association with incident late AMD in all three cohorts. To determine the best set of 
markers for each locus, all SNPs were analyzed per locus in a multivariate Cox proportional hazard 
analysis. A total of 26 SNPs were found to be suitable for further analyses.
Prediction models were built using various sets of risk factors, and tested in RS (Table 4). Model 1, a 
minimal model which included only age and sex, provided an AUC of 0.60 (95% confidence interval 
[CI] 0.55-0.65). Adding environmental and ocular factors improved the AUC to 0.78 (95% CI 0.74-0.82, 
model 2). Adding only major AMD genes to model 1 increased the AUC to 0.73 (95% CI 0.69-0.78, 
model 3). Next, a maximal genetic model was created which included all 26 SNPs. This increased the 
AUC to 0.82 (95% CI 0.79-0.86, model 4). Finally, we combined all variables from models 1-4 to assess 
the best possible prediction. This resulted in an AUC of 0.88 (95% CI 0.85-0.90, model 5). Validation 
of this model in the pooled dataset of BDES and BMES (Table 5) showed an AUC of 0.85 (95% CI 
0.82-0.88). To further improve the prediction model, we pooled all three cohorts and re-estimated 
the risks of the variables included in model 5 (Table 6). The AUC in the three cohorts combined 
was 0.87 (95%CI 0.85-0.89) and the model had a good calibration (P= 0.55). We also investigated 
the possibility to minimalize this model. Using backwards regression, 13 SNPs could be excluded 
from the model and provided a somewhat lower AUC of 0.86 (95% CI 0.84-0.88) (Table 7, available 
at http://aaojournal.org). The model with the best AUC in the three cohorts combined dataset was 
used for further analyses.
We calculated a risk score (Table 6) based on the betas from the pooled analysis, which ranged from 
-3.99 to 7.56. We rounded off the estimates and plotted their distribution stratified for incident or 
no incident late AMD (Figure 2). The plot showed a bimodal distribution with a large frequency 
difference between the groups for scores lower than 2, and scores greater than 3. The frequencies 
of risk scores 2 and 3 showed relatively small differences between cases and non-cases. Of note, all 
persons (n=8) with risk score 8 had risk alleles in the CFH, ARMS2, and C3 genes, and no protective 
alleles in C2/CFB. By contrast, all persons with risk score -3 (n=29) carried a protective variant in C2/
CFB, and were free of variants in CFH and ARMS2, except one person who carried a heterozygous 
variant in ARMS2. Risk of incident late AMD for individuals with risk score 6 to 8 was HR 23.2 (95% CI 
15.9-34.0); for those with risk score -3 to 0 HR 0.02 (95% CI 0.01-0.04).
Cumulative risk of incident late AMD was calculated for each risk score, and compared to the overall 
AMD cumulative risk of incident late AMD. Individuals (n=181) with risk score 6 to 8 had a cumulative 
risk of 65.6% (SE 0.057) to develop late AMD at age 90 years, while those (n=2751) with risk score -3 to 
0 had virtually no risk of developing incident late AMD (0.5%; SE 0.002). The overall risk of AMD for our 
study population prior to testing was 17.4% (SE 0.013) at age 90 (Figure 3), which was significantly 
different from all strata apart from risk score 3 (P= 0.71).
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TABLE 4 - Predictive values for the tested models in the Rotterdam Study 
Model Variables AUC (95% CI) SE No late AMD/ Late AMD (N)
1 Minimal model 0.60 (0.55-0.65) 0.023 4621/132
  Age      
  Sex      
2 Non genetic model 0.78 (0.74-0.82) 0.022 4561/132
  Age      
  Sex      
  AMD baseline grade      
  Smoking      
  BMI      
3 Minimal genetic model 0.73 (0.69-0.78) 0.022 4226/121
  Age      
  Sex      
  ARMS2 rs10490924      
  CFH rs1061170      
  C2/CFB rs641153      
  C3 rs2230199      
  C2/CFB rs4151667      
4 Maximal genetic model 0.82 (0.79-0.86) 0.016 4226/121
  Age      
  Sex      
  ARMS2 rs10490924      
  CFH rs800292      
  CFH rs12144939      
  CETP rs3764261      
  C2/CFB rs641153      
  COL8A1 rs13081855      
  C2/CFB rs4151667      
  C3 rs433594      
  TGBR1 rs334353      
  SKIV2L rs429608      
  C3 rs2230199      
  VEGFA rs943080      
  ADAMTS9 rs6795735      
  CFH rs1061170      
  TIMP3 rs5749482      
  IER3/DDR1 rs3130783      
  LPL rs256      
  MYRIP rs2679798      
  SLC16A8 rs8135665      
  RAD51B rs8017304      
  CFI rs10033900      
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TABLE 4 - (continued) 
Model Variables AUC (95% CI) SE No late AMD/ Late AMD (N)
  FRK/COL10A1 rs3812111      
  ABCA1 rs1883025      
  B3GALTL rs9542236      
  LIPC rs12912415      
  TNFRSF10A rs13278062      
5 Maximal gene-environment model 0.88 (0.85-0.90) 0.015 4171/121
  Age      
  Sex      
  ARMS2 rs10490924      
  CFH rs12144939      
  CFH rs800292      
  C3 rs433594      
  C2/CFB rs641153      
  TGBR1 rs334353      
  SKIV2L rs429608      
  CETP rs3764261      
  C2/CFB rs4151667      
  IER3/DDR1 rs3130783      
  C3 rs2230199      
  ADAMTS9 rs6795735      
  LPL rs256      
  COL8A1 rs13081855      
  SLC16A8 rs8135665      
  FRK/COL10A1 rs3812111      
  CFH rs1061170      
  TIMP3 rs5749482      
  VEGFA rs943080      
  MYRIP rs2679798      
  CFI rs10033900      
  TNFRSF10A rs13278062      
  RAD51B rs8017304      
  B3GALTL rs9542236      
  ABCA1 rs1883025      
  LIPC rs12912415      
  AMD baseline grade      
  Smoking      
  BMI      
Abbreviations: AMD, age-related macular degeneration; AUC, area under the curve; BMI, body mass index; CI, confidence 
interval; SE, standard error
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TABLE 5 - Model 5, the maximal gene-environment model, in the three cohorts
Study AUC (95% CI) SE No late AMD/late AMD (N)
RS 0.88 (0.85-0.90) 0.015 4171/121
BDES + BMES pooled 0.85 (0.82-0.88) 0.015 3634/156
3CC* 0.87 (0.85-0.89) 0.010 7805/277
* based on risk estimates re-analyzed in the complete data set
Abbreviations: 3CC, 3-Continent AMD Consortium; AMD, age-related macular degeneration; AUC, area under the curve; BDES, 
Beaver Dam Eye Study; BMES, Blue Mountains Eye Study; CI, confidence interval, RS, Rotterdam Study; SE, standard error
TABLE 6 - Risk estimates from Cox proportional hazard analysis based on the Three Continent AMD Consortium
Variable Code Beta per code
Age =<65=0 / 65-75=1 / 75+=2 0 / 1.558 / 2.433
Gender M=0 / F=1 0 / 0.320
ARMS2 rs10490924 GG=0 / GT=1 / TT=2 0 / 0.779 / 1.720
CFH rs800292 GG=0 / GA=1 / AA=2 0 / -0.899 / -1.614
C2/CFB rs4151667 TT=0 / TA or AA=1 0 / -1.245
CFH rs12144939 GG=0 / GT=1 / TT=2 0 / -0.947 / -1.195
COL8A1 rs13081855 GG=0 / GT=1 / TT=2 0 / 0.223 / 0.890
C3 rs2230199 CC=0 / GC=1 / GG=2 0 / -0.033 / 0.755
SLC16A8 rs8135665 CC=0 / TC=1 / TT=2 0 / 0.313 / 0.648
C3 rs433594 GG=0 / GA=1 / AA=2 0 / -0.110 / -0.591
C2/CFB rs641153 GG=0 / GA or AA=1 0 / -0.592
SKIV2L rs429608 GG=0 / GA=1 / AA=2 0 / 0.027 / 0.590
CETP rs3764261 CC=0 / CA=1 / AA=2 0 / 0.215 / 0.478
ADAMTS9 rs6795735 CC=0 / TC=1 / TT=2 0 / 0.130 / 0.424
RAD51B rs8017304 AA=0 / AG=1 / GG=2 0 / -0.414 / -0.138
TIMP3 rs5749482 GG=0 / GC or CC=1 0 / -0.357
TGBR1 rs334353 TT=0 / TG=1 / GG=2 0 / 0.039 / -0.336
CFH rs1061170 TT=0 / TC=1 / CC=2 0 / 0.175 / 0.278
FRK/COL10A1 rs3812111 TT=0 / TA=1 / AA=2 0 / -0.278 / -0.118
CFI rs10033900 CC=0 / TC=1 / TT=2 0 / -0.070 / -0.223
TNFRSF10A rs13278062 TT=0 / TG=1 / GG=2 0 / 0.093 / 0.196
B3GALTL rs9542236 TT=0 / TC=1 / CC=2 0 / -0.231 / -0.169
IER3/DDR1 rs3130783 AA=0 / AG=1 / GG=2 0 / 0.029 / 0.166
MYRIP rs2679798 AA=0 / AG=1 / GG=2 0 / 0.059 / 0.156
VEGFA rs943080 CC=0 / TC=1 / TT=2 0 / 0 / 0.098
ABCA1 rs1883025 CC=0 / TC=1 / TT=2 0 / -0.046 / 0.076
LIPC rs12912415 AA=0 / AG or GG=1 0 / -0.098
LPL rs256 CC=0 / TC or TT=1 0 / -0.048
AMD baseline grade Level 10=0 / Level 20=1 / Level 30=2 / Level 40=3 0 / 1.458 / 2.560 / 3.398
Smoking Never=0 / Past=1 / Current=2 0 / 0.164 / 0.651
BMI =<25=0 / 25+=1 0 / 0.007
Abbreviations: AMD, age-related macular degeneration; BMI, body mass index; F, female; M, male
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FIGURE 2 - Distribution of risk score in incident late AMD and no late AMD in 3CC, and hazard ratios of incident 
late AMD
The X-axis represents the risk score category, the left y-axis frequency as percentages, the right y-axis hazard 
ratio of incident late AMD. The red bars represent no late AMD; the purple bar incident late AMD. The dark blue 
line represents the hazard ratio (HR) of incident late AMD. Category 3 is the reference category (R) and has HR 
1.00. Risk score -3 to 0, and risk scores 6 to 8 were combined for HR. Error bars indicate the 95% confidence 
interval (CI) of HR.
Abbreviations: 3CC, Three Continent AMD Consortium; AMD, age-related macular degeneration; R, reference
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DISCUSSION
In three independent population-based studies from three continents, we investigated all well-
known genetic and non-genetic risk factors for AMD. We found that the best prediction for late AMD 
was based on age, sex, 26 genetic variants, two environmental variables, and early AMD phenotype. 
The accuracy of a prediction model including all these variables was 0.88 in the RS. As similar risk 
estimates were found in BDES and BMES, the model proved to be well generalizable to persons 
from Caucasian descent, living on other continents. Translation of the model to the individual level 
provided good discrimination between those at a high life-time risk of late AMD and those with 
virtually no risk , a risk difference of 65%.
A major strength of our study is the inclusion of a general population, unbiased by AMD risk 
factors. The study samples had included a wide spectrum of AMD lesion phenotypes but not only 
the extreme ends of disease, which is representative of real scenario in the population. Inclusion 
of wide spectrum of risk factors distributions and various levels of risk profiles of our population-
based samples ensures a realistic, less biased prediction for all risk categories. Additional strengths 
are the use of longitudinal observational samples to predict incident cases and validation in two 
independent population-based cohorts with similar study designs. All the strengths facilitate our 
comprehensive analyses and calculation of cumulative risk of incident late AMD.
Limitations included the relatively low number of incident late AMD cases (n=363), hampering 
further risk estimation to AMD subtypes. In addition, we did not include several risk factors, such 
as dietary factors, biomarkers, or rare genetic variants10,40-43. Dietary factors and biomarkers are 
difficult variables to obtain, but their inclusion would have improved the sensitivity of the predictive 
value. Inclusion of genetic mutations is unlikely to contribute to population risk, due to their low 
frequencies. Finally, the three cohorts had subtle differences in methodology, which have been 
discussed by Klein et al.37
Most previously published AMD prediction models have been based on case-control studies 
(Table 8)12-28. Most of these models included demographic, genetic and environmental factors, and 
reached a good prediction for AMD (AUC 0.68-0.94). The study which reported the highest AUC 
(0.94) included complement activation22. However, measurement of activation fragments requires 
rather intense work-up and specific expertise, and is therefore unlikely to occur in a standard clinical 
setting. The other studies have some drawbacks as well. Gold et al. reported a sensitivity of 70% 
and a specificity of 50% for their model 14, making the prediction of low risk outcomes inaccurate. 
Hageman et al. showed a better specificity and sensitivity, but their model did not incorporate any 
non-genetic factors including age16. Furthermore, their model was based on prevalence data, which 
is less appropriate for estimation of prognosis44. Most other case control studies also lacked follow-
up data. The reports with follow-up data were almost inclusively based on data from the AREDS 
study 20,23,24,27. Although these investigated persons from the same source population, they differed 
substantially from each other in design and inclusion of risk factors, leading to great variation in 
prediction outcomes. Our study shows that the sensitivity of risk prediction depends on the number 
of variables included in the model, and highest sensitivity is achieved with a full model including 
the major genes, many of the recently discovered minor genetic variants, smoking, BMI, and existing 
AMD phenotypes.
222 Chapter 6.1
TA
BL
E 8
 - 
Pr
ed
ic
tio
n 
m
od
el
s 
in
 th
e 
lit
er
at
ur
e
A
ut
ho
r
Ye
ar
St
ud
y 
po
pu
la
ti
on
/ 
de
si
gn
no
nc
as
es
/ 
ca
se
s
Fo
llo
w
-
up
Pr
ed
ic
ti
on
 m
od
el
 v
ar
ia
bl
es
A
U
C 
Se
ns
it
iv
it
y
Sp
ec
ifi
ci
ty
Va
lid
at
io
n 
in
 
in
de
pe
nd
en
t 
da
ta
se
t?
Re
m
ar
ks
 
D
em
og
ra
ph
ic
En
vi
ro
nm
en
ta
l
G
en
et
ic
O
cu
la
r
G
ol
d 
et
 a
l14
20
06
ca
se
-c
on
tr
ol
11
4/
35
0
 
 
 
CF
H
, C
2/
CB
 
 
0.
74
0.
56
Ye
s
 
H
ug
he
s 
et
 
al
17
20
07
ca
se
-c
on
tr
ol
26
6/
40
1
 
 
sm
ok
in
g
CF
H
, A
RM
S2
 
 
 
 
N
o
Ri
sk
sc
or
e
O
nl
y 
CN
V 
ca
se
s
Ja
ko
bs
do
tt
ir 
et
 a
l18
20
08
ca
se
 c
on
tr
ol
 
an
d 
fa
m
ily
 
co
ho
rt
16
8/
18
7;
 
10
95
/4
29
 
ag
e,
 s
ex
sm
ok
in
g
CF
H
, A
RM
S2
, 
C2
/F
B
 
 
0.
70
0.
74
N
o
 
Ja
ko
bs
do
tt
ir 
et
 a
l19
20
09
ca
se
-c
on
tr
ol
 
an
d 
fa
m
ily
 
co
ho
rt
16
8/
18
7;
 
10
95
/4
29
 
 
 
CF
H
, A
RM
S2
, 
C2
/F
B
 
0.
79
 
 
N
o
 
Se
dd
on
 e
t 
al
23
20
09
A
RE
D
S 
- R
C
T
11
67
/2
79
6.
3 
yr
s
ag
e,
 s
ex
ed
uc
at
io
n,
 
sm
ok
in
g,
 
CF
H
, A
RM
S2
, C
2/
FB
, C
3
ba
se
lin
e 
gr
ad
e
0.
82
2
0.
83
0.
68
N
o
 
BM
I, 
an
tio
xi
da
nt
/z
in
c
or
 b
ot
h
Re
yn
ol
ds
 
et
 a
l22
20
09
ca
se
-c
on
tr
ol
60
/1
10
 
ag
e,
 s
ex
sm
ok
in
g,
 B
M
I, 
ac
tio
n
CF
H
, A
RM
S2
, C
2/
FB
, C
3,
 C
FI
 
0.
94
 
 
N
o
 
 
 
fr
ag
m
en
ts
 
 
 
G
ib
so
n 
et
 
al
13
20
10
ca
se
-c
on
tr
ol
47
0/
47
0
 
ag
e,
 s
ex
sm
ok
in
g
CF
H
, A
RM
S2
, C
3,
 
SE
RP
IN
G
1
 
0.
83
0.
76
0.
76
N
o
 
M
cK
ay
 e
t 
al
21
20
10
ca
se
-c
on
tr
ol
43
6/
43
7
 
ag
e
sm
ok
in
g
CF
H
, A
RM
S2
, C
2/
FB
, C
3
 
0.
86
 
 
N
o
 
Za
nk
e 
et
 a
l28
20
10
Ri
sk
s 
fr
om
 
lit
er
at
ur
e
N
A
 
 
sm
ok
in
g
CF
H
, A
RM
S2
, C
3,
 
m
tA
49
17
G
 
 
 
 
N
o
 
Ch
en
 e
t a
l12
20
11
A
RE
D
S 
(7
23
) 
ca
se
-c
on
tr
ol
 
(1
12
1)
50
9/
13
35
 
ag
e,
 s
ex
sm
ok
in
g,
 B
M
I
CF
H
, A
RM
S2
, C
2/
FB
, C
3
 
0.
82
0.
75
5
0.
74
7
N
o
 
H
ag
em
an
 
et
 a
l16
20
11
ca
se
-c
on
tr
ol
46
7/
48
2
 
 
 
CF
H
, A
RM
S2
, C
2/
FB
, C
3,
 
 
0.
80
0.
82
0.
63
Ye
s
O
nl
y 
CN
V 
ca
se
s
CF
H
R4
, C
FH
R5
, 
F1
3B
223Prediction of AMD in the general population
6
Kl
ei
n 
et
 a
l20
20
11
A
RE
D
S 
- R
C
T
20
34
/6
88
9.
3 
yr
s
ag
e
fa
m
ily
 h
is
to
ry
, 
CF
H
, A
RM
S2
ba
se
lin
e 
gr
ad
e,
 
dr
us
en
0.
87
2^
 
 
Ye
s
 
sm
ok
in
g
pr
es
en
ce
, 
ad
va
nc
ed
 
A
M
D
 in
 
ot
he
r e
ye
 
Se
dd
on
 e
t 
al
24
20
11
A
RE
D
S 
- R
C
T
21
18
/8
19
9.
2 
yr
s
ag
e,
 s
ex
ed
uc
at
io
n,
 
sm
ok
in
g,
 
CF
H
, A
RM
S2
, C
2/
FB
, C
3
dr
us
en
 
si
ze
, 
0.
90
8*
 
 
N
o
 
BM
I, 
an
tio
xi
da
nt
ad
va
nc
ed
 
A
M
D
 in
 
ot
he
r e
ye
0.
87
6^
Sp
en
ce
r e
t 
al
25
20
11
ca
se
-c
on
tr
ol
21
6/
34
9
 
ag
e
sm
ok
in
g
CF
H
, A
RM
S2
, C
2/
FB
, C
3
 
0.
84
0.
77
0
0.
74
1
Ye
s
O
ut
co
m
e 
is
 
ea
rly
an
d 
la
te
 
A
M
D
Sp
en
ce
r e
t 
al
25
20
11
ne
st
ed
 c
as
e-
co
nt
ro
l
14
8/
85
 
ag
e
sm
ok
in
g
CF
H
, A
RM
S2
, C
2/
FB
, C
3
 
 
0.
63
3
0.
70
7
Ye
s
O
ut
co
m
e 
is
 
ea
rly
an
d 
la
te
 
A
M
D
Yi
ng
 e
t a
l26
20
11
CA
PT
 - 
tr
ia
l
61
8/
32
4
5 
yr
s
ag
e
sm
ok
in
g,
…
Ba
se
lin
e 
gr
ad
e,
 
0.
68
 
 
N
o
O
nl
y 
G
A
 
ca
se
s
hy
pe
rt
en
si
on
ni
gh
t 
vi
si
on
 
sc
or
e
G
ra
ss
m
an
n 
et
 a
l15
20
12
ca
se
-c
on
tr
ol
78
6/
98
6
 
 
 
CF
H
, A
RM
S2
, C
2/
FB
, L
IP
C,
 
 
0.
81
3
 
 
N
o
 
A
PO
E,
 P
LA
2G
12
A
, 
TI
M
P3
 
 
Yu
 e
t a
l27
20
12
A
RE
D
S 
- R
C
T
11
12
/1
44
8
10
.3
 y
rs
ag
e,
 s
ex
ed
uc
at
io
n,
 
sm
ok
in
g,
 
CF
H
, A
RM
S2
, C
2/
FB
, C
3,
 
Fe
llo
w
 e
ye
 
st
at
us
0.
89
5*
 
 
N
o
O
ut
co
m
e 
is
 
ea
rly
BM
I, 
an
tio
xi
da
nt
CF
I, 
LI
PC
, T
IM
P3
, 
CE
TP
0.
88
3^
 
 
an
d 
la
te
 
A
M
D
A
BC
A
1,
 C
O
L8
A
1,
 
A
PO
E
 
 
* 
ba
se
d 
on
 1
0 
ye
ar
 fo
llo
w
-u
p.
 ^
 b
as
ed
 o
n 
5 
ye
ar
 fo
llo
w
-u
p.
A
bb
re
vi
at
io
ns
: A
M
D
, a
ge
-r
el
at
ed
 m
ac
ul
ar
 d
eg
en
er
at
io
n;
 A
RE
D
S,
 a
ge
-r
el
at
ed
 e
ye
 d
is
ea
se
 st
ud
y;
 A
U
C,
 a
re
a 
un
de
r t
he
 c
ur
ve
; B
M
I, 
bo
dy
 m
as
s i
nd
ex
; C
A
PT
, c
om
pl
ic
at
io
ns
 o
f a
ge
-r
el
at
ed
 m
ac
ul
ar
 d
eg
en
er
at
io
n 
pr
ev
en
tio
n 
tr
ia
l; 
CN
V,
 c
ho
ro
id
al
 n
eo
va
sc
ul
ar
iz
at
io
n;
 G
A
, g
eo
gr
ap
hi
c 
at
ro
ph
y;
 R
C
T,
 ra
nd
om
iz
ed
 c
on
tr
ol
le
d 
tr
ia
l 
224 Chapter 6.1
What may be the benefits of prediction tests? Most current counseling provided to family members 
of late AMD cases is based on clinical parameters. A prediction test may improve the identification 
of true high-risk individuals. As the estimation of cumulative risk of incident AMD makes the risk 
very apparent, it may encourage an individuals to alter their lifestyle with the aim to decrease the 
risk of AMD. For instance, one can stop smoking, eat foods rich in antioxidants, and increase physical 
exercise to lower risk of progression to late AMD9,45. There may be benefits for patients with late AMD. 
Various studies have shown that persons with neovascular AMD who do not respond to anti-VEGF 
therapy are at higher genetic risk46-49. These patients may need more intensive treatment regimens. 
Lastly, current intervention trials select study participants mainly on the basis of phenotypes. 
Inclusion of high-risk individuals, identified by a prediction test, may improve homogeneity of the 
study population and prediction of AMD outcome events.
In summary, a risk score based on a large number of genetic risk variants for AMD, the environmental 
factors smoking and BMI, and early AMD phenotype provided a good prediction of incident late AMD 
cases in this study. A model incorporating non-genetic factors performed better than a model based 
on a minimal number of genetic factors, but after inclusion of many genes the model performed 
better than a model including only non-genetic factors. Inclusion of all risk factors provided the 
best prediction. As personalized medicine is the future, prediction tests will become more and more 
implemented as clinical tools. In such case, only comprehensive tests will be useful for AMD.
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ABSTRACT
Purpose Genetic testing may be the next step in clinical medicine for a more personalized approach 
in determining risk of disease. Direct-to-consumer (DTC) personal genome tests may fulfill this role. 
We explored the practicability and predictive value of DTC-tests from four companies (23andMe, 
deCODEme, Easy DNA, Genetic testing laboratories) for age-related macular degeneration (AMD).
Methods Body specimens of three individuals were collected and sent to four companies for 
DNA genotyping and disease risk estimation. In addition, DNA was also genotyped using Illumina 
HumanOmniExpress 12v1 array in the Rotterdam Study laboratory, and risk estimates of AMD were 
calculated using the validated prediction model from the population-based Three Continent AMD 
Consortium.
Results Genotyped results of the four DTC-tests matched genotyping performed by the Rotterdam 
Study laboratory. The estimated risks provided by the companies varied considerably in the tested 
individuals, from a 1.6-fold difference for overall relative risk to an up to 12-fold difference for lifetime 
risk. The lifetime risks for the individuals ranged from 1.4-16.1% in the DTC-tests, while they varied 
from 0.5-4.2% in the validated prediction model. Most important reasons for the differences in risks 
were the testing of only a limited set of genetic markers, the choice of the reference population, and 
the methodology applied for risk calculation.
Conclusion Direct-to-consumer personal genome tests are not suitable for clinical application as 
yet. More comprehensive genetic testing and inclusion of environmental risk factors may improve 
risk prediction of AMD.
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INTRODUCTION
Genetic studies of age-related macular degeneration (AMD) have elucidated a major proportion of 
its genetic background. Currently, genome-wide studies (GWAS) have identified associations with 
>30 genetic loci for this disease, explaining a large part of the heritability of AMD1,2. Subsequently, 
these genomic findings have been incorporated into prediction models, many of which provide a 
>80% discriminative accuracy for late AMD3-22. This high predictive ability makes AMD particularly 
suitable for genetic testing, which may be the next step to a more personalized approach in clinical 
medicine.
Direct-to-consumer (DTC) personal genome tests had been made available for consumers and 
thousands have purchased these tests via the internet to determine a personal disease risk. Recently, 
methods of three DTC-tests have been examined and compared for several diseases23. AMD was the 
disease for which each test obtained the best predictive ability. Several companies offered genetic 
tests for AMD and implementation of these tests in the clinic could help identify individuals at risk of 
developing the disease to apply risk dependent patient care and surveillance strategies. Therefore, 
the accuracy of the risk estimates will be a great concern, and will determine whether such tests will 
be meaningful in the clinic.
In this study, we evaluated the results of AMD prediction tests provided by four major companies. We 
sent bio-samples from three individuals to these companies to test proof of principle, and reviewed 
the sampling process, the type of analysis, the genotyping, and the risk information. In addition, we 
compared results to a validated prediction model based on population studies.
METHODS
Experimental design
Evaluation of test methodology
Study participants
Three investigators (GB, JV, CK) agreed to voluntarily participate in the study, and signed informed 
consent.
DTC-tests for AMD
We searched for internet-based DTC-tests for AMD using a web search engine and the word groups 
“genetic testing for age-related macular degeneration”, “genetic prediction of age-related macular 
degeneration”, and “genetic tests for age-related macular degeneration”. Only companies available 
for European citizens and testing more than one single nucleotide polymorphism (SNP) were 
eligible, and of these, four companies were selected; i.e., 23andMe, deCODEme, Easy-DNA, The 
Genetic Testing Laboratories, Inc.
23andMe
https://www.23andme.com/
This privately-held American company was founded in 2006 with the intention to empower individuals 
in accessing their own genetic information and to stimulate a way into more personalized medicine. 
One can order a single ‘spit’ kit for $99 (shipping costs $14.95 - $118.95) from the website on internet, 
and a sample collection kit will be sent by mail with instructions how to provide a saliva sample and 
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details for returning the sample. An assisted collection kit for persons having trouble to spit can be 
ordered together with the DTC-kit for an additional $25, requiring only half the amount of saliva. 
The returned saliva sample will arrive at the contracted LabCorp’s Clinical Laboratory Improvement 
Amendments (CLIA) certified laboratory, where DNA will be isolated from cells in the saliva and 
processed on an Illumina® HumanOmniExpress array customized by 23andMe (>1 million SNPs, 
call rate above 98%). These SNPs provide information about traits, carrier status, and risks for over 
hundred diseases, including AMD. The risk for developing AMD is estimated based on the risk in the 
reference population and an overall relative risk (RR) representing risks of five SNPs: CFH rs1061147; 
C2 rs547154; LOC387715/ARMS2 rs3750847; C3 rs2230199; TIMP3 rs9621532 11,24-36. AMD risk in the 
reference population differed for males and females and was 6.5 and 7% respectively. Methods of risk 
calculation have been described in a white paper37, accessible after login to the 23andMe website. No 
health reports including risk prediction and carrier status are currently provided for new customers.
DeCODE
http://www.decodeme.com/
DeCODE was founded in 1996 and the headquarters are located in Reykjavik, Iceland. This company 
developed the deCODEme test, which provide results for 47 conditions and traits. Unfortunately, 
new tests are no longer offered by the company. Costs were $1100 per test, with no extra costs for 
shipping. After purchasing the test from the internet, a buccal swab kit will was sent in the mail with 
instructions how to collect and return the sample. The samples were processed at a CLIA certified 
lab, the deCODE laboratory in Reykjavik, for DNA isolation. Genotyping was performed on an 
Illumina Human 1M Beadchip (Illumina, Inc., San Diego, California, USA) which determines >1 million 
SNPs. Validation occurred by bi-directional Sanger sequencing and independent SNP genotyping 
platforms.
A overall RR for developing AMD was calculated based on six risk variants: ARMS2/HTRA1 rs3750847, 
C2/FB rs9332739 and rs547154, C3 rs230199 and, CFH rs1061147 and rs1329428 27,38. Subsequently, 
for the tested individual a lifetime risk was calculated based on the overall relative risk and the AMD 
risk in the reference population, which was set at 8%. A white paper39 describing the risk calculation 
is available after login to the deCODEme website.
Easy-DNA
http://www.easy-dna.com / http://www.easydna.co.uk / http://www.easydna.eu
Easy-DNA is an international company which provides a genetic DNA predisposition test on 25 
conditions and diseases. This test can be purchased from the internet for €299/$299/£299 including 
shipping costs. A kit will be sent by mail for collection of a blood sample, and includes submission 
forms, instructions for collecting the blood sample from a punctured finger, the sample collection 
kit and a self-addressed envelope. This company does not provide information on the genotyping 
method, but states that results are provided for CFH rs1061170 and C2 rs800292 40,41. Risk estimates 
are presented as lifetime and overall RR of AMD. Risk of AMD in the reference population was set at 
8%. Methods for risk calculation was not provided by the company.
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The Genetic Testing Laboratories, Inc (GTL)
http://www.gtldna.com/predisposition.html
This company provides a DNA predisposition test which will reveal the genetic and environmental 
predisposition for 25 diseases and conditions including AMD. The DNA predisposition test costs $285 
with additional costs of $45 for shipping outside the Contiguous United States. After purchasing the 
kit from the internet, it will be sent to your own physician or a professional collector agency appointed 
by GTL to collect the sample, which can be a bucal or a blood sample. The sample will be processed by 
a CLIA accredited laboratory. As for Easy-DNA, this company also is unclear on genotyping method, 
but states that results are provided for CFH rs1061170 and C2 rs800292 40,41. Lifetime and overall RR 
are provided for each tested person. Risk of AMD in the reference population was set at 8%.The risk 
calculation method of this company was not available for consumers or professionals.
We followed each company’s instructions for the collection of bio-samples used for DNA extraction. 
We sent the samples to the various laboratories associated with the companies, and awaited the 
results.
Genotyping in Rotterdam
Genotyping for the three individuals was also performed at the Rotterdam Study Laboratory: Genetic 
Laboratory of Internal Medicine at the Erasmus Medical Center in Rotterdam, the Netherlands. 
Genomic DNA was extracted from peripheral leukocytes and all participants were genotyped using 
the Illumina HumanOmniExpress 12v1_J microarray (Illumina, Inc., San Diego, California, USA). Call 
rate for the genotyping was >97.5%.We imputed genotype data to Hapmap 3 release 2 and 1000 
genomes phase I V3.
Assessment of covariates
The covariates age, length, weight, smoking status, and family history regarding AMD were obtained 
by interview. Body mass index (BMI) was calculated by dividing weight (kg) by the height squared 
(m2). AMD phenotype was evaluated by standard ophthalmologic examination including fundus 
photography (Topcon TRC-50EX fundus camera, Topcon Optical Co, Tokyo, Japan and Sony DXC-
950P digital camera, Sony Corporation, Tokyo, Japan) after pharmacological mydriasis. Images 
were graded according to the Wisconsin Age-Related Maculopathy Grading42 and the modified 
international classification system43 by graders from the Rotterdam Study.
Risk score Three Continent AMD Consortium prediction model and DTC-tests
The Three Continent AMD Consortium (3CC) developed a validated prediction model including a 
total risk score based on 31 variables; 26 genetic variants associated with AMD, age, sex, smoking, 
BMI, and AMD phenotype. The prediction model had 87% discriminative accuracy for incident late 
AMD 22. For each individual in this study this summary risk score was calculated. Based on the risk 
score, lifetime risks could be assessed for each individual.
Ancestry assessment
Ancestry of the three individuals was determined using multi-dimensional scaling (MDS) protocol 
from ENIGMA 44 using Hapmap 3 release 2 as the reference.
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Statistical analysis
Test results included predicted risks for several diseases from four companies. For the purpose of this 
study, we only evaluated the predicted risks for AMD. 23andMe provided odds ratios (OR) and the 
other companies relative risks (RR) per SNP per genotype, but all were adjusted for the average risk 
of the SNP in the population, and will be referred to as OR and RR, respectively. Genotype frequency, 
risks per genotype, overall RR, lifetime population risk and lifetime risk of the tested individual were 
obtained from the test results.
Minor allele frequencies were not provided by the companies, but calculated using the formula:
 p+q = 1
With p representing the major allele and q the minor allele. For the different genotypes, frequencies 
could be calculated after applying this information; homozygous for major alleles = p2, heterozygous 
= 2pq and homozygous for minor alleles = q2.
All analyses were performed using SPSS version 20.0 (SPSS INC, Chicago, Illinois) except for the MDS-
analysis which was performed using R software ( R-project, Institute for Statistics and Mathematics, R 
core team (2013), Vienna, Austria, version 3.0.2).
RESULTS
Demographic characteristics of the three study subjects are provided in Table 1. All three were 
younger than the average age of AMD onset, and none had any features of AMD, as determined by 
grading of fundus photographs. One had a history of smoking, and one had a positive family history 
for late AMD. All three were Caucasian and had northern/western European ancestry (Supplementary 
Figure 1).
TABLE 1 - Discriptives of the participants 
Variable Individual 1 Individual 2 Individual 3
Age (yrs) 45 29 51
Sexe Female Female Male
Ethnicity Caucasian Caucasian Caucasian
Ancestry Northern/western European Northern/western European Northern/western European
BMI (kg/m²) 22.7 20.2 24.3
Smoking never never past
AMD phenotype none none none
Family history of AMD grandmother none none
Abbreviations: AMD = age-related macular degeneration, BMI = body mass index, yrs = years
235Commercial prediction of AMD
6
DTC-tests
Details of the DTC-tests are given in Table 2. Tests differed considerably in price, the most costly being 
11x more expensive than the cheapest test. Sampling methods varied from saliva, buccal swap to 
blood from a finger prick. One participant particularly had difficulty to deliver the saliva specimen 
of 2.5 ml for 23andMe, which required ~1 hour of sampling time. Genetic Testing Laboratories 
(GTL) required for all participants and Easy-DNA only for US-residents a physician or another health 
professional assigned by the company to collect the blood sample and only the collectors obtained 
the test results. However, the forms for requesting the test from GTL were open access. Delivery time 
for test results ranged from 2-4 weeks for most tests; results from one Easy-DNA test were delayed up 
to 8 weeks without notice or explanation.
TABLE 2 - Overview genetic testing companies
Company 
name Website
Costs 
per kit
DNA 
source
Easy to 
collect? Additional notes
23andMe https://www.23andme.com $99 /
€ 74
saliva Difficult in one 
participant
Street address is needed to 
deliver DTC-test
deCODEme* https://www.decodeme.com $1100 /
€ 821
bucal yes  - 
Easy-DNA http://www.easygenetictest.com $299 /
€ 299
blood yes For US residents: Sample needs 
to be collected by physiscian or 
professional collector
The Genetic 
Testing 
Laboratories
http://www.gtldna.com/ $285 /
€ 213
blood yes Sample needs to be collected 
by physiscian or professional 
collector
* deCODEme do not offer any new testing possibilities
In contrast to the statement of Easy-DNA and GTL, the SNP rs800292 is located in the CFH gene, 
not in C2 (Table 3). Thus, these two companies only tested risk variants in CFH. DeCODEme and 
23andMe covered 4 and 5 AMD loci, respectively. The tested SNPs varied among tests, however, there 
was considerable overlap. Individual genotypes at these SNP locations are shown in Table 3. Risk-
increasing as well as risk-decreasing variants were present in all three individuals. The effect estimates 
of these variants showed the largest range in individual 2, in particular for the risks predicted by 
23andMe and deCODEme. The lifetime AMD population risk used by the companies varied from 6.5-
8%, and varied for gender in the 23andMe calculations. For 23andMe and deCODEme the ancestry 
of the reference populations was European, for GTL and Easy-DNA this was European Tuscan. Only 
for individual 1 the Easy-DNA test listed European ancestry as the reference population. Genotypes 
identified by the DTC-tests were identical to those determined at the Rotterdam Study laboratory in 
all three individuals.
The inter-test variability of the overall relative and life-time risks was large in all three individuals , but 
most profoundly in individual 3 (Table 3). For this person, these risks were lower and higher than the 
population risk, depending on the test. Lifetime risks between lowest and highest estimate differed 
by factor 1.7, 1.6, and 11.5 for individuals 1, 2, and 3, respectively.
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TABLE 4 - Risk estimates from the Three Continent AMD Consortium prediction model
Variable Code Risk per code Individual 1 Individual 2 Individual 3
ARMS2 rs10490924 GG=0 / GT=1 / TT=2 0 / 0.779 / 1.720 0 0.779 0
ADAMTS9 rs6795735 CC=0 / TC=1 / TT=2 0 / 0.130 / 0.424 0 0.424 0.424
SLC16A8 rs8135665 CC=0 / TC=1 / TT=2 0 / 0.313 / 0.648 0.313 0 0.313
Sexe M=0 / F=1 0 / 0.320 0.320 0.320 0
CETP rs3764261 CC=0 / CA=1 / AA=2 0 / 0.215 / 0.478 0.215 0 0
CFH rs1061170 TT=0 / TC=1 / CC=2 0 / 0.175 / 0.278 0.175 0 0.175
Smoking Never=0 / Past=1 / Current=2 0 / 0.164 / 0.651 0 0 0.164
MYRIP rs2679798 AA=0 / AG=1 / GG=2 0 / 0.059 / 0.156 0.059 0.156 0
VEGFA rs943080 CC=0 / TC=1 / TT=2 0 / 0 / 0.098 0 0 0.098
TNFRSF10A rs13278062 TT=0 / TG=1 / GG=2 0 / 0.093 / 0.196 0.093 0 0
TGBR1 rs334353 TT=0 / TG=1 / GG=2 0 / 0.039 / -0.336 0.039 0.039 0
IER3/DDR1 rs3130783 AA=0 / AG=1 / GG=2 0 / 0.029 / 0.166 0 0.029 0.029
SKIV2L rs429608 GG=0 / GA=1 / AA=2 0 / 0.027 / 0.590 0 0 0.027
Age (yrs) =<65=0 / 65-75=1 / 75+=2 0 / 1.558 / 2.433 0 0 0
AMD baseline grade Level 10=0 / Level 20=1 / 
Level 30=2 / Level 40=3
0 / 1.458 / 2.560 
/ 3.398
0 0 0
BMI (kg/m2) =<25=0 / 25+=1 0 / 0.007 0 0 0
C2/CFB rs4151667 TT=0 / TA or AA=1 0 / -1.245 0 0 0
B3GALTL rs9542236 TT=0 / TC=1 / CC=2 0 / -0.231 / -0.169 0 0 0
LIPC rs12912415 AA=0 / AG or GG=1 0 / -0.098 0 0 0
COL8A1 rs13081855 GG=0 / GT=1 / TT=2 0 / 0.223 / 0.890 0 0 0
TIMP3 rs5749482 GG=0 / GC or CC=1 0 / -0.357 0 0 0
C3 rs2230199 CC=0 / GC=1 / GG=2 0 / -0.033 / 0.755 -0.033 -0.033 0
ABCA1 rs1883025 CC=0 / TC=1 / TT=2 0 / -0.046 / 0.076 -0.046 -0.046 0
LPL rs256 CC=0 / TC or TT=1 0 / -0.048 0 -0.048 -0.048
CFI rs10033900 CC=0 / TC=1 / TT=2 0 / -0.070 / -0.223 0 -0.070 -0.070
C3 rs433594 GG=0 / GA=1 / AA=2 0 / -0.110 / -0.591 -0.110 -0.110 0
FRK/COL10A1 rs3812111 TT=0 / TA=1 / AA=2 0 / -0.278 / -0.118 0 0 -0.118
RAD51B rs8017304 AA=0 / AG=1 / GG=2 0 / -0.414 / -0.138 0 0 -0.414
C2/CFB rs641153 GG=0 / GA or AA=1 0 / -0.592 0 0 -0.592
CFH rs800292 GG=0 / GA=1 / AA=2 0 / -0.899 / -1.614 0 -0.899 -0.899
CFH rs12144939 GG=0 / GT=1 / TT=2 0 / -0.947 / -1.195 0 -0.947 0
Total risk score     1.025 -0.406 -0.911
Lifetime risk (%)     4.2 0.5 0.5
Abbreviations: AMD = age-related macular degeneration; BMI = body mass index; F = female; M= male; yrs = years
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Risk prediction based on Three Continent AMD Consortium
The prediction model developed by the population-based Three Continent AMD Consortium (3CC) 
consists of 31 variables which were represented in a total risk score indicating the risk of developing 
late AMD22. For each individual the total risk score was calculated (Table 4) and used to assess lifetime 
risks. Lifetime population risk for developing late AMD was 17.4% at life expectancy of 90 years in the 
3CC cohort. Lifetime risks for all three individuals were also calculated using the 3CC risk score, and 
were 4.2%, 0.5%, and 0.5% respectively (Table 4). Although the population risk in the 3CC cohort was 
much higher than for the DTC-tests, lifetime risks for the three individuals were considerably lower 
than the lifetime risks provided by the companies (4.9-8.6; 4.0-6.5; 1.4-16.1, Table 3).
DISCUSSION
Until recently, anyone could order a DTC-test and get a personal risk estimate for common diseases. 
Interpretation of the test results and evaluation of their validity has been difficult, even for 
professionals. Our study shows that predicted risks of AMD vary considerably among DTC-tests, and 
none may represent the true disease risk.
We examined four DTC-tests in three individuals, and compared test results to predicted risks from a 
validated model developed in the large population-based Three Continent AMD Consortium (3CC)22. 
Predicted risks varied widely within each individual, and differences between highest and lowest 
estimates for lifetime risk were up to 12-fold. Within the same person, overall relative risks could 
be increased as well as decreased, depending on which test was used. All tests provided higher 
estimates for lifetime risk than the 3CC model. Several key points explain these differences.
First, the DTC-tests genotyped only 2-6 SNPs to calculate the risk of AMD. These risks were often 
based on case-control studies instead of population-based studies which often comprise lower 
risks22. Recent reports show that >30 loci have been associated by GWAS studies1,2. Not testing a 
comprehensive set of SNPs may lead to imbalance of harmful and protective SNPs, and provide a very 
different overall risk estimate. For example, individual 2 had several important risk-increasing as well 
as risk-decreasing variants (Table 4), and not testing these hampered accurate risk profiling (Table 
3). This was also acknowledged for the population at large; inclusion of an extended set of variants 
increased risk prediction in three population-based studies22. We expect that even more common 
and rare variants will be identified for AMD in the near future, and inclusion of these variants will 
further refine personalized risk prediction.
Second, the lifetime population risk and reference population differed among the DTC-tests. The 
lifetime population risk used by 23andMe was lower than that used by the other companies, and 
differed for men and women. Which population had been used as reference for the calculation of the 
lifetime AMD population risk was not specified by any of the companies. They were all lower than 
the lifetime population risk estimate in 3CC (6.5-8% versus 17.4%, respectively). Lifetime population 
risks were based on life expectancy of 79 years for 23andMe and 90 years for 3CC. No information 
was provided on life expectancy by the other companies. The average life expectancy is currently 
above 80 years in western Europe and 79 years in the United States 45. Life expectancy increases 
once a certain age has been reached: for instance, persons who reached the age of 80 years during 
2008-2010 in France still had an average life expectancy of 8.3 years for men and 10.6 years for 
women 46. In these persons, a life expectancy of 90 years is not unrealistic. Ancestry also influences 
the risk estimates. All companies asked the applicant for their ethnicity and used questionnaire 
data for analysis. However, calculation of ancestry is more accurate using multi-dimensional scaling 
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(MDS) analysis with genotype data. In GTL and Easy DNA, all results were based on European Tuscan 
ancestry, although European ethnicity was stated by the individuals at application. MDS analysis 
with genotype data from all three individuals confirmed their northern/western European ancestry 
comparable with their appearance (Supplementary Figure 1). Why a Tuscan ancestry was chosen for 
these individuals is unclear and incorrect. The choice of two different ancestries (European Tuscan 
and European) in one individual (Table 3) in these tests is presumably an unintended error.
The conversion to a different ancestry can lead to an alteration of the risk, since the frequency of 
genotypes may differ among ethnicities. The minor allele frequency (MAF) for the CFH rs1061170 
variant in the Easy-DNA and GTL tests was set at 17% for those with Tuscan ancestry. MAF for this 
variant varies among ethnicities: ~36% in Europeans and Africans, ~17% in Latinos/Hispanics and 
~10-15% in Asians47. Tuscans cluster more closely with northern/western Europeans than with 
Latinos/Hispanics (Supplementary Figure 1), and literature indicates that the actual MAF of the CFH 
rs1061170 variant in an Italian population is also 36%48. Therefore, these companies should have used 
a MAF of 36% rather than 17% for European Tuscans. Not using the correct MAF resulted in higher 
risks since all risks per SNP have been adjusted for the average risk of the SNP in the population, which 
can be calculated using the risk per genotype and genotype frequency. This effect is particularly 
visible in the risks for individual 1 (Table 3); risks provided by Easy-DNA used the European ancestry 
as reference population and a MAF of 36% resulting in an RR of 1.26, while GTL used the European 
Tuscan ancestry with a MAF of 17% resulting in a higher RR of 1.60. For carriers of the CFH rs1061170 
CC-genotype this difference in risk will be even more extreme. In summary, an incorrect reference 
population was assigned to the three individuals and to this reference population (Tuscans) an 
incorrect MAF for the CFH rs1061170 SNP was assigned. In this particular case the largest effect on 
risk prediction of AMD was the incorrect assigned MAF. This most likely influenced the risk prediction 
for the other diseases predicted by the companies as well.
Third, there were mistakes in assignment of an AMD risk variant. Easy-DNA and GTL stated that the 
tested SNP rs800292 was located in the C2 gene, when in fact this particular rs-number is located in 
the CFH gene49. Apart from the incorrect gene, the direction of the risk for this variant was opposite 
of that reported in 3CC22; in the tests from Easy-DNA and GTL the T allele was set as the risk variant, 
increasing the risk of AMD, while in 3CC this allele decreased the risk of AMD.
Fourth, the DTC-tests lacked inclusion of non-genetic risk factors. Only 23andMe took age and gender 
into account in their risk calculation. Age is the most important non-genetic factor associated with 
AMD known to date, and it is therefore prudent to incorporate this factor in risk predictions of AMD 50. 
None of the companies included environmental factors in their risk prediction. We recommend 
inclusion of smoking since this factor is an important environmental risk factor for AMD51, which also 
shows interaction with genetic risk variants40. Inclusion of non-genetic risk factors can improve the 
predictive ability of the test22.
Lastly, the companies applied different methods for their risk calculation. A recent study examined 
and compared the methods from three DTC-tests (23andMe, deCODEme and Navigenics) for several 
diseases including AMD23. The authors showed that the formulas used by deCODEme can lead to a 
predicted risk exceeding 100% in high risk cases. The formulas used by 23andMe followed the Bayes’ 
theorem preventing risks to exceed 100%, leading to more realistic risk estimates. Unfortunately, 
methods for risk calculation were not provided by Easy-DNA or GTL, and could therefore not be 
evaluated.
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Recently, many companies stopped offering DTC-tests. Several issues played a role. First, the 
Food and Drug Administration (FDA) questioned the evidence of the safety and efficacy of these 
prediction tests52. Second, it was unclear what actions the individual will take when made aware 
of his/her genetic profile. Third, health care professionals lacked guidelines for counselling and 
patient management after genetic profiling. Do these issues apply to DTC-tests for AMD? Our 
study encountered no genotyping errors. Nevertheless, predictions were inaccurate based on 
methodology. It is indeed unclear what an individual should do when diagnosed with a high genetic 
risk of AMD, and what a clinician should advise such patients. Cessation of smoking and lowering 
BMI is advice which applies to all persons. However, it is likely that individuals who have been made 
aware of a high genetic risk after testing will be more motivated to make drastic life style changes 
than persons who are ignorant.
Although genetic testing for prediction of disease risk is the next step to personalized medicine, the 
current state of the art is that most DTC-tests are accurate at genotyping, but not at risk prediction. 
Improvement can be achieved by incorporation of a more comprehensive set of genetic markers 
with population-based risks. Inclusion of non-genetic risk factors, a more adequate choice of the 
reference population, and implementation of valid methodology for risk calculation will further 
improve these tests. Only then will these genetic tests become suitable for clinical practice.
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The aim of this thesis was to expand our genetic and epidemiological knowledge of age-related 
macular degeneration (AMD), in order to gain more comprehension of the pathogenesis of AMD. 
This general discussion will summarize and review the most important findings described in this 
thesis and their clinical relevance, discuss methodological considerations, and provide suggestions 
for future research.
MAIN FINDINGS AND CLINICAL RELEVANCE
Burden of AMD
Although the prevalence of AMD in the Western World has been studied extensively in large studies,1,2 
estimates in Europe were based on single studies and a clear overview for Europe was lacking.3 Thus 
far, only a few small studies have described the prevalence of AMD in Europe and its’ relation to visual 
decline.4-6 We therefore investigated the prevalence of AMD over two decades in Europe in Chapter 2.1 
and observed a decreasing prevalence of AMD after the year 2006. This was also seen in other 
studies7,8 and is most likely due to increase of awareness9 and improved lifestyle in the elderly.10,11 
However, the projections we made for the year 2040 indicate that, although age-specific prevalences 
may be decreasing, that the actual number of affected persons with AMD will increase due to the 
aging population, resulting in more affected elderly in Europe than residents currently living in the 
Netherlands.
In Chapter 2.2 we have shown that AMD is the major cause of visual impairment and blindness in an 
elderly population. Visually impaired persons, due to AMD, experience a significantly reduced quality 
of life.12 For society, both visual impairment and blindness cause a considerable economic burden.13 
Annual expenses are inversely correlated with visual acuity; for blind patients costs are almost two-
fold the costs for non-blind patients. Costs are even expected to increase due to the aging population. 
Even though, improved diagnostics and the introduction of anti-vascular endothelial growth factor 
(VEGF) therapy have most likely resulted in fewer visually impaired eyes,14 studies indicated that long 
term visual prognosis after anti-VEGF treatment often show substantial visual decline.15,16 However, 
all improvement in visual outcome, even for a short period, will decrease demands on healthcare and 
costs. Therefore, anti-VEGF therapy should still be continued, since it improves visual outcome on 
the short term.15,16 Our data indicates that AMD is still a major health problem and a more profound 
solution is needed, since long lasting effects of the current therapy is insufficient.
Environmental and phenotypical risk factors of AMD
Risk factors have been investigated to identify those at risk, predict disease outcome and help 
elucidate the complex pathogenesis of AMD. These factors can also be used for screening and 
modifiable factors may even alter disease onset and outcome. As stated in Chapter 1.1 many risk 
factors for AMD were known before the onset of this thesis. Yet, we were able to identify a new 
risk factor for AMD: thyroid hormone. Previous studies identified a positive relationship of thyroid 
medication use17,18 or self-reported hypothyroidism19 associated with a higher risk of AMD. However 
all of these studies were lacking laboratory assessment of thyroid function, and were therefore 
unable to investigate the true relationship. In this thesis we have shown that higher values of free 
thyroxine, even within the normal range, were associated with an increased risk of AMD and retinal 
pigment alterations (Chapter 4.3). Higher levels of free thyroxine can increase metabolism leading 
to oxidative stress, which plays an important role in the pathogenesis of AMD (Figure 1). 20,21 Our 
findings were partly confirmed by the Blue Mountains Eye study. They found a significant positive 
association of overt hyperthyroidism and 10-year incidence of AMD. No association was found for 
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hypothyroidism, but use of thyroxine medication was significantly associated with an increased risk 
of AMD. Both findings seem to be driven by higher free thyroxine levels. Unfortunately, no association 
was found for free thyroxine levels and incident AMD. However, the number of cases in their study 
was small, since data was only available for 5-year incidence of AMD.22 More studies are necessary to 
understand the exact role of thyroid hormone in the pathogenesis of AMD and maybe in the future 
thyroid hormone can be used as a biomarker for AMD.
An important modifiable risk factor is dietary intake. Several studies focusing on dietary intake and 
supplementation of nutrients have shown that in particular carotenoids, zinc, and omega-3 fatty 
acids were associated with a lower risk of AMD. These nutrients are mainly present in dark-leafy 
vegetables, yellow-orange vegetables and fruit, fortified cereal, meats and fatty-fish. (Chapter 4.1) 
Unclear was what the recommended minimum intake of these foods should be to obtain this 
protective effect. In this thesis we have shown that a diet including at least 200 grams of vegetables 
a day, 2 large pieces of fruit a day and 2 times fish per week is associated with a reduced risk of AMD. 
No significant association was found for the intake of grains or meats with AMD (Chapter 4.2). The 
beneficial effect from vegetables, fruit and fish intake on AMD is most likely due to carotenoids, in 
vegetables and fruit, and omega-3-fatty acids in fish. Higher intake of these nutrients could also reduce 
the overall risk of AMD in those with a high genetic risk (Chapter 5.3). Carotenoids, in specific lutein 
and zeaxanthin, are important for macular pigment. The macular pigment is highly concentrated 
with these carotenoids and offer protection to the retina by absorbing hazardous ionizing blue 
and ultraviolet light. Furthermore, it has antioxidant properties and has anti-inflammatory effects.23 
Polyunsaturated fatty acids, like omega-3-fatty acids, are one of the main components of the 
retina. They are highly present in the photoreceptor outer segments and improve fluidity of the 
photoreceptor membranes, resulting in faster response to stimulation. Additionally, omega-3-fatty 
acids may also protect against ischemia, and have antioxidant and anti-inflammatory properties.24 
Both oxidative stress and inflammation are part of the pathogenesis of AMD (Figure 1).20,21 Other 
modifiable risk factors associated with AMD are smoking and body mass index. Cardiovascular risk 
factors may be associated with AMD, although findings have been inconclusive.21,25
Regarding the modifiable risk factors, clinicians should advice patients at risk of AMD, for example 
those with a positive family history, to adopt a healthy life-style. This should include physical exercise, 
a diet with recommended intake of vegetables, fruit and fish, have a normal body mass-index and 
quit smoking, the latter if applicable.
Reticular pseudodrusen (RPD), also known as subretinal drusenoid deposits, have been identified 
as an important clinical risk factor for progression to late AMD. Those with RPD have a higher risk 
compared to other drusen types.26-28 Presence of RPD is often bilateral and the highest prevalence 
is found in late AMD cases.29 Identification of persons at high risk for late AMD can be important 
for patient management. Chapter 3.1 and 3.2 provide evidence that near-infrared imaging was 
the most sensitive for detection of RPD of the tested imaging modalities. Detection improved even 
further when multi-modal imaging was applied. We also found that RPD was associated with a 
different risk profile compared to soft indistinct drusen, another drusen type which coincide often 
with RPD. These findings indicate that RPD are distinct AMD entities.
In neovascular AMD, antiplatelet and anticoagulant (AP/AC) use may potentially worsen clinical 
outcomes, leading to more severe hemorrhages and increase fibrovascular scarring.30 A question 
often asked in the clinic is whether AP/AC therapy should be discontinued in patients with 
neovascular AMD. In Chapter 4.4 we show that the use of AP/AC therapy in patients with active 
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choroidal neovascularization is not associated with visual impairment, nor the presence of retinal 
hemorrhages. We could not find an association of AP/AC use with choroidal neovascularization 
(CNV) lesion size. For retinal foveal thickness a borderline significant association was found for 
aspirin use only. After the start of anti-VEGF medication no differences were observed between users 
and nonusers. In contrast, those using AP/AC medication did not have an increased risk of visual 
impairment and had a lower risk of retinal hemorrhages. Aspirin seemed to be the major driver of the 
beneficial effect of AP/AC in our study. Beside the well-known effect on platelet aggregation, aspirin 
has anti-oxidant properties, reduces inflammation and angiogenesis, and stimulates apoptosis.31 The 
anti-oxidant, anti-inflammatory and anti-angiogenic properties may explain the found protective 
effect. Our findings imply that patients with neovascular AMD can continue their prescribed use of 
AP/AC medication without negative effects on AMD outcome.
Genetic risk factors
Even before the start of genome-wide association studies (GWAS), it was known for many years 
that heritability was an important factor in AMD.32 Only after the start of GWAS identification of 
the disease-associated risk variants became possible. Several risk variants in thirteen genes have 
been associated with AMD, by single or small collaborations between studies (Chapter 5.1). The 
associated genes were part of the complement pathway (CFH, CFB/C2, C3, CFI), lipid related genes 
(APOE, LIPC, CETP), collagen related genes (COL8A1, COL10A1) and other genes (ARMS2, VEGFA, TIMP3, 
TNFRSF10A). The AMD gene consortium conducted a GWAS including ~17,100 advanced AMD cases 
and ~60,000 controls, and confirmed the previous associations and identified seven new loci (COL8A1-
FILIP1L, IER3-DDR1, SLC16A8, TGFBR1, RAD51B, ADAMTS9, B3GALTL) (Chapter 5.2). All nineteen risk 
variants were common and involved in complement activity, lipid metabolism, extracellular matrix 
remodeling and angiogenesis.
More recently, The AMD Gene Consortium published their results using exome chip data from 
~16,100 cases with intermediate or late AMD and ~17,800 controls.33 In total 52 independently 
associated variants in 34 loci were identified, of which 17 loci were replicated from the previously 
mentioned GWAS. The associated variants were mostly common, seven were rare variants. Four 
genes had a significant disease burden: CFH, CFI, TIMP3 and SLC16A8, indicating a causal role for these 
genes. Pathway analyses identified complement, collagen, lipid and extracellular matrix pathways to 
play a role in the pathogenesis of AMD. The heritability of AMD has been determined to be between 
65-70%.34,35 All identified risk variants to date explain approximately 27.2% of disease variability, of 
which 1.4% is contributed by rare variants. This means that approximately 40% of the heritability 
is not explained by the identified genes. The missing heritability might be explained by additional 
genetic variation36, gene-gene or gene-environment interactions.
Identification of risk factors has helped to understand more of the pathogenesis of AMD. This 
information can be used to develop future therapies, but also to identify those at high risk. In Figure 1, 
risk factors for AMD discussed in this this thesis have been incorporated to provide an overview of 
the pathogenesis of AMD.
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FIGURE 1 - Pathogenesis of AMD.
Simplified scheme of the pathogenesis of AMD. Black arrows are the steps in the pathogenesis, red arrow 
displays risk increasing factors, green arrow displays risk reducing factors. Dotted arrows indicate a potential 
relationship.
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Prediction of AMD
In Chapter 6.1 we have provided an overview of previous reported prediction models for late AMD. 
All of these models were based on a case-control study design, in which the extreme ends of disease 
are compared, while excluding the majority of the population with signs of early AMD. We developed 
a prediction model in the population-based Rotterdam Study and validated it in the Three Continent 
AMD Consortium. The full model included the variables: age, sex, smoking, body mass index, baseline 
AMD phenotype, and 26 common risk variants in genes associated with AMD. This model could 
distinguish those who will develop late AMD between those who will not, with an accuracy of 87%. 
Exclusion of variables led to a lower predictive value. Subsequently we showed that the cumulative 
risk of developing late AMD is approximately 17% at the age of 90 years. Using our prediction model, 
the cumulative risk for seven risk categories, ranged from zero to almost 66% at the age of 90 years. 
This indicates that a prediction test can help to identify those at high risk of late AMD.
Although published prediction models led to several web-based risk calculators for prediction of 
late AMD (http://caseyamdcalc.ohsu.edu37; http://www.myvisiontest.com/riskcalc2.php38; http://
www.sightrisk.com) and progression of AMD (www.seddonamdriskscore.org39), implementation in 
the clinic will be difficult, since most of these risk calculators need genetic data beside information 
on lifestyle and phenotypical factors. Currently, there is no easy accessible, inexpensive genetic test 
available for AMD, which tests all known associated genetic variants. There are, however, companies 
offering genetic tests for AMD, which can be purchased on the internet. We have tested the direct-to-
consumer personal genome tests for genotyping quality and accuracy of risk prediction of AMD in 
Chapter 6.2. The genotyping was of high quality, but the risk prediction was not accurate. Inclusion 
of more genetic and environmental risk factors for AMD will improve future tests. Interestingly, from 
the tested companies, one stopped offering genetic tests shortly after we had received our results, 
one offers raw genotype data only, and two companies are currently not offering any tests for AMD.
The costs of sequencing has dropped in a rapid pace over the past years. Sequencing of an entire 
genome, was approximately $10 million in 2007, and currently available for less than $1000.40,41 
Although lower costs for genetic testing will make it more available for clinical practice, cost-
effectiveness42, the possibility of secondary findings43, psychological and decision making risks, all 
need to be addressed before it can be applied for routine genetic testing in AMD as long as no cure 
is available.44
METHODOLOGICAL CONSIDERATIONS
Within this thesis, relevant methodological issues have been addressed in the discussion sections of 
each chapter. Here, we will discuss some general methods and issues we encountered.
Phenotyping issues
The studies described in this thesis have different outcomes, mostly: 1) late AMD, 2) early AMD, 3) any 
AMD, both late and early AMD combined. Late AMD is the visual threatening end-stage of the disease, 
due to a low prevalence in the general population, the power to investigate some associations has 
been challenging. Early AMD is mostly asymptomatic, but more frequently present in the general 
population compared to late AMD. However, several characteristics describe early AMD, leading to 
a large variation of phenotypes. A possibility to increase power is to collaborate with other studies, 
however phenotypical issues could reduce the power. For the collaboration with the Three Continent 
AMD Consortium we harmonized our classification to minimize differences in AMD definitions, which 
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was predominantly the case for early AMD.45 This resulted in a new 5-step AMD severity scale, which 
was used in Chapter 5.3, and 6.1. To increase power for analyses restricted to the Rotterdam Study, 
we mainly used the outcome any AMD.
Another phenotypical issue is improved detection of AMD lesions with multimodal imaging 
compared to color fundus photographs (CFP) only. Differences in detection may lead to changes in 
prevalence and incidence of AMD. For instance, in Chapter 3.1 and 3.2 we showed that detection of 
RPD was better using near-infrared imaging, and the best results were obtained using multi modal 
imaging. This also accounts for other AMD lesions.46-49 Nevertheless, CFP have been the golden 
standard for AMD grading in epidemiological studies, including the Rotterdam Study.50-52 Many new 
techniques have been developed and since 2007, when high resolution imaging was available,53 
imaging techniques like optical coherence tomography (OCT), near-infrared and auto fluorescence 
imaging, have been incorporated in the Rotterdam Study beside CFP. Unfortunately, a consensus for 
grading and classification of these pathologies using imaging other than CFP is lacking.
Genetics
Since the start of the GWAS era, thousands of genetic variants associated with complex diseases and 
traits have been identified successfully.54 However, these types of analyses have limitations: large 
sample sizes are mostly needed to increase the power to find associations. This requires collaborations 
between different studies and could introduce phenotypical and genetical heterogeneity, limiting 
the possibility to find associations. Furthermore, the found association is in most cases a marker 
in high linkage disequilibrium with the causal variant. Identification of the causal variant can be 
difficult due to many or no genes near the associated marker. Identification of the causal variants 
is necessary, since it helps to identify the true relationship with the disease and may provide a drug 
target. In Chapter 5.2 we identified 19 common variants associated with AMD using GWAS data 
from 33 different studies. The heterogeneity was high for some associations, and most likely due 
to differences in methodology and ancestry of study populations (Asian and European descent). 
Of the previously identified loci, 17 were replicated in the most recent study from the AMD gene 
consortium using genomic data from 26 different studies.33 Exome chip data was enriched for the 
previously identified loci and imputed with 1000 genomes data, to increase the chance of finding 
causal risk variants in protein-coding regions of the DNA, also known as the exome. All study samples 
were genotyped at the same facility, which led to a reduction of heterogeneity. The study using 
exome chip data was executed with a larger amount of variants, but with a lower number of cases 
and controls in comparison to the GWAS. Many new risk variants, including rare variants, were 
identified in the recent study, and explained more of the phenotypical variance. However, these 
newly identified variants were involved in largely the same pathways which were also identified in 
the GWAS and there is still missing heritability.
FUTURE DIRECTIONS
The studies described in this thesis have provided new insights in the pathogenesis of AMD. However, 
there are still many questions that can be answered by future studies.
As a start, identifying the missing heritability of AMD could help to understand the complete genetic 
architecture of AMD. Many genes involved in several pathways have been identified, but we are not 
there yet. For instance, it is unknown what the exact function of the ARMS2 gene is and which role 
it plays in the pathogenesis of AMD, although the risk variant in this gene has the most significant 
association of all common variants associated with AMD.33 Unidentified risk variants, gene-gene 
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and gene-environment interaction could help to understand the role of identified genes and 
identify the missing heritability of AMD. For identification of novel risk variants it is difficult to state 
which approach would be the most successful, since several strategies have been explored: Exome 
sequencing of families with AMD55,56 or patients with specific phenotypes,57 sequencing of previously 
associated genes,58-62 and the GWAS approach using large case-control samples for the outcomes 
early63 as well as late AMD.33 Enlargement of the study sample and whole genome sequencing might 
help to identify new risk variants for AMD.
Gene-gene or gene-environment interactions can modulate disease risk. In this thesis we have 
shown that intake of nutrients reduced the overall risk of individuals at high genetic risk based on 
gene-environment interactions (Chapter 5.3). In order to study multifactorial relationships between 
genes and environmental factors, collaboration between epidemiological studies is needed, since 
single studies are quickly outnumbered because of the many different strata in the analyses. Gene-
gene and gene-environment interactions can also be investigated in a genome-wide setting, 
so called genome-wide association gene-gene interaction and genome-wide environmental 
interaction studies. This, however, needs to be done in a large study setting with good quality of 
phenotyping and environmental data, since studies can be quickly underpowered due to countless 
possibilities of interaction combinations and misclassification may introduce bias.64,65
Newer fields of interest in AMD research have been epigenomics, transcriptomics, proteomics, 
and metabolomics. Like GWAS, omic studies are hypothesis-free, enabling association analyses at 
once in a large set of markers. Epigenomics focusses on heritable regulatory mechanisms of gene 
expression without changes in the DNA sequence. Transcriptomics conveys gene expression and 
noncoding RNAs like microRNAs, which are small RNA molecules that regulate gene expression 
after transcription. Proteomics focusses on peptides or proteins and in metabolomics derivatives 
of metabolism are measured and analyzed. Several small studies using these new techniques have 
published interesting results, however findings need to be replicated in independent studies.21,66 The 
most interesting of these new techniques are proteomics and metabolomics. These techniques may 
help to understand what is actually happening in a patient with AMD. Beside data acquired from 
plasma or serum, which is much easier to obtain from the patient, ocular tissue and fluids of patients 
with AMD in various stages of the disease are also necessary, since these are closer to the location 
of the disease. Proteomics and metabolomics may help to identify potential biomarkers, find new 
pathways and link current pathways together. Epigenomics and transcriptomics are also interesting, 
but might be of more interest in a later stage, when more of the pathogenesis of AMD is understood. 
These techniques focus on regulatory mechanisms and may help to understand for example the 
influence of environmental factors on gene expression.
Many different imaging techniques of the posterior pole are available and improvement of current 
and development of newer techniques is ongoing. For example in OCT imaging many different 
methods have been developed, and the latest is OCT angiography.67 This provides a non-invasive 
technique for visualization of functional blood vessels in the eye and is potentially interesting for 
neovascular AMD. However, as stated earlier, a consensus for grading and classification of imaging 
other than CFP is lacking. Currently, we are working on a consensus for OCT grading of macular 
diseases within the E3 consortium.
Manual grading of images is time-consuming, which is one of the reasons that automatic grading 
with machine learning algorithms have been developed for different image modalities.68-71 This 
field is still under development and the predictive power of the machine learning algorithms 
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depend on the size and quality of the dataset.69 Consensus of grading and classification, together 
with collaboration of studies with imaging, may result in large high quality datasets, leading to 
improvement of the algorithms. Automatic grading is especially interesting for screening purposes, 
which has successfully been used for detection of diabetic retinopathy.70 Early detection of AMD 
in persons without any symptoms, may identify those at risk of late AMD, increase awareness and 
lead to positive life-style changes. Another opportunity for machine learning is development of 
prediction models. Currently there models available for prediction of drusen regression72, which is 
associated with development of late AMD, and prediction of anti-VEGF treatment needs73, which 
may help to determine individual treatment intervals. When these prediction models will become 
available for clinical application, this can lead to a substantial improvement of AMD management.
Systems biology can help to link all the pieces together. It is a powerful computational and 
mathematical method of modeling complex diseases to comprehend complex interactions within 
biological systems. For example, in systems biology data on phenome, genome, epigenome, 
transcriptome, proteome, interactome, and metabolome can be integrated to assemble models and 
pathways, which can help explain the pathogenesis of AMD.74
The ultimate goal is to identify patients at an early stage, obtain insights in individual risk profiles and 
how to modulate these, monitor progression of the disease, and measure treatment response, all 
with a simple test. However, before this test will have added value, there is need for better treatment 
options. Understanding the pathogenesis of AMD will help to provide drug targets and understand 
how to prevent progression to visual threatening late AMD.
Currently, many ongoing trials are investigating different therapeutic options.75-78 For neovascular 
AMD the main focus is to decrease treatment burden. Implants providing constant release of 
anti-VEGF are being tested. New anti-VEGF agents have been developed, but also anti-platelet 
derived growth factor and anti-angiopoietin agents are interesting therapies, because of their anti-
angiogenic effect. These new agents are mostly tested in combination with anti-VEGF therapy. Gene 
therapy might be another option to reduce treatment burden. A viral vector containing the code for 
the VEGF receptor is administered via subretinal injections and then expressed by the host retinal 
cells. This reduces the effect of VEGF in the eye with a longer duration compared to current treatment 
with anti-VEGF.
Since no treatment options have been available for geographic atrophy (GA) or early AMD, many 
trials have been focusing on this type of AMD with the main goal of preservation of vision. Ongoing 
trials can be divided in five categories: 1) neuroprotective agents, 2) anti-inflammatory agents, 3) 
lipofuscin and visual cycle inhibitors, 4) choroidal blood flow restoration agents, 5) stem cell therapy. 
Most of these trials have completed phase I or II and a few started phase III. The first results of most 
of these trials have been promising, in particular for stem cell therapy. Human embryonic stem cells 
were injected in the subretinal area, which improved visual acuity in the injected eyes of patients 
with geographic atrophy.79,80 However, larger studies with follow-up measurements are needed 
before some of these therapeutic options will be used as a treatment for AMD.
The latest results of the phase III trial investigating the safety and efficacy of lampalizumab, which 
is an antibody selectively inhibiting complement factor D, was less promising.81 The first results 
did not show a difference in mean GA lesion area in comparison to the sham injection. The target, 
complement factor D, was chosen carefully: genetic studies have indicated that the complement 
system, in particular the alternative pathway in which factor D plays a role, is involved in the 
pathogenesis of AMD. It could be that once geographic atrophy starts to develop, there is no way 
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back. A recent study observed that before GA is visible, small disruptions of the retinal anatomy occur, 
which are best visualized on OCT.49 These disruptions include subsidence of the outer plexiform and 
inner nuclear layers, while the retinal pigment epithelium is still intact. This stage is named nascent 
GA and eventually will result in loss of photoreceptor and retinal pigment epithelial cells, which are 
characteristics of GA. Thus, treatments targeting the complement system might have more success 
when tested in patients with early signs of AMD, since the complement system plays a major role in 
drusen formation.82 Nevertheless, patients with early AMD are mostly asymptomatic, but at risk of 
visual threatening end stage disease. Whether these patients should be treated or not is a difficult 
discussion. As a start, future studies focusing on treatment of early AMD could start with those at 
high risk of developing late AMD.
CONCLUDING REMARKS
AMD is a chronic complex disease and still the leading cause of blindness in the Western World. 
In this thesis we have identified genetic variants associated with AMD through an international 
collaboration of studies, which have helped to elucidate a large part of the genetic architecture 
of AMD. Furthermore, we have investigated environmental risk factors and gene-environment 
interactions, using large well-designed longitudinal studies for which we harmonized our 
methodology and grading protocols. Combining these risk factors in a prediction model offered a 
good method to distinguish between those who will develop late AMD and those who will not. 
These findings can help future studies to further unravel the pathogenesis of AMD and ultimately 
develop preventative measures for this blinding disease.
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SUMMARY 
Age-related macular degeneration (AMD) is the most common cause of irreversible vision loss in 
elderly in the Western world. AMD is characterized by drusen, pigmentary changes, geographic 
atrophy and choroidal neovascularization, which affect the normal anatomy of the macula. Early 
AMD is characterized by the first two features, and late AMD by the latter two. Although several 
demographic, genetic, and environmental risk factors have been identified, the etiology of AMD is 
still largely unknown.
The main objectives described in this theses were: 1) assess frequency and impact of AMD, 2) 
evaluate the merit of new imaging techniques for diagnosis and risk assessment, 3) identify new 
environmental risk factors for AMD, 4) investigate genetic associations and gene-environmental 
interactions, 5) assess predictive value of risk factors associated with AMD.
Our study population included the population-based Rotterdam Study, population-based studies 
from the Three Continent AMD Consortium and from the European Eye Epidemiology (E3) 
Consortium, double blind randomized-controlled multicenter trial BRAMD study, and population-
based and case-control studies from the AMD Gene Consortium.
Chapter 1 provides a general introduction to AMD and describes the main aims of this thesis. 
Chapter 2 discusses the frequency and impact of AMD. In Chapter 2.1 we investigated the 
prevalence of AMD in Europe over the past two decades using 14 population-based studies from the 
E3 Consortium. The frequency of AMD increases with age; overall prevalence of early AMD and late 
AMD was 13.2% and 3.0%, respectively, in those aged 70 years and older. We observed a decreasing 
age-specific prevalence of late AMD. We also observed a decreasing number of visually impaired 
eyes and persons due to choroidal neovascularization after 2006, most likely due to improved 
diagnostic procedures and introduction of anti-vascular endothelial growth factor therapy. We also 
made projections for the year 2040, and predicted that the actual numbers of affected persons will 
still increase. Europe will reside more affected elderly persons, than residents currently living in 
the Netherlands. In Chapter 2.2 we studied the causes of blindness and low vision in relation to 
refractive error using the Rotterdam Study data. We found that the major cause of visual impairment 
in all refractive categories, except for high myopia (spherical equivalent ≤ -6D), was AMD.
In Chapter 3, we explored diagnostic properties for detection of reticular pseudodrusen (RPD) in 
AMD using different imaging techniques and investigated the risk profiles of RPD in a population-
based setting. In Chapter 3.1, we describe the epidemiology of RPD in the Rotterdam Study. We 
showed that detection of RPD was better on near-infrared imaging than on color fundus photographs. 
Subsequently, we assessed demographic, environmental, and genetic risk factors for RPD versus soft 
indistinct drusen, since these drusen types coincide frequently. Several demographic and several 
genetic (ARMS2, C3, VEGFA) risk factors were more associated with RPD than soft indistinct drusen. 
Indicating that these features are distinct AMD entities. Chapter 3.2 proposes an automatic system 
for RPD quantification, which showed similar performance of RPD detection as human graders. The 
study also indicated that multimodal imaging improves detection of RPD for both automatic as 
human grading.
In Chapter 4, we explored risk factors for AMD. We provided an overview of investigated nutrients 
and their associations with AMD in Chapter 4.1. In particular carotenoids, zinc and omega-3 fatty 
acids were associated with a reduced risk of AMD. Diet recommendations from the Dutch food center 
were studied in Chapter 4.2, using data from the Rotterdam Study. Recommended intake of at least 
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200 grams of vegetables a day, 2 large pieces of fruit a day and 2 times fish per week, was associated 
with a reduced the risk of AMD of 42%. However, only 3.5% of the studied population met these 
recommendations. Chapter 4.3 shows that higher values of free thyroxine, even within the normal 
range, are associated with an increased risk of AMD and retinal pigmentary alterations in the macula, 
suggesting a role for thyroid hormone in the pathway of AMD. Chapter 4.4 shows that in the double 
blind randomized-controlled multicenter trial BRAMD study, usage of antiplatelet or anticoagulant 
drugs in active choroidal neovascular AMD did not negatively affect visual outcome, nor presence of 
retinal/subretinal hemorrhages, lesions size, or retinal thickness. From our study, we concluded that 
continuation of antiplatelet or anticoagulant therapy in patients with active choroidal neovascular 
AMD is not contraindicated.
Chapter 5 focusses on genetic risk factors and gene-environment interactions in AMD. Chapter 5.1 
discusses the knowledge about the genetic background of AMD. Most of the genetic risk of AMD can 
be explained by two genes, CFH and ARMS2. In Chapter 5.2, seven new loci for AMD were identified, 
using a large-scale genome wide association study meta-analysis, which was established in the AMD 
Gene consortium. These loci were located near the genes: COL8A1, IER3-DDR1, SLC16A8, TGFBR1, 
RAD51B, ADAMTS9 and B3GALTL, which are involved in complement activity, lipid metabolism, 
extracellular matrix remodeling and angiogenesis. Chapter 5.3 shows that higher intake of lutein 
and zeaxanthin, and weekly consumption of fish, could reduce the overall risk of AMD in individuals 
with a high genetic risk, based on two or more risk variants in major AMD genes (CFH, ARMS2). This 
was observed in two population based studies from the Three Continent AMD Consortium. These 
findings can enable personalized preventive interventions.
In Chapter 6, we discuss prediction and personal genome testing. In Chapter 6.1 we studied the 
predictive value of various prediction models based on demographic, genetic and environmental 
data in the Rotterdam study, and validated this in the Three Continent AMD Consortium. We 
found that the full model, including age, sex, 26 single nucleotide polymorphisms in AMD risk 
genes, smoking, body mass index and baseline AMD phenotype had the best predictive value. The 
prediction model could distinguish between those who will develop late AMD and those who will 
not with an accuracy of 87%. In Chapter 6.2 we tested direct-to-consumer personal genome tests 
available on the internet. Although the genotyping was of a high quality, these tests appeared not 
yet suitable for clinical application, as risk prediction was not accurate. Inclusion of more genetic and 
environmental risk factors for AMD will improve future tests.
Lastly, Chapter 7 provides a general interpretation and implication of these main findings. This 
chapter also addresses methodological considerations, clinical implications, and suggestions for 
future research.
To conclude, the studies described in this thesis have investigated several aspects of AMD. We have 
identified new genetic variants and risk factors, which may lead to new insights in the complex 
pathogenesis of AMD, and eventually to new directions for treatment and/or preventive measures.
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Leeftijdsgebonden maculadegeneratie (LMD) is de meest voorkomende oorzaak van slechtziendheid 
bij ouderen in de Westerse Wereld. LMD wordt gekenmerkt door drusen, pigment veranderingen, 
verdunning van het netvlies (geografische atrofie) en vorming van nieuwe bloedvaten (choroïdale 
neovascularisaties) waardoor de normale anatomie van de macula verloren gaat. De eerste twee 
kenmerken zijn de karakteristieken voor vroege LMD en de laatste twee voor late LMD. Hoewel er 
meerdere demografische, genetische en omgevingsfactoren gevonden zijn die een rol spelen in het 
ontstaan van LMD, is de etiologie van LMD nog steeds grotendeels onbekend.
De belangrijkste vragen die dit proefschrift beoogt te beantwoorden waren: 1) Hoe vaak komt LMD 
voor en wat zijn de gevolgen hiervan? 2) Welke nieuwe beeldvormende technieken zijn nuttig 
voor de diagnostiek van LMD? 3) Welke nog onbekende omgevingsfactoren spelen een rol in het 
ontstaan van LMD? 4) Welke genetisch en gen-omgevingsfactoren veroorzaken LMD? 5) Hoe goed 
kunnen reeds bekende risicofactoren LMD voorspellen?
Onze studiepopulatie bestond uit het Erasmus Rotterdam Gezondheid Onderzoek (ERGO, ook wel 
Rotterdam Studie genoemd), bevolkingsonderzoeken van het Three Continent AMD Consortium 
en van het European Eye Epidemiology (E3) Consortium, de BRAMD studie, een dubbelblinde 
gerandomiseerde gecontroleerde trial, en bevolkingsonderzoeken, patiënt-controle en patiënt 
studies van het AMD Gene Consortium.
Hoofdstuk 1 geeft een algemene introductie over LMD. Hoofdstuk 2 geeft weer hoe vaak 
LMD voorkomt en wat de gevolgen hiervan zijn. In Hoofdstuk 2.1 hebben we onderzocht hoe 
vaak LMD voorkomt in Europa in de laatste twee decennia. Hiervoor hebben we data van 14 
bevolkingsonderzoeken van het E3 Consortium gebruikt. De frequentie van LMD neemt toe met de 
leeftijd; in deelnemers van 70 jaar en ouder bleek 13.2% vroege LMD en 3.0% late LMD te hebben. 
Verder vonden wij dat de leeftijdsspecifieke frequentie van late LMD afnam na het jaar 2006. Ook 
bleek het aantal blinde en slechtziende ogen door choroïdale neovascularisaties af genomen te 
zijn, waarschijnlijk door verbeterde diagnostische technieken en introductie van anti-vasculaire 
endotheliale groeifactor, een behandeling tegen bloedvat nieuwvormingen in het netvlies. Ondanks 
deze dalende frequentie laten de projecties voor het jaar 2040 zien dat het werkelijke aantal 
aangedane personen zal toenemen. Dit betekent dat het totale aantal aangedane ouderen door 
LMD in Europa, het aantal inwoners van Nederland zal overschrijden. In Hoofdstuk 2.2 hebben we 
de oorzaken van blindheid en slechtziendheid in relatie tot refractieafwijkingen bestudeerd binnen 
het ERGO onderzoek. We vonden dat de belangrijkste oorzaak van blindheid en slechtziendheid LMD 
was. Dit was onafhankelijk van refractieafwijkingen, met uitzondering van hoge myopie (sferisch 
equivalent van -6 D of meer) waar myope maculadegeneratie de belangrijkste oorzaak was.
In Hoofdstuk 3 hebben we naar verschillende aspecten van beeldvormende technieken voor het 
diagnosticeren van reticulaire pseudodrusen (RPD) gekeken en onderzochten de risicoprofielen van 
RPD in kader van LMD. In Hoofdstuk 3.1 beschrijven we de epidemiologie van RPD in het ERGO 
onderzoek. We hebben aangetoond dat detectie van RPD beter was op nabij-infraroodbeelden dan 
op kleurenfundusfoto's. Vervolgens hebben we demografische, genetische en omgevingsfactoren 
voor RPD versus zachte drusen geanalyseerd, aangezien deze soorten drusen vaak samen voorkomen. 
Demografische factoren (leeftijd en geslacht) en verschillende genetische factoren (ARMS2, C3, 
VEGFA) waren meer geassocieerd met RPD dan met zachte drusen. Deze bevindingen suggereren 
dat RPD een op zichzelf staande entiteit is binnen LMD. Hoofdstuk 3.2 beschrijft automatische 
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kwantificatie van RPD, die evengoed als humane gradeerders de aanwezigheid van RPD vast stelt. 
Verder komt uit deze studie voort, dat multimodale beeldvorming de detectie van RPD, voor zowel 
automatische als humane gradering verbetert.
In Hoofdstuk 4 hebben we risicofactoren voor LMD onderzocht. We hebben een overzicht gegeven 
van de verschillende voedingsstoffen die bestudeerd zijn in relatie tot LMD in Hoofdstuk 4.1. Met 
name carotenoïden, zink en omega-3 vetzuren waren geassocieerd met een lager risico van LMD. 
Dieetaanbevelingen van het voedingscentrum zijn onderzocht in Hoofdstuk 4.2, met behulp van 
het ERGO onderzoek. Er werd aangetoond dat de aanbevolen inname van tenminste 200 gram 
groenten per dag, 2 grote stukken fruit per dag en 2 keer per week vis, het risico op LMD met 42% 
kan verminderen. Echter, slechts 3,5% van de ouderen behaalde de geadviseerde minimale inname. 
Hoofdstuk 4.3 laat zien dat hogere waarden, die nog binnen de normale spreiding vallen, van 
vrije thyroxine geassocieerd zijn met een verhoogd risico op LMD en pigment veranderingen in de 
macula. Deze bevindingen suggereren een rol voor schildklierhormoon in de pathogenese van LMD. 
Hoofdstuk 4.4 toont aan dat in de BRAMD studie het gebruik van thrombocytenaggregatieremmers 
of anticoagulantia bij actieve choroïdale neovascularisaties, in het kader van LMD, geen negatieve 
invloed heeft op de visus, noch op retinale / subretinale bloedingen, laesiegrootte of retinale dikte. 
Uit deze studie kunnen we concluderen dat het doorgebruiken van deze medicatie bij patiënten met 
actieve choroïdale neovascularisaties in het kader van LMD, niet gecontra-indiceerd is.
Hoofdstuk 5 richt zich op genetische risicofactoren en gen-omgevingsinteracties geassocieerd met 
LMD. Hoofdstuk 5.1 geeft een samenvatting van de genetische achtergrond van LMD. Het grootste 
deel van het genetische risico van AMD kan verklaard worden door slechts twee genen, namelijk 
CFH en ARMS2. In Hoofdstuk 5.2 werden zeven nieuwe genetische varianten geïdentificeerd voor 
LMD met behulp van een grootschalige meta-analyse van genoomwijde associatie studies binnen 
het AMD Gene consortium. Deze varianten bevinden zich nabij de genen: COL8A1, IER3-DDR1, 
SLC16A8, TGFBR1, RAD51B, ADAMTS9 en B3GALTL. Deze genen zijn betrokken bij diverse processen, 
waaronder de complement cascade, lipide metabolisme, weefselstructuren en het vormen van 
nieuwe bloedvaten. Hoofdstuk 5.3 laat zien dat een hogere inname van luteïne en zeaxanthine 
en wekelijkse consumptie van vis het totale risico op LMD verlaagt voor personen met een hoog 
genetisch risico op basis van twee of meer risicovarianten in de belangrijke LMD genen (CFH, 
ARMS2). Dit onderzoek werd verricht in twee bevolkingsonderzoeken van het Three Continent AMD 
Consortium. Deze bevindingen zijn interessant voor counseling van individuele LMD patiënten.
In Hoofdstuk 6 bespreken we predictie en persoonlijke DNA testen. Hoofdstuk 6.1 onderzoekt de 
voorspellende waarde van verschillende predictiemodellen op basis van alle bekende risicofactoren. 
Dit is onderzocht in het ERGO onderzoek en gevalideerd in het Three Continent AMD Consortium. 
We vonden dat het volledige model, inclusief leeftijd, geslacht, 26 genetische risicovarianten, roken, 
‘body mass index’ en het LMD fenotype de beste voorspellende waarde had. Het predictiemodel 
kon met 87% zekerheid onderscheid maken tussen diegenen die wel een eindstadium LMD zullen 
ontwikkelen en diegenen die dat niet doen. In Hoofdstuk 6.2 hebben we persoonlijke DNA testen 
getest die beschikbaar waren op het internet. Hoewel de genotypering van hoge kwaliteit was, bleek 
dat deze testen niet geschikt waren voor klinische toepassingen, aangezien de risicovoorspellingen 
niet nauwkeurig genoeg waren. Daarnaast ontbraken omgevingsfactoren in de predictie modellen 
van de onderzochte testen; incorporatie hiervan zal de voorspelling ook verbeteren.
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Ten slotte geeft Hoofdstuk 7 een algemene interpretatie van deze belangrijkste bevindingen. Dit 
hoofdstuk beschrijft ook methodologische overwegingen, klinische implicaties en suggesties voor 
toekomstig onderzoek.
Concluderend, de beschreven studies in dit proefschrift hebben verschillende aspecten van LMD 
onderzocht. Wij hebben nieuwe genetische varianten en risico factoren geïdentificeerd die kunnen 
zorgen voor nieuwe inzichten in de complexe pathogenese van LMD en zullen leiden tot nieuwe 
richtlijnen voor behandelingen en/of maatregelen ter voorkoming van deze ziekte.
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Name PhD student:  Gabriëlle H.S. Buitendijk
Departments:  Ophthalmology / Epidemiology
Research School:  Netherlands Insititute for Health Sciences
PhD-period:  2010-2017
Supervisors: Prof. dr. C.C.W. Klaver and Prof. dr. J.R. Vingerling
PhD Training Year
Workload
(ECTS*)
Courses
Master of Health Sciences, Genetic Epidemiology (NIHES) 2010-2012 70
Workshop on Photoshop and Illustrator CS5 (MolMed) 2011 0.3
Workshop on InDesign CS5 (MolMed) 2011 0.2
Biomedical English Writing and Communication (David Alexander) 2011 4.0
Research Integrity (prof dr. S. van de Vathorst) 2015 0.3
Seminars, symposia and workshops
Research seminars, department of Epidemiology, Erasmus MC 2010-2014 4.5
International Course Genetics in Retinal Disease, Rotterdam 2010 0.3
Myopia workshop for opticians and optometrists, Rotterdam 2011 0.3
AMD workshop for general practitioners, Rotterdam 2011 0.3
Brainstorm session Nanotechnology, Rotterdam 2011 0.3
1st European Eye Epidemiology Workshop, Bordeaux, France (oral presentation) 2011 1.0
2nd annual meeting International AMD Genetics Consortium, Bethesda, USA (oral presentation) 2011 1.0
2nd ErasmusAge & SIGN-E Workshop Basic Principles of nutritional Epidemiology, Rotterdam 2012 0.3
ARVO-NED, Utrecht (oral presentation) 2011 1.0
2nd European Eye Epidemiology Workshop, Bordeaux, France (oral presentation) 2012 1.0
CHARGE investigators meeting 2013, Rotterdam 2013 0.3
International Course Genetics in Retinal Disease, Ghent, Belgium 2013 0.3
3rd European Eye Epidemiology Workshop, Bordeaux, France (oral presentation) 2013 1.0
Patient day Juvenile Macular degeneration, Nijmegen (oral presentation) 2013 1.0
Exome chip meeting International AMD Genetics Consortium, Miami, USA 2013 0.3
ARVO-NED, Utrecht 2013 0.3
Masterclass for clinical PhD students on Therapies for Inherited Retinal Dystrophies, Nijmegen 2014 0.3
Symposium on Novel Therapies for Inherited Retinal Dystrophies, Nijmegen 2014 0.3
2020 meeting of the department of Epidemiology, Erasmus MC, Rotterdam (oral presentation) 2014 1.0
4th European Eye Epidemiology Workshop, Rome, Italy (oral presentation) 2014 1.0
Exome chip meeting International AMD Genetics Consortium, Regensburg, Germany (oral 
presentation)
2014 1.0
Fundus autofluorescence workshop, Rotterdam 2014 0.3
5th European Eye Epidemiology Workshop, London, UK 2015 0.3
275PhD portfolio
8
PhD Training Year
Workload
(ECTS*)
National conferences
15th Molecular Medicine Day, Rotterdam 2010 0.3
NOG Annual Meeting 2011, Maastricht (oral presentation) 2011 1.0
NOG Annual Meeting 2012, Groningen (oral presentation) 2012 1.0
NOG Annual Meeting 2013, Groningen (oral presentation) 2013 1.0
2nd Dutch Ophthalmology PhD Day, Nijmegen (oral presentation) 2013 1.0
NOG Annual Meeting 2014, Maastricht (oral presentation) 2014 1.0
3rd Dutch Ophthalmology PhD Day, Nijmegen (oral presentation) 2014 1.0
NOG Annual Meeting 2015, Groningen (oral presentation) 2015 1.0
NOG Annual Meeting 2016, Maastricht (oral presentation) 2016 1.0
International conferences
ARVO Annual Meeting 2011, Fort Lauderdale, USA (poster presentation) 2011 1.0
V. International Symposium of the German Ophthalmology Society (DOG), Baden-Baden, 2011 1.0
Germany (oral presentation)
Macula of Paris, 6th international conference on AMD, Paris, France (oral presentation) 2012 1.0
ARVO Annual Meeting 2012, Fort Lauderdale, USA (poster presentation) 2012 1.0
ARVO Annual Meeting 2013, Seattle, USA (poster presentation) 2013 1.0
ARVO Annual Meeting 2014, Orlando, USA (oral presentation) 2014 1.0
14th Euretina Meeting 2014, London, UK (oral presentation) 2014 1.0
European University Professors of Ophthalmology (EUPO), Nice, France (oral presentation) 2014 1.0
ARVO Annual Meeting 2015, Denver, USA (oral presentation) 2015 1.0
6th Euretina Winter Meeting, Rotterdam 2016 0.3
ARVO Annual Meeting 2016, Seattle, USA (oral presentation) 2016 1.0
ARVO Annual Meeting 2017, Baltimore, USA (poster presentation) 2017 1.0
Teaching
Supervising research internship, Ashley Wills 2011 0.4
Supervising master’s thesis, Sheila Backus 2014-2017 3.0
Other
Founder and co-organizer of the 1st Dutch Ophthalmology PhD Conference, Nijmegen 2012 3.0
Chair of AMD session, ARVO Annual Meeting 2014, Orlando, USA 2015 0.1
Chair of AMD session, 6th Euretina Winter Meeting, Rotterdam 2016 0.1
Moderator AMD poster session, ARVO Annual Meeting 2016, Seattle, USA 2016 0.1
* 1 ECTS (European Credit Transfer System) equals a workload of 28 hours.
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